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Ovarian cancer is the leading cause of death from gynecologic cancers. The ten year survival is 
less than 30% and has not improved significantly over the last 30 years. We employed next 
generation sequencing to address three common areas where previous studies have been lacking 
and insight into disease etiology would help improve survival and treatment of patients with ovarian 
cancer. Firstly, one of the challenges to improved diagnostic and therapeutic intervention in ovarian 
cancer has been a limited understanding of the natural history of the disease. It has been proposed 
that fallopian tube cancers may be precursors of high-grade serous ovarian carcinoma (HGSOC) 
but evolutionary evidence for this hypothesis has been limited. We performed whole exome 
sequence and copy number analyses of laser-capture microdissected fallopian tube lesions (p53 
signatures, serous tubal intraepithelial carcinomas (STICs), and fallopian tube carcinomas), ovarian 
cancers, and metastases from nine patients. Secondly, to improve our understanding of ovarian 
cancer, we performed genome-wide analyses of 45 commonly used ovarian cancer cell lines. 
Lastly, endometrioid and mucinous ovarian cancers represent nearly a quarter of ovarian cancers 
and their molecular characteristics and pathologic origins are poorly understood. Whole exome 
sequencing analyses of HGSOC samples demonstrated that p53 signatures and STICs are 
precursors of ovarian carcinoma and identified a window of seven years between development of 
a STIC and initiation of ovarian carcinoma, with metastases following rapidly thereafter. Whole 
genome sequencing analyses of 45 ovarian cancer cell lines showed dose-response analyses to 
targeted therapies revealed unique molecular dependencies, including increased sensitivity of 
tumors with PIK3CA and PPP2R1A alterations to PI3K inhibitor GNE-493, MYC amplifications 
to PARP inhibitor BMN673, and SMAD3/4 alterations to MEK inhibitor MEK162. Finally, whole 
exome and genome sequencing analyses on less common ovarian cancer subtypes revealed ovarian 
and GI mucinous tumors were epigenetically distinct. In contrast, the number of alterations and 
affected genes in ovarian and uterine endometrioid cancers were not distinguishable, suggesting 
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that these tumors may have a similar tissue of origin. Together these analyses provide insights into 
the etiology of ovarian cancer, have implications for prevention, early detection and therapeutic 
intervention of this disease. 
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1.1 Overall introduction 
Ovarian cancer is the leading cause of death from gynecologic cancers1,2.  The ten year survival is 
less than 30% and has not improved significantly over the last 30 years3.  Despite significant efforts, 
various screening and therapeutic strategies have generally not led to improved overall survival4,5.  
One of the major challenges to improved diagnostic and therapeutic intervention in ovarian cancer 
has been a limited understanding of the natural history of the disease.  Ovarian carcinoma is a 
highly heterogeneous group of diseases including different histological subtypes with distinct 
clinicopathological and molecular genetic features that can be generally classified as Type I and 
Type II tumors6.  Among them, high grade serous ovarian carcinoma (HGSOC, the major Type II 
tumor) is the most common histologic subtype of ovarian cancer, accounting for three quarters of 
ovarian carcinoma7-10.   
Despite significant advances in therapies for other solid tumor malignancies, the overall survival 
of patients with late-stage ovarian cancer has remained dismal with few new options for treatment. 
The standard therapy involves debulking surgery followed by chemotherapy. Part of the reason for 
the lack of novel therapies for ovarian cancer has been an inadequate understanding of the 
underlying molecular characteristics of this disease, especially in the context of cancer cell models 
than can facilitate the development of various cancer treatments. 
 
Epithelial ovarian cancer comprises about 90% of all ovarian cancer malignancies and includes 
high grade serous, low grade serous, mucinous, endometrioid and clear cell ovarian carcinoma.  
High grade serous ovarian cancers (HGSOC) represent more than half of all epithelial ovarian 
cancers and is the most widely studied epithelial ovarian tumor, while endometrioid and mucinous 
account for 10% and 6%, respectively11.   Through extensive whole genome, exome, and 
methylation analyses of HGSOC, a variety of genes have been identified as likely drivers in these 
tumors12, and evolutionary analyses have implicated the fallopian tube as the tissue of origin of 
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HGSOC 13-15.  Apart from alterations in a few well known drivers including KRAS and HER2 
amplification in ovarian mucinous carcinomas and mutations in ARID1A, PIK3CA, and PTEN 
genes as well as MMR deficiency in ovarian endometrioid carcinomas, comparatively little is 
known about molecular alterations in these tumors.  Comprehensive genomic analyses of these 
tumor subtypes could delineate additional alterations and pathways frequently altered in these 
cancers and shed light on their likely tissue of origin. 
1.2 High grade serous ovarian carcinomas originate in the fallopian tube introduction 
 
Genomic analyses of HGSOC have identified genetic alterations in TP53, BRCA1, BRCA2, PTEN 
and other genes although few of these discoveries have affected clinical care16,17.  HGSOC is 
diagnosed at advanced stages in approximately 70% of cases, and these women have a significantly 
worse outcome than those with early stage disease.  Until recently, the prevailing view of HGSOC 
was that it developed from the ovarian surface epithelium.  However, early in situ lesions that arise 
from the ovarian surface epithelium and progress to invasive HGSOC have never been reproducibly 
identified. 
Insights into the pathogenesis of HGSOC have emerged from investigating the prevalence of occult 
ovarian and fallopian tube carcinomas in women with germline mutations of BRCA1/BRCA2 
genes18-22.  Potential precursor lesions of HGSOC were identified in the fimbriae of the fallopian 
tubes removed as part of prophylactic surgery21.  Such lesions, including a TP53 mutant single-cell 
epithelial layer (p53 signature) and serous tubal intraepithelial carcinoma (STIC)22,23, have been 
identified in patients with advanced stage sporadic HGSOC of the ovary, fallopian tube and 
peritoneum23.  Immunohistochemical as well as targeted sequencing analyses have shown that 
fallopian tube lesions harbor the same TP53 mutation as surrounding invasive carcinomas22-26.  
These analyses suggest a clonal relationship among such tumors but given the limited number of 
genes analyzed do not conclusively identify the initiating lesions nor exclude the possibility of 
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fallopian tube metastases from primary ovarian carcinomas26,27.  Yet additional studies have 
evaluated clonal intraperitoneal spread of ovarian cancer using whole genome analyses, but this 
effort did not analyze precursor lesions such as STICs that may give rise to this disease28. 
In this study, we use exome-wide sequence and structural analyses of multiple tumor samples from 
the same individual to examine the origins of HGSOC.  We have previously shown that the 
acquisition of somatic alterations can be used as a molecular marker in the development of human 
cancer29.  Here, we examine whether the compendium of somatic alterations identified in different 
lesions may provide insights into the evolutionary relationship between primary fallopian tube 
lesions, including p53 signatures and STIC lesions, ovarian carcinomas, and intraperitoneal 
metastases. 
 
1.3 Integrated genomic, epigenomic and expression analyses of ovarian cancer cell lines 
introduction 
 
Recent studies have highlighted the genomic complexity and heterogeneity of ovarian cancer. 
These have included a catalog of sequence mutations, focal changes in DNA copy number, gene 
expression, and methylation alterations in high grade serous ovarian cancer 16 as well as whole 
exome analyses of ovarian clear cell carcinoma and low grade serous carcinoma30,31. Genome-wide 
sequence analyses of high grade serous ovarian cancer identified drivers associated with primary 
and acquired resistance to chemotherapy13,17. More recently, a catalog of proteomic alterations in 
high grade serous TCGA samples has been integrated with structural alterations and correlated with 
clinical outcomes32.  Hypothesis-generating pharmacogenomic studies involving cancer cell lines, 
some of which were ovarian, have revealed genetic- and expression-based alterations associated 
with resistance or sensitivity to a panel of drugs33,34.  More recent cell line studies have evaluated 
high grade serous, clear cell and other cancers using targeted genomic and other molecular 
analyses35-37. These initial efforts were extended to demonstrate the similarity of molecular 
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alterations in cell lines to those in corresponding tissues, to develop approaches for incorporating 
multiple data types to model sensitivity, and to apply these models to larger drug panels38. Despite 
these advances, a comprehensive analysis of genome-wide structural alterations, including intra- 
and inter-chromosomal translocations and gene fusions, and integration of these data with whole-
exome sequence, epigenetic and expression information are not available for many histological 
subtypes of ovarian cancer. Furthermore, the therapeutic response of these ovarian cancer subtypes 
to common targeted therapies is not well understood. 
 
Here, we performed complementary molecular analyses of  45 ovarian cell lines of different 
histologies, including serous, clear cell, endometrioid, and mucinous cancers.  As these cell lines 
do not have matched normal tissues, we developed novel approaches to characterize tumor-specific 
alterations at sequence and structural levels, and integrated these with methylation and transcript 
changes to identify the compendium of alterations at the gene- and pathway-levels.  Using the same 
cell lines, we evaluated the effect of a few targeted agents of common pathways using in vitro cell 
survival assays.  Our analyses identified novel molecular alterations in ovarian cancer, delineated 
genes modulated by genetic and epigenetic changes, and highlighted specific sequence, structural, 
and epigenetic alterations associated with sensitivity and resistance to common pathway inhibitors. 
 
1.4 Genomic landscapes of endometrioid and mucinous ovarian cancers introduction 
 
Accumulating evidence suggests connections between endometrioid ovarian cancers and 
endometrioid uterine tumors, which accounts for nearly 85% of all epithelial uterine carcinomas 39.  
Synchronous endometrioid ovarian and uterine carcinomas can arise from independent primary 
tumors or as metastases from a single primary tumor 40,41, suggesting that these tumors may share 
the same cell of origin 42,43.  Women who have synchronous ovarian and uterine cancers have an 
improved survival as compared to those with a single cancer, in part due to early diagnosis from 
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the symptoms associated with uterine tumors 44.  Understanding the origin of these cancers could 
lead to more accurate prognoses of survival or more aggressive early intervention.  While whole 
genome and targeted next generation sequencing analyses have been performed of ovarian 
endometrioid carcinomas 45,46 and whole exome studies have been performed on uterine 
endometroid carcinomas 47, the extent to which these cancers share similar alterations and a 
potentially common tissue of origin has not been systematically evaluated.   
 
Distinguishing between primary mucinous ovarian cancer and mucinous adenocarcinoma 
metastases from other sites, including gastrointestinal mucinous tumors, may be challenging.  Some 
histological features can favor primary diagnosis but there are several discordant and overlapping 
features that make a definitive diagnosis difficult 48.  Genomic analyses for mucinous ovarian and 
gastrointestinal cancers, including pancreatic, stomach and colorectal cancer, have largely been 
limited to targeted sequencing 49-52.  Additionally, no studies to date have compared the genomes 
and epigenomes of mucinous carcinomas from the ovary with those of other sites.  Such analyses 
could establish the tissue of origin and lead to better risk stratification and treatment for patients 
with these cancers. 
 
To better understand the genomic landscapes of these ovarian cancer subtypes and their histological 
counterparts, we performed whole exome sequencing and/or whole genome sequencing of 130 
samples from 117 patients with endometrioid cancer of the ovary or uterus or mucinous cancer of 
the ovary or GI tissues (stomach, pancreas, or colon).  Whole exome sequencing analyses identified 
somatic sequence mutations and structural alterations common to these cancers, including 
deletions, amplifications, and loss of heterozygosity.   For samples with whole genome sequencing, 
we additionally identified novel intra- and inter-chromosomal rearrangements and in-frame fusions 
using our recently developed Trellis approach 53.  To further explore the differences in molecular 
landscapes of mucinous cancers, we compared the epigenome of 25 patients with ovarian or GI 
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mucinous cancer using genome-wide methylation analyses in both the cancer and adjacent normal 
tissues.   These analyses highlight major pathways affected by genomic and epigenomics changes 
in these ovarian cancers, and identified a number of novel molecular alterations that may improve 




















Specimens obtained for sequencing analysis 
 
The study was approved by the Institutional Review Board at Brigham and Women’s Hospital and 
the Johns Hopkins Hospital and all patients gave informed consent before inclusion. Five sequential 
patients with stage III sporadic HGSOC, in whom a serous tubal intraepithelial carcinoma (STIC) 
was identified in their fallopian tubes (FT), were included. In addition, we included isolated STICs 
from three patients with germline BRCA deleterious mutation alterations who underwent 
prophylactic bilateral salpingo-oophorectomy and as well as a fourth patient who had bilateral 
salpingo-oophorectomy and hysterectomy in the context of a pelvic mass.  All cases underwent 
complete tubal examination using the SEE-FIM protocol16.  Formalin-fixed paraffin embedded 
(FFPE) blocks were retrieved from the pathology files at Brigham and Women’s Hospital and Johns 
Hopkins Hospital within the 3 months following surgical diagnosis and stored at 4°C to slow down 
nucleic acids degradation.  All the cases were reviewed by a gynecologic pathologist (MH, DL, 
LS) that confirmed the diagnosis of STIC and /or p53 signature in the FT.  Slides from each FFPE 
block were microdissected, including early lesions, invasive carcinomas and metastases, stained 
with Hematoxylin & Eosin (H&E), and using immunohistochemistry were analyzed for p53 
staining.  In each FT, at least one STIC and/or p53 signature was identified and microdissected 
separately. Importantly, STICs were not pooled together even if they were in the same section. 
They were considered separate STICs.  
 
Immunohistochemistry p53 staining for and laser capture microdissection  
 
For accurate microdissection of early lesions including STIC and p53 signature, 
immunohistochemistry staining of p53 was specifically adapted for Laser Capture Microdissection 
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(LCM) as previously described43.  PEN membrane frame slides Arcturus (Life technologies, 
Carlsbad, CA) were used.  Each slide was coated with 350 ul of undiluted poly-L-lysine 0.1% w/v 
(Sigma, St. Louis, MO).  For drying, the slides were placed in a slide holder for 60 minutes at room 
temperature. Tissue sections were cut and mounted on the pretreated membrane slides. 
Deparaffinization was performed in fresh xylene for 5 minutes twice, followed by 100% ethanol 
for 2 minutes, 95% for ethanol 2 minutes and 70% ethanol for 2 minutes. Subsequently, the slides 
were transferred into distilled water for 5 minutes. Heat-epitope antigen retrieval (AR) was 
performed in Citrate Buffer (Dako, Carpinteria, CA) at low temperature (60°C) for 44 hours instead 
of 120°C for 10 minutes to reduce tissue and DNA damage by high temperature.  Retrieval solution 
was pre-warmed to 60°C before usage. After incubation in the oven, the AR solution was left to 
cool down to room temperature and the slides were rinsed for 30 seconds in fresh 1X PBS then 
incubated for 40 minutes with primary antibody anti-p53 (Epitomics, Burlingame) at 1:100 in a 
humidifying chamber. Before adding the secondary antibody, slides were washed twice for 1 
minute in fresh 1X PBS. The secondary antibody, labeled polymer-HRP anti-mouse (Dako 
EnVision System-HRP (DAB), Carpinteria, CA) was applied for 30 minutes.  Then, slides were 
washed twice for 1 minute in fresh 1X PBS.  Chromogenic labeling was performed with 3,3-DAB 
substrate buffer and DAB chromogen (Dako EnVision System-HRP (DAB), Carpinteria, CA) for 
5 minutes.  Slides were washed again for 30 seconds in fresh distilled water.  Dehydration was 
performed as follows: 70% ethanol for 30 seconds, 95% ethanol for 30 seconds, 100% ethanol for 
30 seconds, and xylene for 30 seconds. The stained slides were microdissected within 2 hours with 
the Arcturus XT LCM system (Life technologies, Carlsbad, CA).  
 
Hematoxylin staining for laser capture microdissection 
 
Invasive carcinomas from the ovaries, the fallopian tubes and intraperitoneal metastases or STICs 
from patients with negative p53 IHC staining were microdissected after Hematoxylin staining. 
 11 
Briefly, deparaffinization was performed in fresh xylene for 1 minute twice followed by 100% 
ethanol for 1 minute, 95% for ethanol 1 minute and 70% ethanol for 1 minute. The slides were 
transferred into distilled water for 2 minutes before staining with Hematoxylin for 2 minutes. 
Subsequently, slides were rinsed in distilled water until they became clear before undergoing 
dehydration in 70% ethanol for 1 minute, 95% ethanol for 1 minute, 100% ethanol for 1 minute 
and xylene for 1 minute. The stained slides were microdissected within 2 hours. 
 
Sample preparation and next-generation sequencing 
 
DNA was extracted from patient whole blood using a QIAamp DNA Blood Mini QIAcube Kit 
(Qiagen Valencia, CA). Genomic DNA from FFPE blocks was extracted from the microdissected 
tissues using the QIAamp DNA FFPE Tissue kit (Qiagen, Valencia, CA). In brief, the samples were 
incubated in proteinase K for 16 hours before DNA extraction. The digested mixture was 
transferred to a microtube for DNA fragmentation using the truXTRAC™ FFPE DNA Kit with 10 
min shearing time as per the manufacturer’s instructions (Covaris, Woburn, MA). Following 
fragmentation, the sample was further digested for 24 hours followed by one hour incubation at 
80⁰C. DNA purification was performed using the QIAamp DNA FFPE Tissue kit following the 
manufacturer’s instructions (Qiagen, Valencia, CA). Fragmented genomic DNA from tumor and 
normal samples were used for Illumina TruSeq library construction (Illumina, San Diego, CA) 
according to the manufacturer’s instructions or as previously described44. Exonic or targeted 
regions were captured in solution using the Agilent SureSelect v.4 kit or a custom targeted panel 
according to the manufacturer’s instructions (Agilent, Santa Clara, CA). Paired-end sequencing, 
resulting in 100 bases from each end of the fragments for exome libraries and 150 bases from each 
end of the fragment for targeted libraries, was performed using Illumina HiSeq 2000/2500 and 
Illumina MiSeq instrumentation (Illumina, San Diego, CA).  
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Next generation sequencing data and identification of somatic mutations 
 
Somatic mutations were identified using VariantDx45 custom software for identifying mutations 
in matched tumor and normal samples.  Prior to mutation calling, primary processing of sequence 
data for both tumor and normal samples were performed using Illumina CASAVA software (v1.8), 
including masking of adapter sequences.  Sequence reads were aligned against the human reference 
genome (version hg18 or hg19) using ELAND. Candidate somatic mutations, consisting of point 
mutations, insertions, and deletions were then identified using VariantDx across the either the 
whole exome or regions of interest44. For samples analyzed using targeted sequencing, we 
identified candidate mutations that were altered in >10% of distinct reads. For samples analyzed 
using whole exome sequencing, we identified candidate mutations that were altered in >10% of 
distinct reads with ≥5 altered reads in at least one sample, where coverage at the altered base was 
at least as high as the TP53 alteration in that sample, and where the ratio of the coverage of the 
mutated base to the overall sequence coverage of that sample was >20%.  Identified mutations were 
reported as present in other samples of the same patient if the mutation was present in at least 2 
distinct altered reads. Mutations present in polyN tract ≥ 5 bases, or those with an average distinct 
coverage below 50x were removed from the analysis.  
 
An analysis of each candidate mutated region was performed using BLAT.   For each mutation, 
101 bases including 50 bases 5’ and 3’ flanking the mutated base was used as query sequence 
(http://genome.ucsc.edu/cgi-bin/hgBlat).  Candidate mutations were removed from further 
analysis, if the analyzed region resulted in >1 BLAT hits with 90% identity over 70 SCORE 
sequence length.  All candidate alterations were examined by visual inspection, and any alteration 
present.   
 
Genome-wide allelic imbalance analysis 
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We performed comparative analysis of loss of heterozygosity (LOH) across the tumor samples 
from each patient to identify copy number alterations occurring in the course of tumor evolution. 
Minor allele frequency (MAF) of germline heterozygous SNPs with minimum coverage of 10x in 
each tumor sample were segmented using circular binary segmentation algorithm (CBS)46.  
Genomic segments where the difference between tumor and normal MAF exceeded a threshold of 
0.10 were labeled as harboring LOH. In each tumor sample, the minimum MAF across segments 
with minimum size of 10 Mb was calculated to provide a measure of sample purity. Each segment 
marked as LOH was assigned to one of the three confidence categories: (1) High confidence, 
segment MAF within 0.1 of the minimum sample MAF. (2) Intermediate confidence, segment 
MAF within 0.1 to 0.2 of the minimum sample MAF (3) Low confidence, segment MAF exceeding 
the minimum sample MAF by greater than 0.2.  
 
Next, sample level segments were intersected across the entire set of samples from each patient to 
derive patient level segments while accounting for the possibility of variable segment break points 
in different samples (Supplementary Data 7-11). Patient level segments were filtered to keep those 
covering a minimum of 20 SNPs and with minimum length of 10 Mb. The resulting segments were 
further narrowed down to only include those with high confidence LOH in at least one of the 
samples. Genomic segments with LOH in a subset of samples can serve as informative markers to 
track tumor evolution similar to somatic mutations. To increase the specificity in identifying this 
class of genomic segments, we required a minimum distance of 0.1 between the MAF of samples 
with and without LOH.  To minimize the possibility of over-segmentation which could result in 
inflated estimates of the number independent structural alterations, we evaluated patient level 
segments with boundaries within a 5 Mb window. In cases where the LOH calls were identical and 
the difference of segment minor allele frequencies were less than or equal to 0.05 in all tumor 
samples, the segments were merged. 
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For CGOV62 and CGOV63, the number of germline heterozygous SNPs meeting the coverage 
criteria in p53 signature samples was significantly lower than the other samples from the same 
patient. Thus, we modified the approach above in these two patients to enable sensitive analysis of 
LOH in p53 signature samples. Initially, the patient level genomic segments of interest were 
defined excluding p53 signature samples. Next, in each genomic segment, the minor allele of each 
overlapping germline SNP was determined by taking a majority vote over their minor alleles in the 
other samples. The coverage and minor allele read count for each SNP was derived using samtools 
(v0.1.19) mpileup module47.  The segment minor allele frequency in p53 signature samples were 
calculated by dividing the sum of minor allele read counts across all SNPs by the total coverage of 
SNPs, circumventing the variance resulting from low coverage at individual SNPs. In each p53 
signature sample, segments with MAF lower than that of the normal by at least 0.1 were marked as 
LOH.   
 
Copy number analysis 
 
The genome-wide copy number profiles were determined by analysis of the ratio of read counts in 
the tumor and matched normal whole exome sequenced samples. In each sample, the number of 
reads mapping to genomic bins located in target and off-target regions were corrected for biases 
arising from GC-content, repetitive sequences, and target capture process using CNVKit (v.0.7.6) 
[https://doi.org/10.1371/journal.pcbi.1004873]. The log ratio of the processed tumor to normal read 
counts provides a measure of copy number in each bin, and was segmented to yield genomic 
intervals at constant copy number levels. The difference in sequencing library size between the 
tumor and normal samples is another factor that needs to be accounted for when analyzing reads 
ratios in NGS-based copy number pipelines. In CNVKit, the log ratio values in each sample are 
adjusted by setting the median of autosomal bins to 0 in log space, assuming a median ploidy of 2 
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for the genome. Given the high prevalence of copy number aberrations in ovarian cancer and the 
high frequency of allelic imbalance in the present cohort, this assumption may not be accurate, and 
will manifest itself as a genome-wide bias or shift of log ratio values.  
 
Therefore, an alternative approach for normalization of log ratio values was adopted, which takes 
into account the level of allelic imbalance in each genomic region. Briefly, genomic regions with 
the least degree of allelic imbalance were identified in each tumor sample, and used in a 
normalization process based on the notion that these regions can only be present in an even number 
of copies. The distribution of log ratio values among these regions was inspected to ensure that 
they belong to the same copy number level. Otherwise, a subset of regions at a common log ratio 
(and thus copy number) level were selected. By fixing the copy number of these segments at a 
specified level, one can solve for the genome-wide bias of log ratio values as follows, and thus 
identify the genome-wide integer copy number profile.   
 
𝑅𝑅 = 𝑙𝑙𝑙𝑙𝑙𝑙2 �
𝛼𝛼 𝐶𝐶𝐶𝐶𝑇𝑇 + (1 − 𝛼𝛼)𝐶𝐶𝐶𝐶𝑁𝑁
2 �
−  𝛿𝛿 
 
In the equation above, R represents the observed log ratio of read counts, α is the purity of the 
tumor sample, 𝐶𝐶𝐶𝐶𝑇𝑇 and 𝐶𝐶𝐶𝐶𝑁𝑁 are the integer copy number of tumor and normal samples at a locus, 
and δ is the genome-wide bias term. Given the value of tumor purity and copy number, δ is the only 
unknown in the equation. To favor solutions with less complex genomes, the copy number of 
regions with complete allelic balance was initially set to 2. If the resulting solution was deemed 
implausible (e.g. by implying chromosome or chromosome arm scale homozygous deletions), the 
copy number of regions with complete allelic balance was assigned to 4 and an alternative solution 
was found (Supplementary Figure 10).   
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Details of the genomic segments selected to solve for the genome-wide bias term δ are as follows. 
In CGOV62, chromosomes 4 and 12 did not have allelic imbalance in any tumor samples. The 
solution assigning copy number two to these regions implied homozygous deletion of the p-arm of 
chrX in multiple samples; therefore, the simplest plausible solution assigned them to 4 copies. In 
CGOV63, chromosomes 6 and 15 did not have allelic imbalance in any of the tumor samples, and 
were assigned to 2 copies. No complete chromosome with absence of allelic imbalance across all 
tumor samples could be found in CGOV278. Therefore, four genomic regions with no allelic 
imbalance were selected for the normalization process above. These regions were chr8:38-69Mb, 
chr12:62-85Mb, chr18:7-19Mb, chr20:23-35Mb. The solution assigning these regions to 2 copies 
resulted in an implausible assignment of homozygous deletion to chr5:50-136Mb. Therefore, 
assignment of four copies to the selected regions results in the simplest solution. In CGOV279, two 
genomic regions were selected for the normalization procedure: chr5: 64-131Mb, chr20:17-36Mb. 
Evaluation of log ratio values suggested that the two regions are present at different copy levels, as 
evidenced by a difference of ~0.60 in the log ratio values. The region on chr5, which had the lower 
log ratio level, was assigned to copy number 2. In CGOV280, chr16q had no allelic imbalance in 
any samples excluding the left FT STIC. Examination of log ratio values of chr16q in the left FT 
STIC supports a copy loss in that sample. The genome-wide bias term δ was determined by 
assignment of 2 copies to chr16q in the four samples with no allelic imbalance, and one copy in the 
left FT STIC. 
 
Subclonal hierarchy analysis 
 
The tumor subclonality phylogenetic reconstruction algorithm SCHISM 1.0.025 was used to infer 
tumor subclonal hierarchies from the set of confidently called somatic mutations in each patient. 
Given the estimates of genome-wide copy number profile, most copy number aberrations seem to 
occur early in the evolution of disease and are common across the lesions analyzed from each 
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patient. Thus, the majority of somatic mutations can be assumed to occur following the acquisition 
of copy number aberrations, and can be present in cancer cells with multiplicity of one (one mutated 
copy per cell). Using this assumption, we can estimate mutation cellularity (or cancer cell fraction) 
from the observed reference and alternate read counts, and estimates of copy number, and tumor 
purity as follows. 
𝑉𝑉𝑒𝑒𝑒𝑒𝑒𝑒 =
𝑚𝑚𝛼𝛼𝐶𝐶
𝛼𝛼 𝐶𝐶𝐶𝐶𝑇𝑇 + (1 − 𝛼𝛼)𝐶𝐶𝐶𝐶𝑁𝑁
 
 
In the equation above, V_expis the expected variant allele frequency of the mutation, m is the 
multiplicity of the mutation which is set to 1, α is the purity of the tumor sample, C is the cellularity 
of the mutation, and  〖CN〗_T and 〖CN〗_N are the integer copy number of tumor and normal 
sample at the locus of the mutation. The observed alternate read count of the mutation can be 
modeled as a binomial random variable drawn from a distribution with probability parameter equal 
to V_exp and number of trials equal to the total sequence coverage of the mutation. We calculated 
the likelihood for observation of the alternate read counts for cellularity values spanning the range 
of 0 to 1 in increments of 0.01, and derived the maximum likelihood estimate and confidence 
interval for the mutation cellularity. 
 
To obtain reliable estimates of mutation cellularity, we clustered mutations by joint presence or 
absence across the available tumor samples. This approach makes phylogenetic reconstruction 
more tractable and the cellularity of the resulting clusters can be estimated with higher accuracy 
than that of individual mutations.  For each patient, a mutation was called as present or absent in 
each of the available tumor samples (10 samples from CGOV62, 6 samples from CGOV63, 5 
samples from CGOV280, 4 samples from CGOV279, and 3 samples from CGOV278). To call the 
mutation present, we used a minimum allele frequency of 2% and 2 distinct mutant reads. Mutation 
clustering was performed by a greedy algorithm. Tumor purity in each tumor sample was estimated 
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as the read count fraction of TP53 mutation in each patient. Each patient harbored a single distinct 
TP53 mutation that was present in all tumor samples, and we assumed the wild-type allele was lost, 
as supported by the ubiquitous LOH of chromosome 17. To derive a more comprehensive view of 
the evolution of these samples, we extended the original SCHISM framework to model acquisition 
of large scale somatic copy number alterations, which can be detected by analysis of allelic 
imbalance (including LOH). First, we extracted a set of high confidence genomic regions with 
ubiquitous, partially shared, or private LOH in tumor samples of each patient (Methods). These 
regions of LOH served as binary features that could be used for evolutionary analysis, and were 
clustered into LOH feature groups with identical patterns of presence or absence across samples 
(Figure 2).  Each LOH feature group was compared to the somatic mutation clusters in each patient, 
with respect to its pattern of presence or absence across samples. In cases where a mutation cluster 
with the identical pattern could be found, the cluster and the LOH feature group were assumed to 
have occurred together in the course of tumor evolution. Otherwise, the LOH feature groups were 
modeled as distinct features, and added in post-hoc analysis by application of the lineage 
precedence rule from SCHISM; which requires cellularity of ancestor alterations to be greater than 
or equal to cellularity of descendant alterations in all tumor samples.   SCHISM was run with the 
above inputs and default parameter settings to infer the order of somatic alterations and thus define 
subclonal hierarchy in each patient.  SCHISM software is freely available for non-profit use at 
http://karchinlab.org/appSchism.  
 
Evolutionary trees resulting from SCHISM analysis were compared with those derived by 
maximum parsimony phylogeny using PHYLIP (Phylip-3.695, PARS method).  For CGOV280, an 
adjustment to the tree was applied to account for multiple subclones in Right FT STIC. 
 
Estimating an evolutionary timeline 
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Following the approach of Jones et al., the observed data are the number of somatic mutations in 
the STIC (n_j), the number of mutations in the metastasis (n_k), and the age at which the patient 
was diagnosed (t_k), where somatic mutations include both sequence and structural alterations.  
Unknown is the birth date (t_j) of the cell that was the last common ancestor of the STIC and the 
metastasis.  Assuming the mutation rate of somatic passenger mutations and the length of the cell 
cycle is constant, the number of somatic mutations in the metastasis cell that were present in the 
STIC follows a binomial distribution with parameters N2 and probability t_j/t_k.  As t_j is 
unknown, we posit a conjugate beta probability distribution on the rate t_j/t_k with shape 
parameters a and b estimated from previous studies as described below.  The posterior distribution 
of t_j/t_k  is beta (a + n_j, b + n_k - n_j) from which 90% highest posterior density intervals can 
be constructed with point estimates for the birthdate reported as the posterior mean.  For simplicity, 
we refer to the highest posterior density as a confidence interval.  To construct a prior for t_j/t_k, 
we draw on a previous study of four colorectal cancer patients29 where a small number of 
additional passenger mutations were acquired by the cell that gave birth to the metastasis.  On 
average, 95% of the mutations in the original adenocarcinoma were present in the metastases.  We 
center the mean for the beta prior at 0.95 using shape parameters a = 34 and b = 1.6.   Our prior is 
equivalent to one patient having 34 passenger somatic mutations in the original lesion and 1.6 
additional mutations to be acquired by cells that gave birth to the metastases.  For patients with 
three samples in a linear tree as determined by evolutionary analyses (say, samples j, k, and l where 
sample j is the STIC, l is the metastasis, and k is an intermediate sample), we first derived the 
posterior distribution for t_k comparing mutations in samples k and l.  Next, we derived the 
posterior distribution of t_j  integrating over all possible values of t_k, thereby fully incorporating 
the uncertainty of the intermediate timepoint in the estimate of t_j.  We evaluated three additional 
prior models, and found that that posterior inference under these alternative models given by 90% 
credible intervals for t_k – t_j, results in qualitatively similar timelines among different lesions in 





To elucidate the relationship among tumors in patients with HGSOC, we performed whole-exome 
sequencing of 37 samples from five patients diagnosed with sporadic HGSOC who underwent 
upfront debulking (Supplementary Table 2.1).  This included STIC lesions, fallopian tube 
carcinomas, and ovarian cancers in all five patients; appendiceal, omental or rectal metastases in 
three of patients (CGOV62, CGOV280, CGOV278); p53 signatures in two patients (CGOV62, 
CGOV63); and a STIC lesion in the contralateral fallopian tube from the affected ovarian cancer 
(CGOV280). 
 
In addition, we analyzed isolated STIC lesions from four patients (CGOV64, CGOV65, CGOV303 
and CGOV304), three of whom had germline pathogenic BRCA alterations and underwent 
prophylactic bilateral salpingo-oophorectomy, and a fourth who had bilateral salpingo-
oophorectomy and hysterectomy in the context of a pelvic mass (Supplementary Table 2.1).  For 
all patients, laser capture microdissection was used to isolate lesions after immunohistochemistry 
(IHC) staining of p53 in STICs and p53 signatures if these contained a TP53 missense mutation or 
after hematoxylin staining if the samples contained a TP53 nonsense mutation (Figure 2.1).  All 
other samples were microdissected after hematoxylin staining.  Whole blood, normal ovarian 
stroma, normal fallopian tube stroma, or normal cervix were used as control samples. 
To identify genetic alterations in the coding regions of these cancers, we used next-generation 
sequencing platforms to examine entire exomes in matched tumor and normal specimens of all 
patients (Figure 2.1).  This approach allowed us to identify non-synonymous and synonymous 
sequence changes, including single base and small insertion or deletion mutations, as well as copy 
number alterations in coding genes.  Given the challenges of exome-wide analyses of small tumor 
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samples observed in STICs and p53 signature lesions, we developed experimental and 
bioinformatic approaches for detection of somatic alterations from laser capture microdissected 
tissue.  These included optimized approaches for microdissection of STICs and p53 signatures after 
immunohistochemical staining, improved DNA recovery from laser captured material, library 
construction from limited and stained tissue samples, and error correction methods in next 
generation sequence analyses.  The analyses of p53 signatures were particularly challenging 
because these are extremely small lesions, representing 10-30 cells per section and less than several 
hundred cells total that result in minute amounts (less than a few ng) of isolated DNA.  We 
optimized these approaches using a targeted next generation sequencing approach analyzing 120 
genes in a subset of samples from patient CGOV62, and then used whole-exome analyses to 
evaluate coding sequence alterations in all samples (Supplementary Tables 2.2-2.4).  We obtained 
a total of 719 Gb of sequence data, resulting in an average per-base sequence ~178-fold total 
coverage (~112-fold distinct coverage) for each tumor analyzed by whole-exome sequencing 
(Supplementary Table 2.2). 
 
Analysis of sequence and structural changes 
Whole-exome sequence analyses of the tumor samples from each patient identified somatic 
mutations that were present in all neoplastic samples analyzed as well as specific changes that were 
present in individual or subsets of tumors (Figure 2.2).  As expected, we identified sequence 
changes in the TP53 tumor suppressor gene, a well-known driver gene in HGSOC, in all cases.  
The TP53 alterations were identical in all samples analyzed for each patient including in the p53 
signatures, the STIC lesions, and other carcinomas.  These data suggest that mutation of TP53 was 
among the earliest initiating events for high grade serous ovarian carcinoma development as all 
lesions harbored this alteration. 
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IHC staining for p53 did not identify any nuclear positive staining of p53 on the ovarian surface 
epithelium in any of the cases that had TP53 missense mutation, whereas all carcinomas, STICs, 
and p53 signatures in the fallopian tube were positive.  Whole-exome sequence analyses of normal 
ovarian stroma (no p53 staining) microdissected from three patients (CGOV64, CGOV65, 
CGOV280) did not find any genomic abnormalities.  Analysis of the resected tissues revealed that 
none of the nine cases had ovarian inclusion cysts.  These observations suggest that there is no early 
lesion with TP53 mutation in the surface epithelium or other normal regions within the ovary. 
Because TP53 mutations are expected to be clonal and were all homozygous due to loss of 
heterozygosity (LOH) of the remaining wild-type allele (as determined in our subsequent allelic 
imbalance analyses), we used the mutant allele fraction of TP53 in each sample to estimate tumor 
purity.  We further analyzed sequence alterations in all samples with estimated tumor purities 
>50%, while four samples with tumor cellularities below this threshold (omental metastasis from 
CGOV279 and right ovarian tumor from CGOV278), or that were miliary carcinomas (rectal and 
sigmoidal metastases from CGOV63) were only analyzed for structural changes. 
Using a high-sensitivity mutation detection pipeline, we identified an average of 33 non-
synonymous and synonymous sequence alterations per tumor sample.  Candidate alterations were 
evaluated across samples in an individual to determine if they were present in multiple neoplastic 
lesions or were unique to a particular sample.  To allow for the possibility that a subclone may have 
developed in a tumor lesion prior to becoming a dominant clone at another location, we determined 
if genetic alterations that were present in one tumor were also present in a low fraction of neoplastic 
cells of other lesions.  This method required high coverage of analyzed alterations in all samples 
and excluded potential artifacts related to mapping, sequencing or PCR errors, allowing specific 
detection of alterations present in ≥1% of sequence reads (see Methods for additional information). 
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The composition of sequence alterations was relatively similar among the affected lesions of each 
patient.  For example, for CGOV62, the STIC lesion, fallopian tube carcinomas, left and right 
ovarian cancers, and all four metastatic lesions harbored a common set of somatic mutations (Figure 
2.2).  In CGOV63, CGOV279 and CGOV278, while most of the sequence alterations were the 
same among the tumors of each patient, a subset of mutations could distinguish the STIC lesions 
and fallopian tube carcinomas from ovarian cancers or intraperitoneal metastases. 
 
Given the importance of chromosomal instability in HGSOC16, we extended our analyses to 
examine structural variation in the multiple tumors of each patient.  We focused on regions of allelic 
imbalance that can result from the complete loss of an allele (LOH) or from an increase in copy 
number of one allele relative to the other.  We divided the genome into chromosome segments and 
for each segment compared the minor allele (B-allele) frequency values in tumor and normal 
samples using the ~17,000 whole-exome germline heterozygous single nucleotide polymorphisms 
(SNPs) observed (Figure 2.3, Supplementary Figures 2.1-2.9 and Supplementary Tables 2.7-2.11).  
Overall, we observed that an average of ~26% (range 12% - 39%) of the genome had chromosomal 
imbalances in the samples analyzed (Figure 2.3). 
Integration of sequence and structural alterations identified an average of 47 alterations per sample 
(range 21-74) (Figure 2.2).  The combination of both types of alterations allowed robust genomic 
differentiation between STICs and ovarian cancers or metastatic lesions in all patients analyzed.  In 
patient CGOV62, a loss of heterozygosity (LOH) of 9q (70.8 – 131.7 Mb) provided a clear 
difference between the STIC and all other carcinomas analyzed (Figures 2.2 and 2.3).  Likewise, 
chromosomal changes in 7q were represented a distinguishing feature between the right STIC or 
right fallopian tube tumors and the remaining lesions (ovarian cancers, omental metastasis and left 
STIC)  in CGOV280 (Figures 2.2 and 2.3).  In patient CGOV279, multiple regions of allelic 
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imbalance were present in a STIC near the fallopian tube carcinoma, while these were absent in a 
STIC that was not adjacent to this lesion. 
Evolutionary relationship of neoplastic lesions 
As somatic genetic alterations can be used to recreate the evolutionary history of tumor clones, we 
used the somatic sequence mutations and chromosomal alterations observed in each patient to 
determine the history of tumor clonal evolution.  We employed a subclone hierarchy inference tool 
called SCHISM (SubClonal Hierarchy Inference from Somatic Mutations) which enables improved 
phylogenetic reconstruction by incorporating estimates of the fraction of neoplastic cells in which 
a mutation occurs (mutation cellularity)54.  We estimated the cellularity of each mutation by 
correcting the observed allele frequencies for tumor purity and copy number levels.  In addition to 
the observed structural alterations, this approach allowed us to use 213 synonymous and 
nonsynonymous somatic sequence alterations to construct the phylogenetic trees illustrated in 
Figure 2.4 and Supplementary Table 2.5. 
A SCHISM tree node represents cells harboring a unique compartment of mutations defining a 
subclone whereas an edge represents a set of mutations acquired by the cells in the progeny nodes 
that distinguish them from the cells in the parental node.  By definition, for an individual cancer 
there could only be one parental clone, although there could be many different progeny subclones 
representing invasive or metastatic lesions or further evolution of the primary tumor.  The optimal 
hierarchy among subclones is determined by examining all possible pairwise relationships between 
somatic alterations, and performing a heuristic search over the space of phylogenetic trees to 
identify the simplest model that can explain the observed alterations. 
In all samples, the SCHISM analysis of sequence and structural alterations suggested that the p53 
signature or STIC lesions contained the ancestral clone for the observed cancers (Figure 2.4).  This 
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evolutionary relationship was strengthened by the observation that nearly all of the alterations 
within the p53 signature and STIC lesions were shared by all other lesions.  For example, the 
ovarian tumors of all cases displayed alterations that were shared in fallopian tube lesions but also 
contained additional changes, suggesting that these represented daughter clones of the latter tumors 
(Figure 2.2).  Likewise, the ovarian cancers or their immediate precursors were likely the direct 
parental clones for the metastases in CGOV62, CGOV278 and CGOV280 as demonstrated by the 
shared alterations that were not contained in earlier fallopian tube lesions. Overall, the phylogenetic 
model generated by these data suggests a progression from fallopian tube epithelium to p53 
signatures and to STIC lesions which are then precursors of fallopian tube carcinoma, ovarian 
carcinoma, and metastatic lesions.  In addition to the sequential accumulation of alterations in this 
linear evolution, we also observed branching phylogenetic trees due to continued evolution within 
STIC lesions as well as fallopian tube carcinomas and ovarian carcinomas (Figure 2.4).  We 
compared evolutionary trees resulting from SCHISM analysis with those derived by maximum 
parsimony phylogeny using PHYLIP and the results were similar in all cases (Figure 2.4 and 
Supplementary Data 2.11). 
Interestingly, patient CGOV280 had a right STIC, a right fallopian carcinoma, and a right ovarian 
cancer but also had a STIC in the left fallopian tube (Supplementary Figure 2.5).  In this case the 
SCHISM analysis suggested that the lesion in the left fallopian tube which was pathologically 
determined to be a STIC actually represented a metastatic lesion of the right ovarian cancer (Figure 
2.4).  This lesion shared nearly all the alterations of the ovarian cancer but contained 10 single base 
substitutions and four additional regions of allelic imbalance on chromosomes 1, 13 and 22, and 
both the left STIC and right ovarian cancer had an additional region of allelic imbalance on 
chromosome 7 that was absent in the right STIC.  These observations are consistent with the above 
model of STIC to ovarian cancer progression, but suggest that in advanced disease ovarian cancers 
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may also seed metastatic deposits throughout the peritoneum, including to the fallopian tube on the 
contralateral side. 
Genomic alterations in isolated STICs 
Neoplastic cells observed in the fallopian tubes rather than the ovaries removed from carriers of 
germline mutation of BRCA1 and BRCA2 provided the first indication of the fallopian tube as a 
potential cell of origin of HGSOC20,55.  Since less than 1.25% of HGSOC are diagnosed with stage 
I disease27, BRCA carriers provide a unique opportunity to analyze genomic alterations in isolated 
STICs without associated HGSOC.  We examined neoplastic samples from three individuals with 
germline BRCA alterations where STIC lesions were incidentally identified after prophylactic 
bilateral salpingo-oophorectomy, and one patient where two STICs were identified after resection 
of pelvic mass (Supplementary Table 2.1).  We identified BRCA1 or BRCA2 sequence alterations 
or deletions in the germline of three of these patients (BRCA1 Q1200X, BRCA2 L2653P, and a 
BRCA2 55kb hemizygous deletion in CGOV65, CGOV64, and CGOV304, respectively), as well 
as somatic mutations in TP53, and LOH of both chromosome 13 and 17, encompassing the BRCA1, 
BRCA2 and TP53 loci in all of these cases (Supplementary Figures 2.6, 2.7, 2.8, and 2.9).  Whole 
exome analyses showed that the STIC lesions contained a total of 91, 23, 34 and 46 non-
synonymous and synonymous somatic mutations, in CGOV65, CGOV64, CGOV303, and 
CGOV304 respectively.  Overall, these analyses revealed that STICs in isolation in patients with 
or without germline BRCA changes have a roughly similar number of sequence changes to STICs 
in patients with sporadic tumors.  These observations provide evidence that isolated STICs may act 
as precursors in the same manner as those identified in patients with sporadic advanced stages 
HGSOC analyzed in this study. 
Recurrent molecular alterations 
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We examined tumors from the nine patients to identify recurrent non-silent sequence or 
chromosomal changes.  Although no genes other than TP53 were mutated in all patients analyzed, 
we identified mutations in ten genes that were altered in two or more patients (Supplementary Table 
2.6).  These included mutations in the tumors of two patients of the PIK3R5 gene that encodes a 
regulatory subunit of the PI3-kinase complex.  CGOV64 also had a somatic alteration in PTEN that 
together with changes in PIK3R5 highlight the importance of the PI3K pathway in ovarian cancer16.   
Additional genes that were observed to be altered in other ovarian cancers through other large scale 
sequencing efforts such as TCGA16 are indicated in Supplementary Data 6. 
In addition to recurrent sequence changes, we found alterations in regions of allelic imbalances 
encompassing several tumor suppressor genes involved in ovarian cancer.  Remarkably, these 
included losses of BRCA1, BRCA2 and TP53 in all nine patients, and loss of PTEN for CGOV62, 
CGOV63, CGOV280 and CGOV64 (in addition to the somatic sequence alterations of these genes) 
(Supplementary Figures 2.1-2.9).  In all cases, the LOH observed in the metastatic lesions and 
ovarian tumor lesions for regions encompassing these genes were already present in the fallopian 
tube tumor and STIC lesions.  Considering the evolutionary model above, these data suggest that a 
combination of sequence changes in a few genes including TP53 together with loss of the TP53 
wild-type allele as well as BRCA1, BRCA2, and PTEN may be crucial early events that are needed 
for the initiation of STICs56,57. 
Evolutionary timeline of ovarian cancer development 
To estimate the time between the development of the earliest neoplastic clones in the fallopian tube 
and the development of ovarian and other metastatic lesions we used a mathematical model for 
comparative lesion analysis29,58.  This model estimates the time interval between a founder cell of 
a tumor of interest and the ancestral precursor cell assuming that mutation rates and cell division 
times are constant throughout a patient’s life.  In the patient CGOV62, this model would suggest 
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~1.9 years between the development of the STIC lesion and the ovarian cancer (90% CI, 0.5 – 4.2 
years).  For other patients this transition appears to have been slower as the average time between 
STICs and ovarian cancer among all patients was 6.5 years (range 1.4 to 10.7 years).  Importantly, 
in patients with metastatic lesions, the time between the initiation of the ovarian carcinoma and 
development of metastases appears to have been rapid (average 2.0 years).  There were either no 
additional mutations in metastatic lesions (e.g. CGOV62 omental, rectal or appendiceal metastasis 
or CGOV280 omental metastasis) or the number of additional changes was small (e.g. three 
changes in CGOV278 omental metastasis), reflecting the ease with which cancer cells located on 
the ovaries can subsequently seed additional peritoneal sites.  Although the precise timing of this 
progression depends on assumptions related to mutation rates, which may change during tumor 
progression, models employing different rates all showed longer timeline from STIC lesions to 









Figure 2.1. Schematic of sample isolation and next-generation sequencing analyses.  (Top 
panel) Tumor sites analyzed from CGOV62 with stage III HGSOC.  For each sample, slides were 
stained with hematoxylin and eosin as well as analyzed by immunohistochemical staining of p53. 
(Middle panel) Tumor samples were microdissected for genomic analyses.  For microdissection for 
STIC and p53 signature lesions, tumor cells were identified using immunohistochemical staining 
of p53 and isolated through laser capture microdissection.  (Bottom panel, left) Next-generation 
sequencing analyses were performed for tumor specimens using either whole-exome or targeted 
analyses focused on 120 genes. (Bottom panel, right) Somatic mutations and chromosomal 
alterations were used to evaluate tumor evolution using the tumor subclonality phylogenetic 
reconstruction algorithm SCHISM and to determine a timeline for tumor progression.  




Figure 2.2. Somatic mutation and allelic imbalance profiles among different tumor lesions. 
Somatic mutations and segments of allelic imbalance detected by whole-exome analyses are 
indicated as colored cells in rows for all patients. Darker shades of each color indicate somatic 
mutations while lighter shades indicate allelic imbalances.  The tumor samples analyzed for each 
patient are indicated in columns (p53 sig, p53 signature; STIC, serous tubal intraepithelial 
carcinoma).  For ovarian tumors in CGOV62 and STIC lesions in CGOV63 multiple blocks are 
indicated, including one ovarian tumor where multiple sections were analyzed after hematoxylin 
and eosin staining or after immunohistochemistry (IHC) staining of p53.  These analyses indicated 
that staining methods did not affect detection of somatic alterations.  The color of mutations 
indicates the degree of relatedness among tumor samples: red, shared among all tumor samples 
with TP53 highlighted at the top row; green, shared among all tumor samples except p53 signature 
lesion; purple, shared among fallopian tube tumor and omental metastasis; blue indicates mutations 
that were first detected in the ovarian tumors; and gray indicates mutations that were only detected 
in metastatic lesions.  Additional color shades or patterns indicate mutations that are localized to 





Figure 2.3. Genome-wide allelic imbalance profile. Minor allele frequency of heterozygous 
SNPs identified from normal tissue in each patient are derived in each tumor sample, enabling 
assessment of allelic imbalance in ~17,000 loci across the exome. Circular binary segmentation 
(CBS) is applied to minor allele frequencies of SNPs with minimum coverage of 10x in each tumor 
sample, and the resulting segment means are shown as a heatmap.   Asterisks indicate samples 
where corresponding mutation analyses were not performed due to low tumor purity (omental 
metastasis of CGOV279, right ovarian tumor of CGOV278) or miliary pattern of tumor samples 
(peritoneal metastases of CGOV63). Given the relatively lower number of distinct DNA molecules 
available from the p53 signature samples from CGOV62 and CGOV63, these samples are subject 







Figure 2.4. Schematic of tumor evolution. The history of tumor evolution in each patient is 
modeled as a subclonal hierarchy inferred from the somatic mutations and large scale genomic 
regions harboring loss of heterozygosity (LOH features) using the SCHISM framework, and is 
depicted as tree. Each tree starts from a root node corresponding the normal fallopian tube 
epithelium (germline). In all patients, mutations in TP53 (red boxes) are among the earliest somatic 
alterations and are ubiquitously present in all tumor samples. Somatic alterations (boxes) are 
acquired along edges (arrows) of the tree, and example alterations are indicated in each case. Nodes 
of the tree represent cells whose genotype is described by the presence of somatic mutations and 
LOH features on the path connecting the node to the root of the tree. Each node is labeled with 
tumor samples harboring all upstream and lacking any downstream alterations.  The trees inferred 
for all patients support a pattern of evolution with p53 signatures and STIC lesions as early events 
in tumorigenesis.  Mutation clusters and LOH feature groups follow the same color code as Figure 





Supplementary Figure 2.1. Loss of heterozygosity analyses for CGOV62. The graphs represent 
B allele frequencies (BAFs) for the indicated chromosomes.  A value of 0.5 indicates a 
heterozygous genotype (AB) whereas allelic imbalances in tumor samples are observed as a 
deviation from 0.5.  BAF values of 0 typically indicate loss of heterozygosity, although normal 
contaminating tissue may limit the minimum observed value.  Graphs for CGOV62 include left 
fallopian tube STIC, left fallopian tube tumor, left ovarian tumor block A4, left ovarian tumor block 
A7, right ovarian tumor, rectal metastasis, appendiceal metastasis, and omental metastasis.  LOH 
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Supplementary Figure 2.2. Loss of heterozygosity analyses for CGOV63. The graphs represent 
B allele frequencies (BAFs) for the indicated chromosomes.  A value of 0.5 indicates a 
heterozygous genotype (AB) whereas allelic imbalances in tumor samples are observed as a 
deviation from 0.5.  BAF values of 0 typically indicate loss of heterozygosity, although normal 
contaminating tissue may limit the minimum observed value.  Graphs for CGOV63 include STIC 
block D1, STIC block D2, STIC block D3 , right fallopian tumor, right ovarian tumor, sigmoid 
metastasis, rectal metastasis. LOH events that contain PTEN, BRCA2, TP53 and BRCA1 genes are 
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Supplementary Figure 2.3. Loss of heterozygosity analyses for CGOV280. The graphs 
represent B allele frequencies (BAFs) for the indicated chromosomes.  A value of 0.5 indicates a 
heterozygous genotype (AB) whereas allelic imbalances in tumor samples are observed as a 
deviation from 0.5.  BAF values of 0 typically indicate loss of heterozygosity, although normal 
contaminating tissue may limit the minimum observed value.  Graphs for CGOV280 include STIC 
of the right fallopian tube, right fallopian tube tumor, right ovarian tumor, omental metastasis, stic 
of the left fallopian tube.  LOH events that contain PTEN, BRCA2, TP53 and BRCA1 genes are 
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Supplementary Figure 2.4. Loss of heterozygosity analyses for CGOV279. The graphs 
represent B allele frequencies (BAFs) for the indicated chromosomes.  A value of 0.5 indicates a 
heterozygous genotype (AB) whereas allelic imbalances in tumor samples are observed as a 
deviation from 0.5.  BAF values of 0 typically indicate loss of heterozygosity, although normal 
contaminating tissue may limit the minimum observed value.  Graphs for CGOV279 include STIC 
of the right fallopian tube, STIC of the right fallopian tube close to the tumor, right fallopian tube 
tumor, right ovarian tumor. LOH events that contain BRCA2, TP53 and BRCA1 genes are indicated 
by the red boxes, while the LOH region in chromosome 10 of this sample does not overlap with 
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Supplementary Figure 2.5. Loss of heterozygosity analyses for CGOV278. The graphs 
represent B allele frequencies (BAFs) for the indicated chromosomes.  A value of 0.5 indicates a 
heterozygous genotype (AB) whereas allelic imbalances in tumor samples are observed as a 
deviation from 0.5.  BAF values of 0 typically indicate loss of heterozygosity, although normal 
contaminating tissue may limit the minimum observed value.  Graphs for CGOV278 include STIC 
of left fallopian tumor, left ovarian tumor, omental metastasis. LOH events that contain BRACA2, 
TP53 and BRCA1 genes are indicated by the red boxes, while the LOH region in chromosome 10 








Supplementary Figure 2.6. Loss of heterozygosity analyses for CGOV65. The graphs represent 
B allele frequencies (BAFs) for the indicated chromosomes for the STIC lesion.  A value of 0.5 
indicates a heterozygous genotype (AB) whereas allelic imbalances in tumor samples are observed 
as a deviation from 0.5.  BAF values of 0 typically indicate loss of heterozygosity, although normal 
contaminating tissue may limit the minimum observed value. LOH events that contain PTEN, 
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Supplementary Figure 2.7. Loss of heterozygosity analyses for CGOV64. The graphs represent 
B allele frequencies (BAFs) for the indicated chromosomes for the STIC lesion.  A value of 0.5 
indicates a heterozygous genotype (AB) whereas allelic imbalances in tumor samples are observed 
as a deviation from 0.5.  BAF values of 0 typically indicate loss of heterozygosity, although normal 
contaminating tissue may limit the minimum observed value.  LOH events that contain BRACA2, 
TP53 and BRCA1 genes are indicated by the red boxes, while the LOH region in chromosome 10 






Supplementary Figure 2.8. Loss of heterozygosity analyses for CGOV303. The graphs 
represent B allele frequencies (BAFs) for the indicated chromosomes for the STIC lesion.  A value 
of 0.5 indicates a heterozygous genotype (AB) whereas allelic imbalances in tumor samples are 
observed as a deviation from 0.5.  BAF values of 0 typically indicate loss of heterozygosity, 
although normal contaminating tissue may limit the minimum observed value.  LOH events that 
contain BRACA2, TP53 and BRCA1 genes are indicated by the red boxes, while no LOH in 








































































Supplementary Figure 2.9. Loss of heterozygosity analyses for CGOV304. The graphs 
represent B allele frequencies (BAFs) for the indicated chromosomes for the STIC lesion.  A value 
of 0.5 indicates a heterozygous genotype (AB) whereas allelic imbalances in tumor samples are 
observed as a deviation from 0.5.  BAF values of 0 typically indicate loss of heterozygosity, 
although normal contaminating tissue may limit the minimum observed value.  LOH events that 
contain BRACA2, TP53 and BRCA1 genes are indicated by the red boxes, while no LOH in 


















Supplementary Figure 2.10. Genome-wide copy number profile.  Copy number ratio of 
genomic bins were determined based on target and off-target reads from whole exome sequencing.  
The raw copy ratio were corrected for GC-content, repetitive sequences, and target capture 
enrichment using CNVKit, and then converted to integer copy levels by accounting for tumor purity 
and average genome-wide ploidy (Methods, copy number analysis). The resulting copy number 
profiles suggest a relatively consistent pattern of copy number aberrations across the lesions 


































































































   






































































































































Supplementary Figure 2.11. Schematic of tumor evolution using PHYLIP. Visualization of 
evolutionary trees from each patient based on mutational and LOH changes.  Branch lengths are 



























































































Supplementary Table 2.1. Summary of Patient and Sample Characteristics 
Patient 
ID Age Diagnosis Sample ID Histopathologic Diagnosis    
 
    
CGOV62 61 CGOV62N Blood    
  CGOV62T_4 High grade serous ovarian carcinoma           
  CGOV62T_3_1 High grade serous ovarian carcinoma          
  CGOV62T_2 High grade serous ovarian carcinoma        
  CGOV62T High grade serous ovarian carcinoma      
  CGOV62T_10 High grade serous ovarian carcinoma      
  CGOV62T_9 High grade serous ovarian carcinoma      
  CGOV62T_8 High grade serous ovarian carcinoma      
  CGOV62T_1 High grade serous ovarian carcinoma     
  CGOV62T_6 High grade serous ovarian carcinoma     
  CGOV62T_7 High grade serous ovarian carcinoma     
CGOV63 61 CGOV63N Blood    
  CGOV63T_10 High grade serous miliary ovarian carcinoma            
  CGOV63T_2_1 High grade serous miliary ovarian carcinoma            
  CGOV63T_12 High grade serous miliary ovarian carcinoma            
  CGOV63T_14  High grade serous miliary ovarian carcinoma            
  CGOV63T_7_1 High grade serous miliary ovarian carcinoma           
  CGOV63T_9_1 High grade serous miliary ovarian carcinoma          
  CGOV63T_5_1 High grade serous miliary ovarian carcinoma      
  CGOV63T_6_1 High grade serous miliary ovarian carcinoma       
CGOV280 81 CGOV280N Normal ovarian stroma      
  CGOV280T3 STIC           
  CGOV280T4 High grade serous ovarian carcinoma        
  CGOV280T5 High grade serous ovarian carcinoma       
  CGOV280T2 STIC          
  CGOV280T6 High grade serous ovarian carcinoma      
CGOV279 55 CGOV279N Normal cervix       
  CGOV279T4 High grade serous ovarian carcinoma         
  CGOV279T5 High grade serous ovarian carcinoma      
  CGOV279T1 High grade serous ovarian carcinoma        
  CGOV279T2 High grade serous ovarian carcinoma           
  CGOV279T3 High grade serous ovarian carcinoma      
CGOV278 54 CGOV278N Normal cervix      
  CGOV278T2 High grade serous ovarian carcinoma       
  CGOV278T3 High grade serous ovarian carcinoma          
  CGOV278T4 High grade serous ovarian carcinoma      
 43 
  CGOV278T1 High grade serous ovarian carcinoma       
CGOV64 41 CGOV64N Normal ovarian stroma       
  CGOV64T Serous tubal in situ carcinoma       
CGOV65 56 CGOV65N Normal ovarian stroma       
  CGOV65T_0 Serous tubal in situ carcinoma       
CGOV303 84 CGOV303N Normal fallopian tube stroma               
  CGOV303T Serous tubal in situ carcinoma bi                
  CGOV303T1 Serous tubal in situ carcinoma bi                
CGOV304 61 CGOV304N Normal fallopian tube stroma       




Supplementary Data 2.2. Summary of Next-Generation Sequencing Analyses 



































CGOV62T Targeted 150 932,888,250 356,941,707      
CGOV62T_1 Targeted 150 894,803,700 338,574,182      
CGOV62T_9 Targeted 150 841,124,850 298,377,222      
CGOV62T_10 Targeted 150 814,842,450 305,723,970      
CGOV62T_2 Targeted 150 857,697,600 361,375,554      
CGOV62T_6 Targeted 150 926,878,950 381,400,070      
CGOV62T_7 Targeted 150 941,013,600 397,968,603      
CGOV62T_8 Targeted 150 942,642,900 388,150,695      
CGOV62T_4 Targeted 150 1,078,715,100 557,146,096      
CGOV62N Exome 100 16,477,126,700 8,505,340,214      
CGOV62T_4 Exome 100 17,992,865,800 9,690,155,310      
CGOV62T_3_1 Exome 100 14,181,614,100 7,937,939,584      
CGOV62T_2 Exome 100 14,941,805,600 7,846,722,527      
CGOV62T Exome 100 14,090,629,000 7,391,883,856      
CGOV62T_10 Exome 100 14,543,242,100 7,142,842,723      
CGOV62T_9 Exome 100 18,353,598,700 9,489,914,649      
CGOV62T_8 Exome 100 17,936,056,700 9,267,379,798      
CGOV62T_1 Exome 100 13,287,558,000 6,777,868,722      
CGOV62T_6 Exome 100 15,954,387,900 8,278,513,630      
CGOV62T_7 Exome 100 16,516,806,900 8,688,962,176      
CGOV63N Exome 100 14,725,190,400 7,566,006,080      
CGOV63T_10 Exome 100 17,895,736,300 9,647,692,172      
CGOV63T_2_1 Exome 100 14,680,242,100 8,150,805,108      
CGOV63T_12 Exome 100 19,576,607,700 10,386,204,204      
CGOV63T_14  Exome 100 16,788,306,100 8,874,167,120      
CGOV63T_7_1 Exome 100 15,236,162,400 7,928,083,568      
CGOV63T_9_1 Exome 100 15,167,179,700 8,195,369,998      
CGOV63T_5_1 Exome 100 13,415,779,600 7,186,267,032      
CGOV63T_6_1 Exome 100 18,104,964,100 9,596,432,258      
CGOV280N Exome 100 9,569,584,300 5,535,308,482      
CGOV280T3 Exome 100 19,927,930,700 11,397,858,848      
CGOV280T4 Exome 100 18,981,692,300 9,853,972,056      
CGOV280T5 Exome 100 19,510,760,800 11,521,903,291      
CGOV280T2 Exome 100 19,503,540,000 11,973,304,206      
CGOV280T6 Exome 100 19,226,763,300 7,739,355,157      
CGOV279N Exome 100 9,699,560,900 5,291,411,860      
CGOV279T4 Exome 100 22,387,574,900 13,805,553,635      
 45 
CGOV279T5 Exome 100 20,247,027,900 12,575,991,130      
CGOV279T1 Exome 100 22,128,038,900 12,237,762,174      
CGOV279T2 Exome 100 20,526,235,400 8,335,017,872      
CGOV279T3 Exome 100 22,013,047,100 12,909,800,399      
CGOV278N Exome 100 11,346,856,700 7,232,475,712      
CGOV278T2 Exome 100 25,449,694,700 15,110,349,424      
CGOV278T3 Exome 100 23,961,348,800 13,850,252,057      
CGOV278T4 Exome 100 21,574,201,100 12,573,576,783      
CGOV278T1 Exome 100 22,534,338,000 13,107,330,003      
CGOV64N Exome 100 18,497,697,200 9,963,890,280      
CGOV64T Exome 100 18,717,312,200 9,900,216,092      
CGOV65N Exome 100 17,918,581,500 9,604,269,218      
CGOV65T_0 Exome 100 15,410,288,200 8,241,676,869      
CGOV303N Exome 100 12,512,391,500 7,982,064,286      
CGOV303T Exome 100 20,616,367,500 11,674,202,824      
CGOV303T1 Exome 100 22,335,245,900 10,157,940,995      
CGOV304N Exome 100 11,720,312,800 7,112,810,741      
































Supplementary Data 2.3. Targeted Sequencing Panel 
Gene Symbol Gene Description   
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase  
AKT1 v-akt murine thymoma viral oncogene homolog 1  
AKT2 v-akt murine thymoma viral oncogene homolog 2  
ALK anaplastic lymphoma receptor tyrosine kinase  
APC adenomatous polyposis coli  
AR androgen receptor  
ARID1A AT rich interactive domain 1A (SWI-like)  
ARID1B AT rich interactive domain 1B (SWI1-like)  
ASXL1 additional sex combs like 1   
ATM ataxia telangiectasia mutated  
ATRX alpha thalassemia/mental retardation syndrome X-linked  
BAP1 BRCA1 associated protein-1   
BCR breakpoint cluster region  
BRAF v-raf murine sarcoma viral oncogene homolog B1  
BRCA1 breast cancer 1, early onset  
BRCA2 breast cancer 2, early onset  
CBL Cas-Br-M (murine) ecotropic retroviral transforming sequence  
CCND1 cyclin D1  
CCNE1 cyclin E1  
CDH1 cadherin 1, type 1, E-cadherin (epithelial)  
CDK4 cyclin-dependent kinase 4  
CDK6 cyclin-dependent kinase 6  
CDKN2A cyclin-dependent kinase inhibitor 2A  
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha  
CREBBP CREB binding protein  
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa  
DAXX death-domain associated protein  
DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha  
EGFR epidermal growth factor receptor  
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2  
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3   
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4  
ETV1 ets variant 1  
ETV4 ets variant 4  
ETV5 ets variant 5  
ETV6 ets variant 6  
EWSR1 Ewing sarcoma breakpoint region 1  
EZH2 Enhancer of zeste homolog 2   
FBXW7 F-box and WD repeat domain containing 7  
 47 
FGFR2 fibroblast growth factor receptor 2  
FGFR3 fibroblast growth factor receptor 3  
FGFR4 fibroblast growth factor receptor 4  
FLT3 fms-related tyrosine kinase 3  
FOXL2 forkhead box L2  
GATA1 GATA binding protein 1 (globin transcription factor 1)  
GATA2 GATA binding protein 2  
GNA11 guanine nucleotide binding protein (G protein), alpha 11  
GNAQ guanine nucleotide binding protein (G protein), q polypeptide  
GNAS GNAS complex locus  
HNF1A HNF1 homeobox A  
HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog  
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble  
IDH2 isocitrate dehydrogenase 2 (NADP+), mitochondrial  
IGF1R insulin-like growth factor 1 receptor  
IGF2R insulin-like growth factor 2 receptor  
IKZF1 IKAROS family zinc finger 1 (Ikaros)  
JAK1 Janus kinase 1  
JAK2 Janus kinase 2  
JAK3 Janus kinase 3  
KDR kinase insert domain receptor (a type III receptor tyrosine kinase)  
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog  
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  
MAML1 mastermid-like 1  
MDM2 Mdm2, p53 E3 ubiquitin protein ligase homolog   
MDM4 Mdm4 p53 binding protein homolog  
MED12 mediator complex subunit 12  
MEN1 multiple endocrine neoplasia I  
MET met proto-oncogene (hepatocyte growth factor receptor)  
MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2   
MLL myeloid/lymphoid or mixed-lineage leukemia   
MPL myeloproliferative leukemia virus oncogene  
MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1   
MSH6 mutS homolog 6   
MYC v-myc myelocytomatosis viral oncogene homolog  
MYCN v-myc myelocytomatosis viral related oncogene, neuroblastoma derived  
MYD88 myeloid differentiation primary response gene  
NF1 neurofibromin 1  
NF2 neurofibromin 2 (merlin)  
NOTCH1 notch 1  
NOTCH2 notch 2  
NOTCH3 notch 3  
NOTCH4 notch 4  
 48 
NPM1 nucleophosmin (nucleolar phosphoprotein B23, numatrin)  
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog  
PALB2 partner and localizer of BRCA2  
PAX5 paired box 5  
PBRM1 polybromo 1  
PDGFRA platelet-derived growth factor receptor, alpha polypeptide  
PDGFRB platelet-derived growth factor receptor, beta polypeptide  
PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide  
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha)  
PMS2 PMS2 postmeiotic segregation increased 2   
PTCH1 patched 1  
PTEN phosphatase and tensin homolog  
PTPN11 protein tyrosine phosphatase, non-receptor type 11  
RAF1 v-raf-1 murine leukemia viral oncogene homolog 1  
RAR-alpha 
(PML) retinoic acid receptor, alpha  
RB1 retinoblastoma 1  
RET ret proto-oncogene  
RNF43 ring finger protein 43  
ROS1 c-ros oncogene 1 , receptor tyrosine kinase  
RUNX1 runt-related transcription factor 1  
SF3B1 splicing factor 3b, subunit 1  
SMAD2 SMAD family member 2  
SMAD3 SMAD family member 3  
SMAD4 SMAD family member 4  
SMARCB1 SWI/SNF related,  actin dependent regulator of chromatin, subfamily b, member 1  
SMO smoothened, frizzled family receptor  
STAG2 stromal antigen 2  
STK11 serine/threonine kinase 11  
TET2 tet methylcytosine dioxygenase 2  
TGFBR2 transforming growth factor, beta receptor II (70/80kDa)  
TMPRSS2 transmembrane protease, serine 2  
TNFAIP3 tumor necrosis factor, alpha-induced protein 3  
TP53 Tumor protein p53  
TSC1 tuberous sclerosis 1  
TSC2 tuberous sclerosis 2  
TSHR thyroid stimulating hormone receptor  
VHL von Hippel-Lindau tumor suppressor  







Supplementary Data 2.4. Somatic Sequence Alterations 
Case ID Analysis Type Gene Gene description 
Tran  
Acc     
  
 


















CGOV65T_0 Exome ABI3BP 
target of Nesh-SH3 
precursor NM_01     
  




with thrombospondin type 1 
motif; 9 
CCDS2     
  
    
CGOV65T_0 Exome 
ADAMTSL
3 ADAMTS-like 3 CCDS1          
CGOV65T_0 Exome ANKRD5 ankyrin repeat domain 5 CCDS1     
  
    
CGOV65T_0 Exome ATP10D ATPase; class V; type 10D CCDS3          
CGOV65T_0 Exome BCAS3 
breast carcinoma amplified 
sequence 3 CCDS1          
CGOV65T_0 Exome BCR breakpoint cluster region CCDS1          
CGOV65T_0 Exome C1orf116 
chromosome 1 open reading 
frame 116 CCDS1          
CGOV65T_0 Exome C20orf194 
chromosome 20 open 
reading frame 194 CCDS4          
CGOV65T_0 Exome C3orf77 
hypothetical protein 







CCDS1          
CGOV65T_0 Exome CCDC69 
coiled-coil domain 
containing 69 CCDS4         
CGOV65T_0 Exome COL4A2 collagen; type IV; alpha 2 CCDS4          
CGOV65T_0 Exome CPA3 
carboxypeptidase A3 (mast 




associated protein homolog 
(S. cerevisiae) 
NM_02          
CGOV65T_0 Exome 
DMBT1 
deleted in malignant brain 
tumors 1 protein isoform b 
precursor 
NM_00          
CGOV65T_0 Exome DOCK6 
dedicator of cytokinesis 
protein 6 NM_02         
CGOV65T_0 Exome DOCK6 
dedicator of cytokinesis 
protein 6 NM_02          
CGOV65T_0 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
 50 
CGOV65T_0 Exome EML6 
echinoderm microtubule-
associated protein-like 6 NM_00          
CGOV65T_0 Exome EXOC7 
exocyst complex component 
7 CCDS3          
CGOV65T_0 Exome FANCM 
Fanconi anemia; 
complementation group M CCDS3          
CGOV65T_0 Exome FANCM 
Fanconi anemia; 
complementation group M CCDS3          
CGOV65T_0 Exome FAT3 protocadherin Fat 3 NM_00          
CGOV65T_0 Exome FBF1 fas-binding factor 1 NM_00          
CGOV65T_0 Exome FBXO38 F-box protein 38 CCDS4         
CGOV65T_0 Exome FLRT2 
fibronectin leucine rich 
transmembrane protein 2 CCDS9          
CGOV65T_0 Exome FOXS1 forkhead box S1 CCDS1          
CGOV65T_0 Exome GPR112 
G protein-coupled receptor 
112 CCDS3         
CGOV65T_0 Exome GRAMD2 GRAM domain containing 2 CCDS3          
CGOV65T_0 Exome 
GSR glutathione reductase CCDS3  
 
       
CGOV65T_0 Exome HEATR7B2 
HEAT repeat-containing 




DNA helicase homolog (S. 
cerevisiae) 
CCDS3          
CGOV65T_0 Exome IL11RA 
interleukin 11 receptor; 
alpha CCDS6          
CGOV65T_0 Exome INPP5E 
inositol polyphosphate-5-
phosphatase; 72 kDa CCDS7          
CGOV65T_0 Exome ITGA5 
integrin; alpha 5 (fibronectin 
receptor; alpha polypeptide) CCDS8          
CGOV65T_0 Exome 
KIAA0913 
zinc finger SWIM domain-
containing protein 
KIAA0913 isoform 1 
NM_01          
CGOV65T_0 Exome KIAA1199 KIAA1199 CCDS1          
CGOV65T_0 Exome KIF9 kinesin family member 9 CCDS2         
CGOV65T_0 Exome KLB klotho beta CCDS3          
CGOV65T_0 Exome LRP1B 
low density lipoprotein 
receptor-related protein 1B CCDS2          




MID1 interacting protein 1 
(gastrulation specific G12 
homolog (zebrafish)) 
CCDS1         
CGOV65T_0 Exome MUC16 mucin-16 NM_02          
CGOV65T_0 Exome MUC4 
mucin 4; cell surface 
associated CCDS3     
  
    
CGOV65T_0 Exome MYO1F myosin IF CCDS4          




(congenital cataracts and 
dental anomalies) 
CCDS1          
CGOV65T_0 Exome 
NPR2 
natriuretic peptide receptor 
B/guanylate cyclase B 
(atrionatriuretic peptide 
receptor B) 
CCDS6        
  
CGOV65T_0 Exome OR14I1 
olfactory receptor; family 
14; subfamily I; member 1 CCDS3          
CGOV65T_0 Exome OR4K13 
olfactory receptor; family 4; 
subfamily K; member 13 CCDS3          
CGOV65T_0 Exome OR5P3 
olfactory receptor; family 5; 
subfamily P; member 3 CCDS7          
CGOV65T_0 Exome 
PAN2 
PAN2 poly(A) specific 
ribonuclease subunit 
homolog (S. cerevisiae) 
CCDS8     
  
    
CGOV65T_0 Exome PCNX 
pecanex homolog 
(Drosophila) CCDS9     
  




factor receptor; beta 
polypeptide 
CCDS4          
CGOV65T_0 Exome PIK3R5 
phosphoinositide-3-kinase; 
regulatory subunit 5 CCDS1          
CGOV65T_0 Exome 
PPP1R13L 
protein phosphatase 1; 
regulatory (inhibitor) 
subunit 13 like 
CCDS3          
CGOV65T_0 Exome PRDM10 PR domain containing 10 CCDS8          
CGOV65T_0 Exome PRDM16 PR domain containing 16 CCDS4          
CGOV65T_0 Exome PRKG1 
protein kinase; cGMP-
dependent; type I CCDS7          
CGOV65T_0 Exome PTCHD2 
patched domain containing 




non-receptor type 13 
isoform 4 




phosphatase; receptor type; 
H 
CCDS3          
 52 
CGOV65T_0 Exome RAPGEF2 
Rap guanine nucleotide 
exchange factor (GEF) 2 CCDS4     
  





family member 5 
CCDS3          
CGOV65T_0 Exome RUNDC1 RUN domain containing 1 CCDS1          
CGOV65T_0 Exome RYR1 
ryanodine receptor 1 
(skeletal) CCDS3          
CGOV65T_0 Exome SCML4 
sex comb on midleg-like 4 
(Drosophila) NM_19          
CGOV65T_0 Exome SCUBE2 
signal peptide; CUB 
domain; EGF-like 2 CCDS7         
CGOV65T_0 Exome 
SLC16A13 








solute carrier family 9 
(sodium/hydrogen 
exchanger); member 3 
CCDS3          
CGOV65T_0 Exome 
SPG7 
spastic paraplegia 7 (pure 
and complicated autosomal 
recessive) 
CCDS1          
CGOV65T_0 Exome SRPX 
sushi-repeat-containing 
protein; X-linked CCDS1          
CGOV65T_0 Exome SYNE2 
spectrin repeat containing; 
nuclear envelope 2 CCDS9          
CGOV65T_0 Exome THBS1 thrombospondin 1 CCDS3          
CGOV65T_0 Exome TLX2 T-cell leukemia homeobox 2 CCDS1          
CGOV65T_0 Exome TP53 tumor protein p53 CCDS1          
CGOV65T_0 Exome 
TRPC5 
transient receptor potential 
cation channel; subfamily C; 
member 5 
CCDS1          
CGOV65T_0 Exome 
TRPM1 
transient receptor potential 
cation channel; subfamily 
M; member 1 
CCDS1          
CGOV65T_0 Exome TTLL13 
tubulin tyrosine ligase-like 
family; member 13 CCDS3          
CGOV65T_0 Exome TTN titin 
ENST0
38         
CGOV65T_0 Exome UGGT1 
UDP-glucose glycoprotein 
glucosyltransferase 1 CCDS2          
CGOV65T_0 Exome WDFY4 
WD repeat- and FYVE 
domain-containing protein 4 NM_02          
CGOV65T_0 Exome WDR11 WD repeat domain 11 CCDS7          
CGOV65T_0 Exome ZC3H12B 
probable ribonuclease 
ZC3H12B NM_00          
 53 
CGOV65T_0 Exome ZC3H12C 
zinc finger CCCH-type 
containing 12C NM_03         
CGOV65T_0 Exome ZCCHC6 
zinc finger; CCHC domain 
containing 6 CCDS3          
CGOV65T_0 Exome ZNF446 zinc finger protein 446 CCDS1          
CGOV65T_0 Exome ZNF622 zinc finger protein 622 CCDS3          
CGOV65T_0 Exome ZNF764 zinc finger protein 764 CCDS1          
CGOV65T_0 Exome ZPBP2 
zona pellucida binding 




family A (ABC1); member 
13 
ENST0
79         
CGOV64T Exome DOCK11 dedicator of cytokinesis 11 CCDS3          
CGOV64T Exome DPP10 
dipeptidyl-peptidase 10 




superfamily; DCC subclass; 
member 3 
CCDS1          
CGOV64T Exome KIF13A 
kinesin-like protein KIF13A 
isoform a NM_02          
CGOV64T Exome KLHL6 kelch-like 6 (Drosophila) CCDS3          
CGOV64T Exome LIMK2 LIM domain kinase 2 CCDS3         
CGOV64T Exome MED14 
mediator complex subunit 
14 CCDS1          
CGOV64T Exome MYCBP2 MYC binding protein 2 CCDS3          
CGOV64T Exome NUP35 nucleoporin 35kDa CCDS2          
CGOV64T Exome PAK6 
p21 protein (Cdc42/Rac)-
activated kinase 6 CCDS1          
CGOV64T Exome PIK3R5 
phosphoinositide-3-kinase; 
regulatory subunit 5 CCDS1          
CGOV64T Exome PLS3 plastin 3 CCDS1         
CGOV64T Exome PTEN 
phosphatase and tensin 
homolog CCDS3          
CGOV64T Exome PTH2R 
parathyroid hormone 2 
receptor CCDS2          
CGOV64T Exome 
RGL2 
Ral guanine nucleotide 
dissociation stimulator-like 
2 (RalGDS-like factor) 
(RAS-associated protein 
RAB2L).  
CCDS4        
  
CGOV64T Exome RTKN rhotekin CCDS3     
  
    
 54 
CGOV64T Exome SLC14A2 
solute carrier family 14 
(urea transporter); member 2 CCDS1          
CGOV64T Exome 
TAB3 
TGF-beta activated kinase 
1/MAP3K7 binding protein 
3 
CCDS1          
CGOV64T Exome TLN1 talin 1 CCDS3          
CGOV64T Exome TP53 tumor protein p53 CCDS1          
CGOV64T Exome WDFY4 
WD repeat- and FYVE 
domain-containing protein 4 NM_02          
CGOV64T Exome XPO7 exportin 7 NM_00          
CGOV63T_9
_1 Exome AADACL2 
arylacetamide deacetylase-
like 2 CCDS3          
CGOV63T_9
_1 Exome ABI2 abl-interactor 2 CCDS2          
CGOV63T_9
_1 Exome ACVR1C activin A receptor; type IC CCDS2          
CGOV63T_9
_1 Exome ATP2B3 
ATPase; Ca++ transporting; 
plasma membrane 3 CCDS3          
CGOV63T_9
_1 Exome C12orf43 
chromosome 12 open 
reading frame 43 CCDS9          
CGOV63T_9
_1 Exome C1orf174 
chromosome 1 open reading 
frame 174 CCDS5          
CGOV63T_9
_1 Exome C2orf21 
Uncharacterized protein 
C2orf21.  CCDS2          
CGOV63T_9
_1 Exome C7orf62 
chromosome 7 open reading 
frame 62 CCDS3         
CGOV63T_9
_1 Exome C9orf152 
chromosome 9 open reading 
frame 152 CCDS3     
 
    
CGOV63T_9
_1 Exome CA6 carbonic anhydrase VI 
ENST0
74         
CGOV63T_9




capping protein (actin 
filament) muscle Z-line; 
alpha 3 
CCDS8          
CGOV63T_9
_1 Exome CARD8 
caspase recruitment domain 
family; member 8 
ENST0
61         
CGOV63T_9
_1 Exome CDH5 
cadherin 5; type 2 (vascular 
endothelium) CCDS1          
CGOV63T_9
_1 Exome CEP135 centrosomal protein 135kDa CCDS3         
CGOV63T_9
_1 Exome CLCC1 
chloride channel CLIC-like 
1 CCDS4          
CGOV63T_9
_1 Exome CLSPN 
claspin homolog (Xenopus 




CUB and sushi domain-
containing protein 1 
precursor 
NM_03     
  





CUB and sushi domain-
containing protein 1 
precursor 





associated protein homolog 
(S. cerevisiae) 
NM_02          
CGOV63T_9
_1 Exome DGKB 
diacylglycerol kinase; beta 
90kDa NM_00     
 
    
CGOV63T_9
_1 Exome DLEC1 
deleted in lung and 
esophageal cancer 1 CCDS2     
 
    
CGOV63T_9
_1 Exome DNAH3 
dynein; axonemal; heavy 





leukemia viral oncogene 
homolog 3 (avian) 
CCDS3     
 
    
CGOV63T_9
_1 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_9
_1 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_9
_1 Exome GJB1 
gap junction protein; beta 1; 
32kDa CCDS1     
 
    
CGOV63T_9
_1 Exome HCK hemopoietic cell kinase 
ENST0
52         
CGOV63T_9
_1 Exome HTR1E 
5-hydroxytryptamine 
(serotonin) receptor 1E CCDS5          
CGOV63T_9
_1 Exome INTS9 integrator complex subunit 9 CCDS3     
 
    
CGOV63T_9
_1 Exome KIAA1217 KIAA1217 CCDS3          
CGOV63T_9
_1 Exome KIF13A 
kinesin-like protein KIF13A 
isoform a NM_02          
CGOV63T_9
_1 Exome LINGO4 
leucine rich repeat and Ig 
domain containing 4 CCDS3          
CGOV63T_9
_1 Exome LRRC15 
leucine rich repeat 
containing 15 CCDS3          
CGOV63T_9
_1 Exome MACF1 
microtubule-actin 
crosslinking factor 1 CCDS4     
 
    
CGOV63T_9
_1 Exome MUC7 mucin 7; secreted CCDS3         
CGOV63T_9
_1 Exome NFS1 
Cysteine desulfurase, 
mitochondrial precursor  CCDS1          
CGOV63T_9
_1 Exome NID1 nidogen 1 CCDS1          
CGOV63T_9
_1 Exome NPHS2 
nephrosis 2; idiopathic; 
steroid-resistant (podocin) CCDS1          
CGOV63T_9
_1 Exome NRK nik-related protein kinase NM_19          
CGOV63T_9
_1 Exome OR4F15 
olfactory receptor; family 4; 
subfamily F; member 15 CCDS3     
 
    
CGOV63T_9






phosphatase; receptor type; 
J 
CCDS7          
CGOV63T_9
_1 Exome RDH10 
retinol dehydrogenase 10 
(all-trans) CCDS6          
CGOV63T_9
_1 Exome RPS6KA5 
ribosomal protein S6 kinase; 
90kDa; polypeptide 5 CCDS9          
CGOV63T_9
_1 Exome SEPT6 septin 6 CCDS1     
  
    
CGOV63T_9
_1 Exome SFMBT2 
Scm-like with four mbt 
domains 2 CCDS3          
CGOV63T_9
_1 Exome SHH 
sonic hedgehog homolog 
(Drosophila) CCDS5          
CGOV63T_9
_1 Exome SILV silver homolog (mouse) CCDS8     
 




solute carrier family 17 
(sodium-dependent 
inorganic phosphate 
cotransporter); member 6 
CCDS7       
  
CGOV63T_9
_1 Exome SLC44A3 
solute carrier family 44; 





domain containing receptor 
3 
CCDS7          
CGOV63T_9
_1 Exome STX11 syntaxin 11 CCDS5          
CGOV63T_9
_1 Exome TARBP1 
TAR (HIV-1) RNA binding 
protein 1 CCDS1     
 
    
CGOV63T_9
_1 Exome TMEM62 transmembrane protein 62 CCDS3          
CGOV63T_9
_1 Exome TP53 tumor protein p53 CCDS1          
CGOV63T_9
_1 Exome TRIM35 
tripartite motif-containing 
35 CCDS6          
CGOV63T_9
_1 Exome TRIP12 
thyroid hormone receptor 
interactor 12 CCDS3     
 
    
CGOV63T_9
_1 Exome TTN titin 
ENST0
38         
CGOV63T_9
_1 Exome TWISTNB TWIST neighbor CCDS3          
CGOV63T_9
_1 Exome UNC13A protein unc-13 homolog A NM_00          
CGOV63T_9
_1 Exome UROC1 
urocanase domain 
containing 1 CCDS3          
CGOV63T_9
_1 Exome ZNF345 zinc finger protein 345 CCDS1          
CGOV63T_9
_1 Exome ZNF462 zinc finger protein 462 CCDS3     
 
    
CGOV63T_7
_1 Exome ACVR1C activin A receptor; type IC CCDS2          
 57 
CGOV63T_7
_1 Exome ATP2B3 
ATPase; Ca++ transporting; 
plasma membrane 3 CCDS3          
CGOV63T_7
_1 Exome C12orf43 
chromosome 12 open 
reading frame 43 CCDS9          
CGOV63T_7
_1 Exome C16orf68 
chromosome 16 open 
reading frame 68 CCDS1          
CGOV63T_7
_1 Exome C1orf174 
chromosome 1 open reading 
frame 174 CCDS5          
CGOV63T_7
_1 Exome C2orf21 
Uncharacterized protein 
C2orf21.  CCDS2          
CGOV63T_7
_1 Exome C9orf152 
chromosome 9 open reading 
frame 152 CCDS3     
 
    
CGOV63T_7
_1 Exome CA6 carbonic anhydrase VI 
ENST0
74         
CGOV63T_7




capping protein (actin 
filament) muscle Z-line; 
alpha 3 
CCDS8          
CGOV63T_7
_1 Exome CARD8 
caspase recruitment domain 
family; member 8 
ENST0
61         
CGOV63T_7
_1 Exome CDH5 
cadherin 5; type 2 (vascular 
endothelium) CCDS1          
CGOV63T_7
_1 Exome CEP135 centrosomal protein 135kDa CCDS3         
CGOV63T_7
_1 Exome CLSPN 
claspin homolog (Xenopus 




CUB and sushi domain-
containing protein 1 
precursor 
NM_03     
  





associated protein homolog 
(S. cerevisiae) 
NM_02          
CGOV63T_7
_1 Exome DGKB 
diacylglycerol kinase; beta 
90kDa NM_00     
 
    
CGOV63T_7
_1 Exome DLEC1 
deleted in lung and 
esophageal cancer 1 CCDS2     
 
    
CGOV63T_7
_1 Exome DNAH3 
dynein; axonemal; heavy 





leukemia viral oncogene 
homolog 3 (avian) 
CCDS3     
 
    
CGOV63T_7
_1 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_7
_1 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_7
_1 Exome GJB1 
gap junction protein; beta 1; 
32kDa CCDS1     
 
    
CGOV63T_7
_1 Exome HCK hemopoietic cell kinase 
ENST0
52         
 58 
CGOV63T_7
_1 Exome INTS9 integrator complex subunit 9 CCDS3     
 
    
CGOV63T_7
_1 Exome KIF13A 
kinesin-like protein KIF13A 
isoform a NM_02          
CGOV63T_7
_1 Exome LINGO4 
leucine rich repeat and Ig 
domain containing 4 CCDS3          
CGOV63T_7
_1 Exome LRRC15 
leucine rich repeat 
containing 15 CCDS3          
CGOV63T_7
_1 Exome MACF1 
microtubule-actin 
crosslinking factor 1 CCDS4     
 
    
CGOV63T_7
_1 Exome NFS1 
Cysteine desulfurase, 
mitochondrial precursor  CCDS1          
CGOV63T_7
_1 Exome NID1 nidogen 1 CCDS1          
CGOV63T_7
_1 Exome OR4F15 
olfactory receptor; family 4; 
subfamily F; member 15 CCDS3     
 
    
CGOV63T_7





phosphatase; receptor type; 
J 
CCDS7          
CGOV63T_7
_1 Exome RDH10 
retinol dehydrogenase 10 
(all-trans) CCDS6          
CGOV63T_7
_1 Exome RPS6KA5 
ribosomal protein S6 kinase; 
90kDa; polypeptide 5 CCDS9          
CGOV63T_7
_1 Exome SEPT6 septin 6 CCDS1     
  
    
CGOV63T_7
_1 Exome SFMBT2 
Scm-like with four mbt 
domains 2 CCDS3          
CGOV63T_7
_1 Exome SHH 
sonic hedgehog homolog 
(Drosophila) CCDS5          
CGOV63T_7
_1 Exome SILV silver homolog (mouse) CCDS8     
 




solute carrier family 17 
(sodium-dependent 
inorganic phosphate 
cotransporter); member 6 
CCDS7       
  
CGOV63T_7
_1 Exome SLC44A3 
solute carrier family 44; 





domain containing receptor 
3 
CCDS7          
CGOV63T_7
_1 Exome STX11 syntaxin 11 CCDS5          
CGOV63T_7
_1 Exome TARBP1 
TAR (HIV-1) RNA binding 
protein 1 CCDS1     
 
    
CGOV63T_7
_1 Exome TP53 tumor protein p53 CCDS1          
CGOV63T_7
_1 Exome TTN titin 
ENST0
38         
 59 
CGOV63T_7
_1 Exome UNC13A protein unc-13 homolog A NM_00          
CGOV63T_7
_1 Exome UROC1 
urocanase domain 
containing 1 CCDS3          
CGOV63T_7
_1 Exome ZNF462 zinc finger protein 462 CCDS3     
 
    
CGOV63T_2
_1 Exome ACVR1C activin A receptor; type IC CCDS2          
CGOV63T_2
_1 Exome ATP2B3 
ATPase; Ca++ transporting; 
plasma membrane 3 CCDS3          
CGOV63T_2
_1 Exome C12orf43 
chromosome 12 open 
reading frame 43 CCDS9          
CGOV63T_2
_1 Exome C16orf68 
chromosome 16 open 
reading frame 68 CCDS1          
CGOV63T_2
_1 Exome C1orf174 
chromosome 1 open reading 
frame 174 CCDS5          
CGOV63T_2
_1 Exome C2orf21 
Uncharacterized protein 
C2orf21.  CCDS2          
CGOV63T_2
_1 Exome C9orf152 
chromosome 9 open reading 
frame 152 CCDS3     
 
    
CGOV63T_2
_1 Exome CA6 carbonic anhydrase VI 
ENST0
74         
CGOV63T_2




capping protein (actin 
filament) muscle Z-line; 
alpha 3 
CCDS8          
CGOV63T_2
_1 Exome CARD8 
caspase recruitment domain 
family; member 8 
ENST0
61         
CGOV63T_2
_1 Exome CDH5 
cadherin 5; type 2 (vascular 
endothelium) CCDS1          
CGOV63T_2
_1 Exome CEP135 centrosomal protein 135kDa CCDS3         
CGOV63T_2
_1 Exome CLSPN 
claspin homolog (Xenopus 




CUB and sushi domain-
containing protein 1 
precursor 
NM_03     
  





associated protein homolog 
(S. cerevisiae) 
NM_02          
CGOV63T_2
_1 Exome DGKB 
diacylglycerol kinase; beta 
90kDa NM_00     
 
    
CGOV63T_2
_1 Exome DLEC1 
deleted in lung and 
esophageal cancer 1 CCDS2     
 
    
CGOV63T_2
_1 Exome DNAH3 
dynein; axonemal; heavy 





leukemia viral oncogene 
homolog 3 (avian) 
CCDS3     
 
    
 60 
CGOV63T_2
_1 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_2
_1 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_2
_1 Exome GJB1 
gap junction protein; beta 1; 
32kDa CCDS1     
 
    
CGOV63T_2
_1 Exome HCK hemopoietic cell kinase 
ENST0
52         
CGOV63T_2
_1 Exome INTS9 integrator complex subunit 9 CCDS3     
 
    
CGOV63T_2
_1 Exome KIF13A 
kinesin-like protein KIF13A 
isoform a NM_02          
CGOV63T_2
_1 Exome LINGO4 
leucine rich repeat and Ig 
domain containing 4 CCDS3          
CGOV63T_2
_1 Exome LRRC15 
leucine rich repeat 
containing 15 CCDS3          
CGOV63T_2
_1 Exome MACF1 
microtubule-actin 
crosslinking factor 1 CCDS4     
 
    
CGOV63T_2
_1 Exome NFS1 
Cysteine desulfurase, 
mitochondrial precursor  CCDS1          
CGOV63T_2
_1 Exome NID1 nidogen 1 CCDS1          
CGOV63T_2
_1 Exome OR4F15 
olfactory receptor; family 4; 
subfamily F; member 15 CCDS3     
 
    
CGOV63T_2





phosphatase; receptor type; 
J 
CCDS7          
CGOV63T_2
_1 Exome RDH10 
retinol dehydrogenase 10 
(all-trans) CCDS6          
CGOV63T_2
_1 Exome RPS6KA5 
ribosomal protein S6 kinase; 
90kDa; polypeptide 5 CCDS9          
CGOV63T_2
_1 Exome SEPT6 septin 6 CCDS1     
  
    
CGOV63T_2
_1 Exome SFMBT2 
Scm-like with four mbt 
domains 2 CCDS3          
CGOV63T_2
_1 Exome SHH 
sonic hedgehog homolog 
(Drosophila) CCDS5          
CGOV63T_2
_1 Exome SILV silver homolog (mouse) CCDS8     
 




solute carrier family 17 
(sodium-dependent 
inorganic phosphate 
cotransporter); member 6 
CCDS7       
  
CGOV63T_2
_1 Exome SLC44A3 
solute carrier family 44; 





domain containing receptor 
3 
CCDS7          
 61 
CGOV63T_2
_1 Exome STX11 syntaxin 11 CCDS5          
CGOV63T_2
_1 Exome TARBP1 
TAR (HIV-1) RNA binding 
protein 1 CCDS1     
 
    
CGOV63T_2
_1 Exome TP53 tumor protein p53 CCDS1          
CGOV63T_2
_1 Exome TTN titin 
ENST0
38         
CGOV63T_2
_1 Exome UNC13A protein unc-13 homolog A NM_00          
CGOV63T_2
_1 Exome UROC1 
urocanase domain 
containing 1 CCDS3          
CGOV63T_2
_1 Exome ZNF462 zinc finger protein 462 CCDS3     
 
    
CGOV63T_1
4  Exome 
CAPZA3 
capping protein (actin 
filament) muscle Z-line; 
alpha 3 
CCDS8          
CGOV63T_1
4  Exome MACF1 
microtubule-actin 
crosslinking factor 1 CCDS4     
 
    
CGOV63T_1
4  Exome SILV silver homolog (mouse) CCDS8     
 
    
CGOV63T_1
4  Exome TP53 tumor protein p53 CCDS1          
CGOV63T_1
4 Exome ACVR1C activin A receptor; type IC CCDS2          
CGOV63T_1
4 Exome ATP2B3 
ATPase; Ca++ transporting; 
plasma membrane 3 CCDS3          
CGOV63T_1
4 Exome C12orf43 
chromosome 12 open 
reading frame 43 CCDS9          
CGOV63T_1
4 Exome C1orf174 
chromosome 1 open reading 
frame 174 CCDS5          
CGOV63T_1
4 Exome C2orf21 
Uncharacterized protein 
C2orf21.  CCDS2          
CGOV63T_1
4 Exome C9orf152 
chromosome 9 open reading 
frame 152 CCDS3     
 
    
CGOV63T_1
4 Exome CA6 carbonic anhydrase VI 
ENST0
74         
CGOV63T_1
4 Exome CAPRIN2 caprin family member 2 CCDS3          
CGOV63T_1
4 Exome CARD8 
caspase recruitment domain 
family; member 8 
ENST0
61         
CGOV63T_1
4 Exome CDH5 
cadherin 5; type 2 (vascular 
endothelium) CCDS1          
CGOV63T_1
4 Exome CEP135 centrosomal protein 135kDa CCDS3         
CGOV63T_1
4 Exome CLSPN 
claspin homolog (Xenopus 




CUB and sushi domain-
containing protein 1 
precursor 
NM_03     
  






associated protein homolog 
(S. cerevisiae) 
NM_02          
CGOV63T_1
4 Exome DGKB 
diacylglycerol kinase; beta 
90kDa NM_00     
 
    
CGOV63T_1
4 Exome DLEC1 
deleted in lung and 
esophageal cancer 1 CCDS2     
 
    
CGOV63T_1
4 Exome DNAH3 
dynein; axonemal; heavy 





leukemia viral oncogene 
homolog 3 (avian) 
CCDS3     
 
    
CGOV63T_1
4 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_1
4 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_1
4 Exome GJB1 
gap junction protein; beta 1; 
32kDa CCDS1     
 
    
CGOV63T_1
4 Exome HCK hemopoietic cell kinase 
ENST0
52         
CGOV63T_1
4 Exome INTS9 integrator complex subunit 9 CCDS3     
 
    
CGOV63T_1
4 Exome KIF13A 
kinesin-like protein KIF13A 
isoform a NM_02          
CGOV63T_1
4 Exome LINGO4 
leucine rich repeat and Ig 
domain containing 4 CCDS3          
CGOV63T_1
4 Exome LRRC15 
leucine rich repeat 
containing 15 CCDS3          
CGOV63T_1
4 Exome NFS1 
Cysteine desulfurase, 
mitochondrial precursor  CCDS1          
CGOV63T_1
4 Exome NID1 nidogen 1 CCDS1          
CGOV63T_1
4 Exome OR4F15 
olfactory receptor; family 4; 
subfamily F; member 15 CCDS3     
 
    
CGOV63T_1





phosphatase; receptor type; 
J 
CCDS7          
CGOV63T_1
4 Exome RDH10 
retinol dehydrogenase 10 
(all-trans) CCDS6          
CGOV63T_1
4 Exome RPS6KA5 
ribosomal protein S6 kinase; 
90kDa; polypeptide 5 CCDS9          
CGOV63T_1
4 Exome SEPT6 septin 6 CCDS1     
  
    
CGOV63T_1
4 Exome SFMBT2 
Scm-like with four mbt 
domains 2 CCDS3          
CGOV63T_1
4 Exome SHH 
sonic hedgehog homolog 
(Drosophila) CCDS5          
CGOV63T_1
4 Exome SLC17A6 
solute carrier family 17 
(sodium-dependent CCDS7         
 63 
inorganic phosphate 
cotransporter); member 6 
CGOV63T_1
4 Exome SLC44A3 
solute carrier family 44; 





domain containing receptor 
3 
CCDS7          
CGOV63T_1
4 Exome STX11 syntaxin 11 CCDS5          
CGOV63T_1
4 Exome TARBP1 
TAR (HIV-1) RNA binding 
protein 1 CCDS1     
 
    
CGOV63T_1
4 Exome TTN titin 
ENST0
38         
CGOV63T_1
4 Exome UNC13A protein unc-13 homolog A NM_00          
CGOV63T_1
4 Exome UROC1 
urocanase domain 
containing 1 CCDS3          
CGOV63T_1
4 Exome ZNF462 zinc finger protein 462 CCDS3     
 
    
CGOV63T_1
2 Exome ACVR1C activin A receptor; type IC CCDS2          
CGOV63T_1
2 Exome ATP2B3 
ATPase; Ca++ transporting; 
plasma membrane 3 CCDS3          
CGOV63T_1
2 Exome C12orf43 
chromosome 12 open 
reading frame 43 CCDS9          
CGOV63T_1
2 Exome C16orf68 
chromosome 16 open 
reading frame 68 CCDS1          
CGOV63T_1
2 Exome C1orf174 
chromosome 1 open reading 
frame 174 CCDS5          
CGOV63T_1
2 Exome C2orf21 
Uncharacterized protein 
C2orf21.  CCDS2          
CGOV63T_1
2 Exome C9orf152 
chromosome 9 open reading 
frame 152 CCDS3     
 
    
CGOV63T_1
2 Exome CA6 carbonic anhydrase VI 
ENST0
74         
CGOV63T_1




capping protein (actin 
filament) muscle Z-line; 
alpha 3 
CCDS8          
CGOV63T_1
2 Exome CARD8 
caspase recruitment domain 
family; member 8 
ENST0
61         
CGOV63T_1
2 Exome CDH5 
cadherin 5; type 2 (vascular 
endothelium) CCDS1          
CGOV63T_1
2 Exome CEP135 centrosomal protein 135kDa CCDS3         
CGOV63T_1
2 Exome CLSPN 
claspin homolog (Xenopus 




CUB and sushi domain-
containing protein 1 
precursor 
NM_03     
  






associated protein homolog 
(S. cerevisiae) 
NM_02          
CGOV63T_1
2 Exome DGKB 
diacylglycerol kinase; beta 
90kDa NM_00     
 
    
CGOV63T_1
2 Exome DLEC1 
deleted in lung and 
esophageal cancer 1 CCDS2     
 
    
CGOV63T_1
2 Exome DNAH3 
dynein; axonemal; heavy 





leukemia viral oncogene 
homolog 3 (avian) 
CCDS3     
 
    
CGOV63T_1
2 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_1
2 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_1
2 Exome GJB1 
gap junction protein; beta 1; 
32kDa CCDS1     
 
    
CGOV63T_1
2 Exome HCK hemopoietic cell kinase 
ENST0
52         
CGOV63T_1
2 Exome IGF2R 
insulin-like growth factor 2 
receptor CCDS5     
 
    
CGOV63T_1
2 Exome INTS9 integrator complex subunit 9 CCDS3     
 
    
CGOV63T_1
2 Exome KIF13A 
kinesin-like protein KIF13A 
isoform a NM_02          
CGOV63T_1
2 Exome LINGO4 
leucine rich repeat and Ig 
domain containing 4 CCDS3          
CGOV63T_1
2 Exome LRRC15 
leucine rich repeat 
containing 15 CCDS3          
CGOV63T_1
2 Exome MACF1 
microtubule-actin 
crosslinking factor 1 CCDS4     
 
    
CGOV63T_1
2 Exome NFS1 
Cysteine desulfurase, 
mitochondrial precursor  CCDS1          
CGOV63T_1
2 Exome NID1 nidogen 1 CCDS1          
CGOV63T_1
2 Exome OR4F15 
olfactory receptor; family 4; 
subfamily F; member 15 CCDS3     
 
    
CGOV63T_1





phosphatase; receptor type; 
J 
CCDS7          
CGOV63T_1
2 Exome RDH10 
retinol dehydrogenase 10 
(all-trans) CCDS6          
CGOV63T_1
2 Exome RPS6KA5 
ribosomal protein S6 kinase; 
90kDa; polypeptide 5 CCDS9          
CGOV63T_1
2 Exome SEPT6 septin 6 CCDS1     
  
    
CGOV63T_1
2 Exome SFMBT2 
Scm-like with four mbt 
domains 2 CCDS3          
 65 
CGOV63T_1
2 Exome SHH 
sonic hedgehog homolog 
(Drosophila) CCDS5          
CGOV63T_1
2 Exome SILV silver homolog (mouse) CCDS8     
 




solute carrier family 17 
(sodium-dependent 
inorganic phosphate 
cotransporter); member 6 
CCDS7       
  
CGOV63T_1
2 Exome SLC44A3 
solute carrier family 44; 





domain containing receptor 
3 
CCDS7          
CGOV63T_1
2 Exome STX11 syntaxin 11 CCDS5          
CGOV63T_1
2 Exome TARBP1 
TAR (HIV-1) RNA binding 
protein 1 CCDS1     
 
    
CGOV63T_1
2 Exome TP53 tumor protein p53 CCDS1          
CGOV63T_1
2 Exome TTN titin 
ENST0
38         
CGOV63T_1
2 Exome UNC13A protein unc-13 homolog A NM_00          
CGOV63T_1
2 Exome UROC1 
urocanase domain 
containing 1 CCDS3          
CGOV63T_1
2 Exome ZNF462 zinc finger protein 462 CCDS3     
 
    
CGOV63T_1
0 Exome ATP2B3 
ATPase; Ca++ transporting; 
plasma membrane 3 CCDS3          
CGOV63T_1
0 Exome C12orf43 
chromosome 12 open 




capping protein (actin 
filament) muscle Z-line; 
alpha 3 
CCDS8          
CGOV63T_1
0 Exome CLSPN 
claspin homolog (Xenopus 




CUB and sushi domain-
containing protein 1 
precursor 
NM_03     
  
    
CGOV63T_1
0 Exome DGKB 
diacylglycerol kinase; beta 
90kDa NM_00     
 
    
CGOV63T_1
0 Exome FAM135B 
family with sequence 
similarity 135; member B CCDS6     
 
    
CGOV63T_1
0 Exome HCK hemopoietic cell kinase 
ENST0
52         
CGOV63T_1
0 Exome KIF13A 
kinesin-like protein KIF13A 
isoform a NM_02          
CGOV63T_1
0 Exome LINGO4 
leucine rich repeat and Ig 
domain containing 4 CCDS3          
CGOV63T_1
0 Exome LRRC15 
leucine rich repeat 
containing 15 CCDS3          
 66 
CGOV63T_1
0 Exome MACF1 
microtubule-actin 
crosslinking factor 1 CCDS4     
 
    
CGOV63T_1
0 Exome NID1 nidogen 1 CCDS1          
CGOV63T_1
0 Exome RPS6KA5 
ribosomal protein S6 kinase; 
90kDa; polypeptide 5 CCDS9          
CGOV63T_1
0 Exome SEPT6 septin 6 CCDS1     
  
    
CGOV63T_1
0 Exome SFMBT2 
Scm-like with four mbt 
domains 2 CCDS3          
CGOV63T_1
0 Exome SILV silver homolog (mouse) CCDS8     
 
    
CGOV63T_1




fibronectin type III domain 
containing 1 
CCDS3     
 
    
CGOV62T_9 Exome ANKRD35 ankyrin repeat domain 35 CCDS9     
 
    
CGOV62T_9 Exome APOB 
apolipoprotein B (including 
Ag(x) antigen) CCDS1          
CGOV62T_9 Exome BTNL9 butyrophilin-like 9 CCDS4          
CGOV62T_9 Exome C1S 
complement component 1; s 
subcomponent CCDS3     
 
    
CGOV62T_9 Exome C4orf43 
chromosome 4 open reading 
frame 43 CCDS4          
CGOV62T_9 Exome C5orf25 
chromosome 5 open reading 
frame 25 CCDS4          
CGOV62T_9 Exome C5orf46 
chromosome 5 open reading 
frame 46 CCDS3     
 
    
CGOV62T_9 Exome C6 complement component 6 CCDS3          
CGOV62T_9 Exome CDKAL1 
CDK5 regulatory subunit 
associated protein 1-like 1 CCDS4     
 
    
CGOV62T_9 Exome DNAH6 
dynein heavy chain 6, 
axonemal NM_00          
CGOV62T_9 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV62T_9 Exome EPHA5 EPH receptor A5 CCDS3          
CGOV62T_9 Exome FAM5C 
family with sequence 
similarity 5; member C CCDS1          
CGOV62T_9 Exome KIF17 kinesin family member 17 CCDS2          
CGOV62T_9 Exome KIF3C kinesin family member 3C CCDS1          
CGOV62T_9 Exome PRSS23 protease; serine; 23 CCDS4          
CGOV62T_9 Exome RANBP2 RAN binding protein 2 CCDS2          
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CGOV62T_9 Exome RHBDD1 
rhomboid domain 
containing 1 CCDS2         
CGOV62T_9 Exome ROBO1 
roundabout homolog 1 
isoform a precursor NM_00     
 





(Ig); short basic domain; 
secreted; (semaphorin) 3F 
CCDS2        
  
CGOV62T_9 Exome SI 
sucrase-isomaltase (alpha-
glucosidase) CCDS3     
  
    
CGOV62T_9 Exome 
SLC1A2 
solute carrier family 1 (glial 
high affinity glutamate 
transporter); member 2 
CCDS3          
CGOV62T_9 Exome 
SLC25A3 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier); member 
3 




CGOV62T_9 Exome TP53 tumor protein p53 CCDS1          
CGOV62T_9 Exome TRIO 
triple functional domain 
(PTPRF interacting) CCDS3     
 
    
CGOV62T_9 Exome USP34 
ubiquitin specific peptidase 
34 CCDS4          
CGOV62T_9 Exome WDR11 WD repeat domain 11 CCDS7          
CGOV62T_9 Exome ZBBX 
zinc finger; B-box domain 
containing CCDS3          




fibronectin type III domain 
containing 1 
CCDS3     
 
    
CGOV62T_8 Exome ANKRD35 ankyrin repeat domain 35 CCDS9     
 
    
CGOV62T_8 Exome APOB 
apolipoprotein B (including 
Ag(x) antigen) CCDS1          
CGOV62T_8 Exome BTNL9 butyrophilin-like 9 CCDS4          
CGOV62T_8 Exome C1S 
complement component 1; s 
subcomponent CCDS3     
 
    
CGOV62T_8 Exome C4orf43 
chromosome 4 open reading 
frame 43 CCDS4          
CGOV62T_8 Exome C5orf25 
chromosome 5 open reading 
frame 25 CCDS4          
CGOV62T_8 Exome C5orf46 
chromosome 5 open reading 
frame 46 CCDS3     
 
    
CGOV62T_8 Exome C6 complement component 6 CCDS3          
CGOV62T_8 Exome CDKAL1 
CDK5 regulatory subunit 
associated protein 1-like 1 CCDS4     
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CGOV62T_8 Exome DNAH6 
dynein heavy chain 6, 
axonemal NM_00          
CGOV62T_8 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV62T_8 Exome EPHA5 EPH receptor A5 CCDS3          
CGOV62T_8 Exome FAM5C 
family with sequence 
similarity 5; member C CCDS1          
CGOV62T_8 Exome KIF17 kinesin family member 17 CCDS2          
CGOV62T_8 Exome KIF3C kinesin family member 3C CCDS1          
CGOV62T_8 Exome PRSS23 protease; serine; 23 CCDS4          
CGOV62T_8 Exome RANBP2 RAN binding protein 2 CCDS2          
CGOV62T_8 Exome RHBDD1 
rhomboid domain 
containing 1 CCDS2         
CGOV62T_8 Exome ROBO1 
roundabout homolog 1 
isoform a precursor NM_00     
 





(Ig); short basic domain; 
secreted; (semaphorin) 3F 
CCDS2        
  
CGOV62T_8 Exome SI 
sucrase-isomaltase (alpha-
glucosidase) CCDS3     
  
    
CGOV62T_8 Exome 
SLC1A2 
solute carrier family 1 (glial 
high affinity glutamate 
transporter); member 2 
CCDS3          
CGOV62T_8 Exome 
SLC25A3 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier); member 
3 




CGOV62T_8 Exome TP53 tumor protein p53 CCDS1          
CGOV62T_8 Exome TRIO 
triple functional domain 
(PTPRF interacting) CCDS3     
 
    
CGOV62T_8 Exome USP34 
ubiquitin specific peptidase 
34 CCDS4          
CGOV62T_8 Exome WDR11 WD repeat domain 11 CCDS7          
CGOV62T_8 Exome ZBBX 
zinc finger; B-box domain 
containing CCDS3          




fibronectin type III domain 
containing 1 
CCDS3     
 
    
CGOV62T_7 Exome ANKRD35 ankyrin repeat domain 35 CCDS9     
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CGOV62T_7 Exome APOB 
apolipoprotein B (including 
Ag(x) antigen) CCDS1          
CGOV62T_7 Exome BTNL9 butyrophilin-like 9 CCDS4          
CGOV62T_7 Exome C1S 
complement component 1; s 
subcomponent CCDS3     
 
    
CGOV62T_7 Exome C4orf43 
chromosome 4 open reading 
frame 43 CCDS4          
CGOV62T_7 Exome C5orf25 
chromosome 5 open reading 
frame 25 CCDS4          
CGOV62T_7 Exome C5orf46 
chromosome 5 open reading 
frame 46 CCDS3     
 
    
CGOV62T_7 Exome C6 complement component 6 CCDS3          
CGOV62T_7 Exome CDKAL1 
CDK5 regulatory subunit 
associated protein 1-like 1 CCDS4     
 
    
CGOV62T_7 Exome DNAH6 
dynein heavy chain 6, 
axonemal NM_00          
CGOV62T_7 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV62T_7 Exome EPHA5 EPH receptor A5 CCDS3          
CGOV62T_7 Exome FAM5C 
family with sequence 
similarity 5; member C CCDS1          
CGOV62T_7 Exome KIF17 kinesin family member 17 CCDS2          
CGOV62T_7 Exome KIF3C kinesin family member 3C CCDS1          
CGOV62T_7 Exome PRSS23 protease; serine; 23 CCDS4          
CGOV62T_7 Exome RANBP2 RAN binding protein 2 CCDS2          
CGOV62T_7 Exome RHBDD1 
rhomboid domain 
containing 1 CCDS2         
CGOV62T_7 Exome ROBO1 
roundabout homolog 1 
isoform a precursor NM_00     
 





(Ig); short basic domain; 
secreted; (semaphorin) 3F 
CCDS2        
  
CGOV62T_7 Exome SI 
sucrase-isomaltase (alpha-
glucosidase) CCDS3     
  
    
CGOV62T_7 Exome 
SLC1A2 
solute carrier family 1 (glial 
high affinity glutamate 
transporter); member 2 
CCDS3          
CGOV62T_7 Exome 
SLC25A3 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier); member 
3 




CGOV62T_7 Exome TP53 tumor protein p53 CCDS1          
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CGOV62T_7 Exome TRIO 
triple functional domain 
(PTPRF interacting) CCDS3     
 
    
CGOV62T_7 Exome USP34 
ubiquitin specific peptidase 
34 CCDS4          
CGOV62T_7 Exome WDR11 WD repeat domain 11 CCDS7          
CGOV62T_7 Exome ZBBX 
zinc finger; B-box domain 
containing CCDS3          




fibronectin type III domain 
containing 1 
CCDS3     
 
    
CGOV62T_6 Exome ANKRD35 ankyrin repeat domain 35 CCDS9     
 
    
CGOV62T_6 Exome APOB 
apolipoprotein B (including 
Ag(x) antigen) CCDS1          
CGOV62T_6 Exome BTNL9 butyrophilin-like 9 CCDS4          
CGOV62T_6 Exome C1S 
complement component 1; s 
subcomponent CCDS3     
 
    
CGOV62T_6 Exome C4orf43 
chromosome 4 open reading 
frame 43 CCDS4          
CGOV62T_6 Exome C5orf25 
chromosome 5 open reading 
frame 25 CCDS4          
CGOV62T_6 Exome C5orf46 
chromosome 5 open reading 
frame 46 CCDS3     
 
    
CGOV62T_6 Exome C6 complement component 6 CCDS3          
CGOV62T_6 Exome CDKAL1 
CDK5 regulatory subunit 
associated protein 1-like 1 CCDS4     
 
    
CGOV62T_6 Exome DNAH6 
dynein heavy chain 6, 
axonemal NM_00          
CGOV62T_6 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV62T_6 Exome EPHA5 EPH receptor A5 CCDS3          
CGOV62T_6 Exome FAM5C 
family with sequence 
similarity 5; member C CCDS1          
CGOV62T_6 Exome KIF17 kinesin family member 17 CCDS2          
CGOV62T_6 Exome KIF3C kinesin family member 3C CCDS1          
CGOV62T_6 Exome PRSS23 protease; serine; 23 CCDS4          
CGOV62T_6 Exome RANBP2 RAN binding protein 2 CCDS2          
CGOV62T_6 Exome RHBDD1 
rhomboid domain 
containing 1 CCDS2         
CGOV62T_6 Exome ROBO1 
roundabout homolog 1 
isoform a precursor NM_00     
 






(Ig); short basic domain; 
secreted; (semaphorin) 3F 
CCDS2        
  
CGOV62T_6 Exome SI 
sucrase-isomaltase (alpha-
glucosidase) CCDS3     
  
    
CGOV62T_6 Exome 
SLC1A2 
solute carrier family 1 (glial 
high affinity glutamate 
transporter); member 2 
CCDS3          
CGOV62T_6 Exome 
SLC25A3 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier); member 
3 




CGOV62T_6 Exome TP53 tumor protein p53 CCDS1          
CGOV62T_6 Exome TRIO 
triple functional domain 
(PTPRF interacting) CCDS3     
 
    
CGOV62T_6 Exome USP34 
ubiquitin specific peptidase 
34 CCDS4          
CGOV62T_6 Exome WDR11 WD repeat domain 11 CCDS7          
CGOV62T_6 Exome ZBBX 
zinc finger; B-box domain 
containing CCDS3          




fibronectin type III domain 
containing 1 
CCDS3     
 
    
CGOV62T_4 Exome ANKRD35 ankyrin repeat domain 35 CCDS9     
 
    
CGOV62T_4 Exome C5orf25 
chromosome 5 open reading 
frame 25 CCDS4          
CGOV62T_4 Exome C5orf46 
chromosome 5 open reading 
frame 46 CCDS3     
 
    
CGOV62T_4 Exome EPHA5 EPH receptor A5 CCDS3          
CGOV62T_4 Exome SI 
sucrase-isomaltase (alpha-
glucosidase) CCDS3     
  
    
CGOV62T_4 Exome 
SLC25A3 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier); member 
3 




CGOV62T_4 Exome TP53 tumor protein p53 CCDS1          
CGOV62T_4 Exome TRIO 
triple functional domain 
(PTPRF interacting) CCDS3     
 
    
CGOV62T_4 Exome WDR11 WD repeat domain 11 CCDS7          






fibronectin type III domain 
containing 1 
CCDS3     
 
    
CGOV62T_3
_1 Exome ANKRD35 ankyrin repeat domain 35 CCDS9     
 
    
CGOV62T_3
_1 Exome APOB 
apolipoprotein B (including 
Ag(x) antigen) CCDS1          
CGOV62T_3
_1 Exome BTNL9 butyrophilin-like 9 CCDS4          
CGOV62T_3
_1 Exome C1S 
complement component 1; s 
subcomponent CCDS3     
 
    
CGOV62T_3
_1 Exome C4orf43 
chromosome 4 open reading 
frame 43 CCDS4          
CGOV62T_3
_1 Exome C5orf25 
chromosome 5 open reading 
frame 25 CCDS4          
CGOV62T_3
_1 Exome C5orf46 
chromosome 5 open reading 
frame 46 CCDS3     
 
    
CGOV62T_3
_1 Exome C6 complement component 6 CCDS3          
CGOV62T_3
_1 Exome CDKAL1 
CDK5 regulatory subunit 
associated protein 1-like 1 CCDS4     
 
    
CGOV62T_3
_1 Exome DNAH6 
dynein heavy chain 6, 
axonemal NM_00          
CGOV62T_3
_1 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV62T_3
_1 Exome EPHA5 EPH receptor A5 CCDS3          
CGOV62T_3
_1 Exome FAM5C 
family with sequence 
similarity 5; member C CCDS1          
CGOV62T_3
_1 Exome KIF17 kinesin family member 17 CCDS2          
CGOV62T_3
_1 Exome KIF3C kinesin family member 3C CCDS1          
CGOV62T_3
_1 Exome PRSS23 protease; serine; 23 CCDS4          
CGOV62T_3
_1 Exome RANBP2 RAN binding protein 2 CCDS2          
CGOV62T_3
_1 Exome RHBDD1 
rhomboid domain 
containing 1 CCDS2         
CGOV62T_3
_1 Exome ROBO1 
roundabout homolog 1 
isoform a precursor NM_00     
 






(Ig); short basic domain; 
secreted; (semaphorin) 3F 
CCDS2        
  
CGOV62T_3
_1 Exome SI 
sucrase-isomaltase (alpha-
glucosidase) CCDS3     
  




solute carrier family 1 (glial 
high affinity glutamate 
transporter); member 2 





solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier); member 
3 





_1 Exome TP53 tumor protein p53 CCDS1          
CGOV62T_3
_1 Exome TRIO 
triple functional domain 
(PTPRF interacting) CCDS3     
 
    
CGOV62T_3
_1 Exome USP34 
ubiquitin specific peptidase 
34 CCDS4          
CGOV62T_3
_1 Exome WDR11 WD repeat domain 11 CCDS7          
CGOV62T_3
_1 Exome ZBBX 
zinc finger; B-box domain 
containing CCDS3          
CGOV62T_3




fibronectin type III domain 
containing 1 
CCDS3     
 
    
CGOV62T_2 Exome ANKRD35 ankyrin repeat domain 35 CCDS9     
 
    
CGOV62T_2 Exome APOB 
apolipoprotein B (including 
Ag(x) antigen) CCDS1          
CGOV62T_2 Exome BTNL9 butyrophilin-like 9 CCDS4          
CGOV62T_2 Exome C1S 
complement component 1; s 
subcomponent CCDS3     
 
    
CGOV62T_2 Exome C4orf43 
chromosome 4 open reading 
frame 43 CCDS4          
CGOV62T_2 Exome C5orf25 
chromosome 5 open reading 
frame 25 CCDS4          
CGOV62T_2 Exome C5orf46 
chromosome 5 open reading 
frame 46 CCDS3     
 
    
CGOV62T_2 Exome C6 complement component 6 CCDS3          
CGOV62T_2 Exome CDKAL1 
CDK5 regulatory subunit 
associated protein 1-like 1 CCDS4     
 
    
CGOV62T_2 Exome DNAH6 
dynein heavy chain 6, 
axonemal NM_00          
CGOV62T_2 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV62T_2 Exome EPHA5 EPH receptor A5 CCDS3          
CGOV62T_2 Exome FAM5C 
family with sequence 
similarity 5; member C CCDS1          
CGOV62T_2 Exome KIF17 kinesin family member 17 CCDS2          
CGOV62T_2 Exome KIF3C kinesin family member 3C CCDS1          
CGOV62T_2 Exome PRSS23 protease; serine; 23 CCDS4          
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CGOV62T_2 Exome RANBP2 RAN binding protein 2 CCDS2          
CGOV62T_2 Exome RHBDD1 
rhomboid domain 
containing 1 CCDS2         
CGOV62T_2 Exome ROBO1 
roundabout homolog 1 
isoform a precursor NM_00     
 





(Ig); short basic domain; 
secreted; (semaphorin) 3F 
CCDS2        
  
CGOV62T_2 Exome SI 
sucrase-isomaltase (alpha-
glucosidase) CCDS3     
  
    
CGOV62T_2 Exome 
SLC1A2 
solute carrier family 1 (glial 
high affinity glutamate 
transporter); member 2 
CCDS3          
CGOV62T_2 Exome 
SLC25A3 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier); member 
3 




CGOV62T_2 Exome TP53 tumor protein p53 CCDS1          
CGOV62T_2 Exome TRIO 
triple functional domain 
(PTPRF interacting) CCDS3     
 
    
CGOV62T_2 Exome USP34 
ubiquitin specific peptidase 
34 CCDS4          
CGOV62T_2 Exome WDR11 WD repeat domain 11 CCDS7          
CGOV62T_2 Exome ZBBX 
zinc finger; B-box domain 
containing CCDS3          





fibronectin type III domain 
containing 1 
CCDS3     
 
    
CGOV62T_1
0 Exome ANKRD35 ankyrin repeat domain 35 CCDS9     
 
    
CGOV62T_1
0 Exome APOB 
apolipoprotein B (including 
Ag(x) antigen) CCDS1          
CGOV62T_1
0 Exome BTNL9 butyrophilin-like 9 CCDS4          
CGOV62T_1
0 Exome C1S 
complement component 1; s 
subcomponent CCDS3     
 
    
CGOV62T_1
0 Exome C4orf43 
chromosome 4 open reading 
frame 43 CCDS4          
CGOV62T_1
0 Exome C5orf25 
chromosome 5 open reading 
frame 25 CCDS4          
CGOV62T_1
0 Exome C5orf46 
chromosome 5 open reading 
frame 46 CCDS3     
 
    
CGOV62T_1
0 Exome C6 complement component 6 CCDS3          
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CGOV62T_1
0 Exome CDKAL1 
CDK5 regulatory subunit 
associated protein 1-like 1 CCDS4     
 
    
CGOV62T_1
0 Exome DNAH6 
dynein heavy chain 6, 
axonemal NM_00          
CGOV62T_1
0 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV62T_1
0 Exome EPHA5 EPH receptor A5 CCDS3          
CGOV62T_1
0 Exome FAM5C 
family with sequence 
similarity 5; member C CCDS1          
CGOV62T_1
0 Exome KIF17 kinesin family member 17 CCDS2          
CGOV62T_1
0 Exome KIF3C kinesin family member 3C CCDS1          
CGOV62T_1
0 Exome PRSS23 protease; serine; 23 CCDS4          
CGOV62T_1
0 Exome RANBP2 RAN binding protein 2 CCDS2          
CGOV62T_1
0 Exome RHBDD1 
rhomboid domain 
containing 1 CCDS2         
CGOV62T_1
0 Exome ROBO1 
roundabout homolog 1 
isoform a precursor NM_00     
 






(Ig); short basic domain; 
secreted; (semaphorin) 3F 
CCDS2        
  
CGOV62T_1
0 Exome SI 
sucrase-isomaltase (alpha-
glucosidase) CCDS3     
  




solute carrier family 1 (glial 
high affinity glutamate 
transporter); member 2 




solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier); member 
3 





0 Exome TP53 tumor protein p53 CCDS1          
CGOV62T_1
0 Exome TRIO 
triple functional domain 
(PTPRF interacting) CCDS3     
 
    
CGOV62T_1
0 Exome USP34 
ubiquitin specific peptidase 
34 CCDS4          
CGOV62T_1
0 Exome WDR11 WD repeat domain 11 CCDS7          
CGOV62T_1
0 Exome ZBBX 
zinc finger; B-box domain 
containing CCDS3          
CGOV62T_1




fibronectin type III domain 
containing 1 
CCDS3     
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CGOV62T_1 Exome ANKRD35 ankyrin repeat domain 35 CCDS9     
 
    
CGOV62T_1 Exome APOB 
apolipoprotein B (including 
Ag(x) antigen) CCDS1          
CGOV62T_1 Exome BTNL9 butyrophilin-like 9 CCDS4          
CGOV62T_1 Exome C1S 
complement component 1; s 
subcomponent CCDS3     
 
    
CGOV62T_1 Exome C4orf43 
chromosome 4 open reading 
frame 43 CCDS4          
CGOV62T_1 Exome C5orf25 
chromosome 5 open reading 
frame 25 CCDS4          
CGOV62T_1 Exome C5orf46 
chromosome 5 open reading 
frame 46 CCDS3     
 
    
CGOV62T_1 Exome C6 complement component 6 CCDS3          
CGOV62T_1 Exome CDKAL1 
CDK5 regulatory subunit 
associated protein 1-like 1 CCDS4     
 
    
CGOV62T_1 Exome DNAH6 
dynein heavy chain 6, 
axonemal NM_00          
CGOV62T_1 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV62T_1 Exome EPHA5 EPH receptor A5 CCDS3          
CGOV62T_1 Exome FAM5C 
family with sequence 
similarity 5; member C CCDS1          
CGOV62T_1 Exome KIF17 kinesin family member 17 CCDS2          
CGOV62T_1 Exome KIF3C kinesin family member 3C CCDS1          
CGOV62T_1 Exome PRSS23 protease; serine; 23 CCDS4          
CGOV62T_1 Exome RANBP2 RAN binding protein 2 CCDS2          
CGOV62T_1 Exome RHBDD1 
rhomboid domain 
containing 1 CCDS2         
CGOV62T_1 Exome ROBO1 
roundabout homolog 1 
isoform a precursor NM_00     
 





(Ig); short basic domain; 
secreted; (semaphorin) 3F 
CCDS2        
  
CGOV62T_1 Exome SI 
sucrase-isomaltase (alpha-
glucosidase) CCDS3     
  
    
CGOV62T_1 Exome 
SLC1A2 
solute carrier family 1 (glial 
high affinity glutamate 
transporter); member 2 
CCDS3          
CGOV62T_1 Exome 
SLC25A3 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier); member 
3 





CGOV62T_1 Exome TP53 tumor protein p53 CCDS1          
CGOV62T_1 Exome TRIO 
triple functional domain 
(PTPRF interacting) CCDS3     
 
    
CGOV62T_1 Exome USP34 
ubiquitin specific peptidase 
34 CCDS4          
CGOV62T_1 Exome WDR11 WD repeat domain 11 CCDS7          
CGOV62T_1 Exome ZBBX 
zinc finger; B-box domain 
containing CCDS3          




fibronectin type III domain 
containing 1 
CCDS3     
 
    
CGOV62T Exome ANKRD35 ankyrin repeat domain 35 CCDS9     
 
    
CGOV62T Exome APOB 
apolipoprotein B (including 
Ag(x) antigen) CCDS1          
CGOV62T Exome BTNL9 butyrophilin-like 9 CCDS4          
CGOV62T Exome C1S 
complement component 1; s 
subcomponent CCDS3     
 
    
CGOV62T Exome C4orf43 
chromosome 4 open reading 
frame 43 CCDS4          
CGOV62T Exome C5orf25 
chromosome 5 open reading 
frame 25 CCDS4          
CGOV62T Exome C5orf46 
chromosome 5 open reading 
frame 46 CCDS3     
 
    
CGOV62T Exome C6 complement component 6 CCDS3          
CGOV62T Exome CDKAL1 
CDK5 regulatory subunit 
associated protein 1-like 1 CCDS4     
 
    
CGOV62T Exome DNAH6 
dynein heavy chain 6, 
axonemal NM_00          
CGOV62T Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV62T Exome EPHA5 EPH receptor A5 CCDS3          
CGOV62T Exome FAM5C 
family with sequence 
similarity 5; member C CCDS1          
CGOV62T Exome KIF17 kinesin family member 17 CCDS2          
CGOV62T Exome KIF3C kinesin family member 3C CCDS1          
CGOV62T Exome PRSS23 protease; serine; 23 CCDS4          
CGOV62T Exome RANBP2 RAN binding protein 2 CCDS2          
CGOV62T Exome RHBDD1 
rhomboid domain 
containing 1 CCDS2         
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CGOV62T Exome ROBO1 
roundabout homolog 1 
isoform a precursor NM_00     
 





(Ig); short basic domain; 
secreted; (semaphorin) 3F 
CCDS2        
  
CGOV62T Exome SI 
sucrase-isomaltase (alpha-
glucosidase) CCDS3     
  
    
CGOV62T Exome 
SLC1A2 
solute carrier family 1 (glial 
high affinity glutamate 
transporter); member 2 
CCDS3          
CGOV62T Exome 
SLC25A3 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier); member 
3 




CGOV62T Exome TP53 tumor protein p53 CCDS1          
CGOV62T Exome TRIO 
triple functional domain 
(PTPRF interacting) CCDS3     
 
    
CGOV62T Exome USP34 
ubiquitin specific peptidase 
34 CCDS4          
CGOV62T Exome WDR11 WD repeat domain 11 CCDS7          
CGOV62T Exome ZBBX 
zinc finger; B-box domain 
containing CCDS3          
CGOV62T Exome ZNF71 zinc finger protein 71 CCDS1          
CGOV304T Exome ANKRD62 ankyrin repeat domain 62 NM_00          
CGOV304T Exome ANXA1 annexin A1 CCDS6          
CGOV304T Exome ARFGAP3 
ADP-ribosylation factor 
GTPase activating protein 3 CCDS1          
CGOV304T Exome 
ASPM 
asp (abnormal spindle) 
homolog, microcephaly 
associated (Drosophila) 
CCDS1     
 
    
CGOV304T Exome ATF6 
activating transcription 
factor 6 CCDS1          
CGOV304T Exome BMP2K BMP2 inducible kinase CCDS4          
CGOV304T Exome CDH26 cadherin 26 CCDS1          
CGOV304T Exome CDK18 cyclin-dependent kinase 18 CCDS1          
CGOV304T Exome COL17A1 collagen, type XVII, alpha 1 CCDS7          
CGOV304T Exome DAPK1 
death-associated protein 
kinase 1 CCDS4     
  
    
CGOV304T Exome DDX47 
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 47 CCDS8          
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CGOV304T Exome DOCK8 dedicator of cytokinesis 8 CCDS6         
CGOV304T Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV304T Exome FA2H fatty acid 2-hydroxylase CCDS1          
CGOV304T Exome FAM186B 
family with sequence 
similarity 186, member B CCDS8          
CGOV304T Exome 
FCER2 
Fc fragment of IgE, low 
affinity II, receptor for 
(CD23) 
CCDS1          







ase 3 (GalNAc-T3) 
CCDS2        
  
CGOV304T Exome GLCE glucuronic acid epimerase CCDS3          
CGOV304T Exome GP9 glycoprotein IX (platelet) CCDS3          
CGOV304T Exome 
HECW1 
HECT, C2 and WW domain 
containing E3 ubiquitin 
protein ligase 1 





readthrough CCDS3          
CGOV304T Exome KBTBD8 
kelch repeat and BTB 
(POZ) domain containing 8 CCDS2          
CGOV304T Exome KIAA1462 KIAA1462 CCDS4          
CGOV304T Exome LRRC16B 
leucine rich repeat 
containing 16B CCDS3          
CGOV304T Exome LRRFIP2 
leucine rich repeat (in FLII) 
interacting protein 2 CCDS2          
CGOV304T Exome LYNX1 Ly6/neurotoxin 1 CCDS3          
CGOV304T Exome MAEA 
macrophage erythroblast 
attacher CCDS3          
CGOV304T Exome MUC19 mucin 19, oligomeric NM_17     
  
    
CGOV304T Exome NPDC1 
neural proliferation, 




plasma protein A, 
pappalysin 1 






CCDS5          
CGOV304T Exome PLCE1 phospholipase C, epsilon 1 CCDS4          
 80 
CGOV304T Exome R3HDML R3H domain containing-like CCDS1          
CGOV304T Exome SALL3 sal-like 3 (Drosophila) CCDS1          
CGOV304T Exome SCN2A 
sodium channel, voltage-
gated, type II, alpha subunit CCDS3          
CGOV304T Exome SPPL3 
signal peptide peptidase like 
3 CCDS9          
CGOV304T Exome SULT1B1 
sulfotransferase family, 
cytosolic, 1B, member 1 CCDS3         
CGOV304T Exome 
TAF1L 
TAF1 RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor, 
210kDa-like 
CCDS3        
  
CGOV304T Exome TINF2 
TERF1 (TRF1)-interacting 
nuclear factor 2 CCDS4          
CGOV304T Exome TLR10 toll-like receptor 10 CCDS3         
CGOV304T Exome TMEM215 transmembrane protein 215 CCDS6          
CGOV304T Exome TP53 tumor protein p53 CCDS1          
CGOV304T Exome ZMYM3 zinc finger, MYM-type 3 CCDS1          
CGOV304T Exome ZNF292 zinc finger protein 292 CCDS4          
CGOV304T Exome ZNF41 zinc finger protein 41 CCDS1          
CGOV303T1 Exome AGXT2 
alanine--glyoxylate 
aminotransferase 2 CCDS3          
CGOV303T1 Exome 
BATF 
basic leucine zipper 
transcription factor, ATF-
like 
CCDS9          
CGOV303T1 Exome CDH23 cadherin-related 23 NM_00          
CGOV303T1 Exome DMD dystrophin CCDS1          
CGOV303T1 Exome EMP3 
epithelial membrane protein 
3 CCDS1         
CGOV303T1 Exome IGSF9 
immunoglobulin 
superfamily, member 9 CCDS4          
CGOV303T1 Exome KIF1A kinesin family member 1A CCDS5          
CGOV303T1 Exome KIF1A kinesin family member 1A CCDS5          
CGOV303T1 Exome NOTCH3 notch 3 CCDS1          
CGOV303T1 Exome OFD1 
oral-facial-digital syndrome 






catalytic subunit alpha 
CCDS4          
CGOV303T1 Exome R3HDM1 R3H domain containing 1 CCDS2          
CGOV303T1 Exome RAP1GAP 
RAP1 GTPase activating 
protein CCDS5          
CGOV303T1 Exome RASL12 RAS-like, family 12 CCDS1          
CGOV303T1 Exome SLC38A10 
solute carrier family 38, 
member 10 CCDS1          
CGOV303T1 Exome 
SLCO4C1 
solute carrier organic anion 
transporter family, member 
4C1 
CCDS3          
CGOV303T1 Exome SOX6 
SRY (sex determining 
region Y)-box 6 CCDS7          
CGOV303T1 Exome SPPL2C 
signal peptide peptidase like 
2C CCDS3          
CGOV303T1 Exome TEP1 
telomerase-associated 
protein 1 CCDS9          
CGOV303T1 Exome TM4SF20 
transmembrane 4 L six 
family member 20 CCDS2          
CGOV303T1 Exome TP53 tumor protein p53 CCDS1          
CGOV303T1 Exome VAV3 
vav 3 guanine nucleotide 




family B (MDR/TAP), 
member 6 
CCDS2          
CGOV303T Exome AGXT2 
alanine--glyoxylate 
aminotransferase 2 CCDS3          
CGOV303T Exome AGXT2 
alanine--glyoxylate 
aminotransferase 2 CCDS3          
CGOV303T Exome 
ASAP1 
ArfGAP with SH3 domain, 
ankyrin repeat and PH 
domain 1 
CCDS6          
CGOV303T Exome 
BATF 
basic leucine zipper 
transcription factor, ATF-
like 
CCDS9          
CGOV303T Exome CDH23 cadherin-related 23 NM_00          
CGOV303T Exome DMD dystrophin CCDS1          




(serotonin) receptor 5A, G 
protein-coupled 
CCDS5          
CGOV303T Exome 
HUWE1 
HECT, UBA and WWE 
domain containing 1, E3 
ubiquitin protein ligase 
CCDS3          
 82 
CGOV303T Exome KIF1A kinesin family member 1A CCDS5          
CGOV303T Exome KMT2C 
lysine (K)-specific 
methyltransferase 2C CCDS5          
CGOV303T Exome NOTCH3 notch 3 CCDS1          
CGOV303T Exome OR13A1 
olfactory receptor, family 





catalytic subunit alpha 
CCDS4          
CGOV303T Exome PRRC2C proline-rich coiled-coil 2C CCDS1         
CGOV303T Exome PYGM 
phosphorylase, glycogen, 
muscle CCDS8          
CGOV303T Exome R3HDM1 R3H domain containing 1 CCDS2          
CGOV303T Exome RAP1GAP 
RAP1 GTPase activating 
protein CCDS5          
CGOV303T Exome RASL12 RAS-like, family 12 CCDS1          
CGOV303T Exome SASS6 
spindle assembly 6 homolog 
(C. elegans) CCDS7          
CGOV303T Exome 
SLCO4C1 
solute carrier organic anion 
transporter family, member 
4C1 
CCDS3          
CGOV303T Exome SOX6 
SRY (sex determining 
region Y)-box 6 CCDS7          
CGOV303T Exome SPPL2C 
signal peptide peptidase like 
2C CCDS3          
CGOV303T Exome SYNE1 
spectrin repeat containing, 
nuclear envelope 1 CCDS5          
CGOV303T Exome TCTE1 
t-complex-associated-testis-
expressed 1 CCDS4          
CGOV303T Exome TEP1 
telomerase-associated 
protein 1 CCDS9          
CGOV303T Exome TM4SF20 
transmembrane 4 L six 
family member 20 CCDS2          
CGOV303T Exome TP53 tumor protein p53 CCDS1          
CGOV303T Exome UHRF1 
ubiquitin-like with PHD and 
ring finger domains 1 NM_01          
CGOV303T Exome USP29 
ubiquitin specific peptidase 
29 CCDS3          
CGOV303T Exome VAV3 
vav 3 guanine nucleotide 
exchange factor CCDS7          
CGOV303T Exome ZMYND15 
zinc finger, MYND-type 
containing 15 CCDS5          
CGOV280T6 Exome 
ADAMTSL
4 ADAMTS-like 4 CCDS9     
 
    
 83 
CGOV280T6 Exome C1orf173 
chromosome 1 open reading 
frame 173 CCDS3     
 
    
CGOV280T6 Exome FLG2 filaggrin family member 2 CCDS3     
 
    
CGOV280T6 Exome FOXG1 forkhead box G1 CCDS9     
 
    
CGOV280T6 Exome GPR25 
G protein-coupled receptor 
25 CCDS1     
 
    
CGOV280T6 Exome INPP5E 
 CCDS7     
 
    
CGOV280T6 Exome ISM1 
 CCDS4     
 
    
CGOV280T6 Exome LPIN3 
 CCDS3     
 
    
CGOV280T6 Exome LRP1 
 CCDS8     
 
    
CGOV280T6 Exome MRPS12 
mitochondrial ribosomal 
protein S12 CCDS1     
 
    
CGOV280T6 Exome MS4A14 
 CCDS5     
 
    
CGOV280T6 Exome NALCN 
sodium leak channel, non-
selective CCDS9     
 
    
CGOV280T6 Exome NOS1AP 
nitric oxide synthase 1 
(neuronal) adaptor protein CCDS1     
 
    
CGOV280T6 Exome NPAP1 
nuclear pore associated 
protein 1 CCDS1     
 




(DNA directed), zeta, 
catalytic subunit 
CCDS5     
 
    
CGOV280T6 Exome RHBDL3 
rhomboid, veinlet-like 3 
(Drosophila) CCDS3     
 
    
CGOV280T6 Exome SETBP1 
 CCDS4     
 
    
CGOV280T6 Exome SLX4 
SLX4 structure-specific 
endonuclease subunit CCDS1     
 
    
CGOV280T6 Exome XIRP2 
xin actin-binding repeat 
containing 2 CCDS4     
 
    
CGOV280T6 Exome ZMYM6 zinc finger, MYM-type 6 CCDS3     
 




family A (ABC1), member 
13 
CCDS4          
CGOV280T5 Exome 
ADAMTSL
4 ADAMTS-like 4 CCDS9     
 
    
CGOV280T5 Exome ASB15 
ankyrin repeat and SOCS 
box containing 15 CCDS3          
CGOV280T5 Exome C1orf173 
chromosome 1 open reading 
frame 173 CCDS3     
 




dependent, L type, alpha 1C 
subunit 
CCDS4          
 84 
CGOV280T5 Exome CCR2 
chemokine (C-C motif) 
receptor 2 CCDS4         
CGOV280T5 Exome CDC5L cell division cycle 5-like CCDS4     
 
    
CGOV280T5 Exome DNAH3 
dynein, axonemal, heavy 
chain 3 CCDS1          
CGOV280T5 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV280T5 Exome FLG2 filaggrin family member 2 CCDS3     
 
    
CGOV280T5 Exome FOXG1 forkhead box G1 CCDS9     
 
    
CGOV280T5 Exome GPR158 
G protein-coupled receptor 
158 CCDS3          
CGOV280T5 Exome GPR25 
G protein-coupled receptor 
25 CCDS1     
 
    
CGOV280T5 Exome INPP5E 
 CCDS7     
 
    
CGOV280T5 Exome ISM1 
 CCDS4     
 
    
CGOV280T5 Exome LPIN3 
 CCDS3     
 
    
CGOV280T5 Exome LRP1 
 CCDS8     
 
    
CGOV280T5 Exome MRPS12 
mitochondrial ribosomal 
protein S12 CCDS1     
 
    
CGOV280T5 Exome MS4A14 
 CCDS5     
 
    
CGOV280T5 Exome MTA3 
metastasis associated 1 
family, member 3 CCDS4          
CGOV280T5 Exome NALCN 
sodium leak channel, non-
selective CCDS9     
 
    
CGOV280T5 Exome NOS1AP 
nitric oxide synthase 1 
(neuronal) adaptor protein CCDS1     
 
    
CGOV280T5 Exome NPAP1 
nuclear pore associated 
protein 1 CCDS1     
 
    
CGOV280T5 Exome PCDHGB4 
protocadherin gamma 
subfamily B, 4 CCDS5          
CGOV280T5 Exome PDE2A 
phosphodiesterase 2A, 
cGMP-stimulated CCDS8     
  
    
CGOV280T5 Exome 
PPP1CC 
protein phosphatase 1, 
catalytic subunit, gamma 
isozyme 
CCDS5     
 





Rac exchange factor 1 




(DNA directed), zeta, 
catalytic subunit 
CCDS5     
 
    
CGOV280T5 Exome RHBDL3 
rhomboid, veinlet-like 3 
(Drosophila) CCDS3     
 
    
 85 
CGOV280T5 Exome SETBP1 
 CCDS4     
 
    
CGOV280T5 Exome SETD2 SET domain containing 2 CCDS2          
CGOV280T5 Exome 
SHPRH 
SNF2 histone linker PHD 
RING helicase, E3 ubiquitin 
protein ligase 
CCDS4          
CGOV280T5 Exome SLX4 
SLX4 structure-specific 
endonuclease subunit CCDS1     
 




tumorigenicity 18 (breast 
carcinoma) (zinc finger 
protein) 
CCDS6        
  
CGOV280T5 Exome TMEM64 transmembrane protein 64 CCDS3          
CGOV280T5 Exome TP53 tumor protein p53 CCDS1     
  
    
CGOV280T5 Exome TRHR 
thyrotropin-releasing 
hormone receptor CCDS6          
CGOV280T5 Exome TRIML1 tripartite motif family-like 1 CCDS3          
CGOV280T5 Exome TTN titin CCDS5          
CGOV280T5 Exome XIRP2 
xin actin-binding repeat 
containing 2 CCDS4     
 
    
CGOV280T5 Exome ZMIZ2 
zinc finger, MIZ-type 
containing 2 CCDS4          
CGOV280T5 Exome ZMYM6 zinc finger, MYM-type 6 CCDS3     
 




family A (ABC1), member 
13 
CCDS4          
CGOV280T4 Exome 
ADAMTSL
4 ADAMTS-like 4 CCDS9     
 
    
CGOV280T4 Exome ASB15 
ankyrin repeat and SOCS 
box containing 15 CCDS3          
CGOV280T4 Exome C1orf173 
chromosome 1 open reading 
frame 173 CCDS3     
 




dependent, L type, alpha 1C 
subunit 
CCDS4          
CGOV280T4 Exome CCR2 
chemokine (C-C motif) 
receptor 2 CCDS4         
CGOV280T4 Exome DNAH3 
dynein, axonemal, heavy 
chain 3 CCDS1          
CGOV280T4 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV280T4 Exome EFCAB4B 
EF-hand calcium binding 
domain 4B CCDS4     
 
    
CGOV280T4 Exome FLG2 filaggrin family member 2 CCDS3     
 
    
 86 
CGOV280T4 Exome GPR158 
G protein-coupled receptor 
158 CCDS3          
CGOV280T4 Exome GPR25 
G protein-coupled receptor 
25 CCDS1     
 
    
CGOV280T4 Exome GRM7 
glutamate receptor, 
metabotropic 7 CCDS4     
 
    
CGOV280T4 Exome INPP5E 
 CCDS7     
 
    
CGOV280T4 Exome ISM1 
 CCDS4     
 
    
CGOV280T4 Exome LPIN3 
 CCDS3     
 
    
CGOV280T4 Exome LRP1 
 CCDS8     
 
    
CGOV280T4 Exome MS4A14 
 CCDS5     
 
    
CGOV280T4 Exome MTA3 
metastasis associated 1 
family, member 3 CCDS4          
CGOV280T4 Exome NALCN 
sodium leak channel, non-
selective CCDS9     
 
    
CGOV280T4 Exome PARN 
poly(A)-specific 
ribonuclease CCDS4     
 
    
CGOV280T4 Exome PCDHGB4 
protocadherin gamma 
subfamily B, 4 CCDS5          
CGOV280T4 Exome PDE2A 
phosphodiesterase 2A, 
cGMP-stimulated CCDS8     
  





Rac exchange factor 1 
CCDS1          
CGOV280T4 Exome SETBP1 
 CCDS4     
 
    
CGOV280T4 Exome SETD2 SET domain containing 2 CCDS2          
CGOV280T4 Exome 
SHPRH 
SNF2 histone linker PHD 
RING helicase, E3 ubiquitin 
protein ligase 
CCDS4          
CGOV280T4 Exome SLX4 
SLX4 structure-specific 
endonuclease subunit CCDS1     
 




tumorigenicity 18 (breast 
carcinoma) (zinc finger 
protein) 
CCDS6        
  
CGOV280T4 Exome STK36 serine/threonine kinase 36 CCDS2     
 
    
CGOV280T4 Exome TMEM64 transmembrane protein 64 CCDS3          
CGOV280T4 Exome TP53 tumor protein p53 CCDS1     
  
    
CGOV280T4 Exome TRHR 
thyrotropin-releasing 
hormone receptor CCDS6          
 87 
CGOV280T4 Exome TRIML1 tripartite motif family-like 1 CCDS3          
CGOV280T4 Exome TTN titin CCDS5          
CGOV280T4 Exome XIRP2 
xin actin-binding repeat 
containing 2 CCDS4     
 
    
CGOV280T4 Exome ZFHX4 zinc finger homeobox 4 CCDS4     
 
    
CGOV280T4 Exome ZMIZ2 
zinc finger, MIZ-type 
containing 2 CCDS4          
CGOV280T4 Exome ZMYM6 zinc finger, MYM-type 6 CCDS3     
 
    
CGOV280T4 Exome ZNF804B zinc finger protein 804B CCDS5     
 




family A (ABC1), member 
13 
CCDS4          
CGOV280T3 Exome 
ADAMTSL
4 ADAMTS-like 4 CCDS9     
 
    
CGOV280T3 Exome ASB15 
ankyrin repeat and SOCS 
box containing 15 CCDS3          
CGOV280T3 Exome C1orf173 
chromosome 1 open reading 
frame 173 CCDS3     
 




dependent, L type, alpha 1C 
subunit 
CCDS4          
CGOV280T3 Exome CCR2 
chemokine (C-C motif) 
receptor 2 CCDS4         
CGOV280T3 Exome DNAH3 
dynein, axonemal, heavy 
chain 3 CCDS1          
CGOV280T3 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV280T3 Exome FLG2 filaggrin family member 2 CCDS3     
 
    
CGOV280T3 Exome FOXG1 forkhead box G1 CCDS9     
 
    
CGOV280T3 Exome GPR158 
G protein-coupled receptor 
158 CCDS3          
CGOV280T3 Exome GPR25 
G protein-coupled receptor 
25 CCDS1     
 
    
CGOV280T3 Exome INPP5E 
 CCDS7     
 
    
CGOV280T3 Exome IQSEC1 IQ motif and Sec7 domain 1 CCDS3     
 
    
CGOV280T3 Exome ISM1 
 CCDS4     
 
    
CGOV280T3 Exome LPIN3 
 CCDS3     
 
    
CGOV280T3 Exome LRP1 
 CCDS8     
 
    
 88 
CGOV280T3 Exome MS4A14 
 CCDS5     
 
    
CGOV280T3 Exome MTA3 
metastasis associated 1 
family, member 3 CCDS4          
CGOV280T3 Exome NALCN 
sodium leak channel, non-
selective CCDS9     
 
    
CGOV280T3 Exome NOS1AP 
nitric oxide synthase 1 
(neuronal) adaptor protein CCDS1     
 
    
CGOV280T3 Exome NPAP1 
nuclear pore associated 
protein 1 CCDS1     
 
    
CGOV280T3 Exome PCDHGB4 
protocadherin gamma 
subfamily B, 4 CCDS5          
CGOV280T3 Exome PDE2A 
phosphodiesterase 2A, 
cGMP-stimulated CCDS8     
  
    
CGOV280T3 Exome POU3F2 POU class 3 homeobox 2 CCDS5     
 





Rac exchange factor 1 
CCDS1          
CGOV280T3 Exome SETBP1 
 CCDS4     
 
    
CGOV280T3 Exome 
SHPRH 
SNF2 histone linker PHD 
RING helicase, E3 ubiquitin 
protein ligase 
CCDS4          
CGOV280T3 Exome SLX4 
SLX4 structure-specific 
endonuclease subunit CCDS1     
 




tumorigenicity 18 (breast 
carcinoma) (zinc finger 
protein) 
CCDS6        
  
CGOV280T3 Exome TMEM64 transmembrane protein 64 CCDS3          
CGOV280T3 Exome TP53 tumor protein p53 CCDS1     
  
    
CGOV280T3 Exome TRHR 
thyrotropin-releasing 
hormone receptor CCDS6          
CGOV280T3 Exome TRIML1 tripartite motif family-like 1 CCDS3          
CGOV280T3 Exome TTN titin CCDS5          
CGOV280T3 Exome XIRP2 
xin actin-binding repeat 
containing 2 CCDS4     
 
    
CGOV280T3 Exome ZMIZ2 
zinc finger, MIZ-type 
containing 2 CCDS4          
CGOV280T3 Exome ZMYM6 zinc finger, MYM-type 6 CCDS3     
 




family A (ABC1), member 
13 
CCDS4          
CGOV280T2 Exome ASB15 
ankyrin repeat and SOCS 
box containing 15 CCDS3          
 89 
CGOV280T2 Exome C1orf173 
chromosome 1 open reading 
frame 173 CCDS3     
 




dependent, L type, alpha 1C 
subunit 
CCDS4          
CGOV280T2 Exome CACNB4 
calcium channel, voltage-
dependent, beta 4 subunit CCDS4     
 
    
CGOV280T2 Exome CCR2 
chemokine (C-C motif) 
receptor 2 CCDS4         
CGOV280T2 Exome DNAH3 
dynein, axonemal, heavy 
chain 3 CCDS1          
CGOV280T2 Exome DNAH6 
dynein, axonemal, heavy 
chain 6 CCDS4     
 
    
CGOV280T2 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
CGOV280T2 Exome EYA3 
eyes absent homolog 3 
(Drosophila) CCDS3     
 
    
CGOV280T2 Exome FLG2 filaggrin family member 2 CCDS3     
 












CGOV280T2 Exome GP6 glycoprotein VI (platelet) CCDS4     
 
    
CGOV280T2 Exome GPR158 
G protein-coupled receptor 
158 CCDS3          
CGOV280T2 Exome GPR25 
G protein-coupled receptor 
25 CCDS1     
 
    
CGOV280T2 Exome 
GPRC5B 
G protein-coupled receptor, 
family C, group 5, member 
B 
CCDS1     
 
    
CGOV280T2 Exome INPP5E 
 CCDS7     
 
    
CGOV280T2 Exome ISM1 
 CCDS4     
 
    
CGOV280T2 Exome LPIN3 
 CCDS3     
 
    
CGOV280T2 Exome LRP1 
 CCDS8     
 
    
CGOV280T2 Exome MS4A14 
 CCDS5     
 
    
CGOV280T2 Exome MTA3 
metastasis associated 1 
family, member 3 CCDS4          
CGOV280T2 Exome PCDHGB4 
protocadherin gamma 
subfamily B, 4 CCDS5          
CGOV280T2 Exome PDE2A 
phosphodiesterase 2A, 
cGMP-stimulated CCDS8     
  
    
CGOV280T2 Exome PER1 period circadian clock 1 CCDS1     
 






Rac exchange factor 1 
CCDS1          
CGOV280T2 Exome SAMD4B 
sterile alpha motif domain 
containing 4B CCDS3     
 
    
CGOV280T2 Exome SETBP1 
 CCDS4     
 
    
CGOV280T2 Exome SETD2 SET domain containing 2 CCDS2          
CGOV280T2 Exome 
SHPRH 
SNF2 histone linker PHD 
RING helicase, E3 ubiquitin 
protein ligase 




tumorigenicity 18 (breast 
carcinoma) (zinc finger 
protein) 
CCDS6        
  
CGOV280T2 Exome STK36 serine/threonine kinase 36 CCDS2     
 
    
CGOV280T2 Exome TMEM64 transmembrane protein 64 CCDS3          
CGOV280T2 Exome TP53 tumor protein p53 CCDS1     
  
    
CGOV280T2 Exome TRHR 
thyrotropin-releasing 
hormone receptor CCDS6          
CGOV280T2 Exome TRIML1 tripartite motif family-like 1 CCDS3          
CGOV280T2 Exome TTN titin CCDS5          
CGOV280T2 Exome XIRP2 
xin actin-binding repeat 
containing 2 CCDS4     
 
    
CGOV280T2 Exome ZKSCAN8 
zinc finger with KRAB and 
SCAN domains 8 CCDS4     
 
    
CGOV280T2 Exome ZMIZ2 
zinc finger, MIZ-type 
containing 2 CCDS4          
CGOV280T2 Exome ZMYM6 zinc finger, MYM-type 6 CCDS3     
 




family A (ABC1), member 
13 
CCDS4          
CGOV280T6 Exome ASB15 
ankyrin repeat and SOCS 




dependent, L type, alpha 1C 
subunit 
CCDS4          
CGOV280T6 Exome CCR2 
chemokine (C-C motif) 
receptor 2 CCDS4         
CGOV280T6 Exome DNAH3 
dynein, axonemal, heavy 
chain 3 CCDS1          
CGOV280T6 Exome DUSP27 
dual specificity phosphatase 
27 (putative) CCDS3          
 91 
CGOV280T6 Exome GPR158 
G protein-coupled receptor 
158 CCDS3          
CGOV280T6 Exome MTA3 
metastasis associated 1 
family, member 3 CCDS4          
CGOV280T6 Exome PCDHGB4 
protocadherin gamma 
subfamily B, 4 CCDS5          
CGOV280T6 Exome PDE2A 
phosphodiesterase 2A, 
cGMP-stimulated CCDS8     
  





Rac exchange factor 1 
CCDS1          
CGOV280T6 Exome TMEM64 transmembrane protein 64 CCDS3          
CGOV280T6 Exome TP53 tumor protein p53 CCDS1     
  
    
CGOV280T6 Exome TRHR 
thyrotropin-releasing 
hormone receptor CCDS6          
CGOV280T6 Exome TRIML1 tripartite motif family-like 1 CCDS3          
CGOV280T6 Exome TTN titin CCDS5          
CGOV280T6 Exome ZMIZ2 
zinc finger, MIZ-type 
containing 2 CCDS4          
CGOV279T4 Exome 
ARAP3 
ArfGAP with RhoGAP 
domain, ankyrin repeat and 
PH domain 3 
CCDS4          
CGOV279T4 Exome ATN1 atrophin 1 CCDS3     
 
    
CGOV279T4 Exome ATP13A3 ATPase type 13A3 CCDS4          
CGOV279T4 Exome C20orf194 
chromosome 20 open 
reading frame 194 CCDS4     
 
    
CGOV279T4 Exome CD14 CD14 molecule CCDS4         
CGOV279T4 Exome DLG5 
discs, large homolog 5 
(Drosophila) CCDS7     
 
    
CGOV279T4 Exome EVC2 
Ellis van Creveld syndrome 
2 CCDS3          
CGOV279T4 Exome IGSF21 
immunoglobin superfamily, 





subfamily J, member 10 





subfamily, member 2 
CCDS1     
 
    
CGOV279T4 Exome KIAA1614 KIAA1614 CCDS4          
CGOV279T4 Exome LAMA5 laminin, alpha 5 CCDS3          
 92 
CGOV279T4 Exome MB myoglobin CCDS1     
 
    
CGOV279T4 Exome MCL1 
myeloid cell leukemia 
sequence 1 (BCL2-related) CCDS9          
CGOV279T4 Exome NOL4 nucleolar protein 4 CCDS1     
 
    
CGOV279T4 Exome OR8S1 
olfactory receptor, family 8, 
subfamily S, member 1 CCDS3          
CGOV279T4 Exome 
SLC13A3 




CCDS1       
  
CGOV279T4 Exome SLC41A3 
solute carrier family 41, 
member 3 CCDS3          
CGOV279T4 Exome SP9 Sp9 transcription factor CCDS4     
 
    
CGOV279T4 Exome SV2C 
synaptic vesicle 
glycoprotein 2C CCDS4     
 
    
CGOV279T4 Exome TP53 tumor protein p53 CCDS1          
CGOV279T4 Exome 
TRPC7 
transient receptor potential 
cation channel, subfamily C, 
member 7 
CCDS4         
CGOV279T4 Exome VPS16 
vacuolar protein sorting 16 
homolog (S. cerevisiae) CCDS1     
 
    
CGOV279T3 Exome ATN1 atrophin 1 CCDS3     
 
    
CGOV279T3 Exome ATP13A3 ATPase type 13A3 CCDS4          






CCDS8     
 
    
CGOV279T3 Exome IGSF21 
immunoglobin superfamily, 





subfamily J, member 10 
CCDS1          
CGOV279T3 Exome KIAA1614 KIAA1614 CCDS4          
CGOV279T3 Exome NOL4 nucleolar protein 4 CCDS1     
 
    
CGOV279T3 Exome OR10W1 
olfactory receptor, family 
10, subfamily W, member 1 CCDS7     
 
    
CGOV279T3 Exome OR8S1 
olfactory receptor, family 8, 
subfamily S, member 1 CCDS3          
CGOV279T3 Exome 
SLC13A3 




CCDS1       
  
 93 
CGOV279T3 Exome SLC41A3 
solute carrier family 41, 
member 3 CCDS3          
CGOV279T3 Exome SV2C 
synaptic vesicle 
glycoprotein 2C CCDS4     
 
    
CGOV279T3 Exome TP53 tumor protein p53 CCDS1          
CGOV279T3 Exome 
TRPC7 
transient receptor potential 
cation channel, subfamily C, 
member 7 
CCDS4         
CGOV279T2 Exome ATN1 atrophin 1 CCDS3     
 
    
CGOV279T2 Exome ATP13A3 ATPase type 13A3 CCDS4          






CCDS8     
 
    
CGOV279T2 Exome IGSF21 
immunoglobin superfamily, 





subfamily J, member 10 
CCDS1          
CGOV279T2 Exome KIAA1614 KIAA1614 CCDS4          
CGOV279T2 Exome NOL4 nucleolar protein 4 CCDS1     
 
    
CGOV279T2 Exome OR10W1 
olfactory receptor, family 
10, subfamily W, member 1 CCDS7     
 
    
CGOV279T2 Exome OR8S1 
olfactory receptor, family 8, 
subfamily S, member 1 CCDS3          
CGOV279T2 Exome 
SLC13A3 




CCDS1       
  
CGOV279T2 Exome SLC41A3 
solute carrier family 41, 
member 3 CCDS3          
CGOV279T2 Exome TP53 tumor protein p53 CCDS1          
CGOV279T2 Exome 
TRPC7 
transient receptor potential 
cation channel, subfamily C, 
member 7 
CCDS4         
CGOV279T1 Exome ATN1 atrophin 1 CCDS3     
 
    
CGOV279T1 Exome ATP13A3 ATPase type 13A3 CCDS4          






CCDS8     
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CGOV279T1 Exome IGSF21 
immunoglobin superfamily, 





subfamily J, member 10 
CCDS1          
CGOV279T1 Exome KIAA1614 KIAA1614 CCDS4          
CGOV279T1 Exome NOL4 nucleolar protein 4 CCDS1     
 
    
CGOV279T1 Exome OR10W1 
olfactory receptor, family 
10, subfamily W, member 1 CCDS7     
 
    
CGOV279T1 Exome OR8S1 
olfactory receptor, family 8, 
subfamily S, member 1 CCDS3          
CGOV279T1 Exome 
SLC13A3 




CCDS1       
  
CGOV279T1 Exome SLC41A3 
solute carrier family 41, 
member 3 CCDS3          
CGOV279T1 Exome SV2C 
synaptic vesicle 
glycoprotein 2C CCDS4     
 
    
CGOV279T1 Exome TP53 tumor protein p53 CCDS1          
CGOV279T1 Exome 
TRPC7 
transient receptor potential 
cation channel, subfamily C, 
member 7 
CCDS4         
CGOV278T4 Exome ACTL10 actin-like 10 CCDS3          
CGOV278T4 Exome AHDC1 
AT hook, DNA binding 
motif, containing 1 CCDS3          
CGOV278T4 Exome BAHCC1 
BAH domain and coiled-
coil containing 1 NM_00          
CGOV278T4 Exome COL6A5 collagen, type VI, alpha 5 NM_00          
CGOV278T4 Exome CREB3L1 
cAMP responsive element 
binding protein 3-like 1 CCDS5          
CGOV278T4 Exome CTNND2 
catenin (cadherin-associated 
protein), delta 2 CCDS3          
CGOV278T4 Exome ELL 
 CCDS1     
 




 CCDS5     
 
    
CGOV278T4 Exome GPATCH1 
G patch domain containing 
1 CCDS1          
CGOV278T4 Exome HKDC1 
hexokinase domain 
containing 1 CCDS7          
CGOV278T4 Exome IGHMBP2 
immunoglobulin mu binding 





subfamily, beta member 1 
CCDS3          
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CGOV278T4 Exome KRT3 keratin 3 CCDS4          
CGOV278T4 Exome LCK 
lymphocyte-specific protein 
tyrosine kinase CCDS3     
  
    
CGOV278T4 Exome LMAN2 lectin, mannose-binding 2 CCDS4         
CGOV278T4 Exome MACF1 
microtubule-actin 
crosslinking factor 1 CCDS4          
CGOV278T4 Exome MAGEC1 
melanoma antigen family C, 
1 CCDS3         
CGOV278T4 Exome METAP2 methionyl aminopeptidase 2 CCDS9     
  
    
CGOV278T4 Exome MPZ myelin protein zero CCDS1     
 
    
CGOV278T4 Exome NLRP5 
NLR family, pyrin domain 
containing 5 CCDS1          
CGOV278T4 Exome NPFFR1 
 CCDS5     
 




phosphatase, receptor type, 
N 
CCDS2     
 
    
CGOV278T4 Exome RAD9A 
 CCDS8     
 
    
CGOV278T4 Exome RNF148 ring finger protein 148 CCDS4          
CGOV278T4 Exome SERINC2 serine incorporator 2 CCDS5     
 
    
CGOV278T4 Exome SETD1A SET domain containing 1A CCDS3          
CGOV278T4 Exome SH3PXD2B SH3 and PX domains 2B CCDS3          
CGOV278T4 Exome SMARCA4 
 CCDS1     
 
    
CGOV278T4 Exome SYT12 
 CCDS8     
 
    
CGOV278T4 Exome SZT2 
seizure threshold 2 homolog 
(mouse) CCDS3     
 
    
CGOV278T4 Exome 
TMPPE 
transmembrane protein with 
metallophosphoesterase 
domain 
CCDS3          




family G (WHITE), member 
8 
CCDS1     
 
    
CGOV278T2 Exome ACTL10 actin-like 10 CCDS3          
CGOV278T2 Exome AHDC1 
AT hook, DNA binding 
motif, containing 1 CCDS3          
CGOV278T2 Exome BAHCC1 
BAH domain and coiled-
coil containing 1 NM_00          
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CGOV278T2 Exome COL6A5 collagen, type VI, alpha 5 NM_00          
CGOV278T2 Exome CREB3L1 
cAMP responsive element 
binding protein 3-like 1 CCDS5          
CGOV278T2 Exome CTNND2 
catenin (cadherin-associated 
protein), delta 2 CCDS3          
CGOV278T2 Exome ELL 
 CCDS1     
 




 CCDS5     
 
    
CGOV278T2 Exome GPATCH1 
G patch domain containing 
1 CCDS1          
CGOV278T2 Exome HKDC1 
hexokinase domain 
containing 1 CCDS7          
CGOV278T2 Exome IGHMBP2 
immunoglobulin mu binding 





subfamily, beta member 1 
CCDS3          
CGOV278T2 Exome KRT3 keratin 3 CCDS4          
CGOV278T2 Exome LCK 
lymphocyte-specific protein 
tyrosine kinase CCDS3     
  
    
CGOV278T2 Exome LMAN2 lectin, mannose-binding 2 CCDS4         
CGOV278T2 Exome MACF1 
microtubule-actin 
crosslinking factor 1 CCDS4          
CGOV278T2 Exome MAGEC1 
melanoma antigen family C, 
1 CCDS3         
CGOV278T2 Exome METAP2 methionyl aminopeptidase 2 CCDS9     
  
    
CGOV278T2 Exome MPZ myelin protein zero CCDS1     
 
    
CGOV278T2 Exome NLRP5 
NLR family, pyrin domain 
containing 5 CCDS1          
CGOV278T2 Exome NPFFR1 
 CCDS5     
 
    
CGOV278T2 Exome PCK2 
 CCDS9     
 




phosphatase, receptor type, 
N 
CCDS2     
 
    
CGOV278T2 Exome RAD9A 
 CCDS8     
 
    
CGOV278T2 Exome RNF148 ring finger protein 148 CCDS4          
CGOV278T2 Exome SERINC2 serine incorporator 2 CCDS5     
 
    
CGOV278T2 Exome SETD1A SET domain containing 1A CCDS3          
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CGOV278T2 Exome SH3PXD2B SH3 and PX domains 2B CCDS3          
CGOV278T2 Exome SMARCA4 
 CCDS1     
 
    
CGOV278T2 Exome SYT12 
 CCDS8     
 
    
CGOV278T2 Exome 
TMPPE 
transmembrane protein with 
metallophosphoesterase 
domain 
CCDS3          
CGOV278T2 Exome TP53 tumor protein p53 CCDS1         
CGOV278T1 Exome AHDC1 
AT hook, DNA binding 
motif, containing 1 CCDS3          
CGOV278T1 Exome BAHCC1 
BAH domain and coiled-
coil containing 1 NM_00          
CGOV278T1 Exome COL6A5 collagen, type VI, alpha 5 NM_00          
CGOV278T1 Exome CREB3L1 
cAMP responsive element 
binding protein 3-like 1 CCDS5          
CGOV278T1 Exome CTNND2 
catenin (cadherin-associated 
protein), delta 2 CCDS3          
CGOV278T1 Exome ELL 
 CCDS1     
 




 CCDS5     
 
    
CGOV278T1 Exome GPATCH1 
G patch domain containing 
1 CCDS1          
CGOV278T1 Exome IGHMBP2 
immunoglobulin mu binding 





subfamily, beta member 1 
CCDS3          
CGOV278T1 Exome KRT3 keratin 3 CCDS4          
CGOV278T1 Exome LMAN2 lectin, mannose-binding 2 CCDS4         
CGOV278T1 Exome MACF1 
microtubule-actin 
crosslinking factor 1 CCDS4          
CGOV278T1 Exome METAP2 methionyl aminopeptidase 2 CCDS9     
  
    
CGOV278T1 Exome MPZ myelin protein zero CCDS1     
 
    
CGOV278T1 Exome NLRP5 
NLR family, pyrin domain 




phosphatase, receptor type, 
N 
CCDS2     
 
    
CGOV278T1 Exome RAD9A 
 CCDS8     
 
    
CGOV278T1 Exome SERINC2 serine incorporator 2 CCDS5     
 
    
 98 
CGOV278T1 Exome SMARCA4 
 CCDS1     
 
    
CGOV278T1 Exome 
TMPPE 
transmembrane protein with 
metallophosphoesterase 
domain 
CCDS3          

































Supplementary Data 2.5. Somatic Sequence Alterations used for Evolutionary Cluster 
Analyses 
Case ID Gene symbol Nucleotide (genomic) Amino Acid (protein) Mutation T   
CGOV62 TP53 chr17_7519279-7519279_A_T 126Y>N Substitution   
CGOV62 C5orf25 chr5_175681953-175681953_C_T 635T>M Substitution   
CGOV62 EPHA5 chr4_65872430-65872430_C_A 1037L>F Substitution   
CGOV62 SI chr3_166199018-166199018_T_C _ISV+4> Substitution    
CGOV62 SLC25A3 chr12_97515945-97515945_G_A _ISV+1> Substitution    
CGOV62 WDR11 chr10_122616187-122616187_G_A 371A>T Substitution   
CGOV62 ZNF71 chr19_61825541-61825541_G_T 358E>D Substitution   
CGOV62 ANKFN1 chr17_51786312-51786312_C_T 172S>S Substitution   
CGOV62 ANKRD35 chr1_144274393-144274393_G_C 908T>T Substitution   
CGOV62 TRIO chr5_14333529-14333529_C_T 111L>L Substitution   
CGOV62 C5orf46 chr5_147261489-147261489_C_G 37S>S Substitution   
CGOV62 APOB chr2_21082355-21082355_C_G 3630K>N Substitution   
CGOV62 BTNL9 chr5_180407550-180407550_C_T 43P>S Substitution   
CGOV62 DNAH6 chr2_84686181-84686181_G_A 1043R>H Substitution   
CGOV62 FAM5C chr1_188334053-188334053_C_A 673M>I Substitution   
CGOV62 KIF17 chr1_20881891-20881891_G_A 769R>W Substitution   
CGOV62 KIF3C chr2_26057741-26057741_C_T 184V>I Substitution   
CGOV62 PRSS23 chr6_84290919-84290919_G_T 347G>V Substitution   
CGOV62 RANBP2 chr2_108746226-108746226_G_T 933M>I Substitution   
CGOV62 SEMA3F chr3_50186311-50186311_A_G 65D>G Substitution   
CGOV62 SLC1A2 chr11_35279729-35279729_C_T 257G>E Substitution   
CGOV62 USP34 chr2_61369447-61369447_C_G 1540D>H Substitution   
CGOV62 ZBBX chr3_168482852-168482852_C_A 669A>S Substitution   
CGOV62 RHBDD1 chr2_227437667-227437667_C_G 5S>X Substitution  
CGOV62 C4orf43 chr4_164656017-164656017_G_C 114K>N Substitution   
CGOV62 C6 chr5_41212475-41212475_T_C 343N>D Substitution   
CGOV62 DUSP27 chr1_165353281-165353281_G_A 100V>I Substitution   
CGOV62 C1S chr12_7042822-7042822_G_A 225V>V Substitution   
CGOV62 ROBO1 chr3_78783747-78783747_T_A 879S>S Substitution   
CGOV62 CDKAL1 chr6_20889473-20889473_C_T 212T>T Substitution   
CGOV63 TP53 chr17_7518915-7518915_T_C 220Y>C Substitution   
CGOV63 CAPZA3 chr12_18783119-18783119_A_T 217N>I Substitution   
CGOV63 CLSPN chr1_35975230-35975230_C_A 1261A>S Substitution   
CGOV63 HCK chr20_30135444-30135444_G_A 186G>S Substitution   
CGOV63 LINGO4 chr1_150041185-150041185_A_G 207V>A Substitution   
CGOV63 ATP2B3 chrX_152468932-152468932_T_C 606L>S Substitution   
CGOV63 C12orf43 chr12_119926461-119926461_A_C 223S>A Substitution   
CGOV63 CSMD1 chr8_3002824-3002824_A_T NA Substitution    
CGOV63 LRRC15 chr3_195562695-195562695_C_T 125D>N Substitution   
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CGOV63 NID1 chr1_234268097-234268097_G_T 405D>E Substitution   
CGOV63 SFMBT2 chr10_7270604-7270604_G_A 599T>M Substitution   
CGOV63 KIF13A chr6_17902580-17902580_G_A 1034T>M Substitution   
CGOV63 SEPT6 chrX_118634735-118634735_T_G NA Substitution    
CGOV63 RPS6KA5 chr14_90408176-90408176_C_G 802A>P Substitution   
CGOV63 SILV chr12_54641402-54641402_C_A 100G>G Substitution   
CGOV63 MACF1 chr1_39556802-39556802_C_G 1296A>A Substitution   
CGOV63 FAM135B chr8_139222687-139222687_C_T 1242T>T Substitution   
CGOV63 DGKB chr7_14847378-14847378_A_T 12P>P Substitution   
CGOV63 CA6 chr1_8934113-8934113_G_A 102G>R Substitution   
CGOV63 CAPRIN2 chr12_30775683-30775683_T_G 307K>N Substitution   
CGOV63 CDH5 chr16_64979793-64979793_G_C 189V>L Substitution   
CGOV63 CWC22 chr2_180527216-180527216_C_A 550M>I Substitution   
CGOV63 ACVR1C chr2_158107536-158107536_C_T 343G>E Substitution   
CGOV63 CARD8 chr19_53427033-53427033_T_C 13I>V Substitution   
CGOV63 SLC17A6 chr11_22355858-22355858_C_G 582S>X Substitution  
CGOV63 SORCS3 chr10_106889224-106889224_C_T 431S>L Substitution   
CGOV63 SHH chr7_155291969-155291969_T_A 115N>I Substitution   
CGOV63 SLC44A3 chr1_95062777-95062777_A_T 44K>N Substitution   
CGOV63 CEP135 chr4_56526612-56526612_C_T 292R>X Substitution  
CGOV63 PHOX2B chr4_41445374-41445374_A_G 4M>T Substitution   
CGOV63 STX11 chr6_144549963-144549963_G_C 169G>A Substitution   
CGOV63 TTN chr2_179152719-179152719_A_T 18465I>N Substitution   
CGOV63 DNAH3 chr16_20906631-20906631_C_T 2256R>K Substitution   
CGOV63 UROC1 chr3_127709522-127709522_C_T 173R>Q Substitution   
CGOV63 C1orf174 chr1_3799395-3799395_G_T 14A>E Substitution   
CGOV63 C2orf21 chr2_210349005-210349005_A_T 97N>Y Substitution   
CGOV63 NFS1 chr20_33724100-33724100_C_G 434R>P Substitution   
CGOV63 PTPRJ chr11_48115265-48115265_G_T 670A>S Substitution   
CGOV63 RDH10 chr8_74395748-74395748_G_C 218V>L Substitution   
CGOV63 UNC13A chr19_17602058-17602058_C_T 1277V>M Substitution   
CGOV63 ERBB3 chr12_54765120-54765120_C_T 103R>R Substitution   
CGOV63 OR4F15 chr15_100175930-100175930_C_T 6H>H Substitution   
CGOV63 TARBP1 chr1_232631902-232631902_A_G 918F>F Substitution   
CGOV63 DLEC1 chr3_38079117-38079117_A_G 305L>L Substitution   
CGOV63 FAM135B chr8_139234202-139234202_A_G 566A>A Substitution   
CGOV63 ZNF462 chr9_108731027-108731027_G_T 1671T>T Substitution   
CGOV63 C9orf152 chr9_112003385-112003385_T_C 107Q>Q Substitution   
CGOV63 INTS9 chr8_28694344-28694344_G_A 395T>T Substitution   
CGOV63 GJB1 chrX_70360789-70360789_C_T 169D>D Substitution   
CGOV63 C16orf68 chr16_8630324-8630324_G_A 124V>M Substitution   
CGOV63 IGF2R chr6_160402544-160402544_C_T 1094Y>Y Substitution   
CGOV63 C7orf62 chr7_88261610-88261610_C_A 195G>X Substitution  
 101 
CGOV63 CLCC1 chr1_109287998-109287998_G_C 182P>A Substitution   
CGOV63 CSMD1 chr8_3002856-3002856_G_A 1962P>L Substitution   
CGOV63 KIAA1217 chr10_24871693-24871693_G_C 1200M>I Substitution   
CGOV63 MUC7 chr4_71381361-71381361_C_ NA Deletion  
CGOV63 NPHS2 chr1_177792953-177792953_A_T 190D>E Substitution   
CGOV63 HTR1E chr6_87782039-87782039_C_G 90L>V Substitution   
CGOV63 TMEM62 chr15_41263804-41263804_C_T 554R>W Substitution   
CGOV63 TWISTNB chr7_19704504-19704504_T_C 326K>R Substitution   
CGOV63 AADACL2 chr3_152957546-152957546_C_G 205S>C Substitution   
CGOV63 ABI2 chr2_203975666-203975666_C_A 319Q>K Substitution   
CGOV63 NRK chrX_105040120-105040120_C_T 611P>S Substitution   
CGOV63 TRIM35 chr8_27207719-27207719_C_T 186R>Q Substitution   
CGOV63 ZNF345 chr19_42059738-42059738_C_T 56H>Y Substitution   
CGOV63 TRIP12 chr2_230378721-230378721_T_C 798R>R Substitution   
CGOV280 TP53 chr17_7577608-7577609_CC_AG CC>AG Substitution    
CGOV280 TTN chr2_179485244-179485244_G_C 15335T>S Substitution   
CGOV280 MTA3 chr2_42806274-42806274_G_T 42V>L Substitution   
CGOV280 GPR158 chr10_25887561-25887561_C_A 1002D>E Substitution   
CGOV280 ZMIZ2 chr7_44800129-44800129_G_T 393V>F Substitution   
CGOV280 CACNA1C chr12_2721166-2721166_C_A 1292A>D Substitution   
CGOV280 PDE2A chr11_72300794-72300794_C_T 873+1G>A Substitution    
CGOV280 PREX1 chr20_47317360-47317360_G_A 283A>V Substitution   
CGOV280 DUSP27 chr1_167097006-167097006_G_A 880D>N Substitution   
CGOV280 ABCA13 chr7_48311895-48311895_C_T 878H>Y Substitution   
CGOV280 ASB15 chr7_123270086-123270086_G_T 503D>Y Substitution   
CGOV280 DNAH3 chr16_20976175-20976175_C_T 3011A>T Substitution   
CGOV280 CCR2 chr3_46399061-46399061_G_T 15E>X Substitution  
CGOV280 TMEM64 chr8_91637909-91637909_T_C 378N>S Substitution   
CGOV280 TRIML1 chr4_189068417-189068417_C_T 433P>L Substitution   
CGOV280 PCDHGB4 chr5_140768673-140768673_C_A 408L>I Substitution   
CGOV280 TRHR chr8_110131470-110131470_G_A 328R>H Substitution   
CGOV280 SHPRH chr6_146264286-146264286_C_T 744R>Q Substitution   
CGOV280 ZMYM6 chr1_35454118-35454118_T_C 855P>P Substitution   
CGOV280 C1orf173 chr1_75038703-75038703_C_T 897Q>Q Substitution   
CGOV280 FLG2 chr1_152330070-152330070_A_G 64D>D Substitution   
CGOV280 GPR25 chr1_200842228-200842228_G_A 21L>L Substitution   
CGOV280 XIRP2 chr2_168105159-168105159_G_A 2419L>L Substitution   
CGOV280 INPP5E chr9_139324785-139324785_G_A 582S>S Substitution   
CGOV280 MS4A14 chr11_60165354-60165354_T_A 56I>I Substitution   
CGOV280 LRP1 chr12_57588868-57588868_C_T 2764D>D Substitution   
CGOV280 SETBP1 chr18_42456670-42456670_C_T 227L>L Substitution   
CGOV280 ISM1 chr20_13279761-13279761_C_T 350D>D Substitution   
CGOV280 LPIN3 chr20_39985745-39985745_C_A 623G>G Substitution   
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CGOV280 ADAMTSL4 chr1_150532645-150532645_G_A 1066L>L Substitution   
CGOV280 NALCN chr13_101795467-101795467_G_A 694R>R Substitution   
CGOV280 SLX4 chr16_3641293-3641293_G_C 782L>L Substitution   
CGOV280 ST18 chr8_53084937-53084937_C_T 162D>N Substitution   
CGOV280 SETD2 chr3_47163976-47163976_G_A 717S>L Substitution   
CGOV280 TTN chr2_179485244-179485244_G_C 15335T>S Substitution   
CGOV280 NOS1AP chr1_162337128-162337128_G_A 464S>S Substitution   
CGOV280 FOXG1 chr14_29237277-29237277_G_C 264V>V Substitution   
CGOV280 NPAP1 chr15_24922100-24922100_T_G 362V>V Substitution   
CGOV280 IQSEC1 chr3_12983221-12983221_C_T 70S>S Substitution   
CGOV280 POU3F2 chr6_99283727-99283727_T_A 326P>P Substitution   
CGOV280 STK36 chr2_219561851-219561851_C_T 892P>P Substitution   
CGOV280 GRM7 chr3_6903534-6903534_G_C 153V>V Substitution   
CGOV280 ZNF804B chr7_88964426-88964426_C_G 710S>S Substitution   
CGOV280 ZFHX4 chr8_77767608-77767608_C_T 2817D>D Substitution   
CGOV280 EFCAB4B chr12_3789435-3789435_A_G 103Y>Y Substitution   
CGOV280 PARN chr16_14676132-14676132_A_G 366F>F Substitution   
CGOV280 REV3L chr6_111696849-111696849_C_T 903T>T Substitution   
CGOV280 RHBDL3 chr17_30615900-30615900_G_A 128G>G Substitution   
CGOV280 MRPS12 chr19_39423121-39423121_T_C 66F>F Substitution   
CGOV280 CDC5L chr6_44413454-44413454_A_G 718K>K Substitution   
CGOV280 PPP1CC chr12_111160453-111160453_G_T 191R>R Substitution   
CGOV280 EYA3 chr1_28339722-28339722_A_C 223T>T Substitution   
CGOV280 DNAH6 chr2_84931424-84931424_C_G 2821A>A Substitution   
CGOV280 CACNB4 chr2_152717295-152717295_A_T 266A>A Substitution   
CGOV280 ZKSCAN8 chr6_28121474-28121474_G_A 472R>R Substitution   
CGOV280 GALNT16 chr14_69813784-69813784_C_T 433G>G Substitution   
CGOV280 GPRC5B chr16_19883244-19883244_G_A 308F>F Substitution   
CGOV280 PER1 chr17_8052080-8052080_C_T 310G>G Substitution   
CGOV280 SAMD4B chr19_39868415-39868415_C_T 465P>P Substitution   
CGOV280 GP6 chr19_55543619-55543619_T_G 71A>A Substitution   
CGOV279 TP53 chr17_7577120-7577120_C_T 273R>H Substitution   
CGOV279 KCNJ10 chr1_160011319-160011319_T_G 335K>T Substitution   
CGOV279 ATP13A3 chr3_194126806-194126806_C_A 1175A>S Substitution   
CGOV279 CD14 chr5_140011816-140011820_GGGCT_ Q250Pfs*17 Deletion  
CGOV279 TRPC7 chr5_135692883-135692883_C_A 65E>X Substitution  
CGOV279 SLC13A3 chr20_45242320-45242320_C_T 52W>X Substitution  
CGOV279 IGSF21 chr1_18691928-18691928_C_A 251T>N Substitution   
CGOV279 OR8S1 chr12_48920186-48920186_C_T 258R>C Substitution   
CGOV279 SLC41A3 chr3_125786851-125786851_A_G 71V>A Substitution   
CGOV279 KIAA1614 chr1_180885486-180885486_C_G 83L>V Substitution   
CGOV279 ATN1 chr12_7045885-7045885_A_G 485Q>Q Substitution   
CGOV279 NOL4 chr18_31803134-31803134_C_T 28V>V Substitution   
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CGOV279 OR10W1 chr11_58034983-58034983_G_T 116A>A Substitution   
CGOV279 GRIN2B chr12_14019002-14019002_C_T 47E>E Substitution   
CGOV279 SV2C chr5_75428010-75428010_C_T 145C>C Substitution   
CGOV279 ARAP3 chr5_141041269-141041269_A_T 1034L>H Substitution   
CGOV279 EVC2 chr4_5642363-5642363_T_C 450K>E Substitution   
CGOV279 LAMA5 chr20_60885984-60885984_G_C 3419R>G Substitution   
CGOV279 MCL1 chr1_150551505-150551505_C_G 168E>Q Substitution   
CGOV279 SP9 chr2_175201323-175201323_C_A 170G>G Substitution   
CGOV279 DLG5 chr10_79581731-79581731_C_T 837Q>Q Substitution   
CGOV279 VPS16 chr20_2841211-2841211_C_G 162L>L Substitution   
CGOV279 C20orf194 chr20_3297403-3297403_C_T 502L>L Substitution   
CGOV279 KCNQ2 chr20_62071011-62071011_G_A 289N>N Substitution   
CGOV279 MB chr22_36007027-36007027_A_G 74G>G Substitution   
CGOV278 TP53 chr17_7579420-7579420__G S90Lfs*59 Insertion  
CGOV278 TMPPE chr3_33134370-33134370_T_A 440S>C Substitution   
CGOV278 BAHCC1 chr17_79409990-79409990_C_G 484Q>E Substitution   
CGOV278 NLRP5 chr19_56538687-56538687_G_T 363G>V Substitution   
CGOV278 CTNND2 chr5_11159773-11159773_C_G 692G>R Substitution   
CGOV278 METAP2 chr12_95876989-95876989_A_T 260-2A>T Substitution    
CGOV278 KCNAB1 chr3_156009832-156009832_A_G 46I>V Substitution   
CGOV278 IGHMBP2 chr11_68701367-68701367_C_G 508S>W Substitution   
CGOV278 GPATCH1 chr19_33617638-33617638_C_T 922R>W Substitution   
CGOV278 AHDC1 chr1_27874973-27874973_G_C 1218N>K Substitution   
CGOV278 COL6A5 chr3_130095274-130095274_A_G 88K>E Substitution   
CGOV278 LMAN2 chr5_176764224-176764224_C_A 235E>X Substitution  
CGOV278 KRT3 chr12_53189429-53189429_C_T 133G>E Substitution   
CGOV278 CREB3L1 chr11_46334423-46334423_G_C 328E>D Substitution   
CGOV278 SERINC2 chr1_31905910-31905910_A_G 379A>A Substitution   
CGOV278 MPZ chr1_161275904-161275904_C_A 213G>G Substitution   
CGOV278 PTPRN chr2_220161170-220161170_G_A 793D>D Substitution   
CGOV278 RAD9A chr11_67163393-67163393_C_G 190A>A Substitution   
CGOV278 SMARCA4 chr19_11129684-11129684_G_A 830V>V Substitution   
CGOV278 ELL chr19_18632830-18632830_C_A 12L>L Substitution   
CGOV278 EPPIN-WFDC6 chr20_44174372-44174372_T_C 43Q>Q Substitution   
CGOV278 MACF1 chr1_39748874-39748874_G_T 242D>Y Substitution   
CGOV278 ACTL10 chr20_32255958-32255958_C_A 219L>M Substitution   
CGOV278 HKDC1 chr10_71016879-71016879_A_G 642R>G Substitution   
CGOV278 LCK chr1_32740686-32740686_T_G 278+2T>G Substitution    
CGOV278 MAGEC1 chrX_140995655-140995655_C_A 822S>X Substitution  
CGOV278 RNF148 chr7_122342318-122342318_T_C 163I>V Substitution   
CGOV278 SETD1A chr16_30970105-30970105_G_A 18R>Q Substitution   
CGOV278 SH3PXD2B chr5_171765653-171765653_C_T 819R>Q Substitution   
CGOV278 SYT12 chr11_66812066-66812066_C_T 280A>A Substitution   
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CGOV278 NPFFR1 chr10_72015016-72015016_G_C 330G>G Substitution   
CGOV278 ABCG8 chr2_44102365-44102365_A_C 523P>P Substitution   
CGOV278 PCK2 chr14_24567871-24567871_G_A 216Q>Q Substitution   
















































Supplementary Data 2.6. Recurrent Somatic Sequence Alterations 
Case ID Gene Symbol Name 
 




   
CGOV65 ABCA13 ATP-binding cassette; sub-family A (ABC1); member 13      
 
 
CGOV280 ABCA13 ATP-binding cassette, sub-family A (ABC1), member 13      
 
 
CGOV64 CWC22 CWC22 spliceosome-associated protein homolog (S. cerevisiae)      
 
 
CGOV63 CWC22 CWC22 spliceosome-associated protein homolog (S. cerevisiae)      
 
 
CGOV63 DNAH3 dynein; axonemal; heavy chain 3      
 
 
CGOV280 DNAH3 dynein, axonemal, heavy chain 3      
 
 
CGOV64 DUSP27 dual specificity phosphatase 27 (putative)      
 
 
CGOV62 DUSP27 dual specificity phosphatase 27 (putative)      
 
 
CGOV280 DUSP27 dual specificity phosphatase 27 (putative)      
 
 
CGOV65 KIF13A kinesin-like protein KIF13A isoform a      
 
 
CGOV63 KIF13A kinesin-like protein KIF13A isoform a      
 
 
CGOV65 PIK3R5 phosphoinositide-3-kinase; regulatory subunit 5      
 
 
CGOV64 PIK3R5 phosphoinositide-3-kinase; regulatory subunit 5      
 
 
CGOV65 TP53 tumor protein p53      
 
 
CGOV64 TP53 tumor protein p53      
 
 
CGOV62 TP53 tumor protein p53      
 
 
CGOV63 TP53 tumor protein p53      
 
 
CGOV279 TP53 tumor protein p53      
 
 
CGOV278 TP53 tumor protein p53       
CGOV280 TP53 tumor protein p53         
CGOV303 TP53 tumor protein p53      
 
 
CGOV304 TP53 tumor protein p53      
 
 
CGOV64 TTN titin      
 
 




CGOV280 TTN titin      
 
 
CGOV65 WDFY4 WD repeat- and FYVE domain-containing protein 4      
 
 
CGOV64 WDFY4 WD repeat- and FYVE domain-containing protein 4      
 
 
CGOV62 WDR11 WD repeat domain 11      
 
 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Data 2.8. Regions of Allelic Imbalance in CGOV63 









               
            
chr16 17110302 65503448 48,393,146 229 0.4              
chr16 70561453 87429777 16,868,324 178 0.4              
chr17 37533817 59374080 21,840,263 156 0.4              
chr5 57790608 180601976 122,811,368 564 0.4              
chr14 60517415 72510617 11,993,202 57 0.4              
chr14 90953252 101877424 10,924,172 100 0.4              
chr4 120643177 154733172 34,089,995 67 0.4              
chr4 154733172 177319063 22,585,891 42 0.4              
chr4 178499778 189259414 10,759,636 39 0.4              
chr10 18997653 31174220 12,176,567 54 0.4              
chr10 42926693 93658090 50,731,397 167 0.4              


































Supplementary Data 2.9. Regions of Allelic Imbalance in CGOV280 









              
          
chr15 22925851 102264304 79,338,453 529 0            
chr17 131516 20914635 20,783,119 328 0            
chr17 26676135 72889676 46,213,541 409 0            
chr18 196829 77918221 77,721,392 271 0            
chr19 30314666 41386171 11,071,505 194 0            
chr4 8608634 189061036 180,452,402 545 0            
chr6 348906 29798083 29,449,177 187 0            
chr6 39864730 51732807 11,868,077 86 0            
chr6 62390916 121629167 59,238,251 221 0            
chr6 122766138 168459845 45,693,707 202 0            
chr7 1132153 18788589 17,656,436 112 0            
chr9 117877 140865989 140,748,112 679 0            
chrX 3021798 23898946 20,877,148 43 0            
chrX 23928489 153694187 129,765,698 250 0            
chr7 112724417 158902567 46,178,150 278 0            
chr1 1663861 28209366 26,545,505 294 0            
chr13 21063524 102367888 81,304,364 237 0            
chr13 103346659 115047305 11,700,646 72 0            


























Supplementary Data 2.10. Regions of Allelic Imbalance in CGOV279 









   
    
       
        
chr16 56362725 70817982 14,455,257 155 0.4          
chr16 77769897 90095597 12,325,700 226 0.4          
chr17 9764531 21075343 11,310,812 120 0.4          
chr17 29852092 72959000 43,106,908 573 0.4          
chr8 41525914 66517486 24,991,572 44 0.4          
chr8 120744349 144895553 24,151,204 171 0.4          
chr18 50683691 77896308 27,212,617 127 0.4          
chr2 98277090 109106381 10,829,291 66 0.4          
chr3 391100 13368892 12,977,792 88 0.4          
chr8 75924820 95531419 19,606,599 48 0.4          
chr9 286593 21007935 20,721,342 123 0.4          
chr9 71098987 100995721 29,896,734 190 0.4          
chr2 135180550 153514583 18,334,033 62 0.4          
chr2 69659126 96780986 27,121,860 124 0.4          
chr11 16133413 46406767 30,273,354 135 0.4          






























Supplementary Data 2.11. Regions of Allelic Imbalance in CGOV278 









        
      
chr1 1226102 16385250 15,159,148 185 0.        
chr11 67051857 134244123 67,192,266 311 0.        
chr13 22255167 53422553 31,167,386 108 0.        
chr13 67800935 115091399 47,290,464 103 0.        
chr15 38988760 101924546 62,935,786 402 0.        
chr16 53262964 70818759 17,555,795 109 0.        
chr17 648186 19729495 19,081,309 297 0.        
chr17 26676135 81050982 54,374,847 531 0.        
chr18 20953720 34850846 13,897,126 33 0.        
chr18 43310415 77896242 34,585,827 119 0.        
chr19 308662 12186761 11,878,099 422 0.        
chr2 224919 11924950 11,700,031 41 0.        
chr21 11098626 47970581 36,871,955 233 0.        
chr22 17264904 48940644 31,675,740 274 0.        
chr3 29529907 51971382 22,441,475 147 0.        
chr4 4249297 190862155 186,612,858 414 0.        
chr5 74651084 135692575 61,041,491 149 0.        
chr5 137426447 178419288 40,992,841 235 0.        
chr8 196274 33416222 33,219,948 168 0.        
chr9 214864 20765097 20,550,233 63 0.        
chr9 27455095 140786516 113,331,421 476 0.        
chrX 2825403 154020114 151,194,711 155 0.        
chr6 156275691 170871046 14,595,355 49 0.        
chr10 97116219 134145166 37,028,947 227 0.        
chr20 4776445 14830596 10,054,151 25 0.        
chr10 15106441 26505822 11,399,381 39 0.        






















INTEGRATED GENOMIC, EPIGENOMIC, AND EXPRESSION ANALYSES OF OVARIAN 






Cell Lines and Growth Analyses 
 
All samples were obtained under Institutional Review Board–approved protocols with informed 
consent for research use or were publicly available. Cells were plated into 24-well tissue culture 
plates at a density of 2×105 to 5×105 cells per well and grown in cell line-specific medium without 
or with increasing concentrations of their respective drugs (ranging between 0.001 and 10 μm/L). 
Cells were counted on day 7 using an automated cell viability assay (Vi-CELL XR Cell Viability 
Analyzer; Beckman Coulter, Fullerton, CA), a video imaging system that uses an automated trypan 
blue exclusion protocol. Both adherent and floating viable cells were counted for treatment and 
control wells. Growth inhibition (GI) was calculated as a percentage of untreated controls. The log 
of the fractional GI was then plotted against the log of the drug concentration and the IC50 values 
were interpolated from the resulting linear regression curve fit (CalcuSyn; Biosoft, Ferguson, MO). 




Genomic DNA from all cell lines was PCR amplified using a Geneprint 10 System (Promega, 
Madison, WI) that contains eight STR loci plus Amelogenin, a gender-determining marker. The 
PCR amplification was carried out in a GeneAmp PCR System 9700 following the manufacturer’s 
protocol. The PCR products were electrophoresed on a ABI Prism 3730xl Genetic Analyzer using 
Internal Lane Standard 600 (Promega) for sizing. Data were analyzed using GeneMapper v. 4.0 
software (Applied Biosystems, Foster City, CA). We compared our STR profiles (Johns Hopkins 
University [JHU]) for these cell lines to external STR profiles, including Korch et al59, COSMIC 
(v83; https://cancer.sanger.ac.uk/cosmic), the RIKEN BioResource Center 
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(https://www.jove.com/institutions/AS-asia/JP-japan/20278-riken-bioresource-center), or Yu 
et al.60 The average percent similarity between JHU STRs and external STRs was 98%. An external 
STR was not available for five cell lines. 
 
Whole-Genome Next-Generation Sequencing 
 
DNA was extracted from cell lines using a QIAamp DNA Blood Mini QIAcube Kit (QIAGEN, 
Valencia, CA). In brief, the samples were incubated in proteinase K for 16 hr before DNA 
extraction. DNA purification was performed using the QIAamp DNA Blood Mini QIAcube kit 
following the manufacturer’s instructions (QIAGEN, Valencia, CA). Genomic DNA from tumor 
samples were used for Illumina TruSeq library construction (Illumina, San Diego, CA) according 
to the manufacturer’s instructions. Paired-end sequencing resulting in 100 bases from each end of 
the fragments was performed using Illumina HiSeq2000 instrumentation. 
 
PCR and Sanger Sequencing 
 
PCR and Sanger sequencing confirmed the presence of fusion candidates generated by Trellis. 
Primers were designed 200 bp on either side of the junction. Primers were purchased from IDT 
(Coralville, IA) and purified by desalting. Primers and probes were resuspended to 100 μM in IDTE 
(10 mM Tris, pH 8.0; 0.1 mM EDTA) buffer and stored at −20∘C. Using the primers specific for 
each fusion, PCR amplification was performed in a 50-μL reaction volume in quadruplicate, 
consisting of 10 μL of 5X Phusion buffer, 1 μL of 10 mM dNTP, 2.5 μL of each primer at 10 μM, 
0.5 μL of HotStart Phusion, and 10 ng of cell line DNA. PCR was performed using a Bio-Rad 
S1000 Thermal Cycler. The thermal cycle was programmed for 30 s at 98∘C for 
initial denaturation, followed by 34 cycles of 10 s at 98∘C for denaturation, 30 s at 59∘C for 
annealing, 30 s at 72∘C for extension, and 5 min at 72∘C for final extension. Human mixed 
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genomic DNA (Promega, Madison, WI) and no template were used as negative controls. PCR 
products were purified using Nucleospin Gel and PCR cleanup as per the manufacturer’s 
instructions (Macherey-Nagel, Duren, Germany). PCR products were then subjected to Sanger 
sequencing using the Applied Biosystems 3730xl DNA Analyzer as per manufacturer’s instructions 
(Thermo Fisher, Waltham, MA). Output was compared to original candidate fusion sequence and 
confirmed. 
 
Droplet Digital PCR 
 
The translocation primers were designed on both sides of the translocation. One of these primers 
was used as a common primer for both the translocation and the control. A third primer was 
designed to be used in combination with the common primer to amplify the wild-type sequence of 
one of the two translocation partners. The hydrolysis probes labeled with the FAM-fluorochrome 
at the 5′ end were designed to bind specifically to the translocation PCR product, while the probes 
labeled with the HEX-fluorochrome were designed to bind specifically to the control PCR product. 
As quenchers, a ZEN quencher was used as an internal quencher, while the Iowa Black FQ-
quencher was added to the 3′ end of the probes. Probes were designed to have a higher melting 
temperature than the primers. The primers and hydrolysis probes were purchased from IDT 
(Coralville, IA). The primers were purified by desalting, while the hydrolysis probes were purified 
using high-performance liquid chromatography. Upon arrival, primers and probes were 
resuspended to 100 μM in IDTE (10 mM Tris, pH 8.0; 0.1 mM EDTA) buffer and stored at −20∘C. 
20-μL droplet digital PCR (ddPCR) reactions were prepared, using 10 μL of 2× ddPCR SuperMix 
for Probes (No dUTP) (Bio-Rad, Hercules, CA), 5–30 ng of gDNA, as quantified by the Qubit 
dsDNA high-sensitivity assay kit (Thermo Fisher Scientific, Waltham, MA), primers (each at a 
final concentration of 900 nM), probes (each at a final concentration of 250 nM), and nuclease-free 
water. Human mixed genomic DNA (Promega) was used as negative control. Droplets were 
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generated using the QX200 droplet generator (Bio-Rad) by loading the DG8 cartridge (Bio-Rad) 
with 20μL of the reaction mixture and 70μL of droplet generation oil for probes (Bio-
Rad). 40μL of droplet/oil mixture was transferred to a ddPCR 96-well plate (Bio-Rad). The plate 
was heat-sealed with a pierceable foil heat seal (Bio-Rad). A S1000 Thermal Cycler (Bio-Rad) was 
used with the following amplification protocol: enzyme activation at 95∘C for 10 min, followed by 
six cycles: denaturation at 54∘C for 30 s; annealing/extension at 60∘C for 1 min, followed by 34 
cycles: denaturation at 58°C for 30 s; and annealing/extension at 60∘C for 1 min. Following 
cycling, the samples were held at 98∘C for 10 min. Upon completion of the PCR protocol, the plate 
was read using the QX200 droplet reader (Bio-Rad). Droplet counts and amplitudes were analyzed 
with QuantaSoft software (v1.7) (Bio-Rad). 
 
Alignment and Identification of Sequence Alterations 
 
Prior to mutation calling, primary processing of sequence data for samples was performed using 
Illumina CASAVA software (v1.8.2), including masking of adaptor sequences. Sequence reads 
were aligned against the hg19 human reference genome using ELAND. 
Candidate somatic mutations in the exome, consisting of point mutations, insertions, and 
deletions were identified using VariantDx30. To detect mutations that were more likely to be 
somatic, we excluded mutations that appeared in >10% of the distinct reads and mutations tagged 
as COMMON or MULT in dbSNP VCF files. Additionally, we excluded mutations without a 
record in COSMIC as well as in-frame deletions (COSMIC v72). Exceptions to the COSMIC 
requirement were mutations that predicted truncations in relevant pathways or tumor suppressor 
genes (Table S3.1e). SNPs flagged as clinically associated or reported in COSMIC were not 
excluded regardless of heterozygosity or percentage of distinct reads. All candidate somatic 
mutations were confirmed by visual inspection. Samples with more than 2,000 alterations after 
dbSNP filtering were considered hypermutators. Mutational signatures were based on the fraction 
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of mutations in each of the 96 trinucleotide contexts61. The contribution of each signature to each 
tumor sample was estimated using the deconstructSigs R package (Table S3.1n for R package 
versions). 
 
Implementation of DELLY and LUMPY 
 
Identifying probable somatic structural variants in tumor-only experimental designs is a major 
challenge. False positives arise from germline variants incorrectly reported as somatic and spurious 
alignments misinterpreted as biological variation. We considered two established tools, DELLY 
and LUMPY, for detection of structural variants62,63. Reads were aligned to the hg19 reference 
genome using BWA-MEM (version 0.7.10)64 as recommended by these methods. DELLY (version 
0.7.7) and LUMPY (version 0.2.13) were implemented using default parameters. 
 
A simple leave-one-out cross-validation experiment was implemented using 10 lymphoblastoid 
controls to evaluate the specificity of these methods for identifying somatic structural variants in a 
tumor-only experimental design. Specifically, we treated the held out sample as a tumor and 
identified germline structural alterations in the training set. Excluding structural variants identified 
in the training set, we considered any alteration identified in the held-out sample as a false positive. 
 
Implementation of Trellis 
 
Germline Filters 
Using 10 lymphoblastoid cell lines and 8 normal ovarian samples, we developed sequence and 
germline filters for the hg19 reference genome to flag regions prone to alignment artifacts and/or 
germline structural variation. Sequence filters for the hg19 reference genome that were masked 
prior to copy number analyses comprised 326.4 Mb of the genome and included non-overlapping 
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1-kb genomic intervals (bins) with average mappability less than 0.75 or GC percentage less than 
10%, as well as the gaps track from the University of California, Santa Cruz (UCSC) genome 
browser that includes heterochromatin, centromeric, and subtelomeric regions65. After removing 
these sequence filters as well as chrY (all cell lines were derived from women), we normalized the 
read depth for the remaining 2,680,222 bins. For each bin, we computed the GC-adjusted, log2-
transformed count of aligned reads. GC normalization was implemented using a loess smoother 
with span 1/3 fitted to a scatterplot of the bin-level GC and log2 count. We denote the GC-
adjusted log2 ratios (the residuals from the loess correction) by R, the mean R for a genomic region 
by R¯, and the median absolute deviation of the autosomal Rs by S. Because some bins had an 
unusually high or low number of aligned reads in multiple controls, we defined bin i in normal 
control j as an outlier if |Ri|>(3×Sj). Bins identified as an outlier in two or more normal controls 
were flagged. These analyses flagged 55,764 genomic regions totaling 75.9 Mb of sequence. To 
identify somatic copy number alterations, we segmented the Rs using circular binary segmentation 
implemented in the R package DNAcopy with settings alpha = 0.001, undo.splits = ‘sdundo’, and 
undo.SD = 266,67. To exclude regions that were either copy number altered in the 
lymphoblastoid cell lines as well as segments that span difficult regions to genotype, we flagged 
segments having |R¯|>1. We flagged a total of 919 segments (46.8 Mb) across the 18 normal 
controls. 
 
To characterize copy neutral rearrangements including inversions and translocations in the normal 
controls, we extracted all read pairs from the BAM file that were improperly paired and for which 
the intra-mate distance between paired reads was at least 10 kb. We defined a cluster of improper 
read pairs as a genomic region where at least one base is spanned by five or more improper reads 
and for which the union of the aligned regions is at least 115 bp. Next, we linked these clusters by 
the mates of the constituent reads. Clusters that could not be linked by at least five read pairs were 
excluded from further analysis. For all linked clusters, we required at least 90% of the linking read 
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pairs to support the same structural variant group (Table S3.1l). Linked clusters for which the type 
of rearrangement was not consistent among the linking read pairs were excluded from further 
analysis. For the remaining linked clusters, we realigned all the reads supporting the link using the 
local aligner BLAT (Kent, 2002). A command-line version of BLAT was utilized for this step 
(Standalone BLAT v. 35). Confirmation by BLAT required that the reads only align to one location 
with a BLAT score ≥ 90% in the hg19 reference genome. These germline rearrangements were 
used to screen candidate somatic rearrangements as described in greater detail below. 
 
Somatic Deletions 
Putative focal homozygous and hemizygous deletions greater than 2 kb and less than 3 Mb in the 
ovarian cell lines were identified by R¯<−3 and R¯∈(−3,−0.75], respectively. We excluded focal 
deletions in tumor samples if ≥75% of the region was identified as a deletion in a control sample. 
For each deletion, we investigated whether any improperly paired reads were aligned within 5 kb 
of the segmentation boundaries. When five or more rearranged read pairs were aligned near the 
segmentation boundaries, the distribution of the improper read pair alignments was used to further 
resolve the genomic coordinates of the deletion boundaries. Resolution of the deletion breakpoints 
using this approach depends on the intra-mate distance of the improperly paired reads. On average, 
the intra-mate distance in the ovarian tumors was 262 bp (5th and 95th percentiles, 183 and 353). 
With multiple rearranged read pairs, we expect that the resolution of the deletion breakpoints was 
generally less than 100 bp. As previously described, realignment by BLAT was used to confirm 
that the rearranged read pairs supporting the deletion mapped uniquely and with high fidelity to 
this region of the genome. Hemizygous and homozygous deletions supported by rearranged read 
pairs were indicated by hemizygous+ or homozygous+, respectively. Any deletion for which the 
outlier bins or germline CNVs occupied 75% or more of the width were excluded. Hemizygous 
deletions not supported by rearranged read pairs were also excluded. All deletions were confirmed 




To identify focal amplicons and establish how these amplicons were linked in the tumor genome, 
we seeded a graph with high-copy focal amplicons. Specifically, putative amplifications were 
identified as segments with R¯>1.46, or a 2.75-fold increase from the mean ploidy of the cell line, 
and between 2 kb and 3 Mb in length. Properly paired reads were used to link seed amplicons to 
adjacent low-copy duplications (segments with R¯>0.81 or fold change of 1.75). When five or 
more links were established, the low-copy segments were added as nodes to the graph with an edge 
indicating the connection between the high- and low-copy amplicons. Similarly, we established 
links between the low- and high-copy amplicons that were non-adjacent with respect to the 
reference genome by analysis of improperly paired reads as previously described. 
 
Somatic Copy-Neutral Intra- and Inter-chromosomal Translocations and Inversions 
Candidate somatic copy-neutral rearrangements were identified as previously described in the 
control samples. However, rearrangements in the ovarian tumor cell lines that overlapped any 
rearrangement identified in the controls samples were excluded. In addition to improperly paired 
reads, we required at least one split read supporting the rearrangement. To identify split read 
alignments, we extracted all read pairs for which only one read in the pair was aligned within 5 kb 
of the candidate rearrangement. For all such read pairs, we re-aligned the unmapped mate using 
BLAT68. A read aligned by BLAT to both ends of the candidate sequence junction with a combined 
score ≥90% constituted a split read (e.g., Figure S3.6). 
 
In-Frame Gene Fusions 
To report candidate gene fusions, we identified all candidate somatic rearrangements for which 
both ends of the novel adjacency in the tumor genome was in a coding region of the genome or a 
promoter of a gene defined as within 5 kb of the transcription start site. Rearrangements in which 
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both ends resided in the same gene were excluded as these may represent alternative isoforms. For 
each candidate fusion, we evaluated two possible orientations of the regions joined in the tumor 
genome, and for each orientation we extracted the full amino acid sequence of both 
the 5′ and 3′ transcripts as well as the candidate amino acid sequence that would be created by the 
fusion. We considered the fusion to be in-frame if the amino acid sequence of the 3′ partner was a 
subsequence of the reference amino acid sequence. 
 
Genome-wide Methylation Analyses 
 
We pre-processed and normalized raw IDAT files from the Infinimum MethylationEPIC array 
using the preprocess Funnorm function in the R package minfi Aryee et al.69. Probes on 
chromosomes X or Y, probes with detection p value greater than 0.5, or probes overlapping a SNP 
with dbSNP minor allele frequency greater than 10% were excluded. In order to understand the 
similarity of ovarian cells lines with human ovarian cancer, we compared the ovarian cells lines 
with human ovarian cancer samples available from Genomic Data Commons 
(https://gdc.cancer.gov/). The Genomic Data Commons contained 533 human methylation profiles 
of ovarian cancer and eight normal fallopian tissue samples. Methylation of TCGA ovarian cancers 
was assessed using Infinium HumanMethylation27 BeadChip array (27,578 probes). The number 
of probes in common between the HumanMethylation27 platforms and the MethylationEPIC 
platform was 18,016. On the common set of 18,016 probes, we quantified overall methylation in 
the TCGA samples and the ovarian cell lines as the fraction of CpG sites with β>0.3. To identify 
differentially methylated CpG sites comparing normal fallopian tissue to TCGA ovarian cancers, 
we selected probes from the common set of 18,016 that were hyper-methylated in TCGA ovarian 
cancer (average β>0.4) and unmethylated in normal fallopian tissue (average β<0.2). In addition, 
we also selected probes that were hypo-methylated in TCGA ovarian cancer (average β<0.1) and 
hyper-methylated in normal fallopian (average β>0.3). 
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Gene Expression Analyses 
 
Pre-processing and normalization of the 44k Agilent microarray for the ovarian cell lines has been 
previously described, and normalized expression data were available for 44 of the 45 tumors70. For 
copy number altered genes with known clinical relevance to cancer, we assessed whether amplified 
genes were overexpressed and whether deleted genes were underexpressed. The probability that a 
gene was overexpressed or underexpressed was estimated by a two-component pooled variance 
mixture model implemented in the R package CNPBayes 
(https://bioconductor.org/packages/release/bioc/html/CNPBayes.html). The location of the non-
differentially expressed mixture component was fixed at the median log2 expression of 
unmethylated cell lines without copy number alterations. A gene was considered differentially 
expressed if the posterior probability of membership in the overexpressed or underexpressed 
mixture component exceeded 0.5. 
 
Dose Response Models 
 
Bayesian Model Averaging 
We considered models of the formlogCi=γ1xi,1+…+γpxi,p,+εi,whereCi denotes 
the logIC50 and xi,j is an indicator for the alteration status (0, not altered; 1, altered) of feature j in 
cell line i. The regression coefficient for feature j is the product of a binary indicator zj and a real 
number hj. We used a modified g-prior for γ such that γj was zero whenever zj was zero71. For the 
vector of γ’s with non-zero z’s, we used a multivariate normal prior. We explored the space of the 
possible 2p models using a Gibbs sampler. The binary features comprising the x’s included somatic 
mutations, somatic structural variants (deletions, amplifications, in-frame fusions), methylation, 
and underexpression or overexpression. For the PARP inhibitor, we additionally considered the 
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number of intra-chromosomal rearrangements and the HRD score as potential markers for HRD. 
For rearrangements, we computed the mean of the square-root-transformed frequency across all 
cell lines and defined a binary covariate for whether the square-root-transformed statistic was 
greater than the mean. We used the HRD score without transformation for Bayesian model 
averaging. For the univariate analyses described in the next section, we defined a binary covariate 
for HRD according to whether the score was larger than the mean. We obtained qualitatively similar 
inferences using the continuous HRD score (data not shown). For the inhibitor of the MEK 
pathway, one of the logIC50 concentrations was missing. For this cell line, we used the posterior 
mean from the imputation described in greater detail below. 
Univariate Analysis of Selected Features 
 
For a given feature, our sampling model for the length-3 vector of inhibitor concentrations inducing 
20%, 50%, and 80% cell death is logCi, altered=μ+δ+ϵi,a lteredfor a cell line with an alteration in 
this feature and logCi,WT=μ−δ+ϵi,WT for a cell line without an alteration. With inhibitor 
concentrations on the log scale, the residuals are approximately multivariate-
normal:ϵi,j∼i.i.d. MVN(0,Σ).Computationally convenient conjugate priors for the unknown 
parameters in this model are p(μ,δ,Σ)=p(μ)p(δ)p(Σ),μ∼MVN(μ0,Σ0), δ∼MVN(δ0,Ψ0), and 
Σ−1∼W(ν0,S0−1).  For some cell lines, inhibitor concentrations were incomplete. As 
the logC were highly correlated across cell lines, we imputed missing observations from the 
observed data using a Gibbs sampler. Inference regarding differences in mean logC, given by the 
posterior distribution of 2δ, was based on the marginal probability of the observed data integrating 
over the missing data. We reported 90% highest posterior density (HPD) intervals for the difference 









We aimed to assemble a collection of ovarian cancer cell lines that would be representative of the 
different histological subtypes. These encompassed both publicly available as well as newly 
generated cell lines, ultimately comprising 19 serous, 9 clear-cell, 3 mucinous, 2 undifferentiated, 
2 endometrioid, 1 mixed, and 9 unclassified subtypes (Table S3.1a). Information related to the 
original description and classification of these cell lines is indicated in Table S3.1a, and the origin 
of the lines was confirmed using unique short tandem repeat (STR) analyses. To identify sequence 
and structural changes in these ovarian cancer cell lines, we performed next-generation whole-
genome analyses at an average coverage of 32x and 116.6 Gb per sample (Table S3.1c). As matched 
normal DNA was not available for these samples, we also sequenced a set of 18 unmatched DNA 
samples from normal blood or lymphoblastoid cell lines from individuals of various ethnicities. We 
developed approaches to focus on likely tumor-specific sequence and genome-wide structural 
changes, including amplifications, deletions, and rearrangements. In parallel, genome-wide 
methylation analyses were performed and integrated with genomic and expression data in order to 




A high-sensitivity analysis of sequence alterations, including single-base substitutions and small 
insertions and deletions, was performed for the exomes of these samples. Given the challenges of 
characterizing tumor-specific (somatic) changes in tumor samples without matched normal tissue 
30, we developed stringent bioinformatic approaches to determine likely somatic mutations. 
Removal of common germline variants resulted in an average of 928 alterations per cell line exome, 
 126 
comprising 41,768 changes that included rare germline and somatic alterations. Six cell lines (two 
clear cell and one each of endometrioid, serous, unclassified, and mixed lineage) were 
hypermutated, having alterations in mismatch repair (MMR) genes MLH1, MSH2, MSH6, or 
PMS2, and six times as many sequence changes compared to those tumors that were MMR 
proficient (Table S3.1d). To focus on likely somatic alterations involved in tumorigenesis, we 
analyzed the sequence alterations in each cell line and identified changes that have been previously 
detected in the coding genomes of other cancer patients72. We also identified nonsense or frameshift 
inactivating mutations in a panel of tumor suppressor genes (Table S3.1e). Through these analyses, 
we discovered 659 putative driver somatic mutations across 45 ovarian cell lines (Table S3.1f). 
 
The most frequently mutated gene was the TP53 tumor suppressor gene (altered in 25 non-
hypermutated and 3 hypermutated tumors). Excluding hypermutated samples, other genes 
frequently mutated included ARID1A (14 cancer cell lines), PIK3CA (6), SMAD4 (4), KRAS (4), 
APC (3), CREBBP (3), and PPP2R1A (3). Mutations were predominantly CpG transitions CT or 
GA (48%) followed by non-CpG transitions AG or CT (25%). These observations are consistent 
with mutations in TP53 in a high fraction of serous ovarian cancers16, and PIK3CA, ARID1A, and 
PPP2R1A in clear-cell tumors 31. Analysis of mutation signatures aggregated by ovarian cancer 
subtypes revealed that serous, mucinous, and undifferentiated tumor cell lines had an age-related 
signature previously reported in ovarian adenocarcinomas61. Clear-cell and serous ovarian cancers 
also had a profile consistent with a MMR-associated mutation signature, likely due to the subset of 
tumors with MMR defects in the cell lines17. Overall, both the compendium of mutated genes as 
well as mutation-associated signatures were representative of previous ovarian cancer genome 
analyses (Table S3.1f). 
 
Structural variant analyses 
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Given the importance of structural alterations in the development of ovarian cancer16,17,32 13, we 
used whole-genome sequence data to characterize copy number changes as well as rearrangements 
that may affect key driver genes. We first considered existing approaches for whole-genome 
analyses, including DELLY and LUMPY, but these typically use matched normal sequences to 
accurately identify tumor-specific rearrangements62,63. Given the multitude of tumor cell lines and 
other cancer specimens where matched normal DNA is not available, we developed a framework 
for structural variant detection called Trellis that could be used with tumor genome sequence data 
directly. Additionally, because many structural changes are linked genomically (i.e., an amplified 
gene has both copy number changes and rearrangements that can be located in multiple locations 
of the genome), we aimed to connect the multiple changes that were related to individual genetic 
targets. The features of this approach include (1) detection of tumor-only structural changes through 
removal of germline and artifactual changes, (2) distinction of focal homozygous deletions and 
amplifications from larger structural changes, (3) connection of apparently disparate copy number 
regions using paired sequences in the same amplicons, (4) detection of homozygous and 
hemizygous deletions through copy number and rearrangement data, (5) confirmation of 
rearrangements using a stringent local re-alignment to detect and remove spurious paired read and 
split alignments, and (6) identification of in-frame rearrangements that would likely lead to gene 
fusions. 
 
To implement the Trellis approach, we excluded low complexity sequences by mappability, as well 
as regions of germline copy number variants (CNVs) and rearrangements detected in the genomes 
of 18 samples derived from normal blood cells. We divided the remaining 2.7 Gb of the genome 
into 1-kb bins and examined areas of increased read density (2.75-fold) to identify copy number 
gains, and regions of decreased read density (0.6-fold) to detect hemizygous or homozygous 
deletions greater than 2 kb using approaches similar to digital karyotyping73,74. We identified 
rearrangements from atypical orientation or spacing of paired reads as well as split read alignments. 
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To evaluate the specificity of our approach in a set of non-tumor samples where we expected very 
few somatic structural changes, we used a leave-one-out cross-validation analysis among the 10 
unmatched normal blood samples. Using Trellis, these analyses identified no focal high copy gains. 
On average, we identified 5 hemizygous deletions (interquartile range, 2–15) and 1 homozygous 
deletion (interquartile range, 0–8) in the normal samples (Figure 3.2). Likewise, the average 
number of rearrangements observed per sample was 3 (interquartile range, 0–6). These 
observations are consistent with previous descriptions of germline structural changes in normal 
DNA, in particular in lymphoblastoid DNA75, and suggest a high specificity of our approach for 
detection of bona fide somatic alterations (mean specificity, 0.97). 
 
By contrast, analysis of normal samples with DELLY or LUMPY detected hundreds to thousands 
of structural changes in each normal DNA sample (Figure 3.2). With DELLY and LUMPY, the 
average numbers of focal high-quality copy number alterations were 13 and 21, respectively. The 
average numbers of intra- and inter-chromosomal rearrangements identified by DELLY were 297 
and 433, respectively, and for LUMPY these were higher, at 511 and 2203, respectively. The 
number of alterations observed by DELLY using low-stringency settings was higher yet (Figure 
3.2). False positives for copy number changes appeared to largely be due to inclusion of single-
copy gains and losses, with neither DELLY nor LUMPY distinguishing hemizygous from 
homozygous losses or single-copy gains from high-copy amplifications. The source of the 
rearrangement false positives appeared to be largely the result of mapping artifacts due to low 
sequence complexity in putative rearrangements. 
 
To assess the sensitivity of this approach, we sequenced 16 cell lines using high-coverage next-
generation sequencing of 111 genes comprising 585,216 bp. Computing the fold change of read 
depth at these targeted regions, we found four high-copy amplifications with fold change 6, nine 
 129 
low-copy amplifications with fold change  and 6, and nine homozygous deletions. Trellis detected 
all four high-copy amplifications, including amplifications of AKT2, CCNE1, and KRAS. All nine 
regions identified as low-copy amplifications by targeted sequencing were also determined to be 
low-copy amplifications by Trellis, corroborating quantitative and qualitative characteristics of the 
amplifications. Similarly, all nine deletions discovered by targeted sequencing, comprising 
CDKN2A (8) and NF1 (1), were also characterized as homozygous deletions by Trellis. Overall, 
these analyses established that the Trellis approach had both high specificity and sensitivity for 





We focused our analysis of amplifications to regions smaller than 3 Mb that were present at 2.75-
fold compared to the modal genome copy number, as such alterations have historically been linked 
to amplified driver genes74. An analysis of the 45 ovarian cancer samples identified 538 focal 
amplicons, or an average of 12 amplicons per tumor. As multiple amplicons within the same tumor 
may be derived from an amplification of a single target gene localized to different chromosomal 
regions74,76,77, we examined the possibility that amplicons may be linked. Using our paired read 
whole-genome analyses, we found that reads at the edges of many amplicons were linked with 
aberrant spacing and/or orientation with respect to the reference genome. In order to identify links 
between apparently distant amplicons, we visualized these as undirected graphs where the nodes 
were amplicons and edges between amplicons were defined by multiple paired reads aligned to 
both genomic locations (e.g., Figures 3.3A and 3.3B). Our analyses discovered 57 amplicon groups 
from the 538 amplicons across the ovarian tumor cell lines. Among tumors with at least one 
amplicon, the median number of amplicon groups was 2 and the median number of amplicons 
within an amplicon group was 4 (interquartile range, 2–9). The majority of cell lines (15/28) with 
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an amplicon group contained known driver genes. As an example, cell line ES-2 had 41 apparent 
amplicons, but through this approach we determined that 38 of the amplicons were linked to a 
single group that contained the CCND1 driver gene (Figure S4). Both the copy number (t = 3.3, p 
= 0.003) and number of connections between amplicons (t = 5.3, p  0.001) was significantly higher 
for amplicon groups containing known drivers compared to amplicon groups without known 
drivers (Figure 3C). 
 
Driver genes that were amplified in two or more cell lines as part of amplicon groups that have 
previously been observed in ovarian cancer included well-known oncogenes such as MYC (4), 
ERBB2 (2), CCND1 (2), CCNE1 (2), FGFR4 (2), and KRAS (2). Interestingly, we identified 
amplifications of cancer driver genes that have not been previously appreciated in ovarian cancer, 
including epigenetic regulator ASXL1 (2), H3 histone family member H3F3B (2), NOTCH family 
receptor NOTCH4 (1), repair and recombination paralog RAD51C (1), and ubiquitin ligase RNF43 
(1). ASXL1 amplification and overexpression have been previously identified in cervical cancer78, 
and overexpression of H3F3B has been reported in several tumor types but not ovarian cancer79.  
Several of these genes have been observed as being part of larger structural alterations in recent 
TCGA high-grade serous ovarian carcinoma analyses16 but have not been identified as target genes 
in those cases. 
 
Overall, these analyses greatly simplified the observed amplification events and revealed that many 
focal amplicons would not have been associated with driver genes had they not been linked in 
specific amplicon groups. The observed amplicons were consistent with previously detected genes 





We used a combination of stringent analyses of segmented read depth and aberrant read pair 
spacing to identify homozygous and hemizygous deletions. As deletions may occur in the germline, 
we removed deletions that were in or near structural alterations observed in the normal controls in 
order to identify those deletions that were most likely to be somatic. These analyses revealed 674 
hemizygous+, 41 overlapping hemizygous+, 286 homozygous, and 263  homozygous+ deletions, 
where “+” denotes evidence for deletion supported by rearranged read pairs in addition to read 
depth (Figures 3.3D; Table S3.1h). Deletion breakpoints with rearranged read pairs were more 
precise (typically within 100 bp), while deletions without rearranged read pairs had a resolution of 
1–5 kb. We included homozygous deletions from segmentation analyses even if these were without 
rearranged read pairs as these could have been missed in read pair analyses due to the limited 
mappability at one or both deletion breakpoints. The median number of homozygous and 
hemizygous deletions per tumor was 10.5 (interquartile range, 8–16) and 11.0 (interquartile range, 
6–18), respectively. Genes that were recurrently deleted included cell cycle regulators CDKN2A 
(9) and CDKN2B (8), tyrosine kinase receptor ERBB4 (5), neurofibromin genes NF1 (3) and NF2 
(3), transcriptional regulator CDC73 (2), polycomb-group repressor EZH2 (2), and serine/threonine 
kinase STK11 (2) (Table S1h), of which CDKN2A, NF1, NF2, and STK11 have been previously 
reported to be altered in high-grade serous ovarian carcinomas16,80.  Genes that have been 
implicated through somatic deletion in other tumors but that had not been previously implicated in 
ovarian cancer include CDC73, ERBB4, EZH2, MLH1, as well as TGF-beta pathway members 
TGFBR2, SMAD3, and SMAD4, estrogen receptor ESR1, cell cycle kinase CDK6, notch receptor 
NOTCH1, cohesin member STAG2, and epigenetic regulator ATRX (Table S3.1h). In a fashion 
similar to amplifications, several of these genes have been observed as being part of larger structural 
alterations in recent TCGA high-grade serous ovarian carcinoma analyses16 but have not been 
identified as target genes in those cases or other histologic subtypes. The absence or low frequency 
of such alterations in previous studies may in part reflect the challenges of identifying bona fide 
deletions through existing approaches in primary tumors. 
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Other recurrent deletions occurred in genes encompassing large genomic regions (>1 Mb) that were 
more likely to be affected by structural alterations, including a member of the low-density 
lipoprotein receptor family LRP1B (7), fragile histidine triad involved in purine metabolism FHIT 
(11), a member of the short-chain dehydrogenases/reductases protein family WWOX (15), and the 
deacetylase MACROD2 (7). FHIT and WWOX occur in fragile sites and are often deleted in 
cancers, and some evidence suggests they encode putative tumor suppressors 81-84.   LRP1B deletion 
has been associated with chemotherapy resistance in high-grade serous ovarian cancers and is a 
putative tumor suppressor85. Because of their proximity to CDKN2A, the methylthioadenosine 
phosphorylase MTAP and the transcription factor DMRT1 are commonly co-deleted with 
CDKN2A86, and use of compounds exploiting the loss of MTAP has been proposed as a potential 
therapeutic avenue87 for tumors with CDKN2A deletions. 
 
Rearrangements and fusions 
 
We next examined structural rearrangements that were not associated with segmental copy number 
changes. We detected 834 inter-chromosomal and 2,277 intra-chromosomal rearrangements (Table 
S3.1i). The median per sample of inter- and intra-chromosomal rearrangements was 16 
(interquartile range, 5–31) and 37 (interquartile range, 17–62), respectively, with many of these 
rearrangements involving inversions (median of 8 and 6, respectively). 
 
Among rearrangements for which the sequence junction was within the intron or exon of a gene, 
we detected 128 in-frame fusions of two genes (Table S3.1j). Several of these in-frame fusions 
have not been observed in ovarian cancer but have been previously reported in other cancers. For 
example, YAP1-MAML2 has been reported in nasopharyngeal carcinoma and salivary cancers 88-
90, IKZF2-ERBB4 has been reported in T cell lymphomas91, and fusions involving CCND1 were 
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identified in a patient with leukemic mantle cell lymphoma92. Our study discovered the YAP1-
MAML2 fusion in cell line ES-2 after exon 6 of YAP1 and before exon 2 of MAML2, preserving 
the transactivation domain of MAML2 and its likely role in Notch signaling. The predicted amino 
acid sequence of the affected MAML2 gene is the same as reported in nasopharyngeal carcinoma 
and salivary gland cancers (amino acid 172) 88-90. 
 
The IKZF2-ERBB4 fusion we identified in ovarian tumor KK involves the first three exons of 
IKZF2 and exons 2–27 of ERBB4, a member of the epidermal growth factor receptor (EGFR) 
family. This IKZF2-ERBB4 junction is nearly identical to that reported by Boddicker et al.91 in T 
cell lymphoma and mucinous lung adenocarcinoma, involving the same exons of ERBB4 and 
leaving the ERBB4 kinase domain intact. Gene expression analyses indicated that the ERBB4 
transcript, including the fusion transcript, was overexpressed. ERBB4 overexpression has been 
associated with resistance to platinum-based therapy in ovarian serous carcinomas93, suggesting a 
potentially important role for this translocation event for therapeutic selection. In ovarian tumor 
ES-2, CCND1 was amplified and also participated in a fusion where the promoter of SHANK2 was 
linked to the coding region of CCND1. An amplification and fusion involving CCND1 has been 
previously identified in a patient with leukemic mantle cell lymphoma92. Additional gene fusions 
not previously observed in ovarian cancer involved the negative regulator of the RAS pathway 
NF1, the tumor suppressor regulating mTORC1 signaling TSC2, and the member of the F-box 
protein family FBXW7. The fusion of NF1 (NF1-MYO1D) occurred after the first exon of this 
gene and would be expected to disrupt its function, consistent with its tumor-suppressive role 
Cancer Genome Atlas Research Network16. Similarly, the fusion of MLST8-TSC2 would be 
expected to result in a TSC2 protein lacking the first 373 aa, disrupting the key region of interaction 
with TSC194. As detailed below, the fusion of full-length FBXW7 to the promoter of FAM160A1 
was also likely deleterious due to decreased expression under the new promoter. For each of the 
nine predicted fusions involving at least one gene previously identified in other cancer fusions, we 
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independently validated the novel sequence junction using PCR and Sanger sequencing and a 
recently developed droplet digital PCR approach95. 
 
Epigenetic and expression analyses 
 
We next examined genome-wide methylation profiles in order to evaluate the role of epigenetic 
alterations in these ovarian cancer cell lines. Analyses of over 850,000 methylation sites were 
performed using Infinium MethylationEPIC arrays. Methylation levels were evaluated at individual 
CpG sites within gene promoter regions (1,500 bp upstream of the transcription start site) or within 
individual genes. We compared methylation levels in the ovarian cell lines to methylation levels in 
the normal lymphoblastoid cells, as well as to 8 TCGA normal fallopian tissue and 533 TCGA 
ovarian cancers. Among the 18,619 CpG probes shared by the Infinium HumanMethylation27 
BeadChip array (27,578 probes) and the MethylationEPIC array, we estimated the proportion of 
methylated CpG sites as the fraction of CpG probes with beta > 0.3 . Consistent with previous 
studies96-98, we found that the overall proportion of methylated CpG sites in the lymphoblastoid 
(median, 0.35) and ovarian cell lines (median, 0.41) was higher than the proportion in fallopian 
tissues (median, 0.30) and ovarian cancers (median, 0.29) (Figure 3.4A). Previous studies have 
suggested that differences in methylation between cell cultures and primary tumors often occur at 
genes involved in cell cycle regulation98, and may also result from contamination of normal cells 
in the primary tissues. To examine methylation profiles of the cell lines at individual CpG sites in 
the broader context of ovarian cancer methylation profiles, we identified 96 genes that were 
differentially methylated between normal fallopian tissue and 100 randomly sampled TCGA 
ovarian tumors (Figure 3.4B). While we excluded both the lymphoblastoid cell lines and the 
ovarian cancer cell lines from the probe selection procedure, the normal lymphoblastoid cell lines 
were more highly correlated to the normal fallopian tissues while the ovarian cancer cell lines were 
more correlated to the TCGA ovarian cancers. Taken together, these analyses indicate that the 
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ovarian cell lines retain epigenetic profiles of genes commonly methylated in ovarian cancer and 
that the methylation of these genes is unlikely to be related to growth in culture. 
 
We integrated our genomic and epigenetic analyses with expression data previously obtained for 
these cell lines through the Agilent 44K array70. We assessed whether specific genes affected by 
deletions or other structural changes in some tumors may be silenced through methylation and low 
expression in others. Among genes that were methylated or deleted, expression analyses revealed 
lower expression for many of these genes. Cell lines RMG-I and IGROV-1 both had hemizygous 
deletion and loss of expression of CDC73. Of the 13 drivers homozygously deleted in at least one 
tumor, five genes, including CDKN2A and ESR1, displayed loss of expression and concomitant 
promoter methylation in additional ovarian cancers (Figures 3.4C). When promoter methylation 
and underexpression were considered, the fraction of tumors with alterations in CDKN2A more 
than doubled from 23% to 55%, highlighting the multiple mechanisms by which CDKN2A function 
can be compromised. Similarly, MLH1 was mutated in a single case, but was mutated and/or 
underexpressed in an additional seven cancers. For ESR1, the inactivating methylation is thought 
to be associated with age and has been previously observed in both ovarian cancers and ovarian 
cancer cell lines99,100. Lower expression also resulted from abnormal fusion of non-adjacent 
promoters to the full coding sequence of target genes. In OVCAR-8, the fusion of the promoter of 
FAM160A1 with the full-length FBXW7 gene resulted in dramatically decreased expression of 
FBXW7, consistent with the tumor-suppressive function of this protein and inactivating mutations 
observed in other tumor types101. 
 
We also examined the possibility of increased expression for genes with structural changes. We 
identified 17 genes with focal amplification in one or more cancer cell lines and evidence of 
bimodal expression across the samples analyzed. For these genes, 20 of the 22 tumors (91%) with 
focal amplification also had increased expression. Genes associated with amplification and fusion 
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had particularly high expression, suggesting that the combination of genetic alterations led to 
increased overall transcription of these genes. The amplification of CCND1 and its fusion to 
SHANK2 in sample ES-2 increased the expression of CCND1 relative to other ovarian cell lines 
without the amplification and fusion. The YAP1-MAML2 fusion, which was also duplicated in the 
same sample, resulted in expression of MAML2 that was higher than 85% of the other ovarian 
cancer cell lines. For driver genes that were amplified, we examined whether additional tumors 
may be identified with increased expression of these genes. We found increased expression of 
CCNE1, ERBB2, KRAS, and AKT2 in eight additional cases without genomic alterations in these 
genes (Figure 3.5). These analyses indicate the importance of integrated genomic, epigenetic, and 
expression analyses and have resulted in an expansion of the number of tumors with alterations in 
key driver genes. These observations also highlight the functional consequences of genomic and 
epigenomic alterations in human cancer at the RNA level. 
 
Combining sequence and structural variants with methylation and differential gene expression, we 
found that nearly all ovarian cancer subtypes had alterations in cell cycle, chromatin remodeling, 
DNA repair, RAS, Notch, PI3K, or TGFB signaling pathways (Figure 3.5). Alterations in the cell 
cycle pathway genes, including CDKN2A, were the most common with one or more alterations in 
60%–70% of the three most represented subtypes (serous, adenocarcinoma, and clear cell). 
Chromatin modifications occur in 5/7 (71%) of the clear-cell subtypes but in only 2/21 (11%) of 
the serous samples. We see evidence of mutual exclusivity between CDKN2A, CCNE1, and RB1 
within the cell cycle pathway, but not mutual exclusivity between cell cycle and KRAS pathways, 
underscoring that clonal selection often involves multiple drivers regulating distinct molecular 
processes. 
 
Sensitivity and resistance to pathway inhibitors 
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To begin to understand the relationship between genomic, epigenetic, and expression alterations 
and response to pathway inhibitors, we developed a screening platform for evaluating cellular 
proliferation in the presence of candidate therapeutic agents. As an example of the analyses that 
can be performed and the genotype-phenotype connections that can be obtained, we measured  
IC20, IC50, and IC80 after 7 days of incubation for three inhibitors, GNE-493, BMN673, and 
MEK162, targeting PI3K, PARP, and MEK proteins, respectively (Table S3.1k). Aggregating the 
molecular information from multiple platforms to the gene level, we limited our analyses to genes 
that were altered in 3 or more of the 45 cell lines. Alterations that tend to be mutually exclusive 
between cell lines were combined, including genes in the PI3K pathway (PIK3CA and PPP2R1A) 
and the genes in the TGFBR pathway (SMAD3 and SMAD4). As tumors with homologous 
recombination deficiencies (HRDs) have been known to be sensitive to PARP inhibitors, we 
additionally added covariates summarizing the extent of genome-wide structural alterations for the 
PARP inhibitor BMN673. A priori, we hypothesized that most alterations would not modulate 
response to the targeted inhibitors. Implementing a Bayesian model averaging approach to variable 
selection as has been previously considered for other biomarkers102-104, we specified a positive prior 
probability that the coefficient for each gene is exactly zero. Given the genes or combination of 
genes and structural variant summaries, we explored the space of possible single and multi-variate 
models for logIC50 by Markov chain Monte Carlo. Relevant posterior summaries available for 
each inhibitor include the probability that the regression coefficient is non-zero and the posterior 
distribution of the regression coefficients. We used this approach to focus on those features that 
were present in at least half of the models as these had a higher probability of being predictive for 
drug response (Figure 3.6A). 
 
For PARP inhibition by BMN673, our analyses revealed that the number of genome-wide 
rearrangements and amplification of MYC were important predictors of drug sensitivity (Figure 
3.6). Importantly, the two cell lines with inactivating BRCA1/2 mutations, as well as the HRD 
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score as defined by Abkevich et al. or Swisher et al. and applied through our whole-genome 
analyses, and PARP1 expression showed a trend toward increased sensitivity to PARP inhibition 
but were not statistically significant (Figure 3.6). We found that amplification of MYC or an 
increase in the number of genome-wide rearrangements, including inversions and intra-
chromosomal rearrangements, were significantly associated with sensitivity to this therapy, 
appearing in 94% of the single-variate and multi-variate models. We estimated the difference of 
the mean log IC50  between the group of tumors with alterations in these features and the group of 
tumors without such changes, revealing a 93% (90% confidence interval [CI], 99%–64%) and 86% 
(90% CI, 96%–43%) increased sensitivity to PARP inhibition for cell lines with MYC 
amplification and increased rearrangements, respectively (Figure 3.6). Although other genomic 
signatures and PARP1 expression have been suggested as biomarkers for PARP sensitivity105, 
MYC amplification and rearrangements have not been previously identified as markers of PARP 
sensitivity in serous and endometrioid ovarian cancers. Taken together, these observations suggest 
that alterations of common drivers along with large-scale structural alterations in ovarian cancer 
may identify tumors with high sensitivity to this therapy. 
 
For inhibition of the PI3K pathway by GNE-493, mutations of PPP2R1A or PIK3CA appeared in 
more than 75% of the models evaluated. Cancer cell lines with mutations in PARP1 or PPP2R1A 
had a 66% increased sensitivity to GNE-493 (Figure 3.6). PPP2R1A is a subunit of protein 
phosphatase 2A (PP2A), a known tumor suppressor and regulator of PI3K signaling through AKT 
inhibition106. Somatic mutations in PIK3CA and PPP2R1 have been previously reported in ovarian 
and uterine cancers13,30,107,108.  Our observations suggest that PI3K inhibitors counter the loss of 




For the MEK pathway, mutations or deletions in SMAD3 or SMAD4 were predictive of  IC50 levels 
in response to the inhibitor MEK-162. These were selected in more than 85% of the models and 
resulted in an increased sensitivity of 89% to this therapy. SMAD3 and SMAD4 form a complex 
that activates transcription of TGF-beta-regulated genes important in cellular growth control109. 
Our results are consistent with previous observations showing that loss of SMAD4 can lead to 
activation of Smad-independent MEK/ERK pathway signaling and that inhibition of this pathway 




Figure 3.1. Overview of Genomic, Epigenomic, Expression, and Therapeutic Analyses of 




Figure 3.2. Number of False-Positive Somatic Structural Variant Identifications in 
Lymphoblastoid Cell Lines. (A and B) Estimated number of false-positive somatic deletions and 




Figure 3.3. Trellis Approach for Characterization of Genomic Structural Alterations. (A) 
Circos plot displaying focal deletions (green), amplifications (orange), and intra- and inter-
chromosomal rearrangements (blue) for cell line FU-OV-1. (B) Improperly paired reads established 
connections (edges) between distant amplicons (nodes) visualized as a graph. The size of the 
plotting symbols is proportional to the number of sites in which the amplicon was inserted, and the 
triangle shape indicates an amplicon involving a known driver. (C) The average maximum copy 
number (top) and mean number of amplicon links (bottom) for amplicon groups with and without 
drivers. (D) Top: Segmented normalized coverage identified a homozygous deletion (shaded). 
Bottom: Rearranged read pairs improved the precision of the deletion breakpoints. Lines 
connecting the read pairs indicate whether the positive or negative strand was sequenced (blue, 




Figure 3.4. Methylation of CpG Sites in Ovarian Cancers and Normal Fallopian Tissue. (A) 
The proportion of methylated CpG sites (mean ) in the lymphoblastoid cell lines, ovarian cell lines, 
TCGA ovarian cancers, and TCGA normal fallopian tissues. (B) Plotted are 96 probes that were 
differentially methylated between normal TCGA fallopian tissue and 100 randomly selected TCGA 
ovarian tumors (blue points, A). Among these probes, the lymphoblastoid cell lines were most 
correlated with normal fallopian tissue and the ovarian cell lines were most correlated with TCGA 
ovarian tumors, suggesting that the cell line effect does not dominate among probes that were 
differentially methylated in these tissues. Among probes that were methylated in TCGA ovarian 
and unmethylated in TCGA fallopian, the ovarian cell lines were predominantly methylated and 
have quantitatively higher β values. While copy number analyses suggested that the purity in the 
ovarian cell lines was , the median tumor purity of TCGA ovarian tumors was 85% (interquartile 
range, 78%–88%). (C) Genes CDKN2A and ESR1 exhibit bimodal gene expression explained by 




Figure 3.5. Sequence, Structural, Epigenomic, and Expression Alterations in Ovarian Cancer 
Cell Lines. Cell lines were grouped by tumor subtype (E, endometrioid; Und, undifferentiated; M, 
mixed). For many of the pathways, mutual exclusivity of genomic alterations within the pathway 
is evident (e.g., cell cycle, TK receptors, TGFBR, BRCA, and WNT). The group indicated as Other 
contains genes that are clinically relevant for ovarian cancer but cannot be easily categorized by a 
single molecular process. Methylation and expression were not evaluated for the Large Gene group. 
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Figure 3.6. Sensitivity and Resistance to Pathway Inhibitors. (A) Bayesian model averaging 
was used to identify features associated with response to drug. Features selected in fewer than half 
of the multi-variate models have a posterior probability of being non-zero ≤ 0.5 (vertical dashed 
line, left) and a posterior median of zero (right). (B) Boxplots of inhibitor concentrations for 
features selected by this approach, as well as HRD, PARP1, and BRCA1/2 (left). The two cell 
lines with BRCA1/2 mutations are indicated by triangles in the PARP pathway. Right: The 
difference in mean logIC50 concentrations by alteration status and the 90% highest posterior 
density (HPD) interval for the difference. 
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Table S3.1a. Summary of ovarian cancer cell lines analyzed 
Lab ID Cell line Tissue Subtype D       
CGOV16T OAW42 ovarian serous Unlikely               
CGOV17T OV167 ovarian serous Possibly              
CGOV18T OV177 ovarian serous Possibly              
CGOV21T OV-90 ovarian serous Possibly           
CGOV23T OVCA429 ovarian serous Unlikely    
     
          
CGOV25T OVCAR3 ovarian serous Possibly          
CGOV28T OVKATE ovarian serous Likely h               
CGOV30T OVSAHO ovarian serous Likely h               
CGOV32T PE014 ovarian serous Possibly      
             
  
CGOV34T PEO6 ovarian serous Possibly      
             
  
CGOV44T FUOV1 ovarian serous Possibly              
CGOV45T COV318 ovarian serous Likely h              
CGOV46T JHOS-2 ovarian serous Likely h         
CGOV47T JHOS-4 ovarian serous Likely h          
CGOV4T DOV13 ovarian serous Unlikely              
CGOV5T EFO-21 ovarian serous Unlikely             
CGOV6T EFO-27 ovarian serous Hy            
CGOV8T HEY ovarian serous Unlikely    
   
             
CGOV92T JHOS-3 ovarian serous Unlikely              
CGOV12T KOC-7C ovarian clear cell Hy                   
CGOV20T OV207 ovarian clear cell Possibly              
CGOV27T OVISE ovarian clear cell Unlikely               
CGOV29T OVMANA ovarian clear cell Unlikely               
CGOV31T OVTOKO ovarian clear cell Unlikely    
   
          
CGOV35T RMG-1 ovarian clear cell Unlikely               
CGOV39T TOV-21G ovarian clear cell Hy          
CGOV7T ES-2 ovarian clear cell Possibly    
    
     
CGOV11T_1 KK ovarian clear cell Unlikely                    
CGOV14T MCAS ovarian mucinous Unlikely               
CGOV36T RMUG-S ovarian mucinous Unlikely               
CGOV48T JHOM-1 ovarian mucinous Possibly              
CGOV38T 
TOV-
112D ovarian endometrioid Possibly           
CGOV49T OVK-18 ovarian endometrioid Hy            
CGOV10T IGROV1 ovarian mixed Hy             
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CGOV13T Kuramochi ovarian undifferentiated Likely h               
CGOV40T TYK-nu ovarian undifferentiated Likely h               
CGOV15T OAW28 ovarian unclassified Likely h    
   
          
CGOV1T A2780 ovarian unclassified Unlikely    
    
          
CGOV26T OVCAR5 ovarian unclassified Unlikely              
CGOV2T CAOV-3 ovarian unclassified Likely h    
   
     
CGOV33T PEA2 ovarian unclassified Possibly      




704 ovarian unclassified Hy            
CGOV42T OVCAR8 ovarian unclassified Possibly              
CGOV53T 
OVCAR5-
CisR ovarian unclassified Unlikely              
CGOV37T_3 SKOV-3 ovarian unclassified Possibly               
CGH8N GM10847 
lymphoblast 
culture NA Ut             
CGH7N GM12878 
lymphoblast 




Chinese in M   




Chinese in M   
Col              
CGH5N GM19573 
lymphoblast 
culture NA Japanese               
CGH6N GM19574 
lymphoblast 




Chinese in M   




Chinese in M   
Col              
CGH1N GM19901 
lymphoblast 
culture NA African Ance                
CGH2N GM19902 
lymphoblast 
culture NA African Ance                
* Tomioka Y. Establishment and characterization of human ovarian clear cell carcinoma cell lines KOC-4c, KOC           












Table S3.1c.  Summary of genomic analyses 
Lab ID Cell line 
Mapped to genome (# 
bases) 
Mapped to exome (# 
bases) 
     
  
   
 
CGOV16T OAW-42 
                      
127,314,031,800  
                       
2,120,021,711  
                                       
   
CGOV17T OV-167 
                      
126,889,722,400  
                       
2,082,988,874  
                                       
   
CGOV18T OV177 
                      
120,683,161,500  
                       
2,007,052,935  
                                       
   
CGOV21T OV-90 
                      
111,726,115,300  
                       
1,928,309,879  
                                       




                        
99,277,561,900  
                       
1,612,676,165  
                                       
   
CGOV25T OVCAR-3 
                      
107,345,406,200  
                       
1,777,448,826  
                                       
   
CGOV28T OVKATE 
                      
120,111,997,200  
                       
1,933,406,773  
                                       
   
CGOV30T OVSAHO 
                      
109,589,203,500  
                       
1,837,664,083  
                                       
   
CGOV32T PEO-14 
                      
104,155,218,200  
                       
1,757,681,426  
                                       
   
CGOV34T PEO-6 
                      
118,543,121,800  
                       
1,985,859,928  
                                       
   
CGOV44T FU-OV-1 
                      
120,329,213,000  
                       
2,014,874,040  
                                       
   
CGOV45T COV-318 
                      
119,963,006,000  
                       
2,062,539,382  
                                       
   
CGOV46T JHOS-2 
                      
114,896,903,700  
                       
1,856,445,593  
                                       
   
CGOV47T JHOS-4 
                        
92,656,405,000  
                       
1,512,549,230  
                                       
   
CGOV4T DOV-13 
                      
115,247,452,900  
                       
1,890,926,588  
                                       
   
CGOV5T EFO-21 
                      
131,659,499,000  
                       
2,236,327,562  
                                       
   
CGOV6T EFO-27 
                      
100,169,989,700  
                       
1,636,428,682  
                                       
   
CGOV8T HEY 
                      
119,823,556,000  
                       
2,063,329,007  
                                       
   
CGOV92T JHOS-3 
                      
130,481,536,800  
                       
1,799,381,383  
                                       
   
CGOV12T KOC-7C 
                      
126,543,652,000  
                       
1,880,665,950  
                                       
   
CGOV20T OV207 
                      
133,869,300,700  
                       
2,256,556,953  
                                       
   
CGOV27T OVISE 
                        
93,368,716,800  
                       
1,663,322,332  
                                       
   
CGOV29T OVMANA 
                      
102,777,959,400  
                       
1,744,487,916  
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CGOV31T OVTOKO 
                      
101,813,930,300  
                       
1,606,105,297  
                                       
   
CGOV35T RMG-I 
                        
97,702,225,700  
                       
1,610,003,898  
                                       
   
CGOV39T TOV-21G 
                      
117,004,545,400  
                       
1,961,829,335  
                                       
   
CGOV7T ES-2 
                      
111,500,740,800  
                       
1,851,794,498  
                                       
   
CGOV11T_1 KK 
                      
140,084,001,800  
                       
2,210,022,872  
                                       
   
CGOV14T MCAS 
                      
124,679,677,000  
                       
1,992,307,537  
                                       
   
CGOV36T RMUG-S 
                      
108,068,457,700  
                       
1,800,235,062  
                                       
   
CGOV48T JHOM-1 
                      
135,333,315,800  
                       
2,076,589,350  
                                       




                      
104,131,023,100  
                       
1,792,121,233  
                                       
   
CGOV49T OVK-18 
                        
90,482,755,900  
                       
1,448,721,569  
                                       
   
CGOV10T IGROV-1 
                      
121,519,271,300  
                       
2,045,216,061  
                                       
   
CGOV13T Kuramochi 
                      
127,510,600,400  
                       
2,118,335,846  
                                       
   
CGOV40T TYK-nu 
                      
112,725,891,000  
                       
1,852,556,701  
                                       
   
CGOV15T OAW-28 
                      
124,074,985,900  
                       
2,048,299,245  
                                       
   
CGOV1T A2780 
                      
117,451,750,500  
                       
1,944,777,962  
                                       
   
CGOV26T OVCAR-5 
                        
99,897,404,200  
                       
1,619,448,579  
                                       
   
CGOV2T Caov-3 
                      
131,306,959,000  
                       
2,270,780,071  
                                       
   
CGOV33T PEA2 
                      
120,977,572,400  
                       
1,896,767,863  
                                       




                      
118,365,148,800  
                       
1,992,816,003  
                                       
   
CGOV42T OVCAR-8 
                      
115,593,426,900  
                       
1,814,448,925  
                                       




                        
97,823,176,800  
                       
1,558,538,741  
                                       
   
CGOV37T_3 SK-OV-3 
                      
132,514,663,700  
                       
2,071,847,943  
                                       




Table S3.1d. Summary of sequence alterations 
Lab ID Cell line Subtype 
Total sequence 
alterations 
Puta   
al     
  
  
CGOV16T OAW42 serous 615     
CGOV17T OV167 serous 489     
CGOV18T OV177 serous 466     
CGOV21T OV-90 serous 553     
CGOV23T OVCA429 serous 667     
CGOV25T OVCAR3 serous 419     
CGOV28T OVKATE serous 539     
CGOV30T OVSAHO serous 588     
CGOV32T PE014 serous 503     
CGOV34T PEO6 serous 510     
CGOV44T FUOV1 serous 1108     
CGOV45T COV318 serous 574      
CGOV46T JHOS-2 serous 537     
CGOV47T JHOS-4 serous 655     
CGOV4T DOV13 serous 778     
CGOV5T EFO-21 serous 744     
CGOV6T EFO-27 serous 2417       
CGOV8T HEY serous 638     
CGOV92T JHOS-3 serous 367     
CGOV12T KOC-7C clear cell 3930       
CGOV20T OV207 clear cell 566     
CGOV27T OVISE clear cell 596     
CGOV29T OVMANA clear cell 644     
CGOV31T OVTOKO clear cell 609     
CGOV35T RMG-1 clear cell 516     
CGOV39T TOV-21G clear cell 2292     
CGOV7T ES-2 clear cell 1016     
CGOV11T_1 KK clear cell 423     
CGOV14T MCAS mucinous 844     
CGOV36T RMUG-S mucinous 584     
CGOV48T JHOM-1 mucinous 564     
CGOV38T 
TOV-
112D endometrioid 404     
CGOV49T OVK-18 endometrioid 2643     
CGOV10T IGROV1 mixed 4075  
   
   
CGOV13T Kuramochi undifferentiated 627     
CGOV40T TYK-nu undifferentiated 575      
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CGOV15T OAW28 unclassified 507     
CGOV1T A2780 unclassified 1225     
CGOV26T OVCAR5 unclassified 483     
CGOV2T CAOV-3 unclassified 606     
CGOV33T PEA2 unclassified 511     
CGOV3T 
COLO-
704 unclassified 2009      
CGOV42T OVCAR8 unclassified 619     
CGOV53T 
OVCAR5-
CisR unclassified 987     
CGOV37T_3 SKOV-3 unclassified 746       




Table S3.1e. Driver genes evaluated for inactivating mutations 
Gene symbol Gene name 
POLL polymerase (DNA directed), lambda 
RPA1 replication protein A1, 70kDa 
NEIL1 nei endonuclease VIII-like 1 (E. coli) 
NEIL2 nei endonuclease VIII-like 2 (E. coli) 
NTHL1 nth endonuclease III-like 1 (E. coli) 
PNKP polynucleotide kinase 3'-phosphatase 
APTX aprataxin 
TDP1 tyrosyl-DNA phosphodiesterase 1 
OGG1 8-oxoguanine DNA glycosylase 
AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 
UNG uracil-DNA glycosylase 
APEX1 APEX nuclease (multifunctional DNA repair enzym   
APEX2 APEX nuclease (apurinic/apyrimidinic endonuclea   
POLB polymerase (DNA directed), beta 
FEN1 flap structure-specific endonuclease 1 
ALKBH2 alkB, alkylation repair homolog 2 (E. coli) 
ALKBH3 alkB, alkylation repair homolog 3 (E. coli) 
XAB2 XPA binding protein 2 
CCNH cyclin H 
CDK7 cyclin-dependent kinase 7 
CETN2 centrin, EF-hand protein, 2 
DDB1 damage-specific DNA binding protein 1, 127kD  
ERCC6 excision repair cross-complementation group 6 
ERCC7 excision repair cross-complementation group 7 
ERCC8 excision repair cross-complementation group 8 
LIG1 ligase I, DNA, ATP-dependent 
MNAT1 MNAT CDK-activating kinase assembly factor  
MMS19 MMS19 nucleotide excision repair homolog (S. cere  
RAD23A RAD23 homolog A (S. cerevisiae) 
RAD23B RAD23 homolog B (S. cerevisiae) 
RPA2 replication protein A2, 32kDa 
GTF2H5 general transcription factor IIH, polypeptide 5 
RAD51B RAD51 paralog B 
RAD51D RAD51 paralog D 
XRCC2 X-ray repair complementing defective repair in Chinese ha    
XRCC3 X-ray repair complementing defective repair in Chinese ha    
MUS81 MUS81 structure-specific endonuclease subuni  
EME1 essential meiotic structure-specific endonuclease  
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ATR ATR serine/threonine kinase 
BARD1 BRCA1 associated RING domain 1 
MRE11A MRE11 meiotic recombination 11 homolog A (S. cer  
RAD50 RAD50 homolog (S. cerevisiae) 
RAD51 RAD51 recombinase 
DCLRE1C DNA cross-link repair 1C 
XRCC6 X-ray repair complementing defective repair in Chinese ha    
XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (do   
XRCC4 X-ray repair complementing defective repair in Chinese ha    
PRKDC protein kinase, DNA-activated, catalytic polypept  
HELQ helicase, POLQ-like 
POLG polymerase (DNA directed), gamma 
POLI polymerase (DNA directed) iota 
POLK polymerase (DNA directed) kappa 
POLM polymerase (DNA directed), mu 
POLN polymerase (DNA directed) nu 
POLQ polymerase (DNA directed), theta 
SLX4 SLX4 structure-specific endonuclease subunit 
H2AFX H2A histone family, member X 
CHAF1A chromatin assembly factor 1, subunit A (p150) 
RECQL RecQ helicase-like 
RECQL5 RecQ protein-like 5 
MSH3 mutS homolog 3 
MLH3 mutL homolog 3 
EXO1 exonuclease 1 
CHEK1 checkpoint kinase 1 
MDC1 mediator of DNA-damage checkpoint 1 
TP53BP1 tumor protein p53 binding protein 1 
C11orf30 chromosome 11 open reading frame 30 
ERCC4 excision repair cross-complementation group 4 
RAD51C RAD51 paralog C 
RAD51C RAD51 homolog C (S. cerevisiae) 
BRIP1 BRCA1 interacting protein C-terminal helicase  
BRCA2 breast cancer 2, early onset 
PALB2 partner and localizer of BRCA2 
PALB2 partner and localizer of BRCA2 
FANCL Fanconi anemia, complementation group L 
XRCC1 X-ray repair complementing defective repair in Chinese ha    
DDB2 damage-specific DNA binding protein 2, 48kD  
ERCC1 excision repair cross-complementation group 1 
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ERCC2 excision repair cross-complementation group 2 
ERCC3 excision repair cross-complementation group 3 
ERCC5 excision repair cross-complementation group 5 
ATM ATM serine/threonine kinase 
CHEK2 checkpoint kinase 2 
TP53 tumor protein p53 
BRCA1 breast cancer 1, early onset 
NBN nibrin 
POLE polymerase (DNA directed), epsilon, catalytic sub  
POLH polymerase (DNA directed), eta 
FANCC Fanconi anemia, complementation group C 
FANCD2 Fanconi anemia, complementation group D2 
FANCB Fanconi anemia, complementation group B 
FANCA Fanconi anemia, complementation group A 
FANCE Fanconi anemia, complementation group E 
FANCF Fanconi anemia, complementation group F 
FANCG Fanconi anemia, complementation group G 
FANCI Fanconi anemia, complementation group I 
FANCM Fanconi anemia, complementation group M 
ATRX alpha thalassemia/mental retardation syndrome X-l  
RECQL4 RecQ protein-like 4 
MSH2 mutS homolog 2 
MSH6 mutS homolog 6 
MLH1 mutL homolog 1 
PMS1 PMS1 postmeiotic segregation increased 1 (S. cerev  
PMS2 PMS2 postmeiotic segregation increased 2 (S. cerev  
PTEN phosphatase and tensin homolog 
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (al  
MAX MYC associated factor X 
ARID1A AT rich interactive domain 1A (SWI-like) 
ARID1B AT rich interactive domain 1B (SWI1-like) 
SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chroma      
SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of chroma      
NF1 neurofibromin 1 
CREBBP CREB binding protein 
mTOR mechanistic target of rapamycin (serine/threonine k  
MLL myeloid/lymphoid or mixed-lineage leukemia (trithorax homo   
MLL2 myeloid/lymphoid or mixed-lineage leukemia 2 
MLL3 myeloid/lymphoid or mixed-lineage leukemia 3 
NBS1 Nijmegen Breakage Syndrome 1 
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ATXN1 ataxin 1 
AR androgen receptor 
ARMC4 armadillo repeat containing 4 
DRD4 dopamine receptor D4 
EP300 E1A binding protein p300 
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma     
ANK3 ankyrin 3, node of Ranvier (ankyrin G) 
APC adenomatous polyposis coli 
CACNA1S calcium channel, voltage-dependent, L type, alpha 1S  
FCGBP Fc fragment of IgG binding protein 
FLG filaggrin 
GRM8 glutamate receptor, metabotropic 8 
HYDIN HYDIN, axonemal central pair apparatus protei  
KIAA1217 uncharacterized protein 
KIF3A kinesin family member 3A 
NAA16 N(alpha)-acetyltransferase 16, NatA auxiliary sub  
NFE2L2 nuclear factor (erythroid-derived 2)-like 2 
OR52B4 olfactory receptor, family 52, subfamily B, memb   
PPP2R1A protein phosphatase 2, regulatory subunit A, alp  
RAB17 RAB17, member RAS oncogene family 
RELN reelin 
REST RE1-silencing transcription factor 
RET ret proto-oncogene 
RIPK1 receptor (TNFRSF)-interacting serine-threonine kin   
SIGLEC10 sialic acid binding Ig-like lectin 10 
SLC2A7 solute carrier family 2 (facilitated glucose transporter), m   
SMAD4 SMAD family member 4 
SPEF2 sperm flagellar 2 
USH2A Usher syndrome 2A (autosomal recessive, mild  
VPS13A vacuolar protein sorting 13 homolog A (S. cerevis  
ZFHX4 zinc finger homeobox 4 
ZNF426 zinc finger protein 426 
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 
ACVR1C activin A receptor, type IC 
ACVR1B activin A receptor, type IB 
ALK anaplastic lymphoma receptor tyrosine kinase 
ASXL1 additional sex combs like 1 (Drosophila) 
AURKA aurora kinase A 
AXIN2 axin 2 
BAP1 BRCA1 associated protein-1 (ubiquitin carboxy-terminal  
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BCL2 apoptosis regulator 
BCR breakpoint cluster region 
BLM Bloom syndrome, RecQ helicase-like 
BMPR1A bone morphogenetic protein receptor, type IA 
BTK Bruton agammaglobulinemia tyrosine kinase 
CALR calreticulin 
CBL Cbl proto-oncogene, E3 ubiquitin protein ligas  
CCND1 cyclin D1 
CCNE1 cyclin E1 
CDC73 cell division cycle 73 
CDH1 cadherin 1 
CDK4 cyclin-dependent kinase 4 
CDK6 cyclin dependent kinase 6 
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip  
CDKN2A cyclin-dependent kinase inhibitor 2A 
CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits C  
CEBPA CCAAT/enhancer binding protein (C/EBP), alph  
CIC capicua homolog (Drosophila) 
CSF1R colony stimulating factor 1 receptor 
CYLD cylindromatosis (turban tumor syndrome) 
DAXX death-domain associated protein 
DDR2 discoidin domain receptor tyrosine kinase 2 
DICER1 dicer 1, ribonuclease type III 
DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha 
EGFR epidermal growth factor receptor 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolo    
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog   
ESR1 estrogen receptor 1 
ETV1 ets variant 1 
ETV5 ETS variant 5 
EWSR1 Ewing sarcoma breakpoint region 1 
EXT1 exostosin 1 
EXT2 exostosin 2 
EZH2 enhancer of zeste homolog 2 (Drosophila) 
FGFR1 fibroblast growth factor receptor 1 
FGFR2 fibroblast growth factor receptor 2 
FGFR3 fibroblast growth factor receptor 3 
FGFR4 fibroblast growth factor receptor 4 
FH fumarate hydratase 
FLCN folliculin 
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FLT3 fms-related tyrosine kinase 3 
FLT4 fms-related tyrosine kinase 4 
FOXL2 forkhead box L2 
GATA1 GATA binding protein 1 
GATA2 GATA binding protein 2 
GNA11 guanine nucleotide binding protein (G protein), alpha 11   
GNAQ guanine nucleotide binding protein (G protein), q poly  
GNAS GNAS complex locus 
GPC3 glypican 3 
H3F3A H3 histone family member 3A 
H3F3B H3 histone family member 3B 
HNF1A HNF1 homeobox A 
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 
IDH2 isocitrate dehydrogenase 2 (NADP+), mitochond  
IGF1R insulin-like growth factor 1 receptor 
IGF2R insulin-like growth factor 2 receptor 
IKZF1 IKAROS family zinc finger 1 (Ikaros) 
JAK1 Janus kinase 1 
JAK2 Janus kinase 2 
JAK3 Janus kinase 3 
KDR kinase insert domain receptor (a type III receptor tyrosin   
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene  
MAML1 mastermind-like 1 (Drosophila) 
MAP2K1 mitogen-activated protein kinase kinase 1 
MAP2K4 mitogen-activated protein kinase kinase 4 
MDM2 Mdm2, p53 E3 ubiquitin protein ligase homolog (m  
MDM4 Mdm4 p53 binding protein homolog (mouse) 
MED12 mediator complex subunit 12 
MEN1 multiple endocrine neoplasia I 
MET met proto-oncogene (hepatocyte growth factor rece  
MPL myeloproliferative leukemia virus oncogene 
MUTYH mutY DNA glycosylase 
MYC v-myc myelocytomatosis viral oncogene homolog (  
MYCL1 v-myc myelocytomatosis viral oncogene homolog 1, lung carcino    
MYCN v-myc myelocytomatosis viral related oncogene, neuroblastom    
MYD88 myeloid differentiation primary response 88 
NCOA3 nuclear receptor coactivator 3 
NF2 neurofibromin 2 (merlin) 
NKX2-1 NK2 homeobox 1 
NOTCH1 notch 1 
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NOTCH3 notch 3 
NOTCH4 notch 4 
NPM1 nucleophosmin (nucleolar phosphoprotein B23, num  
NTRK1 neurotrophic tyrosine kinase, receptor, type 1 
PALB2 partner and localizer of BRCA2 
PALB2 partner and localizer of BRCA2 
PAX5 paired box 5 
PBRM1 polybromo 1 
PDGFRA platelet-derived growth factor receptor, alpha polyp  
PHOX2B paired-like homeobox 2b 
POLD1 polymerase (DNA directed), delta 1, catalytic sub  
POT1 protection of telomeres 1 
PRKAR1A protein kinase, cAMP-dependent, regulatory, type I,  
PRSS1 serine protease 1 
PTCH1 patched 1 
PTPN11 protein tyrosine phosphatase, non-receptor type  
RAD51C RAD51 paralog C 
RAD51C RAD51 homolog C (S. cerevisiae) 
RAF1 v-raf-1 murine leukemia viral oncogene homolog  
RNF43 ring finger protein 43 
RUNX1 runt-related transcription factor 1 
SBDS SBDS, ribosome maturation factor 
SDHAF2 succinate dehydrogenase complex assembly facto   
SDHB succinate dehydrogenase complex, subunit B, iron sul   
SDHC succinate dehydrogenase complex subunit C 
SDHD succinate dehydrogenase complex, subunit D, integral mem   
SF3B1 splicing factor 3b, subunit 1, 155kDa 
SMAD2 SMAD family member 2 
SMAD3 SMAD family member 3 
SMARCB1 SWI/SNF related, matrix associated, actin dependent regulator of chroma      
SMO smoothened, frizzled family receptor 
SRC SRC proto-oncogene, non-receptor tyrosine kina  
STAG2 stromal antigen 2 
SUFU suppressor of fused homolog (Drosophila) 
TERT telomerase reverse transcriptase 
TET2 tet methylcytosine dioxygenase 2 
TGFBR2 transforming growth factor, beta receptor II (70/80  
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 
TOP1 topoisomerase (DNA) I 
TSC1 tuberous sclerosis 1 
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TSC2 tuberous sclerosis 2 
TSHR thyroid stimulating hormone receptor 
WAS Wiskott-Aldrich syndrome 
WRN Werner syndrome, RecQ helicase-like 
WT1 Wilms tumor 1 
XPA DNA damage recognition and repair factor 
XPC xeroderma pigmentosum, complementation group  
DNAJB1 DnaJ heat shock protein family (Hsp40) member  
ETV4 ets variant 4 
ETV6 ETS variant 6 
PDGFRB platelet-derived growth factor receptor, beta polype  
PRKACA protein kinase, cAMP-dependent, catalytic, alph  
RARA retinoic acid receptor, alpha 
TACC3 transforming, acidic coiled-coil containing protei   
TMPRSS2 transmembrane protease, serine 2 
AKT2 AKT serine/threonine kinase 2 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88k  
ACVR1 activin A receptor type 1 
AKT1 v-akt murine thymoma viral oncogene homolog  
BUB1B BUB1 mitotic checkpoint serine/threonine kinase  
CDKN2B cyclin dependent kinase inhibitor 2B 
VHL von Hippel-Lindau tumor suppressor, E3 ubiquitin prot   
SMARCC1 SWI/SNF related, matrix associated, actin dependent regulator of chroma      
SMARCD2 SWI/SNF related, matrix associated, actin dependent regulator of chroma      
SMARCE1 SWI/SNF related, matrix associated, actin dependent regulator of chroma      
FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin p   
NOTCH2 notch 2 
AXIN1 axin 1 
PARP1 poly (ADP-ribose) polymerase 1 
STK11 serine/threonine kinase 11 




Table S3.1f. Sequence alterations 
Lab ID Cell line 
Gene 
symbol     







CGOV1T A2780 ARID1A AT           
CGOV1T A2780 ARID1A AT           
CGOV1T A2780 DRD4      
 
   
CGOV1T A2780 FCGBP F         
 
   
CGOV1T A2780 MAX       
 
   
CGOV1T A2780 PIK3CA phosphatidylinosit        
 
   
CGOV1T A2780 SMARCA4 SWI/SNF related, matrix associa             
 
   
CGOV1T A2780 WRN W       
  
   
CGOV10T IGROV-1 ABL1 c-abl o           
CGOV10T IGROV-1 AKAP6         
 
   
CGOV10T IGROV-1 AMBRA1      
 
   
CGOV10T IGROV-1 
ARHGAP2
7        
 
   
CGOV10T IGROV-1 ARID1A AT           
CGOV10T IGROV-1 ARID1A AT           
CGOV10T IGROV-1 ATXN1        
CGOV10T IGROV-1 AXIN2        
CGOV10T IGROV-1 BRCA1           
CGOV10T IGROV-1 CHEK1         
CGOV10T IGROV-1 DIABLO diab       
 
   
CGOV10T IGROV-1 DICER1           
CGOV10T IGROV-1 ERCC5 excision repair cross-comp             
CGOV10T IGROV-1 
FAM160A
2 family         
 
   
CGOV10T IGROV-1 FAM46C family         
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CGOV10T IGROV-1 FBN2     
 
   
CGOV10T IGROV-1 FBXW7 F-box and WD rep           
  
   
CGOV10T IGROV-1 FLG    
 
   
CGOV10T IGROV-1 GLI3        
 
   
CGOV10T IGROV-1 GRB14 gro        
 
   
CGOV10T IGROV-1 GRM8          
CGOV10T IGROV-1 IGHMBP2 im        
 
   
CGOV10T IGROV-1 ITPR3 inosi        
 
   
CGOV10T IGROV-1 JAK1         
CGOV10T IGROV-1 KIAA0100     
 
   
CGOV10T IGROV-1 KIAA1217        
CGOV10T IGROV-1 MED12          
CGOV10T IGROV-1 MLH1 mutL homolo               
CGOV10T IGROV-1 MLH3           
CGOV10T IGROV-1 MLL myeloid/lymphoid or m           
CGOV10T IGROV-1 MLL2 myeloi           
CGOV10T IGROV-1 MLL3 myeloi           
CGOV10T IGROV-1 MSH2 mutS homolo            
 
   
CGOV10T IGROV-1 MSH3           
CGOV10T IGROV-1 MSH6           
CGOV10T IGROV-1 NCOR2       
 
   
CGOV10T IGROV-1 NOTCH3        
CGOV10T IGROV-1 OR1S2 olfactory          
 
   
CGOV10T IGROV-1 PDE4DIP pho       
 
   
CGOV10T IGROV-1 PDGFRB platelet-der            
CGOV10T IGROV-1 PIK3CA phosphatidylinosit        
 
   
CGOV10T IGROV-1 PIK3CA phosphatidylinosit        
 
   
 162 
CGOV10T IGROV-1 PMS1 PMS1 postm            
CGOV10T IGROV-1 PMS1 PMS1 postm            
CGOV10T IGROV-1 POLN          
CGOV10T IGROV-1 POLQ          
CGOV10T IGROV-1 PPP5C pro        
 
   
CGOV10T IGROV-1 PTEN       
 
   
CGOV10T IGROV-1 PTEN          
CGOV10T IGROV-1 RAD50          
CGOV10T IGROV-1 RSPH6A radial sp         
 
   
CGOV10T IGROV-1 SCN8A sodium ch          
 
   
CGOV10T IGROV-1 SHPRH SNF2 histone link           
 
   
CGOV10T IGROV-1 SIM1 sin       
 
   
CGOV10T IGROV-1 SLC43A3         
 
   
CGOV10T IGROV-1 SMAD4          
CGOV10T IGROV-1 SPEF2         
CGOV10T IGROV-1 STAG2           
CGOV10T IGROV-1 TASP1       
 
   
CGOV10T IGROV-1 TOP1           
CGOV10T IGROV-1 VHL von Hippel-Lin          
 
   
CGOV10T IGROV-1 WDR62       
 
   
CGOV10T IGROV-1 ZBTB4 zinc         
 
   
CGOV10T IGROV-1 ZDHHC6 zi        
 
   
CGOV10T IGROV-1 ZFHX4          
CGOV10T IGROV-1 ZFHX4          
CGOV10T IGROV-1 ZFHX4          
 163 
CGOV11T
_1 KK ACAA2      
 




1     
 
   
CGOV11T
_1 KK AFF2       
 
   
CGOV11T
_1 KK ANKRD11       
 




C       
 
   
CGOV11T
_1 KK ARID1A AT           
CGOV11T
_1 KK BAZ2A bromod          
 
   
CGOV11T
_1 KK BBX       
 
   
CGOV11T
_1 KK CLCN1 c       
 
   
CGOV11T
_1 KK CLEC4E C-ty          
 
   
CGOV11T
_1 KK COL11A1        
 
   
CGOV11T
_1 KK COL4A6        
 
   
CGOV11T
_1 KK CRB1       
 
   
CGOV11T
_1 KK CSTF1 cleavage stim          
 
   
CGOV11T
_1 KK DDX39A DEAD       
 
   
CGOV11T
_1 KK DNAH1        
 
   
CGOV11T
_1 KK DOCK5       
 
   
CGOV11T
_1 KK DSG1     
 
   
CGOV11T
_1 KK DTNA     
 
   
CGOV11T
_1 KK FBN2     
 
   
CGOV11T
_1 KK FLG2       
 
   
CGOV11T
_1 KK FTCD for     
 
   
CGOV11T
_1 KK GAD2 glutamate dec          
 
   
CGOV11T
_1 KK GCSAML germinal c       
 
   
CGOV11T
_1 KK GRM3       
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CGOV11T
_1 KK HOMEZ ho        
 
   
CGOV11T
_1 KK KRT3     
 




2       
 
   
CGOV11T
_1 KK LAIR2 leukocyte       
 
   
CGOV11T
_1 KK LAMP5 lysosomal-a         
 
   
CGOV11T
_1 KK LRRC8E leucine          
 
   
CGOV11T
_1 KK LZTS1 leuc         
 
   
CGOV11T
_1 KK MEGF11      
 
   
CGOV11T
_1 KK MUC20        
 
   
CGOV11T
_1 KK MYH11 my         
 
   
CGOV11T
_1 KK MYOM1     
 
   
CGOV11T
_1 KK NCKAP5      
 
   
CGOV11T
_1 KK NPC1L1     
 
   
CGOV11T
_1 KK NR2C2AP nu       
 
   
CGOV11T
_1 KK NUP153     
 
   
CGOV11T
_1 KK OR10J1 olfactory          
 
   
CGOV11T
_1 KK PCMTD1 protein-L-isoaspartate        
 
   
CGOV11T
_1 KK PLXNB2     
 
   
CGOV11T
_1 KK PNMA3       
 
   
CGOV11T
_1 KK PPP2R1A protein p         
 
   
CGOV11T
_1 KK PRSS3      
 
   
CGOV11T
_1 KK PRSS53      
 
   
CGOV11T
_1 KK QRICH2      
 
   
CGOV11T
_1 KK RHBDF2 r        
 
   
CGOV11T
_1 KK RTFDC1 replicatio          
 
   
 165 
CGOV11T
_1 KK SELENBP1       
 
   
CGOV11T
_1 KK SLC1A6 solute carrier family 1         
 
   
CGOV11T
_1 KK SLC22A8 solute carrier          
 
   
CGOV11T
_1 KK SLC39A14 solute car          
 
   
CGOV11T
_1 KK SLC4A10 solute carrier fam          
 
   
CGOV11T
_1 KK SORCS1 sortilin-r         
 
   
CGOV11T
_1 KK TBC1D8B TBC1 dom          
 
   
CGOV11T
_1 KK TCF3      
 
   
CGOV11T
_1 KK UNC13C        
 
   
CGOV11T
_1 KK USH2A Usher        
 
   
CGOV11T
_1 KK WNK4 W         
 
   
CGOV11T
_1 KK ZNF382       
 
   
CGOV12T KOC-7C ABCB11 ATP-binding         
 
   
CGOV12T KOC-7C ADAM20 A       
 
   
CGOV12T KOC-7C ANK2      
 
   
CGOV12T KOC-7C ARID1A AT           
CGOV12T KOC-7C ARID1A AT           
CGOV12T KOC-7C ARID1A AT           
CGOV12T KOC-7C ARID1B AT r           
CGOV12T KOC-7C ATM         
CGOV12T KOC-7C BAP1 BRCA1 associat           
CGOV12T KOC-7C BCL9L      
 
   
CGOV12T KOC-7C BLM B          
CGOV12T KOC-7C CCDC93       
 
   
CGOV12T KOC-7C CHIT1      
 
   
CGOV12T KOC-7C CORIN      
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CGOV12T KOC-7C COX10 cytochro          
 
   
CGOV12T KOC-7C FAT1 FAT tu        
 
   
CGOV12T KOC-7C FBXW7 F-box and WD rep           
 
   
CGOV12T KOC-7C FLG    
 
   
CGOV12T KOC-7C GRIK3 glu        
 
   
CGOV12T KOC-7C HAO1 hyd        
 
   
CGOV12T KOC-7C IDH2 isocitrate            
CGOV12T KOC-7C IGF2BP3 insulin-lik           
 
   
CGOV12T KOC-7C KCND1 potassium voltag         
 
   
CGOV12T KOC-7C KCNH7 potassium voltage          
 
   
CGOV12T KOC-7C KRT34     
 
   
CGOV12T KOC-7C L1CAM       
 
   
CGOV12T KOC-7C MEN1          
CGOV12T KOC-7C MLL2 myeloi           
CGOV12T KOC-7C MNS1 m       
 
   
CGOV12T KOC-7C MSH2 mutS homolo               
CGOV12T KOC-7C MSH2 mutS homolo               
CGOV12T KOC-7C MSH3           
CGOV12T KOC-7C MYCN v-myc myelocytomato             
CGOV12T KOC-7C MYOM1     
 
   
CGOV12T KOC-7C NAA16 N(alpha)-        
 
   
CGOV12T KOC-7C NETO2 neur         
 
   
CGOV12T KOC-7C NFE2L2 nuc        
 
   
CGOV12T KOC-7C NOTCH1        
CGOV12T KOC-7C NUTF2       
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CGOV12T KOC-7C PCCA propio        
 
   
CGOV12T KOC-7C PIK3CA phosphatidylinosit        
 
   
CGOV12T KOC-7C PMS1 PMS1 postm            
CGOV12T KOC-7C PREX2 phosphatidylinosito        
 
   
CGOV12T KOC-7C PSMD6 proteasome (p         
 
   
CGOV12T KOC-7C PTEN          
CGOV12T KOC-7C PTEN          
CGOV12T KOC-7C PTPRS protei         
 
   
CGOV12T KOC-7C RAD23A        
  
   
CGOV12T KOC-7C RAD50          
CGOV12T KOC-7C RPA1          
CGOV12T KOC-7C RSG1 R         
 
   
CGOV12T KOC-7C SAMD9L steril         
 
   
CGOV12T KOC-7C SDHAF2 succinate           
CGOV12T KOC-7C SIGLEC10         
 
   
CGOV12T KOC-7C SLC24A1 solute carrier family        
 
   
CGOV12T KOC-7C SLC7A8 solute carrier family 7            
 
   
CGOV12T KOC-7C SLIT2       
 
   
CGOV12T KOC-7C SMAD3          
CGOV12T KOC-7C SNX13      
 
   
CGOV12T KOC-7C TBX18     
 
   
CGOV12T KOC-7C TGM2 transglutaminase 2 (C po     
 
   
CGOV12T KOC-7C TMEM2      
 
   
CGOV12T KOC-7C TMIGD1 transmembr         
 
   
CGOV12T KOC-7C TP53      
 
   
 168 
CGOV12T KOC-7C TUSC3       
 
   
CGOV12T KOC-7C VPS13A vacuolar p          
 
   
CGOV12T KOC-7C VPS13A vacuolar p             
CGOV12T KOC-7C ZNF415       
 
   
CGOV13T 
Kuramoc
hi BRCA2           
CGOV13T 
Kuramoc
hi CDH18       
 
   
CGOV13T 
Kuramoc
hi EWSR1 E           
CGOV13T 
Kuramoc
hi SMAD4       
 
   
CGOV13T 
Kuramoc
hi SMO sm          
CGOV13T 
Kuramoc
hi TP53      
 
   
CGOV14T MCAS C1orf168 ch         
 
   
CGOV14T MCAS ENPP4 ectonucleotide      
 
   
CGOV14T MCAS KRAS v-Ki-ras2         
 
   
CGOV14T MCAS PIK3CA phosphatidylinosit        
 
   
CGOV14T MCAS PPP3CA protein ph         
 
   
CGOV14T MCAS RIMS1 regu        
 
   
CGOV14T MCAS RNF43          
CGOV14T MCAS SMAD4       
 
   
CGOV14T MCAS SPG11 spas        
 
   
CGOV14T MCAS SYT16     
 
   
CGOV14T MCAS USH2A Usher        
 
   
CGOV14T MCAS USP21       
 
   
CGOV15T OAW-28 
ALDH16A
1 aldehy         
 
   
CGOV15T OAW-28 ERCC2 excision repair cross-comp               
CGOV15T OAW-28 TP53         
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CGOV15T OAW-28 TSC2      
  
   
CGOV16T OAW-42 ARID1A AT           
CGOV16T OAW-42 ARID1A AT           
CGOV16T OAW-42 FAM129C family         
 
   
CGOV16T OAW-42 FANCD2 Fanc             
CGOV16T OAW-42 PIK3CA phosphatidylinosit        
 
   
CGOV16T OAW-42 SLC14A2 solute car          
 
   
CGOV16T OAW-42 SUSD3       
 
   
CGOV17T OV-167 ARMC4       
 
   
CGOV17T OV-167 TP53         
CGOV17T OV-167 USH2A Usher        
  
   
CGOV18T OV177 ASCC3 activatin          
 
   
CGOV18T OV177 TP53      
 
   
CGOV2T Caov-3 ARMC4       
 
   
CGOV2T Caov-3 TP53         
CGOV20T OV207 ARID1A AT           
CGOV20T OV207 KIF3A       
 
   
CGOV20T OV207 NID1     
 
   
CGOV20T OV207 SLC2A7 solute carrier fa          
 
   
CGOV20T OV207 SPEF2         
CGOV20T OV207 TP53      
 
   
CGOV21T OV-90 CDKN2A cy          
CGOV21T OV-90 EPHA1      
 
   
CGOV21T OV-90 HNF1A         
CGOV21T OV-90 IFIT1 interferon-in         
 
   
CGOV21T OV-90 KIAA1958     
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CGOV21T OV-90 SMAD4          
CGOV21T OV-90 TP53      
 
   
CGOV23T 
OVCA-
429 DAAM2 dishevell         
 
   
CGOV23T 
OVCA-
429 MSH6           
CGOV23T 
OVCA-
429 PCDHA5      
 
   
CGOV23T 
OVCA-
429 REST      
 
   
CGOV25T 
OVCAR-
3 ADCY1       
 
   
CGOV25T 
OVCAR-
3 MAMDC4       
 
   
CGOV25T 
OVCAR-
3 PIK3R1 phosphoin        
  
   
CGOV25T 
OVCAR-
3 POLK          
CGOV25T 
OVCAR-
3 STAG2           
CGOV25T 
OVCAR-
3 TP53      
 
   
CGOV26T 
OVCAR-
5 ANK3 an          
 
   
CGOV26T 
OVCAR-
5 APC      
 
   
CGOV26T 
OVCAR-
5 CREBBP      
 
   
CGOV26T 
OVCAR-
5 EP300          
CGOV26T 
OVCAR-
5 KRAS v-Ki-ras2         
 
   
CGOV26T 
OVCAR-
5 RIPK1 receptor (T       
 
   
CGOV27T OVISE ARID1A AT           
CGOV27T OVISE ARID1A AT           
CGOV27T OVISE ARID1B AT r           
CGOV27T OVISE FCGBP F         
  
   
CGOV27T OVISE GRM8       
 
   
CGOV27T OVISE KIF1A       
 
   
CGOV27T OVISE NOTCH1        
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CGOV27T OVISE PIK3CA phosphatidylinosit        
 
   
CGOV27T OVISE PPP2R1A protein p         
 
   
CGOV28T 
OVKAT
E CNTNAP2       
 
   
CGOV28T 
OVKAT
E DNMT3A DNA      
  
   
CGOV28T 
OVKAT
E DNMT3A DNA      
  
   
CGOV28T 
OVKAT
E GPR17       
 
   
CGOV28T 
OVKAT
E GXYLT1      
 
   
CGOV28T 
OVKAT
E PLA2G12B       
 
   
CGOV28T 
OVKAT
E ROS1 c-ro          
 
   
CGOV28T 
OVKAT
E SMAD4          
CGOV28T 
OVKAT
E TM4SF4 tran          
 
   
CGOV28T 
OVKAT
E TP53      
 
   
CGOV29T 
OVMAN
A ARID1A AT           
CGOV29T 
OVMAN
A ARID1A AT           
CGOV29T 
OVMAN
A PIK3CA phosphatidylinosit        
 
   
CGOV3T 
COLO-
704 ALKBH2 alkB             
CGOV3T 
COLO-
704 ALKBH2 alkB             
CGOV3T 
COLO-
704 AR        
CGOV3T 
COLO-
704 AR        
CGOV3T 
COLO-
704 BLM B          
CGOV3T 
COLO-
704 BMS1 BMS1 h        
 
   
CGOV3T 
COLO-
704 BRCA2           
CGOV3T 
COLO-
704 COL1A1        
 
   
CGOV3T 
COLO-
704 DBC1        
 
   
CGOV3T 
COLO-




704 GRM8          
CGOV3T 
COLO-
704 HNF1A         
CGOV3T 
COLO-
704 INTS1       
 
   
CGOV3T 
COLO-
704 MLL2 myeloi           
CGOV3T 
COLO-
704 MSH3           
CGOV3T 
COLO-
704 MSH6           
CGOV3T 
COLO-
704 MYCL1 v-myc myelocytomatosis              
CGOV3T 
COLO-
704 NRP2     
 
   
CGOV3T 
COLO-
704 PTEN          
CGOV3T 
COLO-
704 SHROOM4       
 
   
CGOV3T 
COLO-
704 WRN W       
  
   
CGOV3T 
COLO-
704 WRN W       
  
   
CGOV3T 
COLO-
704 ZFHX2          
CGOV3T 
COLO-
704 ZFHX4       
 
   
CGOV3T 
COLO-
704 ZFHX4          
CGOV30T 
OVSAH
O NSD1 nuclea          
 
   
CGOV30T 
OVSAH
O PIAS4 pr         
 





B        
 
   
CGOV30T 
OVSAH
O TP53         
CGOV30T 
OVSAH
O ZNF556       
 
   
CGOV31T 
OVTOK
O ARID1A AT           
CGOV31T 
OVTOK
O ARID1A AT           
CGOV31T 
OVTOK
O BCAS1 br        
 
   
CGOV31T 
OVTOK
O EBF3       
 
   
CGOV31T 
OVTOK




O PNPLA3 patatin        
 
   
CGOV31T 
OVTOK
O PPP2R1A protein p         
 
   
CGOV31T 
OVTOK
O SYCP1       
 
   
CGOV32T PEO-14 SLC22A14 s         
 
   
CGOV32T PEO-14 TP53      
 
   
CGOV33T PEA2 BARD1 B           
CGOV33T PEA2 CACNA1S calcium chann          
 
   
CGOV33T PEA2 RECQL5      
  
   
CGOV33T PEA2 TLL2     
 
   
CGOV33T PEA2 TP53         
CGOV34T PEO-6 LSS lanosterol sy      
 
   
CGOV34T PEO-6 NF1          
CGOV34T PEO-6 RELN    
 
   
CGOV34T PEO-6 TP53      
 
   
CGOV35T RMG-I FANCL Fanc           
CGOV35T RMG-I MORN3       
 
   
CGOV35T RMG-I TRIM37       
 
   
CGOV35T RMG-I TRUB1 TruB pseu          
 
   
CGOV36T RMUG-S BUB1B BUB1 m        
 
   
CGOV36T RMUG-S CCDC54       
 
   
CGOV36T RMUG-S SEMA5B 
sema domain, seven thrombospondin repeat             
     
 
   
CGOV37T
_3 SK-OV-3 ABCD1 ATP-bind          
 
   
CGOV37T
_3 SK-OV-3 ANK3 an             
CGOV37T
_3 SK-OV-3 APC         
CGOV37T
_3 SK-OV-3 ARID1A AT           
CGOV37T
_3 SK-OV-3 ATF6       
 





2 beta-1      
 
   
CGOV37T
_3 SK-OV-3 BCL11B B-cell        
 
   
CGOV37T
_3 SK-OV-3 C11orf30 ch            
CGOV37T
_3 SK-OV-3 C1QTNF9 C1q an          
 
   
CGOV37T
_3 SK-OV-3 C7orf26 ch         
 
   
CGOV37T
_3 SK-OV-3 CCDC15       
 
   
CGOV37T
_3 SK-OV-3 CD5L     
 
   
CGOV37T
_3 SK-OV-3 CDAN1     
 
   
CGOV37T
_3 SK-OV-3 CDC25B       
 
   
CGOV37T
_3 SK-OV-3 CHIA     
 
   
CGOV37T
_3 SK-OV-3 COL4A5        
 
   
CGOV37T
_3 SK-OV-3 CSPP1 centros          
 
   
CGOV37T
_3 SK-OV-3 DOCK2       
 
   
CGOV37T
_3 SK-OV-3 EEF1A2 eukaryo          
 
   
CGOV37T
_3 SK-OV-3 ELMSAN1 ELM2        
 
   
CGOV37T
_3 SK-OV-3 FBXW7 F-box and WD rep           
 
   
CGOV37T
_3 SK-OV-3 FCRL1      
 
   
CGOV37T
_3 SK-OV-3 FMO3 f       
 
   
CGOV37T
_3 SK-OV-3 GNMT     
 
   
CGOV37T
_3 SK-OV-3 GPR34       
 
   
CGOV37T
_3 SK-OV-3 GSDMA     
 
   
CGOV37T
_3 SK-OV-3 GUCY2F       
 
   
CGOV37T
_3 SK-OV-3 ILVBL ilvB      
 
   
CGOV37T
_3 SK-OV-3 IRS4       
 
   
CGOV37T
_3 SK-OV-3 KANSL1 KA         
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CGOV37T
_3 SK-OV-3 KDM8       
 
   
CGOV37T
_3 SK-OV-3 LINGO4 leucin           
 
   
CGOV37T
_3 SK-OV-3 LOXHD1       
 
   
CGOV37T
_3 SK-OV-3 LRRN4        
 
   
CGOV37T
_3 SK-OV-3 MEF2D       
 
   
CGOV37T
_3 SK-OV-3 MEIS3      
 
   
CGOV37T
_3 SK-OV-3 NADSYN1      
 
   
CGOV37T
_3 SK-OV-3 NDST4 N-deacetylas       
 
   
CGOV37T
_3 SK-OV-3 NEDD4 neural precursor cell expressed           
 
   
CGOV37T
_3 SK-OV-3 NOTCH2        
CGOV37T
_3 SK-OV-3 NTSR2      
 
   
CGOV37T
_3 SK-OV-3 OR51L1 olfactory          
 
   
CGOV37T
_3 SK-OV-3 PHEX phosphate       
 
   
CGOV37T
_3 SK-OV-3 PHIP pleckst        
 
   
CGOV37T
_3 SK-OV-3 PI4KA phosp       
 
   
CGOV37T
_3 SK-OV-3 PIGN phosphatid         
 
   
CGOV37T
_3 SK-OV-3 PIK3CA phosphatidylinosit        
 
   
CGOV37T
_3 SK-OV-3 POLD1 polymera          
  
   
CGOV37T
_3 SK-OV-3 PPFIA2 protein tyrosine phosphatase, recep             
 
   
CGOV37T
_3 SK-OV-3 PPFIBP2 PTPRF inter           
 
   
CGOV37T
_3 SK-OV-3 PRLR     
 
   
CGOV37T
_3 SK-OV-3 PSKH1       
 
   
CGOV37T
_3 SK-OV-3 PTGER4 pro         
 




A R        
 
   
CGOV37T
_3 SK-OV-3 RBM47        
 
   
 176 
CGOV37T
_3 SK-OV-3 RHBDF2 r        
 
   
CGOV37T
_3 SK-OV-3 RPTOR regulato          
 
   
CGOV37T
_3 SK-OV-3 SELENBP1       
 
   
CGOV37T
_3 SK-OV-3 SIK1      
 
   
CGOV37T
_3 SK-OV-3 SLC12A9         
 
   
CGOV37T
_3 SK-OV-3 SLC2A6 solute carrier fa          
 
   
CGOV37T
_3 SK-OV-3 SMARCC1 SWI/SNF related, matrix associa                
CGOV37T
_3 SK-OV-3 SSC5D scavenger rece          
 
   
CGOV37T
_3 SK-OV-3 STRA6        
 
   
CGOV37T
_3 SK-OV-3 TBC1D2        
 
   
CGOV37T
_3 SK-OV-3 TOX3 TOX h          
 
   
CGOV37T
_3 SK-OV-3 TP53         
CGOV37T
_3 SK-OV-3 TP63      
 
   
CGOV37T
_3 SK-OV-3 TP63      
 
   
CGOV37T
_3 SK-OV-3 TSHZ3        
 
   
CGOV37T
_3 SK-OV-3 TYK2      
 
   
CGOV37T
_3 SK-OV-3 USP26       
 
   
CGOV37T
_3 SK-OV-3 VWCE von         
 
   
CGOV37T
_3 SK-OV-3 WNK1 W         
 
   
CGOV37T
_3 SK-OV-3 WRNIP1 W        
 
   
CGOV37T
_3 SK-OV-3 ZNF30       
 
   
CGOV37T
_3 SK-OV-3 ZNF831       
 
   
CGOV38T 
TOV-
112D CTNNB1 catenin (        
 
   
CGOV38T 
TOV-
112D SMARCA4 SWI/SNF related, matrix associa                
CGOV38T 
TOV-
112D TP53      
 




112D ZAN    
 
   
CGOV39T 
TOV-
21G ABCC1 ATP-binding         
 
   
CGOV39T 
TOV-
21G ARID1A AT           
CGOV39T 
TOV-
21G ARID1A AT           
CGOV39T 
TOV-
21G ARID1B AT r           
CGOV39T 
TOV-
21G AXIN1        
CGOV39T 
TOV-
21G CCND1        
CGOV39T 
TOV-
21G CSF2RA colony stimulating facto         
 
   
CGOV39T 
TOV-
21G ERBB3 v-erb-b2 erythro             
CGOV39T 
TOV-
21G FANCD2 Fanc             
CGOV39T 
TOV-
21G FGFR3           
CGOV39T 
TOV-
21G JAK1         
CGOV39T 
TOV-
21G JAK1         
CGOV39T 
TOV-
21G KIAA1161     
 
   
CGOV39T 
TOV-
21G KRAS v-Ki-ras2         
 
   
CGOV39T 
TOV-
21G MCCC1 meth       
 
   
CGOV39T 
TOV-
21G MEN1          
CGOV39T 
TOV-
21G MLL3 myeloi           
CGOV39T 
TOV-
21G NBN       
CGOV39T 
TOV-
21G NUP50     
 
   
CGOV39T 
TOV-
21G NXF5        
 
   
CGOV39T 
TOV-
21G PDGFRB platelet-der            
CGOV39T 
TOV-
21G PIK3CA phosphatidylinosit        
 
   
CGOV39T 
TOV-
21G PIK3R1 phosphoin           
CGOV39T 
TOV-




21G PTEN          
CGOV39T 
TOV-
21G RNF43          
CGOV39T 
TOV-
21G SHMT2 serine hy      
 
   
CGOV39T 
TOV-
21G SLC24A2 solute carrier family        
 
   
CGOV39T 
TOV-
21G STK11         
CGOV39T 
TOV-
21G USH2A Usher           
CGOV39T 
TOV-
21G VGLL4       
 
   
CGOV4T DOV-13 
KRTAP12-
1       
 
   
CGOV4T DOV-13 NF1        
CGOV4T DOV-13 NF1          
CGOV4T DOV-13 NOTCH3          
CGOV4T DOV-13 OGG1         
CGOV4T DOV-13 SLC22A10 s         
 
   
CGOV4T DOV-13 SPTA1 spectri         
 
   
CGOV4T DOV-13 TRPM8 transient recepto           
 
   
CGOV40T TYK-nu ARID1A AT           
CGOV40T TYK-nu MSH6           
CGOV40T TYK-nu NRAS neurobla         
 
   
CGOV40T TYK-nu NRAS neurobla         
 
   
CGOV40T TYK-nu SIGLEC10         
 
   
CGOV40T TYK-nu TP53      
 
   
CGOV40T TYK-nu ZDHHC1 zi        
 
   
CGOV42T 
OVCAR-
8 CREBBP         
CGOV42T 
OVCAR-
8 EP300          
CGOV42T 
OVCAR-
8 ERBB2 v-erb-b2 erythroblastic leukemia viral on           
 




8 NCOA2       
 
   
CGOV42T 
OVCAR-
8 TP53      
  
   
CGOV44T FU-OV-1 ADCYAP1 adenylate        
 
   
CGOV44T FU-OV-1 BTRC beta-transduc          
 
   
CGOV44T FU-OV-1 DNER de       
 
   
CGOV44T FU-OV-1 MLL myeloid/lymphoid or m        
 
   
CGOV44T FU-OV-1 MYO10     
 
   
CGOV44T FU-OV-1 POLG p          
CGOV44T FU-OV-1 PPM1D protein       
 
   
CGOV44T FU-OV-1 PRKDC protein k            
CGOV44T FU-OV-1 PROZ protein Z        
 
   
CGOV44T FU-OV-1 SPEF2      
 
   
CGOV44T FU-OV-1 TP53      
 
   
CGOV44T FU-OV-1 TP53      
 
   
CGOV45T COV-318 CD209     
 
   
CGOV45T COV-318 KBTBD6 kelch re          
 
   
CGOV45T COV-318 KIF16B       
 
   
CGOV45T COV-318 OGG1         
CGOV45T COV-318 REST      
 
   
CGOV45T COV-318 TP53      
 
   
CGOV45T COV-318 ZNF45       
 
   
CGOV46T JHOS-2 AR     
 
   
CGOV46T JHOS-2 EPSTI1 ep        
 
   
CGOV46T JHOS-2 GPR158       
 
   
CGOV46T JHOS-2 HYDIN HYDIN              
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CGOV46T JHOS-2 NLRP10 NL         
 
   
CGOV46T JHOS-2 ZNF426       
 
   
CGOV47T JHOS-4 BRCA1        
  
   
CGOV47T JHOS-4 KCTD6 potassium        
 
   
CGOV47T JHOS-4 SLC2A7 solute carrier fa          
 
   
CGOV47T JHOS-4 TP53      
 
   
CGOV48T JHOM-1 ANKRD33       
 
   
CGOV48T JHOM-1 PTEN          
CGOV48T JHOM-1 RB1     
 
   
CGOV48T JHOM-1 STK11      
 
   
CGOV48T JHOM-1 STK11      
 
   
CGOV48T JHOM-1 TP53         
CGOV48T JHOM-1 TRIM65       
 
   
CGOV49T OVK-18 ALDH1L1 aldehy         
 
   
CGOV49T OVK-18 ARID1A AT           
CGOV49T OVK-18 ARID1A AT           
CGOV49T OVK-18 BLM B          
CGOV49T OVK-18 C2CD2L    
 
   
CGOV49T OVK-18 FANCD2 Fanc             
CGOV49T OVK-18 GBF1 golgi brefeldin          
 
   
CGOV49T OVK-18 GBP6 guan         
 
   
CGOV49T OVK-18 IGF2R i             
CGOV49T OVK-18 JAK2         
CGOV49T OVK-18 KIAA1109     
 
   
CGOV49T OVK-18 KRAS v-Ki-ras2         
 
   
CGOV49T OVK-18 MDC1 me        
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CGOV49T OVK-18 MLL3 myeloi           
CGOV49T OVK-18 MNAT1 menage a trois ho              
CGOV49T OVK-18 MYCL1 v-myc myelocytomatosis              
CGOV49T OVK-18 NEIL1 n            
CGOV49T OVK-18 NOTCH4        
CGOV49T OVK-18 PIK3R1 phosphoin           
CGOV49T OVK-18 POLG p          
CGOV49T OVK-18 POU4F1        
 
   
CGOV49T OVK-18 PTEN          
CGOV49T OVK-18 PTEN          
CGOV49T OVK-18 RET     
 
   
CGOV49T OVK-18 SMAD2          
CGOV49T OVK-18 SMARCA4 SWI/SNF related, matrix associa                
CGOV49T OVK-18 SMARCA4 SWI/SNF related, matrix associa                
CGOV49T OVK-18 TP53         
CGOV49T OVK-18 TSC2         
CGOV49T OVK-18 WRN W          
CGOV49T OVK-18 ZFHX4       
 
   
CGOV49T OVK-18 ZFHX4          
CGOV49T OVK-18 ZFHX4          
CGOV5T EFO-21 ANK3 an             
CGOV5T EFO-21 CYP11B1 cytochrome          
 
   
CGOV5T EFO-21 FER1L6       
 
   
CGOV5T EFO-21 NOTCH2     
 
   
CGOV5T EFO-21 TP53      
 
   
CGOV53T 
OVCAR-
5-CisR ANK3 an          
 
   
CGOV53T 
OVCAR-
5-CisR APC      
 




5-CisR CREBBP      
 
   
CGOV53T 
OVCAR-
5-CisR KRAS v-Ki-ras2         
 
   
CGOV53T 
OVCAR-
5-CisR RIPK1 receptor (T       
 
   
CGOV6T EFO-27 ARID1A AT           
CGOV6T EFO-27 ARID1A AT           
CGOV6T EFO-27 ARID1B AT r           
CGOV6T EFO-27 ARID1B AT r           
CGOV6T EFO-27 AXIN1        
CGOV6T EFO-27 CNGA3 cy         
 
   
CGOV6T EFO-27 CREBBP         
CGOV6T EFO-27 DCDC5       
 
   
CGOV6T EFO-27 DCP1B DCP1 de         
 
   
CGOV6T EFO-27 EIF2D euk        
 
   
CGOV6T EFO-27 ELMO2        
 
   
CGOV6T EFO-27 EPHX1 epoxi        
 
   
CGOV6T EFO-27 ERBB2 v-erb-b2 erythroblastic leukemia viral on           
 
   
CGOV6T EFO-27 ERCC2 excision repair cross-comp          
  
   
CGOV6T EFO-27 ERCC3 excision repair cross-comp               
CGOV6T EFO-27 ERCC6 excision repair cross-comp             
CGOV6T EFO-27 EYA2 e        
 
   
CGOV6T EFO-27 FLCN       
CGOV6T EFO-27 GDF6       
 
   
CGOV6T EFO-27 GPR50       
 
   
CGOV6T EFO-27 LACTB     
 
   
CGOV6T EFO-27 MLL2 myeloi           
CGOV6T EFO-27 MSH2 mutS homolo               
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CGOV6T EFO-27 MSH2 mutS homolo                 
CGOV6T EFO-27 MSH6           
CGOV6T EFO-27 MTMR6       
 
   
CGOV6T EFO-27 MUC6 mu       
 
   
CGOV6T EFO-27 NAA35 N(alpha)-        
 
   
CGOV6T EFO-27 NES    
 
   
CGOV6T EFO-27 PER1       
 
   
CGOV6T EFO-27 PIK3R1 phosphoin           
CGOV6T EFO-27 PMS1 PMS1 postm            
CGOV6T EFO-27 POU3F4        
 
   
CGOV6T EFO-27 PTEN          
CGOV6T EFO-27 RAB17 RA        
 
   
CGOV6T EFO-27 RD3      
 
   
CGOV6T EFO-27 RFX2 regulatory fa           
 
   
CGOV6T EFO-27 RFX5 regulatory fa           
 
   
CGOV6T EFO-27 ROBO2 roundabout, a         
 
   
CGOV6T EFO-27 SEMA3D sema domain, immunoglobu            
 
   
CGOV6T EFO-27 SLC7A14 solute carr          
 
   
CGOV6T EFO-27 SMAD4            
CGOV6T EFO-27 TP53      
 
   
CGOV6T EFO-27 USH2A Usher        
 
   
CGOV6T EFO-27 VPS13A vacuolar p             
CGOV7T ES-2 BRAF v-raf mu         
 
   
CGOV7T ES-2 CYP11A1 cytochrome          
 
   
CGOV7T ES-2 FANCD2 Fanc             
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CGOV7T ES-2 FANCM Fanc        
 
   
CGOV7T ES-2 FASTKD2       
 
   
CGOV7T ES-2 GRM8       
 
   
CGOV7T ES-2 HOXD12     
 
   
CGOV7T ES-2 HYDIN HYDIN            
CGOV7T ES-2 NRD1 nard       
 
   
CGOV7T ES-2 POLM          
CGOV7T ES-2 TEX14      
 
   
CGOV7T ES-2 TP53      
 
   
CGOV7T ES-2 TRRAP transforma      
 
   
CGOV8T HEY ANKRD40       
 
   
CGOV8T HEY ARMC4       
 
   
CGOV8T HEY BRAF v-raf mu         
 
   
CGOV8T HEY KRAS v-Ki-ras2         
 
   
CGOV8T HEY STARD10 StAR-related         
 
   
CGOV8T HEY TP53BP1 t            
CGOV92T JHOS-3 ACAT2      
 
   
CGOV92T JHOS-3 ADAM21 A       
 
   
CGOV92T JHOS-3 CCDC141       
 
   
CGOV92T JHOS-3 CD96     
 
   
CGOV92T JHOS-3 CPA4     
 
   
CGOV92T JHOS-3 DCC       
 
   
CGOV92T JHOS-3 EXTL3 e      
 
   
CGOV92T JHOS-3 FBXO2      
 
   
CGOV92T JHOS-3 FNDC3B fibr         
 




SCHIP1     
 
   
CGOV92T JHOS-3 LAIR1 leukocyte       
 
   
CGOV92T JHOS-3 MISP      
 
   
CGOV92T JHOS-3 MMP12 matrix m       
 
   
CGOV92T JHOS-3 NCSTN    
 
   
CGOV92T JHOS-3 OR6C6 olfactory          
 
   
CGOV92T JHOS-3 PIK3CG phosphatidylinosito        
 
   
CGOV92T JHOS-3 PPAPDC3 phosphatidi           
 
   
CGOV92T JHOS-3 RAD1       
 
   
CGOV92T JHOS-3 RHBDF2 r        
 
   
CGOV92T JHOS-3 RNF152       
 
   
CGOV92T JHOS-3 RNF175       
 
   
CGOV92T JHOS-3 ROBO2 roundabout, a         
 
   
CGOV92T JHOS-3 ROS1 c-ro             
CGOV92T JHOS-3 RSBN1        
 
   
CGOV92T JHOS-3 SLC4A10 solute carrier fam          
 
   
CGOV92T JHOS-3 SON       
 
   
CGOV92T JHOS-3 TAS1R2         
 
   
CGOV92T JHOS-3 TAS1R2         
 
   
CGOV92T JHOS-3 TENM1       
 
   
CGOV92T JHOS-3 TP53      
  
   
CGOV92T JHOS-3 USP34       
 
   
CGOV92T JHOS-3 ZBTB7C zinc         
 
   
CGOV92T JHOS-3 ZIK1 zinc fi          
 
   
CGOV92T JHOS-3 ZNF229       
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CGOV92T JHOS-3 ZNF248       
 
   
CGOV92T JHOS-3 ZNF280A       
 









Table S3.1h. Deletions* 
Lab id Chr Deletion Width    
 




CGOV16T chr2 g.(215426360_215426460)_(215959491_215959591) 533232    
   
  
CGOV16T chr5 g.(33324914_33325014)_(33330942_33331042) 6129      
CGOV16T chr5 g.(97047904_97048004)_(97095995_97096095) 48192      
CGOV16T chr6 g.(26343903_26344003)_(26351413_26351513) 7611      
CGOV16T chr9 g.(90817091_90817191)_(90821828_90821928) 4838      
CGOV16T chr12 g.(866873_866973)_(874651_874751) 7879      
CGOV16T chr13 g.(69244759_69244859)_(69268602_69268702) 23944      
CGOV16T chr13 g.(71912501_71913501)_(71920501_71921501) 8001      
CGOV16T chr16 g.(73344503_73344603)_(73352006_73352106) 7604      
CGOV16T chr18 g.(7588958_7589058)_(7906687_7906787) 317830      
CGOV16T chr18 g.(42868944_42869044)_(43173129_43173229) 304286       
CGOV16T chr22 g.(37744469_37744569)_(37749862_37749962) 5494       
CGOV17T chr1 g.(49410038_49410138)_(49497764_49497864) 87827      
CGOV17T chr1 g.(191661486_191661586)_(191674499_191674599) 13114      
CGOV17T chr2 g.(109689949_109690049)_(109695076_109695176) 5228      
CGOV17T chr2 g.(126814885_126814985)_(126819929_126820029) 5145      
CGOV17T chr2 g.(141314638_141314738)_(141475895_141475995) 161358       
CGOV17T chr2 g.(141782591_141782691)_(142026688_142026788) 244198  
 
    
CGOV17T chr2 g.(141965917_141966917)_(142026288_142027288) 60372      
CGOV17T chr2 g.(213716368_213717368)_(213892174_213893174) 175807        
CGOV17T chr2 g.(227832551_227832651)_(227836940_227837040) 4490      
CGOV17T chr3 g.(20311501_20312501)_(20315501_20316501) 4001      
CGOV17T chr4 g.(20386477_20386577)_(20705675_20705775) 319299    
   
  
CGOV17T chr4 g.(151957497_151957597)_(152147129_152147229) 189733        
CGOV17T chr4 g.(161046501_161047501)_(161071501_161072501) 25001      
CGOV17T chr6 g.(54846454_54846554)_(54851295_54851395) 4942      
CGOV17T chr6 g.(69687219_69688219)_(69691315_69692315) 4097      
CGOV17T chr6 g.(167142424_167142524)_(167222835_167222935) 80512      
CGOV17T chr8 g.(89809161_89809261)_(90083591_90083691) 274531      
CGOV17T chr9 g.(44232501_44233501)_(44264501_44265501) 32001      
CGOV17T chr10 g.(90940586_90940686)_(90947863_90947963) 7378      
CGOV17T chr11 g.(23454678_23455678)_(23479800_23480800) 25123      
CGOV17T chr11 g.(85234699_85234799)_(85542725_85542825) 308127    
   
    
CGOV17T chr13 g.(80343605_80343705)_(80346833_80346933) 3329      
CGOV17T chr13 g.(85200001_85200101)_(85260901_85261001) 61001      
CGOV17T chr13 g.(110822820_110822920)_(110835741_110835841) 13022      
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CGOV17T chr13 g.(110838244_110839244)_(111046054_111047054) 207811        
CGOV17T chr14 g.(67389152_67389252)_(67395409_67395509) 6358      
CGOV17T chr15 g.(24055436_24055536)_(24061479_24061579) 6144      
CGOV17T chr17 g.(29590319_29590419)_(29666366_29666466) 76148         
CGOV17T chr19 g.(12039036_12040036)_(12045477_12046477) 6442      
CGOV17T chr20 g.(15031714_15031814)_(15079252_15079352) 47639      
CGOV17T chr22 g.(46321088_46321188)_(46482539_46482639) 161552    
  
  
    
CGOV17T chrX g.(127145414_127145514)_(127250834_127250934) 105521      
CGOV17T chrX g.(127630674_127630774)_(128669484_128669584) 1038911       
CGOV17T chrX g.(139495001_139495101)_(139501901_139502001) 7001      
CGOV18T chr1 g.(101774312_101774412)_(101780700_101780800) 6489      
CGOV18T chr1 g.(162575449_162575549)_(162592605_162592705) 17257      
CGOV18T chr2 g.(141923625_141923725)_(141982074_141982174) 58550      
CGOV18T chr2 g.(142325365_142325465)_(142328863_142328963) 3599      
CGOV18T chr2 g.(164640715_164641715)_(164645557_164646557) 4843      
CGOV18T chr3 g.(75423501_75424501)_(75639501_75640501) 216001      
CGOV18T chr3 g.(116318845_116318945)_(116388047_116388147) 69303      
CGOV18T chr3 g.(116483786_116483886)_(116588167_116588267) 104482      
CGOV18T chr3 g.(149585200_149585300)_(149588754_149588854) 3655      
CGOV18T chr3 g.(168898366_168898466)_(169084656_169084756) 186391      
CGOV18T chr4 g.(90559345_90559445)_(90563418_90563518) 4174      
CGOV18T chr4 g.(181992235_181992335)_(182175918_182176018) 183784      
CGOV18T chr7 g.(141744316_141744416)_(141865034_141865134) 120819       
CGOV18T chr8 g.(94955418_94955518)_(94960757_94960857) 5440      
CGOV18T chr8 g.(114040518_114040618)_(114046603_114046703) 6186      
CGOV18T chr9 g.(9541307_9541407)_(9698897_9698997) 157691      
CGOV18T chr11 g.(3238797_3238897)_(3243910_3244010) 5214       
CGOV18T chr14 g.(84183968_84184068)_(84477397_84477497) 293530      
CGOV18T chr18 g.(41976805_41976905)_(41981953_41982053) 5249      
CGOV18T chr20 g.(52647133_52647233)_(52657827_52657927) 10795      
CGOV18T chrX g.(30470501_30471501)_(30480501_30481501) 10001      
CGOV18T chrX g.(30728384_30728484)_(31382222_31382322) 653939         
CGOV18T chrX g.(53513501_53514501)_(53518501_53519501) 5001      
CGOV18T chrX g.(96345362_96345462)_(96491606_96491706) 146345      
CGOV21T chr1 g.(26460207_26460307)_(26464652_26464752) 4546      
CGOV21T chr3 g.(60372339_60372439)_(60725881_60725981) 353643       
CGOV21T chr7 g.(118292669_118292769)_(118304100_118304200) 11532      
CGOV21T chr8 g.(97551060_97551160)_(97742085_97742185) 191126       
CGOV21T chr8 g.(106653250_106653350)_(106956785_106956885) 303636       
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CGOV21T chr9 g.(44248501_44249501)_(44790501_44791501) 542001       
CGOV21T chr14 g.(98030843_98030943)_(99417216_99417316) 1386474    
  
   
CGOV21T chr16 g.(83920397_83920497)_(84074537_84074637) 154241    
   
  
CGOV21T chr16 g.(87265770_87265870)_(87272506_87272606) 6837      
CGOV21T chr18 g.(40054143_40054243)_(40057497_40057597) 3455      
CGOV21T chr20 g.(7398773_7398873)_(7403434_7403534) 4762      
CGOV23T chr3 g.(15049874_15049974)_(15135111_15135211) 85338        
CGOV23T chr4 g.(3895501_3896501)_(4153501_4154501) 258001      
CGOV23T chr4 g.(5615038_5615138)_(5644533_5644633) 29596      
CGOV23T chr4 g.(152204141_152204241)_(152569648_152569748) 365608       
CGOV23T chr4 g.(164612926_164613026)_(164619107_164619207) 6282      
CGOV23T chr4 g.(164872420_164872520)_(165055066_165055166) 182747      
CGOV23T chr6 g.(2568234_2568334)_(2571823_2571923) 3690      
CGOV23T chr6 g.(137069374_137069474)_(137549475_137549575) 480202    
   
   
  







CGOV23T chr9 g.(21958156_21959156)_(21992501_21993501) 34346    
  
  
CGOV23T chr9 g.(78004351_78004451)_(78011639_78011739) 7389      
CGOV23T chr9 g.(97451386_97451486)_(97465908_97466008) 14623      
CGOV23T chr10 g.(53665015_53665115)_(53863090_53863190) 198176      
CGOV23T chr11 g.(49709850_49709950)_(49757566_49757666) 47817      
CGOV23T chr11 g.(93020222_93020322)_(93029805_93029905) 9684      
CGOV23T chr12 g.(866868_866968)_(874636_874736) 7869      
CGOV23T chr15 g.(74016851_74017851)_(74025774_74026774) 8924      
CGOV23T chr16 g.(78686083_78686183)_(79072508_79072608) 386526      
CGOV23T chr17 g.(75038653_75038753)_(75158148_75158248) 119596    
   
  
CGOV23T chr19 g.(4008434_4008534)_(4084764_4084864) 76431       
CGOV23T chr20 g.(7398765_7398865)_(7403432_7403532) 4768      
CGOV23T chr20 g.(14781484_14781584)_(14827331_14827431) 45948      
CGOV25T chr1 g.(30479718_30479818)_(30489321_30489421) 9704      
CGOV25T chr1 g.(72377134_72377234)_(72471536_72471636) 94503      
CGOV25T chr2 g.(14704234_14704334)_(14709948_14710048) 5815      
CGOV25T chr2 g.(141878286_141878386)_(142041589_142041689) 163404  
 
    
CGOV25T chr2 g.(141974556_141974656)_(142139672_142139772) 165217  
 
    
CGOV25T chr2 g.(141974056_141975056)_(142041189_142042189) 67134      
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CGOV25T chr3 g.(4385597_4385697)_(4455795_4455895) 70299      
CGOV25T chr3 g.(116153523_116153623)_(116250118_116250218) 96696      
CGOV25T chr3 g.(116376722_116376822)_(116970205_116970305) 593584        
CGOV25T chr4 g.(181802859_181802959)_(182463377_182463477) 660619      
CGOV25T chr6 g.(75600365_75600465)_(75606987_75607087) 6723      
CGOV25T chr7 g.(42019946_42020046)_(42162089_42162189) 142244      
CGOV25T chr7 g.(153920400_153920500)_(154109738_154109838) 189439      
CGOV25T chr8 g.(3662157_3662257)_(3730050_3730150) 67994      
CGOV25T chr10 g.(56263776_56263876)_(56332079_56332179) 68404      
CGOV25T chr10 g.(97027671_97027771)_(97044788_97044888) 17218      
CGOV25T chr12 g.(99695055_99695155)_(99927923_99928023) 232969  
 
    
CGOV25T chr12 g.(99694555_99695555)_(99727384_99728384) 32830      
CGOV25T chr12 g.(99793970_99794070)_(99802652_99802752) 8783      
CGOV25T chr12 g.(99917238_99918238)_(99927523_99928523) 10286      
CGOV25T chr13 g.(35558501_35559501)_(35562501_35563501) 4001      
CGOV25T chr14 g.(33502125_33502225)_(33806675_33806775) 304651      
CGOV25T chr16 g.(81175878_81175978)_(81188246_81188346) 12469      
CGOV25T chr20 g.(6589166_6589266)_(6614154_6614254) 25089      
CGOV25T chr20 g.(14920162_14920262)_(15024789_15024889) 104728      
CGOV25T chrX g.(6725420_6725520)_(7140011_7140111) 414692        
CGOV25T chrX g.(34043060_34043160)_(34072729_34072829) 29770      
CGOV28T chr3 g.(160355949_160356049)_(160366031_160366131) 10183      
CGOV28T chr4 g.(175961671_175961771)_(175986690_175986790) 25120      
CGOV28T chr6 g.(14494026_14494126)_(14499739_14499839) 5814      
CGOV28T chr6 g.(155135096_155135196)_(155172208_155172308) 37213       
CGOV28T chr7 g.(133260013_133260113)_(133702135_133702235) 442223       
CGOV28T chr7 g.(151590831_151590931)_(151599609_151599709) 8879      
CGOV28T chr7 g.(157591843_157591943)_(157598292_157598392) 6550      
CGOV28T chr8 g.(2440119_2440219)_(2470609_2470709) 30591      
CGOV28T chr8 g.(9862648_9862748)_(9880889_9880989) 18342      
CGOV28T chr9 g.(7827533_7827633)_(7846534_7846634) 19102      
CGOV28T chr9 g.(23289601_23290601)_(23299358_23300358) 9758      
CGOV28T chr9 g.(136396620_136396720)_(136428109_136428209) 31590      
CGOV28T chr10 g.(37020375_37020475)_(37030380_37030480) 10106      
CGOV28T chr10 g.(90543987_90544987)_(90571212_90572212) 27226      
CGOV28T chr10 g.(105715355_105716355)_(105720256_105721256) 4902      
CGOV28T chr11 g.(42252030_42252130)_(42266836_42266936) 14907      
CGOV28T chrX g.(46468558_46469558)_(46471706_46472706) 3149      
CGOV28T chrX g.(136185614_136186614)_(136193754_136194754) 8141      
 191 
CGOV28T chrX g.(154392501_154393501)_(154409501_154410501) 17001      
CGOV30T chr2 g.(186644331_186644431)_(186957966_186958066) 313736       
CGOV30T chr3 g.(7634615_7634715)_(7830256_7830356) 195742      
CGOV30T chr3 g.(153599268_153599368)_(153613832_153613932) 14665      
CGOV30T chr4 g.(16043746_16043846)_(16051820_16051920) 8175      
CGOV30T chr4 g.(31463501_31464501)_(31467501_31468501) 4001      
CGOV30T chr4 g.(106418218_106418318)_(106513846_106513946) 95729       
CGOV30T chr4 g.(148274180_148274280)_(148907570_148907670) 633491    
  
    
CGOV30T chr6 g.(73345273_73345373)_(73521299_73521399) 176127       
CGOV30T chr6 g.(122159169_122159269)_(122168780_122168880) 9712      
CGOV30T chr7 g.(8118612_8118712)_(8192039_8192139) 73528       
CGOV30T chr8 g.(20101643_20101743)_(20114694_20114794) 13152      
CGOV30T chr8 g.(142927661_142927761)_(142934110_142934210) 6550      
CGOV30T chr9 g.(72832227_72832327)_(73061137_73061237) 229011    
   
  
CGOV30T chr9 g.(129753263_129754263)_(130059501_130060501) 306239        
CGOV30T chr9 g.(130243462_130243562)_(130323641_130323741) 80280       
CGOV30T chr9 g.(130595085_130596085)_(130635960_130636960) 40876        
CGOV30T chr9 g.(132442256_132443256)_(132454263_132455263) 12008      
CGOV30T chr12 g.(122155247_122155347)_(122376876_122376976) 221730    
   
     
CGOV30T chr14 g.(80803045_80803145)_(80914933_80915033) 111989      
CGOV30T chr15 g.(63697036_63698036)_(63701360_63702360) 4325      
CGOV30T chr15 g.(75029360_75029460)_(75172915_75173015) 143656    
    
   
  
CGOV30T chr20 g.(14134326_14134426)_(14142623_14142723) 8398      
CGOV30T chr21 g.(44023501_44024501)_(44038501_44039501) 15001      
CGOV30T chr22 g.(30882816_30882916)_(30885793_30885893) 3078      
CGOV30T chr22 g.(40883801_40884801)_(40894559_40895559) 10759      
CGOV30T chr22 g.(50683538_50684538)_(50690839_50691839) 7302        
CGOV30T chr22 g.(50706820_50707820)_(50714143_50715143) 7324       
CGOV30T chr22 g.(50974351_50975351)_(50977749_50978749) 3399      
CGOV30T chrX g.(23266755_23266855)_(23330923_23331023) 64269      
CGOV30T chrX g.(31837277_31837377)_(31894267_31894367) 57091      
CGOV30T chrX g.(128154820_128154920)_(128610714_128610814) 455995      
CGOV30T chrX g.(130731297_130731397)_(130746355_130746455) 15159      
CGOV30T chrX g.(138263632_138263732)_(138267768_138267868) 4237      
CGOV32T chr2 g.(153796005_153796105)_(153799568_153799668) 3664      
CGOV32T chr2 g.(213184021_213184121)_(213191846_213191946) 7926      
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CGOV32T chr2 g.(226832018_226832118)_(226838239_226838339) 6322      
CGOV32T chr3 g.(115736880_115736980)_(115879326_115879426) 142547      
CGOV32T chr3 g.(175887258_175887358)_(175914744_175914844) 27587      
CGOV32T chr5 g.(87378945_87379045)_(87381902_87382002) 3058      
CGOV32T chr6 g.(14712629_14712729)_(16058481_16058581) 1345953        
CGOV32T chr6 g.(39068610_39068710)_(39072708_39072808) 4199      
CGOV32T chr6 g.(57284962_57285062)_(57289212_57289312) 4351      
CGOV32T chr6 g.(101934624_101934724)_(101938894_101938994) 4371      
CGOV32T chr6 g.(110396120_110396220)_(110414160_110414260) 18141      
CGOV32T chr6 g.(128432727_128432827)_(128437441_128437541) 4815      
CGOV32T chr6 g.(159212184_159212284)_(159318039_159318139) 105956         
CGOV32T chr7 g.(101724549_101724649)_(101727392_101727492) 2944      
CGOV32T chr9 g.(121861410_121861510)_(121878416_121878516) 17107      
CGOV32T chr11 g.(107231501_107232501)_(107242501_107243501) 11001      
CGOV32T chr11 g.(117923302_117923402)_(117942777_117942877) 19576       
CGOV32T chr12 g.(27648190_27648290)_(27655003_27655103) 6914      
CGOV32T chr14 g.(85454792_85454892)_(85547158_85547258) 92467      
CGOV32T chr14 g.(91810963_91811063)_(91987467_91987567) 176605       
CGOV32T chr18 g.(40054133_40054233)_(40057514_40057614) 3482      
CGOV32T chrX g.(26543501_26544501)_(29198501_29199501) 2655001    
   
   
  
CGOV32T chrX g.(150707112_150707212)_(150712157_150712257) 5146      
CGOV34T chr1 g.(21845729_21845829)_(21849090_21849190) 3462      
CGOV34T chr2 g.(9925548_9925648)_(9928862_9928962) 3415      
CGOV34T chr2 g.(128197626_128197726)_(128292743_128292843) 95218       
CGOV34T chr2 g.(142114370_142114470)_(142423709_142423809) 309440      
CGOV34T chr3 g.(160680335_160680435)_(160685849_160685949) 5615      
CGOV34T chr4 g.(83913482_83914482)_(83918930_83919930) 5449      
CGOV34T chr4 g.(92280214_92280314)_(92285052_92285152) 4939      
CGOV34T chr4 g.(93124501_93125501)_(93142501_93143501) 18001      
CGOV34T chr4 g.(112237002_112238002)_(112241890_112242890) 4889      
CGOV34T chr5 g.(17600501_17601501)_(17643501_17644501) 43001      
CGOV34T chr6 g.(2568252_2568352)_(2571823_2571923) 3672      
CGOV34T chr6 g.(41442616_41442716)_(41447949_41448049) 5434      
CGOV34T chr6 g.(142237501_142238501)_(142242501_142243501) 5001      
CGOV34T chr6 g.(146869348_146869448)_(146875743_146875843) 6496      
CGOV34T chr7 g.(85044501_85045501)_(85046501_85047501) 2001      
CGOV34T chr7 g.(132136647_132136747)_(132146427_132146527) 9881      
CGOV34T chr8 g.(2508866_2508966)_(2526090_2526190) 17325      
CGOV34T chr8 g.(16262079_16262179)_(16274536_16274636) 12558      
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CGOV34T chr9 g.(20919501_20920501)_(23847501_23848501) 2928001    
    
  
   
    
    
   
    





CGOV34T chr9 g.(115661708_115661808)_(115667530_115667630) 5923      
CGOV34T chr10 g.(24147354_24147454)_(24156837_24156937) 9584      
CGOV34T chr10 g.(88380446_88380546)_(88402375_88402475) 22030      
CGOV34T chr11 g.(46819792_46819892)_(46835963_46836063) 16272      
CGOV34T chr11 g.(47612771_47612871)_(47635915_47636015) 23245        
CGOV34T chr11 g.(49116350_49116450)_(49119531_49119631) 3282      
CGOV34T chr11 g.(49709847_49709947)_(49757556_49757656) 47810      
CGOV34T chr11 g.(105612470_105612570)_(105619182_105619282) 6813      
CGOV34T chr11 g.(106551771_106551871)_(106584954_106585054) 33284      
CGOV34T chr11 g.(116255656_116255756)_(116267686_116267786) 12131      
CGOV34T chr12 g.(129405278_129405378)_(129455069_129455169) 49892      
CGOV34T chr13 g.(35558501_35559501)_(35562501_35563501) 4001      
CGOV34T chr15 g.(78637775_78637875)_(78648422_78648522) 10748      
CGOV34T chr16 g.(78144600_78144700)_(78869655_78869755) 725156      
CGOV34T chr17 g.(73458567_73459567)_(73492918_73493918) 34352        
CGOV34T chr22 g.(29993607_29993707)_(30009861_30009961) 16355      
CGOV34T chrX g.(143628747_143628847)_(143637610_143637710) 8964      
CGOV44T chr1 g.(60525683_60525783)_(60534852_60534952) 9270      
CGOV44T chr1 g.(72824099_72824199)_(72927841_72927941) 103843      
CGOV44T chr2 g.(60525347_60525447)_(60532673_60532773) 7427      
CGOV44T chr2 g.(95730268_95731268)_(95736462_95737462) 6195      
CGOV44T chr3 g.(117122100_117122200)_(117284577_117284677) 162578      
CGOV44T chr4 g.(22602001_22602101)_(22605901_22606001) 4001      
CGOV44T chr4 g.(26289989_26290989)_(26294876_26295876) 4888      
CGOV44T chr4 g.(40377081_40377181)_(40440094_40440194) 63114      
CGOV44T chr4 g.(92857501_92858501)_(92945501_92946501) 88001      
CGOV44T chr5 g.(41226856_41226956)_(41243798_41243898) 17043      
CGOV44T chr5 g.(180590874_180591874)_(180595940_180596940) 5067      
CGOV44T chr6 g.(77016759_77016859)_(77028997_77029097) 12339      
CGOV44T chr6 g.(169506347_169506447)_(169520999_169521099) 14753      
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CGOV44T chr7 g.(2902501_2903501)_(5191501_5192501) 2289001    
   
  
   
  
   
  
CGOV44T chr7 g.(5205501_5206501)_(5291501_5292501) 86001      
CGOV44T chr7 g.(5337501_5338501)_(5512501_5513501) 175001        
CGOV44T chr7 g.(97635501_97636501)_(97874501_97875501) 239001        
CGOV44T chr7 g.(152251843_152252843)_(152276201_152277201) 24359      
CGOV44T chr14 g.(72805851_72805951)_(72810773_72810873) 5023      
CGOV44T chr15 g.(63201003_63201103)_(63209143_63209243) 8241      
CGOV44T chr17 g.(29447326_29448326)_(29705997_29706997) 258672         
CGOV44T chr20 g.(37008042_37009042)_(37014845_37015845) 6804      
CGOV44T chr21 g.(17874424_17874524)_(17891690_17891790) 17367      
CGOV44T chr22 g.(24873967_24874067)_(24886524_24886624) 12658       
CGOV44T chrX g.(56811501_56812501)_(56861501_56862501) 50001      
CGOV44T chrX g.(92796360_92796460)_(92801380_92801480) 5121      
CGOV45T chr1 g.(72755761_72755861)_(72763911_72764011) 8251      
CGOV45T chr4 g.(29035847_29035947)_(29140721_29140821) 104975      
CGOV45T chr4 g.(134385737_134385837)_(134392731_134392831) 7095      
CGOV45T chr4 g.(148551875_148551975)_(148888647_148888747) 336873    
  
   
CGOV45T chr5 g.(58400155_58400255)_(58878623_58878723) 478569      
CGOV45T chr6 g.(77438501_77439501)_(77452501_77453501) 14001      
CGOV45T chr6 g.(161817300_161817400)_(162361689_162361789) 544490      
CGOV45T chr9 g.(112048997_112049097)_(112191979_112192079) 143083       
CGOV45T chr13 g.(19449094_19450094)_(19641121_19642121) 192028    
  
  





   
   
CGOV45T chr15 g.(45153623_45154623)_(45159015_45160015) 5393      
CGOV45T chr19 g.(40329972_40330072)_(40334288_40334388) 4417      
CGOV45T chr22 g.(40812967_40813067)_(40960092_40960192) 147226       
CGOV45T chrX g.(32250501_32251501)_(32254501_32255501) 4001      
CGOV45T chrX g.(79977350_79977450)_(80201290_80201390) 224041      
CGOV46T chr1 g.(39128575_39128675)_(39137102_39137202) 8628      
CGOV46T chr5 g.(11128325_11128425)_(11135083_11135183) 6859      
CGOV46T chr5 g.(58845780_58845880)_(59135606_59135706) 289927      
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CGOV46T chr6 g.(77016750_77016850)_(77028996_77029096) 12347      
CGOV46T chr9 g.(19770501_19771501)_(20340501_20341501) 570001       
CGOV46T chr9 g.(20341501_20342501)_(21806501_21807501) 1465001    
    
   
   
    
    
   
    
    
CGOV46T chr9 g.(21806526_21807526)_(26655233_26656233) 4848708    
  







CGOV46T chr14 g.(72805866_72805966)_(72810765_72810865) 5000      
CGOV46T chr14 g.(100733823_100733923)_(100739919_100740019) 6197       
CGOV46T chr16 g.(60081157_60081257)_(60098400_60098500) 17344      
CGOV46T chr18 g.(66745661_66745761)_(66756849_66756949) 11289      
CGOV46T chr20 g.(37008031_37009031)_(37014845_37015845) 6815      
CGOV46T chr21 g.(48092501_48093501)_(48099501_48100501) 7001      
CGOV46T chrX g.(143628756_143628856)_(143637615_143637715) 8960      
CGOV47T chr1 g.(78884355_78884455)_(78889914_78890014) 5660      
CGOV47T chr2 g.(119527185_119527285)_(119559322_119559422) 32238      
CGOV47T chr2 g.(189800635_189800735)_(189817521_189817621) 16987      
CGOV47T chr3 g.(34707050_34707150)_(34728997_34729097) 22048      
CGOV47T chr3 g.(34855905_34856005)_(36213991_36214091) 1358187    
  
  
CGOV47T chr3 g.(153599185_153599285)_(153613832_153613932) 14748      
CGOV47T chr4 g.(24488790_24488890)_(24510302_24510402) 21613      
CGOV47T chr4 g.(177728919_177729019)_(177733206_177733306) 4388      
CGOV47T chr5 g.(9519086_9519186)_(9541565_9541665) 22580    
  
  
CGOV47T chr5 g.(19809241_19809341)_(19814977_19815077) 5837      
CGOV47T chr5 g.(41226884_41226984)_(41243801_41243901) 17018      
CGOV47T chr5 g.(96247341_96248341)_(96257220_96258220) 9880      
CGOV47T chr5 g.(170760162_170760262)_(170765955_170766055) 5894      
CGOV47T chr6 g.(71648501_71649501)_(71652501_71653501) 4001      
CGOV47T chr7 g.(128857006_128858006)_(128860706_128861706) 3701       
CGOV47T chr8 g.(42397231_42397331)_(42402702_42402802) 5572       
 196 




    
  
   
   
   




CGOV47T chr9 g.(119016898_119016998)_(119020684_119020784) 3887      
CGOV47T chr10 g.(77463909_77464009)_(78040863_78040963) 577055      
CGOV47T chr10 g.(83901865_83901965)_(85290509_85290609) 1388745       
CGOV47T chr14 g.(41552735_41552835)_(41579743_41579843) 27109      
CGOV47T chr15 g.(73858030_73858130)_(73922322_73922422) 64393       
CGOV47T chr15 g.(77451538_77451638)_(77462213_77462313) 10776      
CGOV47T chr16 g.(60081169_60081269)_(60098425_60098525) 17357      
CGOV47T chr17 g.(58239224_58239324)_(58250351_58250451) 11228       
CGOV47T chr17 g.(62686931_62687031)_(62691831_62691931) 5001      
CGOV47T chr18 g.(66745583_66745683)_(66756838_66756938) 11356      
CGOV47T chr19 g.(15985069_15985169)_(16017239_16017339) 32271      
CGOV47T chr20 g.(37008082_37009082)_(37014795_37015795) 6714      
CGOV47T chrX g.(14209295_14209395)_(14253155_14253255) 43961      
CGOV4T chr1 g.(157986802_157986902)_(158076357_158076457) 89656      
CGOV4T chr1 g.(207841132_207841232)_(207845666_207845766) 4635      
CGOV4T chr1 g.(246294852_246294952)_(246330154_246330254) 35403      
CGOV4T chr3 g.(116679538_116679638)_(116715479_116715579) 36042      
CGOV4T chr4 g.(91433300_91433400)_(91895466_91895566) 462267      
CGOV4T chr5 g.(16974890_16974990)_(16979126_16979226) 4337      
CGOV4T chr6 g.(55341703_55341803)_(55345507_55345607) 3905      
CGOV4T chr8 g.(16321297_16321397)_(16326435_16326535) 5239      
CGOV4T chr9 g.(21792496_21793496)_(21881429_21882429) 88934      




   
 
 





CGOV4T chr9 g.(22428152_22429152)_(22468445_22469445) 40294      
CGOV4T chr9 g.(26365138_26366138)_(26423261_26424261) 58124      
CGOV4T chr12 g.(44348174_44349174)_(44553448_44554448) 205275      
CGOV4T chr12 g.(45790501_45791501)_(47514501_47515501) 1724001    
   
   
   
  
 197 
CGOV4T chr14 g.(70017049_70017149)_(70022314_70022414) 5366      
CGOV4T chr19 g.(46956435_46957435)_(46962402_46963402) 5968      
CGOV4T chr22 g.(30039501_30040501)_(30093501_30094501) 54001      
CGOV4T chr22 g.(33755264_33756264)_(33759554_33760554) 4291      
CGOV4T chr22 g.(49709664_49709764)_(49713003_49713103) 3440      
CGOV4T chrX g.(62577501_62578501)_(62585501_62586501) 8001      
CGOV5T chr1 g.(67391182_67391282)_(67414068_67414168) 22987       
CGOV5T chr2 g.(26489459_26489559)_(26535565_26535665) 46207       
CGOV5T chr2 g.(116622904_116623004)_(117153250_117153350) 530447      
CGOV5T chr2 g.(141909501_141910501)_(141979501_141980501) 70001      
CGOV5T chr2 g.(149085501_149086501)_(149203501_149204501) 118001      
CGOV5T chr2 g.(153796001_153796101)_(153799582_153799682) 3682      
CGOV5T chr2 g.(212342019_212342119)_(212423262_212423362) 81344      
CGOV5T chr2 g.(225364116_225364216)_(225419013_225419113) 54998      
CGOV5T chr2 g.(238549106_238549206)_(238661611_238661711) 112606      
CGOV5T chr3 g.(59887527_59888527)_(60109181_60110181) 221655      
CGOV5T chr3 g.(114799749_114799849)_(114812218_114812318) 12570      
CGOV5T chr3 g.(117321313_117321413)_(117747515_117747615) 426303      
CGOV5T chr3 g.(148963434_148963534)_(148969548_148969648) 6215      
CGOV5T chr4 g.(64134424_64134524)_(64154373_64154473) 20050      
CGOV5T chr4 g.(101975478_101975578)_(102031399_102031499) 56022      
CGOV5T chr4 g.(114603947_114604047)_(114631283_114631383) 27437      
CGOV5T chr4 g.(149252909_149253009)_(149391931_149392031) 139123      
CGOV5T chr4 g.(162525115_162525215)_(162530651_162530751) 5637      
CGOV5T chr4 g.(168869625_168869725)_(168878642_168878742) 9118      
CGOV5T chr4 g.(172645223_172646223)_(172651274_172652274) 6052      
CGOV5T chr5 g.(56103139_56103239)_(56136450_56136550) 33412  
 
    
CGOV5T chr5 g.(56119617_56120617)_(56136050_56137050) 16434      
CGOV5T chr5 g.(112331964_112332064)_(112432489_112432589) 100626       
CGOV5T chr6 g.(2568260_2568360)_(2571821_2571921) 3662      
CGOV5T chr6 g.(90121181_90121281)_(90213196_90213296) 92116       
CGOV5T chr6 g.(123817241_123817341)_(123825556_123825656) 8416      
CGOV5T chr7 g.(32533101_32533201)_(32547986_32548086) 14986       
CGOV5T chr7 g.(76886077_76887077)_(76928048_76929048) 41972      
CGOV5T chr7 g.(113870135_113870235)_(113900868_113900968) 30834      
CGOV5T chr7 g.(115931734_115931834)_(115941083_115941183) 9450      
CGOV5T chr7 g.(132564147_132564247)_(132725544_132725644) 161498       
CGOV5T chr8 g.(26131921_26132021)_(26172032_26172132) 40212      
CGOV5T chr8 g.(61619114_61619214)_(61694530_61694630) 75517      
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CGOV5T chr9 g.(6700069_6701069)_(6710134_6711134) 10066      
CGOV5T chr9 g.(33885970_33886070)_(34014974_34015074) 129105    
   
  
CGOV5T chr10 g.(54537328_54537428)_(54554716_54554816) 17489      
CGOV5T chr10 g.(78833359_78833459)_(79049403_79049503) 216145       
CGOV5T chr11 g.(14093330_14093430)_(14333554_14333654) 240325       
CGOV5T chr12 g.(11156098_11157098)_(11182501_11183501) 26404    
   
  
CGOV5T chr12 g.(11183501_11184501)_(11198501_11199501) 15001        
CGOV5T chr12 g.(11199501_11200501)_(11248501_11249501) 49001    
   
  
CGOV5T chr12 g.(89533079_89534079)_(89541612_89542612) 8534      
CGOV5T chr12 g.(114599607_114599707)_(115017948_115018048) 418442       
CGOV5T chr12 g.(121268792_121268892)_(121348605_121348705) 79914       
CGOV5T chr13 g.(96153185_96153285)_(96169361_96169461) 16277       
CGOV5T chr14 g.(67139489_67139589)_(67217879_67217979) 78491      
CGOV5T chr14 g.(70017053_70017153)_(70022328_70022428) 5376      
CGOV5T chr15 g.(64675677_64675777)_(64711628_64711728) 36052       
CGOV5T chr16 g.(19945646_19945746)_(19967505_19967605) 21960      
CGOV5T chr16 g.(58566092_58566192)_(58640891_58640991) 74900        
CGOV5T chr17 g.(29663521_29663621)_(29675526_29675626) 12106  
 
    
CGOV5T chr17 g.(29663031_29664031)_(29671895_29672895) 8865      
CGOV5T chr18 g.(45971240_45971340)_(46052073_46052173) 80934      
CGOV5T chr19 g.(1873871_1873971)_(1895073_1895173) 21303      
CGOV5T chr19 g.(55265501_55266501)_(55286501_55287501) 21001    
  
  
CGOV5T chr19 g.(56594560_56595560)_(56612790_56613790) 18231       
CGOV5T chr21 g.(38745983_38746083)_(38834317_38834417) 88435      
CGOV5T chrX g.(7010785_7010885)_(7018229_7018329) 7545      
CGOV5T chrX g.(34043034_34043134)_(34072726_34072826) 29793      
CGOV6T chr1 g.(72755752_72755852)_(72763911_72764011) 8260      
CGOV6T chr3 g.(60169866_60169966)_(60399371_60399471) 229606  
 
    
CGOV6T chr3 g.(60378753_60379753)_(60398971_60399971) 20219      
CGOV6T chr9 g.(133030714_133030814)_(133034653_133034753) 4040      
CGOV6T chr16 g.(78745605_78745705)_(78776539_78776639) 31035      
CGOV6T chr20 g.(7398784_7398884)_(7403433_7403533) 4750      
CGOV6T chr20 g.(52647132_52647232)_(52657841_52657941) 10810      
CGOV6T chrX g.(6946313_6946413)_(7200948_7201048) 254736        
CGOV8T chr3 g.(165041002_165041102)_(165083203_165083303) 42302      
CGOV8T chr7 g.(8826562_8826662)_(8866118_8866218) 39657      
CGOV8T chr8 g.(40182911_40183011)_(40189654_40189754) 6844      
 199 
CGOV8T chr9 g.(21513318_21513418)_(23236722_23236822) 1723505    
  
   




CGOV8T chr9 g.(133382642_133383642)_(133386900_133387900) 4259      
CGOV8T chr12 g.(96674843_96674943)_(96797912_96798012) 123170      
CGOV8T chr13 g.(105680183_105680283)_(105690552_105690652) 10470      
CGOV8T chr18 g.(41976771_41976871)_(41981913_41982013) 5243      
CGOV8T chr18 g.(63906673_63907673)_(63911231_63912231) 4559      
CGOV8T chr20 g.(59111694_59111794)_(59124714_59124814) 13121      
CGOV8T chr22 g.(27220819_27220919)_(27224406_27224506) 3688      
CGOV8T chr22 g.(30066862_30066962)_(30100486_30100586) 33725      
CGOV92T chr1 g.(39679839_39679939)_(39788784_39788884) 109046      
CGOV92T chr1 g.(41464636_41464736)_(41566388_41566488) 101853    
   
  
CGOV92T chr1 g.(48191487_48191587)_(48202675_48202775) 11289      
CGOV92T chr2 g.(7060501_7061501)_(7074501_7075501) 14001       
CGOV92T chr2 g.(23999810_23999910)_(24149156_24149256) 149447      
CGOV92T chr2 g.(43450966_43451066)_(43569072_43569172) 118207        
CGOV92T chr2 g.(153339700_153339800)_(153502769_153502869) 163170      
CGOV92T chr3 g.(19045992_19046992)_(19050838_19051838) 4847      
CGOV92T chr3 g.(88468267_88468367)_(88479958_88480058) 11792      
CGOV92T chr3 g.(114827592_114827692)_(114847752_114847852) 20261      
CGOV92T chr4 g.(113208974_113209074)_(113392305_113392405) 183432       
CGOV92T chr5 g.(36938427_36938527)_(37036434_37036534) 98108      
CGOV92T chr5 g.(108446283_108446383)_(108732196_108732296) 286014       
CGOV92T chr6 g.(47052279_47052379)_(47057840_47057940) 5662      
CGOV92T chr6 g.(123102293_123102393)_(123133958_123134058) 31766       
CGOV92T chr6 g.(144601606_144602606)_(145042912_145043912) 441307      
CGOV92T chr6 g.(152766491_152766591)_(152781341_152781441) 14951      
CGOV92T chr7 g.(15912386_15912486)_(15928765_15928865) 16480  
 
    
CGOV92T chr7 g.(15912501_15913501)_(15926501_15927501) 14001      
CGOV92T chr7 g.(36949872_36949972)_(37130059_37130159) 180288        
CGOV92T chr7 g.(73183508_73183608)_(73272055_73272155) 88648    
   
  
CGOV92T chr7 g.(95823219_95823319)_(95827392_95827492) 4274      
CGOV92T chr7 g.(109821953_109822053)_(110121835_110121935) 299983      
CGOV92T chr7 g.(119297676_119298676)_(119302120_119303120) 4445      
CGOV92T chr8 g.(11666494_11666594)_(11701747_11701847) 35354       
CGOV92T chr8 g.(56690639_56690739)_(56720755_56720855) 30217       
CGOV92T chr8 g.(61327681_61327781)_(61536789_61536889) 209209       
 200 
CGOV92T chr8 g.(61613200_61613300)_(61772127_61772227) 159028      
CGOV92T chr10 g.(58894847_58894947)_(58936981_58937081) 42235      
CGOV92T chr10 g.(74507435_74507535)_(74530685_74530785) 23351      
CGOV92T chr11 g.(27380143_27380243)_(27397690_27397790) 17648       
CGOV92T chr11 g.(59056058_59056158)_(59567931_59568031) 511974    
   
   
    
    
CGOV92T chr11 g.(78691152_78691252)_(79000488_79000588) 309437      
CGOV92T chr12 g.(24067469_24067569)_(24550505_24550605) 483137        
CGOV92T chr12 g.(99573589_99573689)_(99956476_99956576) 382988  
 
    
CGOV92T chr12 g.(99573501_99574501)_(99584501_99585501) 11001      
CGOV92T chr12 g.(99585501_99586501)_(99954501_99955501) 369001      
CGOV92T chr13 g.(96621899_96621999)_(96643785_96643885) 21987      
CGOV92T chr14 g.(50921928_50922928)_(51230510_51231510) 308583         
CGOV92T chr16 g.(18821410_18821510)_(18838772_18838872) 17463      
CGOV92T chr16 g.(19332935_19333035)_(19397623_19397723) 64789      
CGOV92T chr16 g.(23317517_23317617)_(23370413_23370513) 52997      
CGOV92T chr17 g.(15043969_15044069)_(15058563_15058663) 14695      
CGOV92T chr17 g.(61226501_61227501)_(61374501_61375501) 148001       
CGOV92T chr17 g.(61381501_61382501)_(61453501_61454501) 72001      
CGOV92T chr20 g.(40698580_40698680)_(40703597_40703697) 5118      
CGOV92T chr21 g.(29653613_29653713)_(29786849_29786949) 133337      
CGOV92T chr22 g.(46985937_46986037)_(46989975_46990075) 4139      
CGOV92T chr22 g.(50722482_50722582)_(50778127_50778227) 55746        
CGOV92T chrX g.(63686350_63686450)_(63965597_63965697) 279348      
CGOV92T chrX g.(83236456_83236556)_(83429572_83429672) 193217      
CGOV92T chrX g.(127300220_127300320)_(127495502_127495602) 195383      
CGOV92T chrX g.(128236172_128236272)_(128348866_128348966) 112795      
CGOV12T chr1 g.(16751245_16751345)_(16754940_16755040) 3796      
CGOV12T chr1 g.(203919144_203919244)_(203932932_203933032) 13889      
CGOV12T chr3 g.(173422155_173422255)_(173641993_173642093) 219939       
CGOV12T chr3 g.(174446190_174446290)_(174483754_174483854) 37665      
CGOV12T chr4 g.(151883961_151884061)_(151910604_151910704) 26744      
CGOV12T chr7 g.(111020069_111020169)_(111198263_111198363) 178295      
CGOV12T chr8 g.(79746431_79746531)_(79902820_79902920) 156490      
CGOV12T chr9 g.(11947435_11947535)_(12188439_12188539) 241105      
CGOV12T chr11 g.(83965068_83965168)_(84000318_84000418) 35351      
CGOV12T chr16 g.(72078972_72079072)_(72157134_72157234) 78263    
    
  
CGOV12T chr16 g.(78194275_78194375)_(78260423_78260523) 66249      
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CGOV12T chr21 g.(27184281_27184381)_(27236785_27236885) 52605      
CGOV20T chr1 g.(111748043_111748143)_(111758616_111758716) 10674      
CGOV20T chr1 g.(154691759_154691859)_(154835131_154835231) 143473      
CGOV20T chr2 g.(4116305_4117305)_(4125389_4126389) 9085      
CGOV20T chr2 g.(191754503_191754603)_(191774080_191774180) 19678      
CGOV20T chr3 g.(142055351_142055451)_(142074299_142074399) 19049      
CGOV20T chr4 g.(30738167_30738267)_(30880428_30880528) 142362      
CGOV20T chr5 g.(3957872_3957972)_(3970555_3970655) 12784      
CGOV20T chr5 g.(17342810_17342910)_(17357022_17357122) 14313      
CGOV20T chr5 g.(180632057_180632157)_(180641742_180641842) 9786      
CGOV20T chr7 g.(101724584_101724684)_(101727384_101727484) 2901      
CGOV20T chr7 g.(111024561_111024661)_(111048560_111048660) 24100      
CGOV20T chr7 g.(130607267_130607367)_(130646248_130646348) 39082       
CGOV20T chr7 g.(148427284_148427384)_(148500744_148500844) 73561       
CGOV20T chr8 g.(16262122_16262222)_(16274520_16274620) 12499      
CGOV20T chr9 g.(24502136_24502236)_(24518938_24519038) 16903      
CGOV20T chr11 g.(132992254_132992354)_(133004295_133004395) 12142      
CGOV20T chr12 g.(13356624_13356724)_(13436104_13436204) 79581      
CGOV20T chr13 g.(48899250_48899350)_(48953887_48953987) 54738      
CGOV20T chr14 g.(38133163_38133263)_(38137648_38137748) 4586      
CGOV20T chr15 g.(54883501_54884501)_(54886501_54887501) 3001      
CGOV20T chr16 g.(74376501_74377501)_(74390501_74391501) 14001      
CGOV20T chr16 g.(78552722_78552822)_(78569810_78569910) 17189      
CGOV20T chr16 g.(89516738_89516838)_(89526411_89526511) 9774       
CGOV20T chr18 g.(37355778_37355878)_(37371489_37371589) 15812      
CGOV20T chr18 g.(40054149_40054249)_(40057502_40057602) 3454      
CGOV20T chr18 g.(54339023_54339123)_(54493894_54493994) 154972      
CGOV20T chr20 g.(12147980_12148080)_(13150916_13151016) 1003037    
  
   
CGOV20T chrX g.(133082255_133082355)_(133121130_133121230) 38976      
CGOV27T chr1 g.(105832867_105832967)_(105844203_105844303) 11437      
CGOV27T chr2 g.(223865143_223865243)_(223869740_223869840) 4698      
CGOV27T chr3 g.(53267005_53267105)_(53283225_53283325) 16321      
CGOV27T chr3 g.(115663498_115663598)_(116209139_116209239) 545742       
CGOV27T chr7 g.(3882244_3882344)_(3905752_3905852) 23609      
 202 






   
   
   
   
  
   
CGOV27T chr12 g.(117005397_117005497)_(117007669_117007769) 2373      
CGOV27T chr13 g.(113514115_113514215)_(113526001_113526101) 11987      
CGOV27T chr14 g.(24264965_24265065)_(24271869_24271969) 7005      
CGOV27T chr16 g.(78762005_78762105)_(78772346_78772446) 10442      
CGOV27T chr18 g.(66745659_66745759)_(66756846_66756946) 11288      
CGOV27T chrX g.(143628749_143628849)_(143637602_143637702) 8954      
CGOV29T chr3 g.(60415943_60416043)_(60462114_60462214) 46272      
CGOV29T chr3 g.(60676489_60676589)_(60727657_60727757) 51269      
CGOV29T chr3 g.(72779769_72780769)_(72784558_72785558) 4790      
CGOV29T chr13 g.(23640718_23640818)_(23643958_23644058) 3341      
CGOV29T chr13 g.(108947081_108947181)_(108951658_108951758) 4678      
CGOV31T chr2 g.(212283626_212283726)_(212361477_212361577) 77952      
CGOV31T chr4 g.(25712067_25712167)_(25735734_25735834) 23768      
CGOV31T chr4 g.(161013866_161013966)_(161019488_161019588) 5723      
CGOV31T chr5 g.(51466747_51466847)_(51471207_51471307) 4561      
CGOV31T chr9 g.(20799110_20800110)_(20804125_20805125) 5016      





CGOV31T chr9 g.(43503501_43504501)_(43658501_43659501) 155001       
CGOV31T chr9 g.(119016894_119016994)_(119020687_119020787) 3894      
CGOV31T chr11 g.(97818282_97818382)_(97877935_97878035) 59754      
CGOV31T chr13 g.(110928407_110928507)_(110993965_110994065) 65659        
CGOV31T chr22 g.(42519278_42519378)_(42531382_42531482) 12205    
  
   
CGOV31T chrX g.(76764950_76765050)_(76769316_76769416) 4467      
CGOV31T chrX g.(137045303_137046303)_(137054389_137055389) 9087      
CGOV35T chr1 g.(16751232_16751332)_(16754942_16755042) 3811      
CGOV35T chr1 g.(82317730_82317830)_(82356590_82356690) 38961      
CGOV35T chr1 g.(162054321_162054421)_(162114665_162114765) 60445      
CGOV35T chr1 g.(192931990_192932090)_(192976607_192976707) 44718      
CGOV35T chr1 g.(193211752_193211852)_(193310082_193310182) 98431       
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CGOV35T chr1 g.(193412100_193412200)_(193625361_193625461) 213362      
CGOV35T chr1 g.(236232977_236233077)_(236238818_236238918) 5942      
CGOV35T chr2 g.(34991190_34991290)_(35024397_35024497) 33308      
CGOV35T chr2 g.(58119113_58119213)_(58266111_58266211) 147099      
CGOV35T chr2 g.(141529999_141530099)_(141711725_141711825) 181827      
CGOV35T chr2 g.(186750647_186750747)_(186794045_186794145) 43499      
CGOV35T chr2 g.(213880087_213880187)_(213975706_213975806) 95720      
CGOV35T chr2 g.(236733493_236733593)_(236950305_236950405) 216913      
CGOV35T chr3 g.(6191068_6191168)_(6220739_6220839) 29772      
CGOV35T chr3 g.(67537842_67537942)_(67584362_67584462) 46621      
CGOV35T chr3 g.(70199247_70200247)_(70315743_70316743) 116497      
CGOV35T chr3 g.(71104703_71104803)_(71551796_71551896) 447194       
CGOV35T chr3 g.(116214454_116214554)_(116777983_116778083) 563630        
CGOV35T chr3 g.(178284052_178284152)_(178363289_178363389) 79338       
CGOV35T chr4 g.(67379750_67379850)_(67393459_67393559) 13810      
CGOV35T chr4 g.(151272601_151272701)_(151495680_151495780) 223180      
CGOV35T chr4 g.(181823765_181823865)_(182062343_182062443) 238679      
CGOV35T chr4 g.(182200049_182200149)_(182440492_182440592) 240544      
CGOV35T chr5 g.(12276683_12276783)_(12292247_12292347) 15665      
CGOV35T chr5 g.(59265559_59265659)_(59546661_59546761) 281203  
 
    
CGOV35T chr5 g.(59266501_59267501)_(59404501_59405501) 138001      
CGOV35T chr5 g.(59405340_59406340)_(59546297_59547297) 140958      
CGOV35T chr5 g.(59781013_59781113)_(59967067_59967167) 186155        
CGOV35T chr5 g.(60681576_60681676)_(60770103_60770203) 88628      
CGOV35T chr5 g.(130851788_130851888)_(130943070_130943170) 91383      
CGOV35T chr5 g.(162521084_162521184)_(162805032_162805132) 284049      
CGOV35T chr5 g.(173061278_173061378)_(173096490_173096590) 35313      
CGOV35T chr6 g.(77016777_77016877)_(77029005_77029105) 12329      
CGOV35T chr6 g.(100940693_100940793)_(101193380_101193480) 252788      
CGOV35T chr6 g.(109042913_109043013)_(109229211_109229311) 186399    
  
  
CGOV35T chr6 g.(162726253_162726353)_(162791582_162791682) 65430      
CGOV35T chr7 g.(16269984_16270084)_(16459393_16459493) 189510       
CGOV35T chr7 g.(35858815_35858915)_(35881925_35882025) 23211      
CGOV35T chr7 g.(110787147_110787247)_(110894630_110894730) 107584      
CGOV35T chr7 g.(148516934_148517034)_(148544440_148544540) 27607      
CGOV35T chr9 g.(10977771_10977871)_(11039577_11039677) 61907      









CGOV35T chr9 g.(108101838_108101938)_(108840089_108840189) 738352    
    
  
CGOV35T chr10 g.(556290_556390)_(582581_582681) 26392      
CGOV35T chr10 g.(20228769_20228869)_(20377976_20378076) 149308      
CGOV35T chr10 g.(35698356_35698456)_(35785482_35785582) 87227      
CGOV35T chr10 g.(60186785_60186885)_(60333223_60333323) 146539      
CGOV35T chr10 g.(77573487_77573587)_(77592952_77593052) 19566      
CGOV35T chr10 g.(112019953_112020053)_(112027567_112027667) 7715      
CGOV35T chr11 g.(9944084_9944184)_(10058832_10058932) 114849       
CGOV35T chr11 g.(29021852_29021952)_(29214082_29214182) 192331      
CGOV35T chr11 g.(93586244_93586344)_(93710286_93710386) 124143      
CGOV35T chr12 g.(15927615_15927715)_(16072744_16072844) 145230        
CGOV35T chr12 g.(32688373_32688473)_(32804685_32804785) 116413  
 
    
CGOV35T chr12 g.(32790562_32791562)_(32804285_32805285) 13724      
CGOV35T chr12 g.(32791062_32791162)_(32824460_32824560) 33499  
 
    
CGOV35T chr12 g.(79959640_79959740)_(79995899_79995999) 36360      
CGOV35T chr14 g.(46127209_46127309)_(46162996_46163096) 35888      
CGOV35T chr14 g.(64490205_64490305)_(64553115_64553215) 63011       
CGOV35T chr15 g.(25601425_25601525)_(25665725_25665825) 64401      
CGOV35T chr15 g.(49410612_49410712)_(49589004_49589104) 178493    
   
  
CGOV35T chr15 g.(64774738_64774838)_(64819881_64819981) 45244      
CGOV35T chr15 g.(67418598_67418698)_(67476818_67476918) 58321      
CGOV35T chr16 g.(20632787_20632887)_(20671284_20671384) 38598      
CGOV35T chr16 g.(72686200_72686300)_(72875566_72875666) 189467       
CGOV35T chr16 g.(78531906_78532006)_(78717421_78717521) 185616  
 
    
CGOV35T chr16 g.(78561196_78562196)_(78717021_78718021) 155826      
CGOV35T chr16 g.(79029196_79029296)_(79077123_79077223) 48028      
CGOV35T chr17 g.(9924658_9924758)_(9927853_9927953) 3296      
CGOV35T chr18 g.(8035157_8035257)_(8041215_8041315) 6159      
CGOV35T chr21 g.(38792673_38792773)_(38834029_38834129) 41457      
CGOV35T chr22 g.(47201644_47201744)_(47323642_47323742) 122099       
CGOV35T chrX g.(6748902_6749002)_(6922726_6922826) 173925      
CGOV35T chrX g.(6978933_6979033)_(7010753_7010853) 31921      
CGOV35T chrX g.(9619187_9619287)_(9903884_9903984) 284798        
CGOV35T chrX g.(10115127_10115227)_(10546593_10546693) 431567        
CGOV35T chrX g.(28520819_28520919)_(28525862_28525962) 5144      
CGOV35T chrX g.(56145982_56146082)_(56242433_56242533) 96552      
CGOV35T chrX g.(93695433_93696433)_(93953334_93954334) 257902      
 205 
CGOV35T chrX g.(96475496_96475596)_(96487316_96487416) 11921      
CGOV35T chrX g.(120275502_120275602)_(120280297_120280397) 4896      
CGOV39T chr1 g.(26459605_26460605)_(26464273_26465273) 4669      
CGOV39T chr2 g.(185166764_185166864)_(185180947_185181047) 14284      
CGOV39T chr4 g.(112236956_112237956)_(112241890_112242890) 4935      
CGOV39T chr5 g.(27606207_27606307)_(27633232_27633332) 27126      
CGOV39T chr9 g.(43503501_43504501)_(43658501_43659501) 155001       
CGOV39T chr12 g.(6241499_6241599)_(6247972_6248072) 6574      
CGOV7T chr2 g.(141801123_141801223)_(141845756_141845856) 44734      
CGOV7T chr3 g.(175887255_175887355)_(175914747_175914847) 27593      
CGOV7T chr4 g.(29355881_29355981)_(29436257_29436357) 80477      
CGOV7T chr6 g.(152282226_152282326)_(152298780_152298880) 16655      
CGOV7T chr7 g.(101724536_101724636)_(101727432_101727532) 2997      






   
   
   
   
  
   
CGOV7T chr8 g.(81990694_81990794)_(81993860_81993960) 3267      
CGOV7T chr10 g.(57932452_57932552)_(57954488_57954588) 22137      
CGOV7T chr12 g.(79980150_79980250)_(80293410_80293510) 313361       
CGOV7T chr13 g.(36129417_36129517)_(36140362_36140462) 11046       
CGOV7T chr16 g.(78548743_78548843)_(78556729_78556829) 8087      
CGOV7T chr16 g.(78646020_78646120)_(78695574_78695674) 49655      
CGOV7T chr18 g.(6103935_6104035)_(6109267_6109367) 5433      
CGOV7T chr18 g.(55093038_55093138)_(55124573_55124673) 31636      
CGOV7T chr18 g.(66745650_66745750)_(66756847_66756947) 11298      
CGOV7T chrX g.(29655863_29655963)_(29825683_29825783) 169921      
CGOV11T_1 chr1 g.(43460100_43460200)_(43464195_43464295) 4196      
CGOV11T_1 chr2 g.(179573984_179574084)_(179820766_179820866) 246883        
CGOV11T_1 chr4 g.(53825244_53825344)_(54132027_54132127) 306884      
CGOV11T_1 chr6 g.(6948886_6948986)_(6953333_6953433) 4548      
CGOV11T_1 chr6 g.(53924871_53924971)_(53934671_53934771) 9901      
CGOV11T_1 chr11 g.(80306216_80306316)_(80312975_80313075) 6860      
CGOV11T_1 chr11 g.(81089108_81089208)_(81138743_81138843) 49736      
CGOV11T_1 chr12 g.(100453239_100453339)_(100630303_100630403) 177165    
   
  
 206 
CGOV11T_1 chr13 g.(58589205_58589305)_(58599626_58599726) 10522      
CGOV11T_1 chr13 g.(110930279_110930379)_(111152795_111152895) 222617    
   
  
CGOV11T_1 chr18 g.(7888970_7889070)_(8246655_8246755) 357786      
CGOV11T_1 chr18 g.(31655160_31655260)_(31686013_31686113) 30954      
CGOV11T_1 chrX g.(120768859_120768959)_(121017533_121017633) 248775      
CGOV14T chr1 g.(193777526_193777626)_(193794588_193794688) 17163      
CGOV14T chr1 g.(231535433_231535533)_(231545846_231545946) 10514      
CGOV14T chr3 g.(60273501_60274501)_(60444501_60445501) 171001      
CGOV14T chr3 g.(60561988_60562088)_(60675475_60675575) 113588  
 
     
CGOV14T chr3 g.(60591926_60592926)_(60675075_60676075) 83150       
CGOV14T chr3 g.(60831480_60831580)_(61223873_61223973) 392494      
CGOV14T chr3 g.(61652007_61652107)_(61805810_61805910) 153904      
CGOV14T chr4 g.(30193251_30193351)_(30199442_30199542) 6292      
CGOV14T chr5 g.(67438096_67438196)_(67470485_67470585) 32490      
CGOV14T chr7 g.(18550890_18550990)_(18567966_18568066) 17177      
CGOV14T chr7 g.(106639172_106639272)_(106647605_106647705) 8534      
CGOV14T chr9 g.(18045835_18045935)_(18048938_18049038) 3204      
CGOV14T chr16 g.(78627527_78627627)_(78639492_78639592) 12066      
CGOV36T chr1 g.(217854654_217854754)_(218003578_218003678) 149025       
CGOV36T chr2 g.(153796026_153796126)_(153799612_153799712) 3687      
CGOV36T chr2 g.(236906617_236906717)_(237028180_237028280) 121664      
CGOV36T chr3 g.(37978429_37978529)_(37986777_37986877) 8449      
CGOV36T chr3 g.(45920231_45920331)_(45924147_45924247) 4017       
CGOV36T chr3 g.(60546038_60546138)_(60807141_60807241) 261204       
CGOV36T chr4 g.(477193_477293)_(483925_484025) 6833      
CGOV36T chr4 g.(64134366_64134466)_(64154377_64154477) 20112      
CGOV36T chr4 g.(156457596_156457696)_(156909170_156909270) 451675    
   
   
CGOV36T chr4 g.(181616277_181616377)_(182320440_182320540) 704264      
CGOV36T chr6 g.(130482079_130483079)_(132397929_132398929) 1915851    
   
   
   
     
CGOV36T chr6 g.(169247518_169248518)_(169255233_169256233) 7716      
CGOV36T chr6 g.(169272099_169273099)_(169745980_169746980) 473882       
CGOV36T chr6 g.(169760688_169761688)_(170269060_170270060) 508373    
   
   
  
CGOV36T chr7 g.(16348899_16348999)_(16402033_16402133) 53235      
CGOV36T chr9 g.(28514890_28514990)_(28521597_28521697) 6808      
CGOV36T chr9 g.(29414314_29415314)_(29493663_29494663) 79350      
 207 
CGOV36T chr11 g.(98822208_98822308)_(98896885_98896985) 74778      
CGOV36T chr13 g.(67464318_67464418)_(68397963_68398063) 933746    
  
    
CGOV36T chr15 g.(68750329_68750429)_(68763974_68764074) 13746      
CGOV36T chr16 g.(47544078_47544178)_(47550398_47550498) 6421      
CGOV36T chr16 g.(60081171_60081271)_(60098411_60098511) 17341      
CGOV36T chr18 g.(13337272_13337372)_(13368161_13368261) 30990      
CGOV36T chr18 g.(30081909_30082909)_(30323322_30324322) 241414       
CGOV36T chr18 g.(48110088_48111088)_(48636743_48637743) 526656    
    
  
CGOV36T chr18 g.(48646704_48647704)_(48924002_48925002) 277299       
CGOV36T chr18 g.(48969198_48969298)_(49587451_49587551) 618354      
CGOV36T chr18 g.(54734501_54735501)_(54737501_54738501) 3001      
CGOV36T chr18 g.(64557877_64558877)_(65001416_65002416) 443540      
CGOV36T chr18 g.(66745649_66745749)_(66756842_66756942) 11294      
CGOV36T chr19 g.(1194869_1194969)_(1208881_1208981) 14113      
CGOV36T chrX g.(33662265_33662365)_(33675743_33675843) 13579      
CGOV36T chrX g.(41454974_41455074)_(41560090_41560190) 105217       
CGOV36T chrX g.(78679335_78679435)_(78708145_78708245) 28911      
CGOV36T chrX g.(80088296_80088396)_(80174822_80174922) 86627      
CGOV36T chrX g.(81166475_81166575)_(81569724_81569824) 403350      
CGOV36T chrX g.(83721783_83721883)_(84144376_84144476) 422694      
CGOV48T chr2 g.(129456302_129456402)_(129463002_129463102) 6801      
CGOV48T chr2 g.(221011506_221011606)_(221369811_221369911) 358406      
CGOV48T chr2 g.(233905717_233905817)_(233984309_233984409) 78693      
CGOV48T chr4 g.(31463462_31463562)_(31469423_31469523) 6062      
CGOV48T chr4 g.(161013855_161013955)_(161019485_161019585) 5731      
CGOV48T chr4 g.(169825579_169825679)_(169878880_169878980) 53402      
CGOV48T chr9 g.(21814704_21814804)_(22523689_22523789) 709086    
  




CGOV48T chr9 g.(113604657_113604757)_(113610039_113610139) 5483      
CGOV48T chr9 g.(115777752_115777852)_(115782052_115782152) 4401      
CGOV48T chr10 g.(87337803_87337903)_(87353880_87353980) 16178      
CGOV48T chr12 g.(85756813_85756913)_(86225814_86225914) 469102      
CGOV48T chr18 g.(9743935_9744035)_(9754335_9754435) 10501      
CGOV48T chr19 g.(4988019_4989019)_(4993797_4994797) 5779      
CGOV48T chr19 g.(49183621_49183721)_(49206388_49206488) 22868        
CGOV48T chr22 g.(33755272_33756272)_(33759555_33760555) 4284      
CGOV48T chrX g.(143628747_143628847)_(143637624_143637724) 8978      
CGOV38T chr1 g.(6437685_6438685)_(6445386_6446386) 7702      
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CGOV38T chr1 g.(43445793_43446793)_(43452756_43453756) 6964      
CGOV38T chr1 g.(151980225_151980325)_(152000455_152000555) 20331       
CGOV38T chr2 g.(153796000_153796100)_(153799581_153799681) 3682      
CGOV38T chr6 g.(77438501_77439501)_(77452501_77453501) 14001      
CGOV38T chr6 g.(101934600_101934700)_(101938866_101938966) 4367      
CGOV38T chr9 g.(27777159_27777259)_(27798066_27798166) 21008      
CGOV38T chr13 g.(35558501_35559501)_(35562501_35563501) 4001      
CGOV38T chr15 g.(71474475_71474575)_(71477776_71477876) 3402       
CGOV38T chr18 g.(63906636_63907636)_(63911257_63912257) 4622      
CGOV38T chr19 g.(28294496_28294596)_(28318752_28318852) 24357      
CGOV38T chrX g.(6501878_6502878)_(6506061_6507061) 4184      
CGOV38T chrX g.(123104860_123104960)_(123121780_123121880) 17021      
CGOV49T chr3 g.(20311501_20312501)_(20315501_20316501) 4001      
CGOV49T chr3 g.(153599278_153599378)_(153613833_153613933) 14656      
CGOV49T chr4 g.(178821252_178821352)_(178872143_178872243) 50992       
CGOV49T chr6 g.(162322953_162323053)_(162440273_162440373) 117421      
CGOV49T chr9 g.(22599342_22599442)_(22606500_22606600) 7259      
CGOV49T chr9 g.(133030683_133030783)_(133034655_133034755) 4073      
CGOV49T chr10 g.(105715870_105715970)_(105720595_105720695) 4826      
CGOV49T chr15 g.(72016688_72016788)_(72104337_72104437) 87750       
CGOV49T chr18 g.(66784036_66784136)_(66807797_66807897) 23862      
CGOV49T chr19 g.(55266691_55266791)_(55281325_55281425) 14735    
  
  
CGOV10T chr1 g.(26460210_26460310)_(26464644_26464744) 4535      
CGOV10T chr1 g.(98168988_98169088)_(98176058_98176158) 7171      
CGOV10T chr1 g.(192945596_192945696)_(193418417_193418517) 472922    
   
   
  
CGOV10T chr2 g.(78565959_78566059)_(78666645_78666745) 100787      
CGOV10T chr2 g.(176203347_176203447)_(176210931_176211031) 7685      
CGOV10T chr2 g.(180411501_180412501)_(180420501_180421501) 9001      
CGOV10T chr3 g.(59811733_59811833)_(60140716_60140816) 329084      
CGOV10T chr3 g.(60246710_60246810)_(60435013_60435113) 188404  
 
    
CGOV10T chr3 g.(60318539_60318639)_(60632927_60633027) 314489  
 
     
CGOV10T chr3 g.(60318039_60319039)_(60433501_60434501) 115463      
CGOV10T chr3 g.(60866915_60867015)_(60958337_60958437) 91523      
CGOV10T chr3 g.(97293289_97293389)_(97440831_97440931) 147643      









CGOV10T chr4 g.(12677485_12677585)_(12711162_12711262) 33778      
CGOV10T chr4 g.(13119160_13119260)_(13208066_13208166) 89007      
CGOV10T chr4 g.(19084501_19085501)_(19169501_19170501) 85001      
CGOV10T chr5 g.(59161500_59161600)_(59534753_59534853) 373354      
CGOV10T chr5 g.(59850099_59850199)_(60140400_60140500) 290402       
CGOV10T chr5 g.(60314810_60314910)_(60417192_60417292) 102483      
CGOV10T chr5 g.(65288688_65288788)_(65294084_65294184) 5497      
CGOV10T chr5 g.(96372415_96372515)_(96417202_96417302) 44888      
CGOV10T chr5 g.(97047921_97048021)_(97095986_97096086) 48166      
CGOV10T chr5 g.(161893168_161893268)_(162058723_162058823) 165656      
CGOV10T chr5 g.(165767447_165767547)_(165779810_165779910) 12464      
CGOV10T chr6 g.(77438501_77439501)_(77452501_77453501) 14001      
CGOV10T chr6 g.(162769012_162769112)_(162803405_162803505) 34494      
CGOV10T chr7 g.(40115044_40115144)_(40240948_40241048) 126005        
CGOV10T chr7 g.(90013231_90013331)_(90142691_90142791) 129561    
  
  
CGOV10T chr7 g.(104662593_104662693)_(104713698_104713798) 51206      
CGOV10T chr7 g.(109632363_109632463)_(110037416_110037516) 405154      
CGOV10T chr7 g.(110768465_110768565)_(110780452_110780552) 12088       
CGOV10T chr7 g.(133518916_133519016)_(133761517_133761617) 242702      
CGOV10T chr8 g.(40182947_40183047)_(40189649_40189749) 6803      
CGOV10T chr9 g.(9053905_9054005)_(9259998_9260098) 206194      
CGOV10T chr9 g.(9990197_9990297)_(10379332_10379432) 389236      
CGOV10T chr9 g.(74827975_74828075)_(74915865_74915965) 87991       
CGOV10T chr11 g.(29027686_29027786)_(29457684_29457784) 430099      
CGOV10T chr11 g.(70155057_70155157)_(70238991_70239091) 84035      
CGOV10T chr12 g.(93178251_93178351)_(94329770_94329870) 1151620    
  
   
   
   
  
CGOV10T chr14 g.(70017062_70017162)_(70022324_70022424) 5363      
CGOV10T chr16 g.(78162775_78162875)_(78352369_78352469) 189695      
CGOV10T chr16 g.(78609922_78610022)_(78626990_78627090) 17169      
CGOV10T chr16 g.(78741639_78741739)_(78811297_78811397) 69759      
CGOV10T chr16 g.(78847865_78847965)_(78955560_78955660) 107796      
CGOV10T chr17 g.(22060527_22060627)_(22066595_22066695) 6169      
CGOV10T chr20 g.(14676042_14676142)_(15296859_15296959) 620918  
 
     
CGOV10T chr20 g.(14723501_14724501)_(14754501_14755501) 31001      
CGOV10T chr20 g.(14724034_14724134)_(14934392_14934492) 210459  
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CGOV10T chr20 g.(14755501_14756501)_(14778501_14779501) 23001      
CGOV10T chr20 g.(14876501_14877501)_(14933990_14934990) 57490       
CGOV10T chr20 g.(14939501_14940501)_(14984501_14985501) 45001      
CGOV10T chr20 g.(15096346_15096446)_(15139610_15139710) 43365      
CGOV10T chr20 g.(15155501_15156501)_(15214501_15215501) 59001      
CGOV10T chr20 g.(15255748_15256748)_(15296459_15297459) 40712      
CGOV10T chrX g.(6686876_6686976)_(6987973_6988073) 301198  
 
    
CGOV10T chrX g.(6686376_6687376)_(6736501_6737501) 50126      
CGOV10T chrX g.(7022694_7022794)_(7044555_7044655) 21962      
CGOV13T chr2 g.(212321097_212321197)_(213408760_213408860) 1087764       
CGOV13T chr3 g.(80863479_80863579)_(80972333_80972433) 108955      
CGOV13T chr4 g.(21900075_21900175)_(21910945_21911045) 10971      
CGOV13T chr5 g.(128926970_128927070)_(128929826_128929926) 2957      
CGOV13T chr7 g.(1388847_1388947)_(1462551_1462651) 73805      
CGOV13T chr7 g.(51816029_51816129)_(51828512_51828612) 12584      
CGOV13T chr12 g.(23123501_23124501)_(23153501_23154501) 30001      
CGOV13T chr12 g.(27648223_27648323)_(27654963_27655063) 6841      
CGOV13T chr12 g.(120577774_120577874)_(120599725_120599825) 22052       
CGOV13T chr13 g.(84820374_84820474)_(84999433_84999533) 179160      
CGOV13T chr14 g.(72805874_72805974)_(72810762_72810862) 4989      
CGOV13T chr18 g.(41325958_41326958)_(41330769_41331769) 4812      
CGOV13T chr18 g.(54021489_54022489)_(54026036_54027036) 4548      
CGOV13T chr18 g.(69591274_69591374)_(69607621_69607721) 16448      
CGOV13T chrX g.(8017546_8017646)_(8459534_8459634) 442089  
 
      
CGOV13T chrX g.(8017501_8018501)_(8206501_8207501) 189001       
CGOV13T chrX g.(8207501_8208501)_(8430501_8431501) 223001      
CGOV13T chrX g.(71532361_71533361)_(71608180_71609180) 75820      
CGOV40T chr3 g.(30109860_30110860)_(30448241_30449241) 338382      
CGOV40T chr3 g.(30476177_30477177)_(30518460_30519460) 42284      
CGOV40T chr3 g.(30664108_30665108)_(30702536_30703536) 38429      
CGOV40T chr3 g.(60322103_60322203)_(60462343_60462443) 140341  
 
    
CGOV40T chr3 g.(60365451_60365551)_(60580322_60580422) 214972  
 
    
CGOV40T chr3 g.(60364959_60365959)_(60461943_60462943) 96985      
CGOV40T chr3 g.(60467710_60467810)_(60555646_60555746) 88037      
CGOV40T chr4 g.(176779205_176779305)_(176950653_176950753) 171549      
CGOV40T chr6 g.(12478890_12478990)_(12483270_12483370) 4481      
CGOV40T chr6 g.(142237501_142238501)_(142243028_142244028) 5528      
CGOV40T chr8 g.(83693267_83693367)_(83703040_83703140) 9874      
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CGOV40T chr9 g.(43503501_43504501)_(43658501_43659501) 155001       
CGOV40T chr9 g.(107361193_107362193)_(107367012_107368012) 5820       
CGOV40T chr9 g.(115777732_115777832)_(115782089_115782189) 4458      
CGOV40T chr10 g.(67905425_67906425)_(67915416_67916416) 9992      
CGOV40T chr13 g.(69244761_69244861)_(69268614_69268714) 23954      
CGOV40T chr13 g.(108112115_108112215)_(108129320_108129420) 17306      
CGOV40T chr16 g.(78169069_78169169)_(78178012_78178112) 9044      
CGOV40T chr16 g.(78581883_78581983)_(78624144_78624244) 42362      
CGOV40T chr17 g.(28939501_28940501)_(28949501_28950501) 10001       
CGOV40T chr18 g.(66745659_66745759)_(66756839_66756939) 11281      
CGOV40T chr19 g.(11130042_11131042)_(11133876_11134876) 3835      
CGOV40T chr19 g.(11153594_11154594)_(11160561_11161561) 6968      
CGOV40T chr21 g.(43343501_43344501)_(43349501_43350501) 6001      
CGOV40T chr22 g.(19892068_19892168)_(20024323_20024423) 132356    
   
    
CGOV40T chrX g.(6855501_6856501)_(6910501_6911501) 55001      
CGOV15T chr1 g.(21966870_21966970)_(21980618_21980718) 13849      
CGOV15T chr1 g.(77031928_77032028)_(77047415_77047515) 15588      
CGOV15T chr1 g.(180742702_180742802)_(180875651_180875751) 133050      
CGOV15T chr1 g.(210582343_210582443)_(210620517_210620617) 38275      
CGOV15T chr2 g.(3732876_3732976)_(3737864_3737964) 5089      
CGOV15T chr2 g.(122767609_122767709)_(122787150_122787250) 19642      
CGOV15T chr3 g.(83342471_83342571)_(83368227_83368327) 25857      
CGOV15T chr4 g.(28131351_28131451)_(28177945_28178045) 46695      
CGOV15T chr4 g.(55072681_55072781)_(55081578_55081678) 8998      
CGOV15T chr4 g.(92100501_92101501)_(92334501_92335501) 234001      
CGOV15T chr5 g.(44548972_44549072)_(44554728_44554828) 5857      
CGOV15T chr5 g.(111939649_111939749)_(111944175_111944275) 4627      




   
   
   
CGOV15T chr5 g.(179132631_179132731)_(179148657_179148757) 16127      
CGOV15T chr6 g.(62759791_62759891)_(62792146_62792246) 32456      
CGOV15T chr6 g.(65221140_65221240)_(65227676_65227776) 6637      
CGOV15T chr7 g.(49168703_49168803)_(49233800_49233900) 65198      
CGOV15T chr7 g.(107899737_107899837)_(107929802_107929902) 30166      
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CGOV15T chr10 g.(1105261_1105361)_(1118994_1119094) 13834      
CGOV15T chr10 g.(23415227_23415327)_(23436931_23437031) 21805      
CGOV15T chr10 g.(51003501_51004501)_(51009501_51010501) 6001      
CGOV15T chr12 g.(8378501_8379501)_(8411501_8412501) 33001    
  
  
CGOV15T chr12 g.(104282150_104282250)_(104311358_104311458) 29309      
CGOV15T chr12 g.(106811523_106811623)_(106824336_106824436) 12914      
CGOV15T chr13 g.(110177155_110177255)_(110468862_110468962) 291808       
CGOV15T chr14 g.(25373790_25373890)_(25458530_25458630) 84841      
CGOV15T chr15 g.(29864654_29864754)_(29918051_29918151) 53498      
CGOV15T chr15 g.(54851057_54851157)_(54973874_54973974) 122918      
CGOV15T chr16 g.(19945577_19945677)_(19967459_19967559) 21983      
CGOV15T chr16 g.(55956023_55956123)_(56056729_56056829) 100807      
CGOV15T chr16 g.(62612601_62612701)_(62833269_62833369) 220769      
CGOV15T chr17 g.(151746_151846)_(227412_227512) 75767       
CGOV15T chr17 g.(9590501_9591501)_(9946501_9947501) 356001    
   
    
CGOV15T chr17 g.(10619784_10620784)_(12488757_12489757) 1868974    
   
   
  
    
CGOV15T chr17 g.(13082022_13082122)_(13822892_13822992) 740971      
CGOV15T chr17 g.(19615501_19616501)_(20548501_20549501) 933001    
   
   
   
  
CGOV15T chr17 g.(20785501_20786501)_(21504501_21505501) 719001    
  
   
   
   
  
CGOV15T chr18 g.(75508039_75508139)_(75555191_75555291) 47253      
CGOV15T chr19 g.(3350028_3350128)_(3394707_3394807) 44780      
CGOV15T chr20 g.(15927164_15927264)_(16058289_16058389) 131226       
CGOV15T chr21 g.(15957697_15958697)_(16976324_16977324) 1018628    
  
   
CGOV15T chr22 g.(46475503_46475603)_(46492250_46492350) 16848       
CGOV15T chrX g.(26225501_26226501)_(26710501_26711501) 485001       
CGOV15T chrX g.(39610501_39611501)_(39623501_39624501) 13001      
CGOV15T chrX g.(57745501_57746501)_(57767501_57768501) 22001      
CGOV15T chrX g.(71347989_71348089)_(71433156_71433256) 85268    
    
  
CGOV15T chrX g.(86649199_86649299)_(86658925_86659025) 9827      
CGOV15T chrX g.(140344044_140345044)_(140562189_140563189) 218146      
 213 
CGOV15T chrX g.(143628754_143628854)_(143637595_143637695) 8942      
CGOV1T chr1 g.(19599702_19599802)_(19614010_19614110) 14409       
CGOV1T chr1 g.(26459640_26460640)_(26464310_26465310) 4671      
CGOV1T chr1 g.(98689985_98690085)_(99141697_99141797) 451813       
CGOV1T chr2 g.(7229968_7230068)_(7235598_7235698) 5731      
CGOV1T chr2 g.(9925530_9925630)_(9928887_9928987) 3458      
CGOV1T chr3 g.(60345982_60346082)_(60383574_60383674) 37693      
CGOV1T chr4 g.(19278234_19278334)_(19460166_19460266) 182033      
CGOV1T chr4 g.(156594266_156594366)_(156598138_156598238) 3973      
CGOV1T chr4 g.(181848196_181848296)_(182031250_182031350) 183155      
CGOV1T chr4 g.(182123700_182123800)_(182647725_182647825) 524126      
CGOV1T chr5 g.(155577264_155577364)_(155591242_155591342) 14079      
CGOV1T chr6 g.(21090286_21090386)_(21160245_21160345) 70060      
CGOV1T chr6 g.(121795537_121795637)_(121800209_121800309) 4773      
CGOV1T chr6 g.(140530722_140530822)_(140537014_140537114) 6393      
CGOV1T chr7 g.(6908501_6909501)_(6915501_6916501) 7001      
CGOV1T chr7 g.(40085858_40085958)_(40124311_40124411) 38554      
CGOV1T chr7 g.(69458323_69458423)_(69800753_69800853) 342531      
CGOV1T chr7 g.(110580825_110580925)_(110634198_110634298) 53474      
CGOV1T chr7 g.(133043937_133044037)_(133408317_133408417) 364481      
CGOV1T chr8 g.(16262064_16262164)_(16274526_16274626) 12563      
CGOV1T chr8 g.(82974620_82975620)_(82980136_82981136) 5517      
CGOV1T chr10 g.(67324149_67324249)_(67336328_67336428) 12280      
CGOV1T chr11 g.(15807501_15808501)_(15814501_15815501) 7001      
CGOV1T chr11 g.(25019501_25020501)_(25034501_25035501) 15001      
CGOV1T chr11 g.(25702329_25702429)_(25720746_25720846) 18518      
CGOV1T chr11 g.(84163691_84163791)_(84211492_84211592) 47902      
CGOV1T chr11 g.(84389850_84389950)_(84418921_84419021) 29172      
CGOV1T chr13 g.(92386303_92386403)_(92392209_92392309) 6007      
CGOV1T chr13 g.(93962563_93962663)_(93995411_93995511) 32949      
CGOV1T chr14 g.(68712272_68712372)_(69157739_69157839) 445568      
CGOV1T chr15 g.(24055429_24055529)_(24061470_24061570) 6142      









CGOV1T chr16 g.(78925208_78925308)_(79006380_79006480) 81273      
CGOV1T chr17 g.(13876885_13876985)_(14059858_14059958) 183074        
 214 
CGOV1T chr18 g.(36656930_36657030)_(36666550_36666650) 9721      
CGOV1T chr18 g.(36905374_36905474)_(37108979_37109079) 203706      
CGOV1T chrX g.(32475980_32476080)_(32598402_32598502) 122523       
CGOV26T chr2 g.(184794361_184794461)_(184803883_184803983) 9623      
CGOV26T chr3 g.(59763028_59763128)_(59894791_59894891) 131864      
CGOV26T chr4 g.(37925922_37926022)_(37960519_37960619) 34698       
CGOV26T chr4 g.(39704426_39704526)_(39713802_39713902) 9477      
CGOV26T chr5 g.(97047921_97048021)_(97096045_97096145) 48225      
CGOV26T chr7 g.(3863809_3863909)_(3911770_3911870) 48062      
CGOV26T chr7 g.(48581358_48581458)_(48592493_48592593) 11236      
CGOV26T chr7 g.(145997335_145997435)_(146005687_146005787) 8453  
 
    
CGOV26T chr7 g.(145996923_145997923)_(146000290_146001290) 3368      
CGOV26T chr9 g.(21714247_21714347)_(22214586_22214686) 500440    
  
   
 
 
CGOV26T chr9 g.(30501164_30501264)_(30537747_30537847) 36684      
CGOV26T chr9 g.(133030507_133030607)_(133034660_133034760) 4254      
CGOV26T chr9 g.(139365645_139365745)_(139384969_139385069) 19425        
CGOV26T chr10 g.(58512930_58513030)_(58526800_58526900) 13971      
CGOV26T chr12 g.(51376582_51376682)_(51380169_51380269) 3688      
CGOV26T chr14 g.(55788248_55788348)_(56113943_56114043) 325796    
    
  
CGOV26T chr17 g.(49079114_49079214)_(49109589_49109689) 30576      
CGOV26T chr19 g.(348972_349072)_(364146_364246) 15275       
CGOV26T chr20 g.(7398616_7398716)_(7403427_7403527) 4912      
CGOV26T chr20 g.(52647045_52647145)_(52657841_52657941) 10897      
CGOV26T chr22 g.(46515882_46515982)_(46521451_46521551) 5670      
CGOV26T chrX g.(127626935_127627035)_(127719603_127719703) 92769      
CGOV2T chr1 g.(31600723_31600823)_(31624480_31624580) 23858      
CGOV2T chr1 g.(71728900_71729000)_(71829880_71829980) 101081      
CGOV2T chr1 g.(158624153_158624253)_(158633733_158633833) 9681      
CGOV2T chr1 g.(161573501_161574501)_(161618501_161619501) 45001        
CGOV2T chr1 g.(162830890_162830990)_(162845977_162846077) 15188      
CGOV2T chr2 g.(18597257_18597357)_(18630511_18630611) 33355      
CGOV2T chr3 g.(33136817_33137817)_(33142637_33143637) 5821       
CGOV2T chr3 g.(187567957_187568957)_(187833820_187834820) 265864      
 215 
CGOV2T chr3 g.(187834830_187835830)_(192707252_192708252) 4872423    
    
   
   
   
   
  
    
     
CGOV2T chr4 g.(43408501_43409501)_(45009501_45010501) 1601001    
    
  
CGOV2T chr4 g.(45032340_45033340)_(46949830_46950830) 1917491    
   
  
CGOV2T chr4 g.(155875122_155876122)_(163851396_163852396) 7976275    
  
   
   
   
   
   
   
   
   
CGOV2T chr5 g.(16115873_16115973)_(16126604_16126704) 10832      
CGOV2T chr5 g.(87378949_87379049)_(87381901_87382001) 3053      






   
   
   
   
  
   
CGOV2T chr8 g.(40182925_40183025)_(40189629_40189729) 6805      
CGOV2T chr8 g.(140371181_140371281)_(140468282_140468382) 97202      
CGOV2T chr10 g.(67298233_67298333)_(67436538_67436638) 138406      
CGOV2T chr10 g.(87781729_87781829)_(87803914_87804014) 22286      
CGOV2T chr11 g.(63918342_63918442)_(63984807_63984907) 66566        
CGOV2T chr11 g.(134927501_134928501)_(134945501_134946501) 18001      
CGOV2T chr12 g.(86426154_86426254)_(86432770_86432870) 6717      
CGOV2T chr13 g.(67377894_67377994)_(67397021_67397121) 19228       
 216 
CGOV2T chr15 g.(39995634_39995734)_(41216175_41216275) 1220642    
   
    
    
   
   
    
   
   
  
   
   
CGOV2T chr16 g.(8615789_8616789)_(8622860_8623860) 7072      
CGOV2T chr17 g.(39211079_39212079)_(39221423_39222423) 10345    
  
  
CGOV2T chr18 g.(4780017_4780117)_(4790262_4790362) 10346      
CGOV2T chr19 g.(1119281_1119381)_(1229318_1229418) 110138        
CGOV2T chr22 g.(37744478_37744578)_(37749835_37749935) 5458       
CGOV2T chr22 g.(46809126_46809226)_(46969802_46969902) 160777      
CGOV2T chrX g.(63188501_63189501)_(63866501_63867501) 678001        
CGOV2T chrX g.(74871448_74871548)_(75307078_75307178) 435731       
CGOV33T chr1 g.(82370899_82370999)_(82391959_82392059) 21161      
CGOV33T chr1 g.(164263758_164263858)_(164271462_164271562) 7805      
CGOV33T chr2 g.(213184027_213184127)_(213191834_213191934) 7908      
CGOV33T chr2 g.(224183534_224183634)_(225009990_225010090) 826557    
    
  
CGOV33T chr3 g.(13670383_13670483)_(13685181_13685281) 14899      
CGOV33T chr3 g.(116750517_116750617)_(116925985_116926085) 175569      
CGOV33T chr3 g.(197050011_197051011)_(197056527_197057527) 6517      
CGOV33T chr4 g.(187294251_187295251)_(188895548_188896548) 1601298    
   
   
CGOV33T chr5 g.(801501_802501)_(835501_836501) 34001      
CGOV33T chr5 g.(97047920_97048020)_(97095996_97096096) 48177      
CGOV33T chr7 g.(115931689_115931789)_(115941208_115941308) 9620      
CGOV33T chr9 g.(6700548_6700648)_(6710469_6710569) 10022      
CGOV33T chr11 g.(78768586_78768686)_(78783435_78783535) 14950      
CGOV33T chr11 g.(115161091_115161191)_(115167329_115167429) 6339      
CGOV33T chr13 g.(69244758_69244858)_(69268600_69268700) 23943      
CGOV33T chr15 g.(83353829_83353929)_(83384013_83384113) 30285        
CGOV33T chr16 g.(78507078_78507178)_(78703215_78703315) 196238      
CGOV33T chr17 g.(9218275_9218375)_(9222529_9222629) 4355      
CGOV33T chr21 g.(38742100_38742200)_(38758613_38758713) 16614      
CGOV33T chr22 g.(18625566_18626566)_(18629269_18630269) 3704      
CGOV33T chrX g.(82319877_82320877)_(82324858_82325858) 4982      
 217 
CGOV3T chr4 g.(112236959_112237959)_(112241898_112242898) 4940      
CGOV3T chr9 g.(134260046_134261046)_(134265461_134266461) 5416      
CGOV3T chr10 g.(82879485_82879585)_(82891184_82891284) 11800      
CGOV3T chr11 g.(85263096_85263196)_(85274620_85274720) 11625      
CGOV3T chr13 g.(83788283_83788383)_(83792440_83792540) 4258      
CGOV3T chr13 g.(98529959_98530059)_(98532905_98533005) 3047      
CGOV3T chr17 g.(22060527_22060627)_(22066594_22066694) 6168      
CGOV42T chr1 g.(182728047_182728147)_(182732806_182732906) 4860      
CGOV42T chr1 g.(183501670_183501770)_(183507549_183507649) 5980      
CGOV42T chr2 g.(14843450_14843550)_(14941023_14941123) 97674      
CGOV42T chr2 g.(15217654_15217754)_(15405895_15405995) 188342      
CGOV42T chr2 g.(33852018_33852118)_(33937227_33937327) 85310      
CGOV42T chr3 g.(21338538_21338638)_(21397459_21397559) 59022      




    
   
   
CGOV42T chr3 g.(167922501_167923501)_(169239501_169240501) 1317001    
  
   
CGOV42T chr4 g.(16343864_16343964)_(16356548_16356648) 12785      
CGOV42T chr4 g.(81209059_81209159)_(81228236_81228336) 19278      
CGOV42T chr4 g.(166772764_166772864)_(166780052_166780152) 7389      
CGOV42T chr4 g.(177955251_177956251)_(179420870_179421870) 1465620    
   
  
CGOV42T chr5 g.(1489490_1489590)_(1525158_1525258) 35769       
CGOV42T chr5 g.(125109232_125109332)_(125143529_125143629) 34398      
CGOV42T chr5 g.(162048798_162048898)_(162055663_162055763) 6966      
CGOV42T chr5 g.(178348356_178348456)_(178352983_178353083) 4728      
CGOV42T chr6 g.(126839504_126839604)_(126941747_126941847) 102344      
CGOV42T chr7 g.(69834817_69834917)_(69890868_69890968) 56152      
CGOV42T chr7 g.(78035451_78035551)_(78379562_78379662) 344212      
CGOV42T chr7 g.(101724570_101724670)_(101727913_101728013) 3444      
CGOV42T chr8 g.(89828384_89828484)_(89922135_89922235) 93852      
CGOV42T chr11 g.(28184661_28184761)_(28461232_28461332) 276672      
CGOV42T chr11 g.(123866862_123866962)_(123909743_123909843) 42982    
   
  
CGOV42T chr12 g.(29316667_29316767)_(29697815_29697915) 381249    
  
   
  
CGOV42T chr12 g.(86426152_86426252)_(86432770_86432870) 6719      
CGOV42T chr12 g.(111976338_111976438)_(111979740_111979840) 3503      
 218 
CGOV42T chr13 g.(80681134_80681234)_(80686285_80686385) 5252      
CGOV42T chr13 g.(109949122_109949222)_(109957783_109957883) 8762      
CGOV42T chr15 g.(33986177_33986277)_(34030418_34030518) 44342      
CGOV42T chr16 g.(78262211_78262311)_(78326681_78326781) 64571      
CGOV42T chr16 g.(79015446_79015546)_(79057892_79057992) 42547      
CGOV42T chr16 g.(83566487_83566587)_(83572114_83572214) 5728      
CGOV42T chr16 g.(88895413_88895513)_(88905737_88905837) 10425      
CGOV42T chr19 g.(244501_245501)_(437501_438501) 193001    
   
   
CGOV42T chr19 g.(51467945_51468945)_(51493584_51494584) 25640       
CGOV42T chr19 g.(54356009_54356109)_(54369515_54369615) 13607      
CGOV42T chr20 g.(52285529_52285629)_(52291766_52291866) 6338      
CGOV42T chr21 g.(46057573_46057673)_(46066375_46066475) 8903    
  
  
CGOV42T chrX g.(3703400_3703500)_(3711152_3711252) 7853      
CGOV42T chrX g.(6501501_6502501)_(6505501_6506501) 4001      
CGOV42T chrX g.(10390812_10390912)_(10559740_10559840) 169029      
CGOV42T chrX g.(63700501_63701501)_(63715501_63716501) 15001      
CGOV42T chrX g.(74663501_74664501)_(74666501_74667501) 3001      
CGOV42T chrX g.(96006783_96006883)_(96025741_96025841) 19059      
CGOV53T chr1 g.(7975030_7975130)_(7987470_7987570) 12541      
CGOV53T chr2 g.(184794483_184794583)_(184803894_184803994) 9512      
CGOV53T chr2 g.(212274020_212274120)_(212485092_212485192) 211173      
CGOV53T chr3 g.(59763116_59763216)_(59894753_59894853) 131738      
CGOV53T chr3 g.(60477380_60477480)_(60692910_60693010) 215631       
CGOV53T chr4 g.(37925940_37926040)_(37960502_37960602) 34663       
CGOV53T chr4 g.(39704403_39704503)_(39713735_39713835) 9433      
CGOV53T chr4 g.(143066945_143067045)_(143745255_143745355) 678411      
CGOV53T chr5 g.(97047935_97048035)_(97095991_97096091) 48157      
CGOV53T chr5 g.(178348453_178348553)_(178353016_178353116) 4664      
CGOV53T chr7 g.(3863816_3863916)_(3911763_3911863) 48048      
CGOV53T chr7 g.(48581358_48581458)_(48592487_48592587) 11230      
CGOV53T chr7 g.(145997407_145997507)_(146005681_146005781) 8375  
 
    
CGOV53T chr7 g.(145997501_145998501)_(145999501_146000501) 2001      
CGOV53T chr8 g.(131253805_131253905)_(131333657_131333757) 79953       
CGOV53T chr9 g.(21714106_21714206)_(22214507_22214607) 500502    
  
   
 
 
CGOV53T chr10 g.(58513114_58513214)_(58526789_58526889) 13776      
CGOV53T chr10 g.(72599046_72599146)_(72602587_72602687) 3642      
CGOV53T chr11 g.(102303643_102303743)_(102307320_102307420) 3778      
 219 
CGOV53T chr12 g.(20808640_20808740)_(20950019_20950119) 141480       
CGOV53T chr12 g.(44456088_44456188)_(44630675_44630775) 174688      
CGOV53T chr12 g.(51376835_51376935)_(51380217_51380317) 3483      
CGOV53T chr12 g.(81711183_81711283)_(81773125_81773225) 62043       
CGOV53T chr16 g.(78686925_78687025)_(78860448_78860548) 173624  
 
    
CGOV53T chr16 g.(78779546_78779646)_(78796468_78796568) 17023      
CGOV53T chr16 g.(78811577_78812577)_(78858501_78859501) 46925      
CGOV53T chr16 g.(78812077_78812177)_(78863098_78863198) 51122  
 
    
CGOV53T chr17 g.(49079112_49079212)_(49109481_49109581) 30470      
CGOV53T chr20 g.(7398778_7398878)_(7403413_7403513) 4736      
CGOV53T chr20 g.(52647122_52647222)_(52657842_52657942) 10821      
CGOV53T chr22 g.(46516094_46516194)_(46521450_46521550) 5457      
CGOV53T chrX g.(17167316_17167416)_(17179418_17179518) 12203      
CGOV53T chrX g.(104368659_104368759)_(104520276_104520376) 151718  
 
     
CGOV53T chrX g.(104368501_104369501)_(104443501_104444501) 75001      
CGOV53T chrX g.(104443941_104444941)_(104519867_104520867) 75927       
CGOV53T chrX g.(127626941_127627041)_(127719603_127719703) 92763      
CGOV37T_3 chr1 g.(41087863_41087963)_(41221210_41221310) 133448    
   
   
CGOV37T_3 chr1 g.(72755758_72755858)_(72763943_72764043) 8286      
CGOV37T_3 chr1 g.(152311258_152311358)_(152351084_152351184) 39927       
CGOV37T_3 chr2 g.(153795954_153796054)_(153799583_153799683) 3730      
CGOV37T_3 chr3 g.(37046030_37046130)_(37185482_37185582) 139553       
CGOV37T_3 chr3 g.(160680330_160680430)_(160685849_160685949) 5620      
CGOV37T_3 chr3 g.(165041000_165041100)_(165083201_165083301) 42302      
CGOV37T_3 chr3 g.(192776933_192777033)_(192782436_192782536) 5604      
CGOV37T_3 chr4 g.(64134360_64134460)_(64154376_64154476) 20117      
CGOV37T_3 chr7 g.(36037453_36037553)_(36041197_36041297) 3845      
CGOV37T_3 chr7 g.(159117501_159118501)_(159127501_159128501) 10001      
CGOV37T_3 chr8 g.(40182920_40183020)_(40189648_40189748) 6829      
CGOV37T_3 chr8 g.(90171824_90171924)_(90277807_90277907) 106084      





CGOV37T_3 chr10 g.(58513132_58513232)_(58526794_58526894) 13763      
CGOV37T_3 chr12 g.(99041398_99041498)_(99503060_99503160) 461763    
   
  
CGOV37T_3 chr14 g.(46749199_46749299)_(46770458_46770558) 21360      
CGOV37T_3 chr14 g.(73526897_73526997)_(73531837_73531937) 5041      
 220 
CGOV37T_3 chr17 g.(3914657_3915657)_(4208274_4209274) 293618    
   
   
CGOV37T_3 chr18 g.(7920468_7920568)_(7988489_7988589) 68122      
CGOV37T_3 chr18 g.(41764002_41764102)_(41776785_41776885) 12884      
CGOV37T_3 chr20 g.(15726759_15726859)_(15789129_15789229) 62471      
CGOV37T_3 chrX g.(143628759_143628859)_(143637626_143637726) 8968      
* Deletions were identified by segmentation of the normalized read depth. Deletions were called as hemizygous+                        




Table S3.1i. Predicted in-frame coding fusions* 
















     
CGOV16T OAW-42 TICAM1 PKN1 NM_182919     
 
      
CGOV16T OAW-42 HORMAD2 BAIAP2L2 NM_152510      
 
      
CGOV16T OAW-42 BAIAP2L2 HORMAD2 NM_025045      
 
      
CGOV16T OAW-42 SLC9A4 PSMD14 NM_001011552     
 
      
CGOV16T OAW-42 ACOXL RYR3 NM_001142807      
 
      
CGOV16T OAW-42 RYR3 ACOXL NM_001036      
 
      
CGOV16T OAW-42 ZNF619 ADAMTS9 NM_001145082      
 
      
CGOV16T OAW-42 ADAMTS9 ZNF619 NM_182920      
 
      
CGOV16T OAW-42 SLC44A1 FSD1L NM_001286730      
 
      




      




      
CGOV16T OAW-42 PIR IQGAP1 NM_001018109      
 
      
CGOV17T OV-167 FHIT NLGN1 NM_001166243     
 
      
CGOV17T OV-167 NLGN1 FHIT NM_014932     
 
      
CGOV17T OV-167 INTS12 GSTCD NM_001142471      
 
      
CGOV17T OV-167 GSTCD INTS12 NM_024751      
 
      




      
CGOV17T OV-167 MPC2 ADCY10 NM_001143674     
 
      
CGOV17T OV-167 LMO7 TFDP1 NM_005358      
 
      
CGOV17T OV-167 TFDP1 LMO7 NM_007111      
 
      
CGOV17T OV-167 FBXL3 COL4A2 NM_012158     
 
      
CGOV18T OV177 BPIFB2 CCM2L NM_025227     
 
      
 222 




      
CGOV18T OV177 DMD GK NM_004014      
 
      
CGOV18T OV177 VAMP8 TCF7L1 NM_003761     
 
      
CGOV18T OV177 CPAMD8 EPB41L5 NM_015692     
 
      
CGOV18T OV177 RASSF1 GNAI2 NM_170713     
 
      




      
CGOV18T OV177 ANKRD33B MARCH6 NM_001164440      
 
      
CGOV18T OV177 FBXO32 ANXA13 NM_001242463     
 
      
CGOV18T OV177 NEK6 UROS NM_001145001     
 
      
CGOV18T OV177 UROS NEK6 NM_000375      
 
      
CGOV18T OV177 NRXN2 LRRC4B NM_015080     
 
      
CGOV18T OV177 LRRC4B NRXN2 NM_001080457      
 
      
CGOV18T OV177 KLC2 KDM2A NM_001134775      
 
      
CGOV18T OV177 KDM2A KLC2 NM_012308      
 
      




      
CGOV18T OV177 CAPN5 UVRAG NM_004055     
 
      
CGOV18T OV177 KSR2 WSB2 NM_173598      
 
      
CGOV18T OV177 WSB2 KSR2 NM_001278558     
 
      
CGOV18T OV177 PTP4A2 MYH14 NM_080391     
 
      
CGOV18T OV177 TMEM63C SPTLC2 NM_020431     
 
      




      
CGOV18T OV177 PCSK6 LINS NM_001291309      
 
      
CGOV18T OV177 PDPR VAC14 NM_017990      
 
      




      
CGOV18T OV177 SUMO2 UBE2O NM_001005849      
 
      
 223 
CGOV18T OV177 UBE2O SUMO2 NM_022066      
 
      
CGOV21T OV-90 RIPK2 GPR158 NM_003821      
 
      
CGOV21T OV-90 GPR158 RIPK2 NM_020752      
 
      
CGOV25T OVCAR-3 SEMA5B DYM NM_001031702     
 
      
CGOV25T OVCAR-3 DYM SEMA5B NM_017653      
 
      
CGOV25T OVCAR-3 ENDOU PEF1 NM_001172439     
 
      
CGOV25T OVCAR-3 TET2 GSTCD NM_001127208      
 
      
CGOV25T OVCAR-3 MZB1 GAB2 NM_016459     
 
      
CGOV25T OVCAR-3 ANKS1A PPARD NM_015245      
 
      
CGOV25T OVCAR-3 PPARD ANKS1A NM_177435     
 
      
CGOV25T OVCAR-3 PGC TFEB NM_002630     
 
      
CGOV25T OVCAR-3 KCNN3 ASH1L NM_170782      
 
      
CGOV25T OVCAR-3 ASH1L KCNN3 NM_018489      
 
      
CGOV25T OVCAR-3 MPP7 BICD1 NM_173496      
 
      
CGOV25T OVCAR-3 BICD1 MPP7 NM_001003398      
 
      
CGOV25T OVCAR-3 ANK3 CCDC6 NM_001149     
 
      
CGOV25T OVCAR-3 NUP98 BEAN1 NM_016320     
 
      
CGOV25T OVCAR-3 BEAN1 NUP98 NM_001136106     
 
      
CGOV25T OVCAR-3 SLC1A2 LDLRAD3 NM_001195728     
 
      
CGOV25T OVCAR-3 LDLRAD3 SLC1A2 NM_001304264     
 
      
CGOV25T OVCAR-3 RBM14 PELI3 NM_001198836     
 
      
CGOV25T OVCAR-3 FCHSD2 P2RY6 NM_014824      
 
      
CGOV25T OVCAR-3 P2RY6 FCHSD2 NM_001277205     
 
      
CGOV25T OVCAR-3 PRDM10 APLP2 NM_020228     
 
      
CGOV25T OVCAR-3 APLP2 PRDM10 NM_001142276      
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CGOV25T OVCAR-3 TEAD4 TSPAN9 NM_003213     
 
      
CGOV25T OVCAR-3 TSPAN9 TEAD4 NM_001168320     
 
      
CGOV25T OVCAR-3 UBALD1 UBN1 NM_145253      
 
      
CGOV25T OVCAR-3 UBN1 UBALD1 NM_001079514      
 
      
CGOV25T OVCAR-3 RASD1 LRRC75A NM_001199989     
 
      
CGOV25T OVCAR-3 PCTP ANKFN1 NM_021213      
 
      




      
CGOV25T OVCAR-3 ZNF142 POLR1A NM_001105537     
 
      
CGOV28T OVKATE 
PHOSPHO2-
KLHL23 NALCN NM_001199290     
 
      
CGOV28T OVKATE NALCN 
PHOSPHO2-




      
CGOV28T OVKATE 
PHOSPHO2-
KLHL23 NALCN NM_001199290     
 
      
CGOV28T OVKATE NALCN 
PHOSPHO2-




      
CGOV28T OVKATE HELQ FAM175A NM_001297755      
 
      
CGOV28T OVKATE FAM175A HELQ NM_139076      
 
      
CGOV30T OVSAHO PDE4D UBE2D2 NM_001165899     
 
      
CGOV30T OVSAHO UBE2D2 PDE4D NM_003339      
 
      




      
CGOV30T OVSAHO CATSPER3 DDX46 NM_178019      
 
      
CGOV30T OVSAHO RNF8 GRID1 NM_003958      
 
      




      




      
CGOV30T OVSAHO UBE2V1 KIFC2 NM_001032288      
 
      
CGOV30T OVSAHO RALGPS1 ENG NM_001190730      
 
      
CGOV30T OVSAHO ENG RALGPS1 NM_001278138     
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CGOV30T OVSAHO LGALS14 KLF12 NM_020129     
 
      
CGOV30T OVSAHO ISM2 COX16 NM_182509     
 
      
CGOV30T OVSAHO CSNK1G2 AP3D1 NM_001319     
 
      
CGOV30T OVSAHO AP3D1 CSNK1G2 NM_001261826      
 
      
CGOV30T OVSAHO GNB1L MKL1 NM_053004     
 
      
CGOV30T OVSAHO MKL1 HDAC10 NM_001282661     
 
      
CGOV30T OVSAHO TUBGCP6 MKL1 NM_020461     
 
      
CGOV30T OVSAHO ZCWPW2 RBMS3 NM_001040432      
 
      
CGOV30T OVSAHO RBMS3 ZCWPW2 NM_001177712      
 
      
CGOV32T PEO-14 NFASC TMCC2 NM_001005389     
 
      
CGOV32T PEO-14 TMCC2 NFASC NM_014858      
 
      
CGOV32T PEO-14 PUM1 SDC3 NM_001020658      
 
      
CGOV32T PEO-14 GMPS RNF180 NM_003875      
 
      
CGOV32T PEO-14 MECOM TNIK NM_001205194     
 
      




      
CGOV32T PEO-14 ADCY1 C7orf72 NM_021116     
 
      
CGOV32T PEO-14 C7orf72 ADCY1 NM_001161834      
 
      
CGOV32T PEO-14 UPP1 ABCA13 NM_001287426      
 
      
CGOV32T PEO-14 ABCA13 UPP1 NM_152701      
 
      
CGOV32T PEO-14 AIFM2 LRRC20 NM_001198696     
 
      
CGOV32T PEO-14 LRRC20 AIFM2 NM_001278214     
 
      
CGOV32T PEO-14 MAT1A TSPAN14 NM_000429     
 
      
CGOV32T PEO-14 KCNC1 SAA4 NM_001112741      
 
      
CGOV32T PEO-14 SAA4 KCNC1 NM_006512      
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CGOV32T PEO-14 SOX5 CCDC91 NM_001261414     
 
      
CGOV32T PEO-14 CCDC91 SOX5 NM_018318      
 
      
CGOV32T PEO-14 SOX5 CCDC91 NM_001261414     
 
      




      
CGOV32T PEO-14 GEMIN2 CTAGE5 NM_001009182      
 
      
CGOV32T PEO-14 CTAGE5 GEMIN2 NM_001247988     
 
      




      
CGOV32T PEO-14 PPP1R13B KLC1 NM_015316      
 
      
CGOV32T PEO-14 ZNF106 
JMJD7-
PLA2G4B NM_001284306      
 
      




      




      
CGOV32T PEO-14 DLGAP4 NDRG3 NM_001042486     
 
      




      
CGOV32T PEO-14 TOMM22 TAB1 NM_020243     
 
      
CGOV32T PEO-14 TAB1 TOMM22 NM_006116      
 
      
CGOV32T PEO-14 CAMSAP2 PPP1R12B NM_001297707      
 
      
CGOV32T PEO-14 PPP1R12B CAMSAP2 NM_001167857      
 
      




      
CGOV34T PEO-6 USP32 NFASC NM_032582      
 
      




      
CGOV34T PEO-6 SAV1 ATL1 NM_021818     
 
      
CGOV34T PEO-6 MLPH PRDM12 NM_001281474      
 
      
CGOV34T PEO-6 PRDM12 MLPH NM_021619      
 
      




      




      
 227 
CGOV44T FU-OV-1 GLS2 RBMS2 NM_001280796      
 
      
CGOV44T FU-OV-1 RBMS2 GLS2 NM_002898      
 
      
CGOV44T FU-OV-1 IFNL1 ACTN4 NM_172140     
 
      
CGOV44T FU-OV-1 DEFB123 REM1 NM_153324     
 
      
CGOV44T FU-OV-1 CMTM8 CLASP2 NM_178868      
 
      
CGOV44T FU-OV-1 DOK3 ZNF527 NM_001144875      
 
      
CGOV44T FU-OV-1 ZNF527 DOK3 NM_032453     
 
      
CGOV45T COV-318 C3orf22 FBXO42 NM_152533     
 
      
CGOV45T COV-318 MAST4 CHD1 NM_198828      
 
      




      
CGOV45T COV-318 BSCL2 ZNF536 NM_001130702      
 
      
CGOV45T COV-318 ZNF536 BSCL2 NM_014717     
 
      
CGOV46T JHOS-2 CDK11B KIAA2013 NM_001291345      
 
      
CGOV46T JHOS-2 KIAA2013 CDK11B NM_138346     
 
      




      




      
CGOV46T JHOS-2 ARMC8 SF3B3 NM_001282342     
 
      




      
CGOV46T JHOS-2 NUB1 ABCF2 NM_001243351     
 
      
CGOV46T JHOS-2 THEM6 FANCI NM_016647      
 
      




      
CGOV46T JHOS-2 PAAF1 RBFOX3 NM_001267806     
 
      
CGOV46T JHOS-2 RBFOX3 PAAF1 NM_001082575     
 
      




      
CGOV46T JHOS-2 SARNP ITGA7 NM_033082      
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CGOV46T JHOS-2 MBTPS1 CDH13 NM_003791     
 
      




      
CGOV46T JHOS-2 KCNE1 SCAF4 NM_001270403     
 
      
CGOV47T JHOS-4 NEGR1 CNTNAP5 NM_173808      
 
      




      
CGOV47T JHOS-4 PHF3 PNISR NM_001290259     
 
      
CGOV47T JHOS-4 PNISR PHF3 NM_015491     
 
      




      
CGOV47T JHOS-4 SGK1 TTF2 NM_001143676      
 
      
CGOV47T JHOS-4 PFN4 ATAD2B NM_199346     
 
      
CGOV47T JHOS-4 TMEM108 KNG1 NM_001136469      
 
      
CGOV47T JHOS-4 KNG1 TMEM108 NM_001102416      
 
      
CGOV4T DOV-13 CCL27 PHF21B NM_006664     
 
      
CGOV4T DOV-13 POU6F1 GLTSCR2 NM_002702      
 
      
CGOV4T DOV-13 GLTSCR2 POU6F1 NM_015710      
 
      




      




      




      
CGOV5T EFO-21 KIAA0226L ZFR NM_001286762     
 
      
CGOV5T EFO-21 HCN1 
PALM2-
AKAP2 NM_021072      
 
      
CGOV5T EFO-21 
PALM2-
AKAP2 HCN1 NM_007203      
 
      
CGOV5T EFO-21 FAM193B B4GALT7 NM_001190946     
 
      
CGOV92T JHOS-3 NDUFAF2 ZNF366 NM_174889      
 
      
CGOV92T JHOS-3 ZNF366 NDUFAF2 NM_152625     
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CGOV92T JHOS-3 ANK1 DEPTOR NM_001142446      
 
      
CGOV92T JHOS-3 DEPTOR ANK1 NM_001283012      
 
      




      
CGOV92T JHOS-3 CASQ2 NIN NM_001232     
 
      
CGOV92T JHOS-3 DDX21 DDX50 NM_004728     
 
      
CGOV92T JHOS-3 ERLIN1 CHUK NM_006459     
 
      
CGOV92T JHOS-3 API5 SIK3 NM_001142930     
 
      




      
CGOV92T JHOS-3 WFIKKN1 FRY NM_053284     
 
      
CGOV92T JHOS-3 RCBTB2 CYSLTR2 NM_001268     
 
      
CGOV92T JHOS-3 CYSLTR2 RCBTB2 NM_001308465     
 
      
CGOV92T JHOS-3 NETO2 ITFG1 NM_001201477      
 
      




      




      
CGOV92T JHOS-3 CHTF8 TANGO6 NM_001040146     
 
      
CGOV92T JHOS-3 WNK4 GNA13 NM_032387     
 
      




      
CGOV92T JHOS-3 CAMSAP2 ASZ1 NM_001297707      
 
      
CGOV92T JHOS-3 ASZ1 CAMSAP2 NM_001301821      
 
      
CGOV92T JHOS-3 ADORA1 KDM5B NM_000674     
 
      
CGOV92T JHOS-3 TTC28 ZNRF3 NM_001145418      
 
      
CGOV92T JHOS-3 ZNRF3 TTC28 NM_001206998      
 
      
CGOV92T JHOS-3 HORMAD2 SF3A1 NM_152510      
 
      
CGOV92T JHOS-3 CCDC157 HORMAD2 NM_001017437     
 
      
CGOV92T JHOS-3 SMYD3 ZHX3 NM_022743      
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CGOV92T JHOS-3 ZHX3 SMYD3 NM_015035     
 
      
CGOV12T KOC-7C PKLR FAM189B NM_181871      
 
      
CGOV12T KOC-7C NR2E3 THSD4 NM_016346     
 
      
CGOV12T KOC-7C C22orf39 ACOT11 NM_001166242     
 
      
CGOV20T OV207 MEGF8 MUC21 NM_001271938     
 
      
CGOV20T OV207 ATG5 TRUB2 NM_001286106      
 
      
CGOV20T OV207 COQ4 ATG5 NM_001305942     
 
      
CGOV20T OV207 STOX1 IZUMO2 NM_001130159      
 
      
CGOV20T OV207 IZUMO2 STOX1 NM_152358      
 
      
CGOV20T OV207 C10orf76 CUEDC2 NM_024541     
 
      
CGOV20T OV207 CUEDC2 C10orf76 NM_024040     
 
      
CGOV20T OV207 RPAP3 VDR NM_001146075      
 
      
CGOV20T OV207 VDR RPAP3 NM_000376     
 
      
CGOV20T OV207 SLC4A8 GALNT6 NM_001267615     
 
      
CGOV20T OV207 MYL6 INHBC NM_021019      
 
      
CGOV20T OV207 INHBC MYL6 NM_005538      
 
      
CGOV20T OV207 RUSC1 ACLY NM_001105203     
 
      




      
CGOV20T OV207 ITPK1 BTBD7 NM_001142594      
 
      
CGOV20T OV207 BTBD7 ITPK1 NM_001289133      
 
      
CGOV20T OV207 LAMC1 NMNAT2 NM_002293      
 
      
CGOV20T OV207 NMNAT2 LAMC1 NM_015039      
 
      
CGOV20T OV207 MIEN1 KIAA0195 NM_032339     
 
      
CGOV20T OV207 DNTTIP1 SNX21 NM_052951      
 
      
CGOV20T OV207 SNX21 DNTTIP1 NM_001042633      
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CGOV20T OV207 STK40 CFTR NM_001282546     
 
      
CGOV20T OV207 FMNL2 FOXP1 NM_052905      
 
      
CGOV20T OV207 FOXP1 FMNL2 NM_001244816     
 
      
CGOV20T OV207 CERS6 ABCB11 NM_001256126      
 
      




      
CGOV20T OV207 METAP1D SLC25A12 NM_199227     
 
      
CGOV20T OV207 DGKD YAP1 NM_152879      
 
      
CGOV20T OV207 YAP1 DGKD NM_001130145      
 
      
CGOV20T OV207 CCDC51 CABIN1 NM_001256964     
 
      




      
CGOV20T OV207 BTLA TMEM175 NM_001085357     
 
      
CGOV20T OV207 SEC22A ADCY5 NM_012430      
 
      




      
CGOV20T OV207 SMARCAD1 PDLIM5 NM_001128430      
 
      
CGOV20T OV207 PDLIM5 SMARCAD1 NM_001256425     
 
      
CGOV20T OV207 KIF2A ADGRV1 NM_001098511      
 
      




      
CGOV27T OVISE TNXB CREB5 NM_019105     
 
      
CGOV27T OVISE DLL3 BCLAF1 NM_016941     
 
      
CGOV27T OVISE DUSP27 DIAPH3 NM_001080426      
 
      




      
CGOV27T OVISE RFX3 GLIS3 NM_001282116     
 
      
CGOV27T OVISE GLIS3 RFX3 NM_152629      
 
      
CGOV27T OVISE MDM1 BEST3 NM_001205028     
 
      
CGOV27T OVISE NLRP8 GP6 NM_176811      
 
      
 232 
CGOV27T OVISE MAP1LC3A BPIFB4 NM_032514     
 
      
CGOV29T OVMANA PTPN7 ASH1L NM_080588     
 
      
CGOV29T OVMANA KAT5 RASIP1 NM_001206833      
 
      
CGOV29T OVMANA ATXN10 ABCA7 NM_001167621      
 
      
CGOV29T OVMANA ZNF14 EPS15L1 NM_021030     
 
      
CGOV29T OVMANA EIF2B4 BRE NM_172195     
 
      
CGOV29T OVMANA BRE SNX17 NM_001261840      
 
      
CGOV29T OVMANA SEC14L4 HORMAD2 NM_001161368     
 
      
CGOV29T OVMANA HERC1 RELB NM_003922     
 
      
CGOV31T OVTOKO ST6GALNAC4 CIZ1 NM_175039     
 
      
CGOV31T OVTOKO RBCK1 SLC52A3 NM_006462      
 
      
CGOV31T OVTOKO CRELD2 PIM3 NM_001135101     
 
      
CGOV31T OVTOKO PIM3 ALG12 NM_001001852     
 
      
CGOV31T OVTOKO NKAIN1 KDM4B NM_024522      
 
      
CGOV31T OVTOKO KDM4B NKAIN1 NM_015015     
 
      
CGOV35T RMG-I CD164L2 AHDC1 NM_207397     
 
      
CGOV35T RMG-I KLF16 FANCD2 NM_031918     
 
      
CGOV35T RMG-I C22orf39 ACOT11 NM_001166242     
 
      
CGOV35T RMG-I GDA CCDC7 NM_001242507     
 
      
CGOV35T RMG-I CCDC7 GDA NM_024688     
 
      
CGOV35T RMG-I TRAF2 MYADML2 NM_021138      
 
      
CGOV35T RMG-I MYADML2 TRAF2 NM_001145113     
 
      
CGOV35T RMG-I RAB3IP CNOT2 NM_022456      
 
      
CGOV35T RMG-I CNOT2 RAB3IP NM_014515      
 
      
CGOV35T RMG-I COL4A1 NUMB NM_001845      
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CGOV35T RMG-I NUMB COL4A1 NM_001005743      
 
      
CGOV35T RMG-I GRB7 IKZF3 NM_005310      
 
      
CGOV35T RMG-I IKZF3 GRB7 NM_001284514     
 
      
CGOV7T ES-2 CCND1 SHANK2 NM_053056      
 
      
CGOV7T ES-2 SHANK2 CCND1 NM_133266      
 
      
CGOV7T ES-2 SHANK2 CNTN5 NM_133266      
 
      
CGOV7T ES-2 CNTN5 SHANK2 NM_001243271     
 
      
CGOV7T ES-2 SHANK2 CNTN5 NM_133266      
 
      
CGOV7T ES-2 CNTN5 SHANK2 NM_001243271     
 
      
CGOV7T ES-2 SHANK2 AAMDC NM_133266      
 
      
CGOV7T ES-2 AAMDC SHANK2 NM_024684     
 
      
CGOV7T ES-2 MAML2 YAP1 NM_032427      
 
      
CGOV7T ES-2 YAP1 MAML2 NM_001130145      
 
      
CGOV7T ES-2 FAM53A CNTN5 NM_001013622     
 
      
CGOV7T ES-2 CNTN5 FAM53A NM_001243271     
 
      
CGOV7T ES-2 CRMP1 AMOTL1 NM_001288662      
 
      
CGOV7T ES-2 AMOTL1 CRMP1 NM_001301007      
 
      
CGOV7T ES-2 CRMP1 CHKA NM_001288662      
 
      
CGOV7T ES-2 CHKA CRMP1 NM_001277      
 
      
CGOV7T ES-2 SORCS2 TYR NM_020777      
 
      
CGOV7T ES-2 TYR SORCS2 NM_000372      
 
      
CGOV11T_1 KK C3orf67 FHIT NM_198463      
 
      
CGOV11T_1 KK FHIT C3orf67 NM_001166243      
 
      
CGOV11T_1 KK FNDC3B PGPEP1L NM_022763     
 
      
CGOV11T_1 KK SST LPP NM_001048     
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CGOV11T_1 KK TMEM219 ACSM3 NM_001083613     
 
      
CGOV11T_1 KK ERBB4 IKZF2 NM_001042599      
 
      
CGOV11T_1 KK IKZF2 ERBB4 NM_016260      
 
      




      
CGOV11T_1 KK TUT1 USP37 NM_022830     
 
      
CGOV14T MCAS C22orf39 ACOT11 NM_001166242     
 
      
CGOV14T MCAS ARL4A RAB11FIP4 NM_001037164     
 
      
CGOV14T MCAS ISPD TRAF4 NM_001101417      
 
      
CGOV14T MCAS TRAF4 ISPD NM_004295      
 
      
CGOV14T MCAS AUTS2 GTF2IRD1 NM_001127231      
 
      
CGOV14T MCAS GTF2IRD1 AUTS2 NM_001199207     
 
      
CGOV48T JHOM-1 ATAD2 PPHLN1 NM_014109      
 
      
CGOV48T JHOM-1 PPHLN1 ATAD2 NM_001143788      
 
      
CGOV48T JHOM-1 XRRA1 ACER3 NM_001270380      
 
      
CGOV48T JHOM-1 ACER3 XRRA1 NM_001300954     
 
      
CGOV48T JHOM-1 SLCO2B1 RAB30 NM_001145212      
 
      
CGOV48T JHOM-1 RAB30 SLCO2B1 NM_001286061     
 
      
CGOV48T JHOM-1 TMEM133 RAB30 NM_032021     
 
      
CGOV48T JHOM-1 CNTN1 ADAMTS20 NM_001256063     
 
      
CGOV48T JHOM-1 ADAMTS20 CNTN1 NM_025003      
 
      




      
CGOV48T JHOM-1 USP15 ADAMTS20 NM_001252079      
 
      
CGOV48T JHOM-1 SDSL ATF7 NM_001304993     
 
      
CGOV10T IGROV-1 GTF2IRD1 GTF2I NM_001199207     
 
      
CGOV10T IGROV-1 GTF2I GTF2IRD1 NM_001280800     
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CGOV10T IGROV-1 CALD1 AGBL3 NM_004342     
 
      
CGOV10T IGROV-1 AGBL3 CALD1 NM_178563      
 
      
CGOV10T IGROV-1 ZFYVE27 MMS19 NM_001002262     
 
      
CGOV10T IGROV-1 TWSG1 RALBP1 NM_020648      
 
      
CGOV10T IGROV-1 RALBP1 TWSG1 NM_006788     
 
      




      
CGOV13T Kuramochi LRRC16A FAM65B NM_001173977      
 
      
CGOV13T Kuramochi LRP5 SORL1 NM_002335      
 
      
CGOV40T TYK-nu KITLG MTMR4 NM_000899      
 
      
CGOV40T TYK-nu HSF5 KITLG NM_001080439     
 
      
CGOV40T TYK-nu NF1 TMEM104 NM_001128147      
 
      
CGOV40T TYK-nu TMEM104 NF1 NM_017728      
 
      
CGOV40T TYK-nu OSBPL5 LUZP2 NM_001144063      
 
      
CGOV40T TYK-nu LUZP2 OSBPL5 NM_001009909      
 
      
CGOV15T OAW-28 HMG20A LINGO1 NM_001304504     
 
      
CGOV15T OAW-28 LINGO1 HMG20A NM_032808      
 
      
CGOV15T OAW-28 EBF4 IFNAR2 NM_001110514      
 
      
CGOV15T OAW-28 IFNAR2 EBF4 NM_000874      
 
      
CGOV15T OAW-28 ATP9A PMEPA1 NM_006045      
 
      
CGOV15T OAW-28 PMEPA1 ATP9A NM_001255976      
 
      
CGOV15T OAW-28 ADGRF3 OTOF NM_153835      
 
      




      
CGOV15T OAW-28 MAP4 CBFA2T3 NM_001134364      
 
      
CGOV15T OAW-28 CBFA2T3 MAP4 NM_005187      
 
      
CGOV15T OAW-28 MVD NME6 NM_002461     
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CGOV15T OAW-28 EPHA6 FAM19A2 NM_001080448      
 
      
CGOV15T OAW-28 FAM19A2 EPHA6 NM_178539      
 
      




      
CGOV15T OAW-28 CCDC77 RASGRF2 NM_001130147     
 
      
CGOV15T OAW-28 FAM26D RWDD1 NM_001256887     
 
      
CGOV15T OAW-28 RWDD1 FAM26D NM_001007464     
 
      
CGOV15T OAW-28 NAPEPLD MET NM_001122838      
 
      
CGOV15T OAW-28 MET NAPEPLD NM_000245      
 
      
CGOV15T OAW-28 UMOD PLXNA4 NM_001008389     
 
      
CGOV1T A2780 RAB11FIP5 ALMS1 NM_015470     
 
      
CGOV1T A2780 C22orf39 ACOT11 NM_001166242     
 
      
CGOV26T OVCAR-5 RSRC1 NDUFAF2 NM_001271834     
 
      
CGOV2T Caov-3 ZBTB20 GAP43 NM_001164343     
 
      
CGOV2T Caov-3 GAP43 ZBTB20 NM_001130064      
 
      




      
CGOV2T Caov-3 GABRA4 TMUB2 NM_001204266      
 
      
CGOV2T Caov-3 TMUB2 GABRA4 NM_001076674     
 
      
CGOV2T Caov-3 CTNND2 TRIO NM_001288715      
 
      
CGOV2T Caov-3 TRIO CTNND2 NM_007118      
 
      
CGOV2T Caov-3 CSF1R PDGFRB NM_005211     
 
      
CGOV2T Caov-3 PDGFRB CSF1R NM_002609     
 
      
CGOV2T Caov-3 OPRM1 IPCEF1 NM_001145280     
 
      
CGOV2T Caov-3 IPCEF1 OPRM1 NM_001130699      
 
      
CGOV2T Caov-3 WIPF3 NUDCD3 NM_001080529      
 
      
CGOV2T Caov-3 NUDCD3 WIPF3 NM_015332     
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CGOV2T Caov-3 GRM8 ZNF800 NM_000845      
 
      
CGOV2T Caov-3 ZNF800 GRM8 NM_176814      
 
      
CGOV2T Caov-3 DDAH1 FAM189B NM_001134445     
 
      
CGOV2T Caov-3 GBA DDAH1 NM_001005741     
 
      
CGOV2T Caov-3 FZD3 INTS9 NM_017412      
 
      
CGOV2T Caov-3 INTS9 FZD3 NM_001172562      
 
      
CGOV2T Caov-3 KCNB2 GSDMD NM_004770      
 
      
CGOV2T Caov-3 GSDMD KCNB2 NM_001166237     
 
      
CGOV2T Caov-3 RUSC2 MTUS2 NM_014806     
 
      
CGOV2T Caov-3 APBA1 MAMDC2 NM_001163     
 
      
CGOV2T Caov-3 SFXN2 WBP1L NM_178858     
 
      
CGOV2T Caov-3 WBP1L ARL3 NM_017787     
 
      
CGOV2T Caov-3 OR2H1 RCSD1 NM_030883     
 
      
CGOV2T Caov-3 OR4K14 HNRNPC NM_001004712     
 
      
CGOV2T Caov-3 NOL4L HNF4A NM_080616      
 
      
CGOV2T Caov-3 HNF4A NOL4L NM_001030004      
 
      
CGOV2T Caov-3 ITM2C CAB39 NM_001287240     
 
      




      
CGOV2T Caov-3 FARP2 HDLBP NM_001282983      
 
      
CGOV33T PEA2 MTFR1 NCOA2 NM_014637      
 
      
CGOV33T PEA2 SPATA13 ATP8A2 NM_001286792      
 
      




      
CGOV33T PEA2 NUMB RPS6KA5 NM_001005743      
 
      




      
CGOV3T 
COLO-
704 SLC8A2 CYTH2 NM_015063      
 




704 CYTH2 SLC8A2 NM_004228      
 
      
CGOV42T OVCAR-8 FAM160A1 FBXW7 NM_001109977     
 
      
CGOV42T OVCAR-8 FBXW7 FAM160A1 NM_033632     
 
      
CGOV42T OVCAR-8 PODXL CHST8 NM_001018111      
 
      
CGOV42T OVCAR-8 NRXN2 SLCO2B1 NM_138734      
 
      
CGOV42T OVCAR-8 FLYWCH2 FLYWCH1 NM_001142499      
 
      
CGOV42T OVCAR-8 FLYWCH1 FLYWCH2 NM_020912      
 
      
CGOV42T OVCAR-8 KCNE5 DCX NM_012282     
 
      
CGOV53T 
OVCAR-
5-CisR BLVRA STK17A NM_000712     
 
      
CGOV53T 
OVCAR-




      
CGOV53T 
OVCAR-




      
CGOV53T 
OVCAR-
5-CisR DLG2 USP25 NM_001300983      
 
      
CGOV53T 
OVCAR-




      
CGOV53T 
OVCAR-
5-CisR PEX5L ASH2L NM_001256750      
 
      
CGOV53T 
OVCAR-
5-CisR ASH2L PEX5L NM_001282272      
 
      
CGOV37T_3 SK-OV-3 KDM3B SIL1 NM_016604      
 
      
CGOV37T_3 SK-OV-3 SIL1 KDM3B NM_001037633      
 
      




      
CGOV37T_3 SK-OV-3 NUDT17 RNF130 NM_001012758     
 
      
CGOV37T_3 SK-OV-3 TMEM180 FAM213A NM_024789     
 
      
CGOV37T_3 SK-OV-3 AP2A2 CHID1 NM_001242837     
 
      
CGOV37T_3 SK-OV-3 LOR GATAD2B NM_000427     
 
      
CGOV37T_3 SK-OV-3 SMCO2 PPFIBP1 NM_001145010      
 
      
CGOV37T_3 SK-OV-3 PPFIBP1 SMCO2 NM_001198915     
 
      
CGOV37T_3 SK-OV-3 ANKS1B SCYL2 NM_152788      
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CGOV37T_3 SK-OV-3 SCYL2 ANKS1B NM_017988      
 
      
CGOV37T_3 SK-OV-3 SPINT1 HIF1A NM_003710      
 
      
CGOV37T_3 SK-OV-3 LAMC1 SH2D4B NM_002293      
 
      
CGOV37T_3 SK-OV-3 SH2D4B LAMC1 NM_207372      
 
      
CGOV37T_3 SK-OV-3 RASL12 MTFMT NM_001307930     
 
      
CGOV37T_3 SK-OV-3 MLST8 TSC2 NM_001199173     
 
      
CGOV37T_3 SK-OV-3 CTCF PSKH1 NM_001191022     
 
      
CGOV37T_3 SK-OV-3 PSKH1 CTCF NM_006742      
 
      
CGOV37T_3 SK-OV-3 FAM222B MYO18A NM_001288634     
 
      
CGOV37T_3 SK-OV-3 MYO18A FAM222B NM_078471     
 
      
CGOV37T_3 SK-OV-3 FBXL20 RFX2 NM_001184906     
 
      
CGOV37T_3 SK-OV-3 CNBD2 HSF2BP NM_001207076      
 
      
CGOV37T_3 SK-OV-3 HSF2BP CNBD2 NM_007031      
 
      
CGOV37T_3 SK-OV-3 PTTG1IP ITGB2 NM_001286822     
 
      




      




      




      




Table S3.1k. Pathway inhibitors 
Drug 
Pathway 
inhibition Cell line Lab id IC20 IC50  
BMN673 
PARP 
inhibitor JHOS-4 CGOV47T -8.76 -7.7  
BMN673 
PARP 
inhibitor JHOS-3 CGOV92T -9.07 -7.62  
BMN673 
PARP 
inhibitor OVMANA CGOV29T -8.59 -6.89  
BMN673 
PARP 
inhibitor OV177 CGOV18T -8.14 -6.5  
BMN673 
PARP 
inhibitor PEO-14 CGOV32T -7.31 -5.52  
BMN673 
PARP 
inhibitor FU-OV-1 CGOV44T -6.9 -4.79  
BMN673 
PARP 
inhibitor A2780 CGOV1T -6.21 -4.42  
BMN673 
PARP 
inhibitor TYK-nu CGOV40T -5.7 -4.21  
BMN673 
PARP 
inhibitor COV-318 CGOV45T -6.7 -4.2  
BMN673 
PARP 
inhibitor OAW-28 CGOV15T -5.94 -4.19  
BMN673 
PARP 
inhibitor JHOM-1 CGOV48T -6.45 -4.13  
BMN673 
PARP 
inhibitor OVSAHO CGOV30T -7.38 -3.92  
BMN673 
PARP 
inhibitor Caov-3 CGOV2T -5.86 -3.54  
BMN673 
PARP 
inhibitor JHOS-2 CGOV46T -5.93 -3.49  
BMN673 
PARP 
inhibitor Kuramochi CGOV13T -5.33 -3.32  
BMN673 
PARP 
inhibitor OV-167 CGOV17T -4.97 -2.46  
BMN673 
PARP 
inhibitor OAW-42 CGOV16T -3.98 -2.27  
BMN673 
PARP 
inhibitor KK CGOV11T_1 -4.71 -2.11  
BMN673 
PARP 
inhibitor OVISE CGOV27T -4.61 -2.04  
BMN673 
PARP 
inhibitor ES-2 CGOV7T -2.97 -1.58  
BMN673 
PARP 





429 CGOV23T -2.85 -0.85  
BMN673 
PARP 




inhibitor OVTOKO CGOV31T -3.83 -0.69  
BMN673 
PARP 
inhibitor RMUG-S CGOV36T -3.28 -0.48  
BMN673 
PARP 
inhibitor OV207 CGOV20T -2.37 -0.21  
BMN673 
PARP 
inhibitor OV-90 CGOV21T -2.49 -0.16  
BMN673 
PARP 
inhibitor DOV-13 CGOV4T -2.18 -0.14  
BMN673 
PARP 
inhibitor OVKATE CGOV28T -1.06 0  
BMN673 
PARP 
inhibitor HEY CGOV8T -2.82 0.09  
BMN673 
PARP 
inhibitor RMG-I CGOV35T -1.5 0.14  
BMN673 
PARP 





112D CGOV38T -1.24 0.2  
BMN673 
PARP 
inhibitor EFO-21 CGOV5T -3.09 0.21  
BMN673 
PARP 
inhibitor MCAS CGOV14T -1.4 0.68  
BMN673 
PARP 
inhibitor PEA2 CGOV33T -1.41 0.7  
BMN673 
PARP 

















































































































































inhibitor TYK-nu CGOV40T -1.16 -0.06  
MEK162 
MEK 




inhibitor Caov-3 CGOV2T -3.02 1.82  
MEK162 
MEK 
inhibitor DOV-13 CGOV4T -1.15 1.97  
MEK162 
MEK 
inhibitor EFO-21 CGOV5T 0.05 1.48  
MEK162 
MEK 
inhibitor ES-2 CGOV7T -2.48 -1.07  
MEK162 
MEK 
inhibitor HEY CGOV8T -2.5 -0.63  
MEK162 
MEK 
inhibitor KK CGOV11T_1 0.33 1.55  
MEK162 
MEK 
inhibitor Kuramochi CGOV13T 0.27 1.93  
MEK162 
MEK 
inhibitor MCAS CGOV14T -4.47 -2.33  
MEK162 
MEK 
inhibitor OAW-28 CGOV15T -1.69 0.33  
MEK162 
MEK 
inhibitor OAW-42 CGOV16T 0.25 1.27  
MEK162 
MEK 
inhibitor OV-167 CGOV17T -4.24 -1.51  
MEK162 
MEK 
inhibitor OV177 CGOV18T -2.5 -0.92  
MEK162 
MEK 
inhibitor OV207 CGOV20T -1.23 1.56  
MEK162 
MEK 





429 CGOV23T -1.49 2.11  
MEK162 
MEK 
inhibitor OVCAR-5 CGOV26T -4.31 -0.91  
MEK162 
MEK 
inhibitor OVISE CGOV27T -2.5 0.25  
MEK162 
MEK 
inhibitor OVKATE CGOV28T -4.98 -3.7  
MEK162 
MEK 
inhibitor OVMANA CGOV29T -5.14 -4.11  
MEK162 
MEK 
inhibitor OVSAHO CGOV30T -3.7 0.44  
MEK162 
MEK 
inhibitor OVTOKO CGOV31T -3.8 -1.62  
MEK162 
MEK 
inhibitor PEA2 CGOV33T -3.34 -1.51  
MEK162 
MEK 
inhibitor PEO-14 CGOV32T -1.35 1.52  
MEK162 
MEK 
inhibitor PEO-6 CGOV34T -3.22 -0.18  
MEK162 
MEK 









112D CGOV38T 1.84 3.76  
MEK162 
MEK 























Deletion + - TRUE FALSE   
Deletion - + FALSE FALSE   
Amplification + - TRUE FALSE   
Amplification + - FALSE FALSE   
Amplification - + FALSE FALSE   
Amplification - + TRUE FALSE   
Translocation + - NA TRUE   
Translocation - + NA TRUE   
Translocation + - NA TRUE   
Translocation - + NA TRUE   
Inversion + + TRUE FALSE   
Inversion + + FALSE FALSE   
Inversion - - TRUE FALSE   
Inversion - - FALSE FALSE   
Inverted translocation + + NA TRUE   
Inverted translocation + + NA TRUE   
Inverted translocation - - NA TRUE   




Table S3.1n. R package versions* 
R package Version Source 
acepack 1.4.1 CRAN (R 3.5.0) 
AnnotationDbi 1.42.1 cran (@1.42.1) 
AnnotationFilter 1.4.0 Bioconductor 
assertthat 0.2.0 CRAN (R 3.5.0) 
backports 1.1.2 CRAN (R 3.5.0) 
base 3.5.0 local 
base64enc 0.1-3 CRAN (R 3.5.0) 
bindr 0.1.1 CRAN (R 3.5.0) 
bindrcpp 0.2.2 CRAN (R 3.5.0) 
Biobase 2.40.0 Bioconductor 
BiocGenerics 0.26.0 Bioconductor 
BiocInstaller 1.30.0 Bioconductor 
BiocParallel 1.14.1 Bioconductor 
biomaRt 2.36.1 Bioconductor 
Biostrings 2.48.0 Bioconductor 
biovizBase 1.28.0 Bioconductor 
bit 1.1-14 CRAN (R 3.5.0) 
bit64 0.9-7 CRAN (R 3.5.0) 
bitops 1.0-6 CRAN (R 3.5.0) 
blob 1.1.1 CRAN (R 3.5.0) 
boot 1.3-20 CRAN (R 3.5.0) 
broom 0.4.4 CRAN (R 3.5.0) 
BSgenome 1.48.0 Bioconductor 
cellranger 1.1.0 CRAN (R 3.5.0) 
checkmate 1.8.5 CRAN (R 3.5.0) 
circlize 0.4.3 CRAN (R 3.5.0) 
cli 1.0.0 CRAN (R 3.5.0) 
cluster 2.0.7-1 CRAN (R 3.5.0) 
CNPBayes 1.11.1 local 
coda 0.19-1 CRAN (R 3.5.0) 
colorspace 1.3-2 CRAN (R 3.5.0) 
combinat 0.0-8 CRAN (R 3.5.0) 
compiler 3.5.0 local 
ComplexHeatmap 1.18.0 Bioconductor (R 3.5.0) 
crayon 1.3.4 CRAN (R 3.5.0) 
curl 3.2 CRAN (R 3.5.0) 
data.table 1.11.4 CRAN (R 3.5.0) 
datasets 3.5.0 local 
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DBI 1.0.0 CRAN (R 3.5.0) 
deconstructSigs 1.8.0 CRAN (R 3.5.0) 
DelayedArray 0.6.0 Bioconductor 
devtools 1.13.5 CRAN (R 3.5.0) 
dichromat 2.0-0 CRAN (R 3.5.0) 
digest 0.6.15 CRAN (R 3.5.0) 
DNAcopy 1.54.0 Bioconductor 
dplyr 0.7.5 CRAN (R 3.5.0) 
ensembldb 2.4.1 Bioconductor 
evaluate 0.10.1 CRAN (R 3.5.0) 
forcats 0.3.0 CRAN (R 3.5.0) 
foreign 0.8-70 CRAN (R 3.5.0) 
Formula 1.2-3 CRAN (R 3.5.0) 
GenomeInfoDb 1.16.0 Bioconductor 
GenomeInfoDbData 1.1.0 Bioconductor 
GenomicAlignments 1.16.0 Bioconductor 
GenomicFeatures 1.32.0 Bioconductor 
GenomicRanges 1.32.3 Bioconductor 
GetoptLong 0.1.6 CRAN (R 3.5.0) 
GGally 1.4.0 CRAN (R 3.5.0) 
ggbio 1.28.0 Bioconductor 
ggplot2 2.2.1 CRAN (R 3.5.0) 
GlobalOptions 0.0.13 CRAN (R 3.5.0) 
glue 1.2.0 CRAN (R 3.5.0) 
graph 1.58.0 Bioconductor 
graphics 3.5.0 local 
grDevices 3.5.0 local 
grid 3.5.0 local 
gridExtra 2.3 CRAN (R 3.5.0) 
gtable 0.2.0 CRAN (R 3.5.0) 
gtools 3.5.0 CRAN (R 3.5.0) 
haven 1.1.1 CRAN (R 3.5.0) 
Hmisc 4.1-1 CRAN (R 3.5.0) 
hms 0.4.2 CRAN (R 3.5.0) 
htmlTable 1.12 CRAN (R 3.5.0) 
htmltools 0.3.6 CRAN (R 3.5.0) 
htmlwidgets 1.2 CRAN (R 3.5.0) 
httr 1.3.1 CRAN (R 3.5.0) 
integration 0.0.3 local 
integration.data 0.0.1 local 
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IRanges 2.14.10 Bioconductor 
jsonlite 1.5 CRAN (R 3.5.0) 
kableExtra 0.9.0 CRAN (R 3.5.0) 
knitr 1.2 CRAN (R 3.5.0) 
lattice 0.20-35 CRAN (R 3.5.0) 
latticeExtra 0.6-28 CRAN (R 3.5.0) 
lazyeval 0.2.1 CRAN (R 3.5.0) 
lubridate 1.7.4 CRAN (R 3.5.0) 
magrittr 1.5 CRAN (R 3.5.0) 
Matrix 1.2-14 CRAN (R 3.5.0) 
matrixStats 0.53.1 CRAN (R 3.5.0) 
mclust 5.4 CRAN (R 3.5.0) 
memoise 1.1.0 CRAN (R 3.5.0) 
methods 3.5.0 local 
mnormt 1.5-5 CRAN (R 3.5.0) 
modelr 0.1.2 CRAN (R 3.5.0) 
munsell 0.4.3 CRAN (R 3.5.0) 
naniar 0.2.0 CRAN (R 3.5.0) 
nlme 3.1-137 CRAN (R 3.5.0) 
nnet 7.3-12 CRAN (R 3.5.0) 
OrganismDbi 1.22.0 Bioconductor 
ovarian.cell.line.data 0.0.1 local 
ovarian.manuscript 0.0.34 local 
ovexpress 0.0.3 local 
parallel 3.5.0 local 
pastecs 1.3.21 CRAN (R 3.5.0) 
pillar 1.2.3 CRAN (R 3.5.0) 
pkgconfig 2.0.1 CRAN (R 3.5.0) 
plyr 1.8.4 CRAN (R 3.5.0) 
prettyunits 1.0.2 CRAN (R 3.5.0) 
progress 1.1.2 CRAN (R 3.5.0) 
ProtGenerics 1.12.0 Bioconductor 
psych 1.8.4 CRAN (R 3.5.0) 
purrr 0.2.5 cran (@0.2.5) 
R6 2.2.2 CRAN (R 3.5.0) 
RBGL 1.56.0 Bioconductor 
RColorBrewer 1.1-2 CRAN (R 3.5.0) 
Rcpp 0.12.17 CRAN (R 3.5.0) 
RCurl 1.95-4.10 CRAN (R 3.5.0) 
readr 1.1.1 CRAN (R 3.5.0) 
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readxl 1.1.0 CRAN (R 3.5.0) 
rentrez 1.2.1 CRAN (R 3.5.0) 
reshape 0.8.7 CRAN (R 3.5.0) 
reshape2 1.4.3 CRAN (R 3.5.0) 
rjson 0.2.19 CRAN (R 3.5.0) 
rlang 0.2.1 CRAN (R 3.5.0) 
rmarkdown 1.9 CRAN (R 3.5.0) 
rpart 4.1-13 CRAN (R 3.5.0) 
rprojroot 1.3-2 CRAN (R 3.5.0) 
Rsamtools 1.32.0 Bioconductor 
RSQLite 2.1.1 cran (@2.1.1) 
rstudioapi 0.7 CRAN (R 3.5.0) 
rtracklayer 1.40.3 Bioconductor 
rvest 0.3.2 CRAN (R 3.5.0) 
S4Vectors 0.18.2 Bioconductor 
scales 0.5.0 CRAN (R 3.5.0) 
shape 1.4.4 CRAN (R 3.5.0) 
splines 3.5.0 local 
stats 3.5.0 local 
stats4 3.5.0 local 
stringi 1.2.2 CRAN (R 3.5.0) 
stringr 1.3.1 cran (@1.3.1) 
SummarizedExperiment 1.10.1 cran (@1.10.1) 
survival 2.42-3 CRAN (R 3.5.0) 
svovarian 0.0.7 local 
tibble 1.4.2 CRAN (R 3.5.0) 
tidyr 0.8.1 CRAN (R 3.5.0) 
tidyselect 0.2.4 CRAN (R 3.5.0) 
tidyverse 1.2.1 CRAN (R 3.5.0) 
tools 3.5.0 local 
trellis 0.0.36 local 
utils 3.5.0 local 
VariantAnnotation 1.26.0 Bioconductor 







XML 3.98-1.11 CRAN (R 3.5.0) 
xml2 1.2.0 CRAN (R 3.5.0) 
XVector 0.20.0 Bioconductor 
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zlibbioc 1.26.0 Bioconductor 























Specimens obtained for sequencing analysis 
 
Matched tumor and normal tissue was collected from patients at time of resection.  All tumor 
samples analyzed had ≥20% viable tumor cell content by histopathologic assessment.  Clinical data 
for all patients included and sample data for the tissue types assayed in this study are listed in Table 
S1.  All samples were obtained under Institutional Review Board (IRB) approved protocols with 
informed consent for research use at participating institutions. 
 
Sample preparation and next-generation sequencing 
 
DNA was extracted from patient whole blood using a QIAamp DNA Blood Mini QIAcube Kit 
(Qiagen Valencia, CA). Genomic DNA from FFPE blocks was extracted from the microdissected 
tissues using the QIAamp DNA FFPE Tissue kit (Qiagen, Valencia, CA). In brief, the samples were 
incubated in proteinase K for 16 hours before DNA extraction. The digested mixture was 
transferred to a microtube for DNA fragmentation using the truXTRAC™ FFPE DNA Kit with 10 
min shearing time as per the manufacturer’s instructions (Covaris, Woburn, MA). Following 
fragmentation, the sample was further digested for 24 hours followed by one hour incubation at 
80⁰C. DNA purification was performed using the QIAamp DNA FFPE Tissue kit following the 
manufacturer’s instructions (Qiagen, Valencia, CA). Fragmented genomic DNA from tumor and 
normal samples were used for Illumina TruSeq library construction (Illumina, San Diego, CA) 
according to the manufacturer’s instructions or as previously described111. Exonic or targeted 
regions were captured in solution using the Agilent SureSelect v.4 kit or a custom targeted panel 
according to the manufacturer’s instructions (Agilent, Santa Clara, CA). Paired-end sequencing, 
resulting in 100 bases from each end of the fragments for exome libraries and 150 bases from each 
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end of the fragment for targeted libraries, was performed using Illumina HiSeq 2000/2500 and 
Illumina MiSeq instrumentation (Illumina, San Diego, CA). 
 
Next generation sequencing data and identification of somatic mutations 
 
Somatic mutations were identified using VariantDx45 custom software for identifying mutations 
in matched tumor and normal samples.  Prior to mutation calling, primary processing of sequence 
data for both tumor and normal samples were performed using Illumina CASAVA software (v1.8), 
including masking of adapter sequences.  Sequence reads were aligned against the human reference 
genome (version hg18 or hg19) using ELAND. Candidate somatic mutations, consisting of point 
mutations, insertions, and deletions were then identified using VariantDx across the either the 
whole exome or regions of interest44. For samples analyzed using targeted sequencing, we 
identified candidate mutations that were altered in >10% of distinct reads. For samples analyzed 
using whole exome sequencing, we identified candidate mutations that were altered in >10% of 
distinct reads with ≥5 altered reads in at least one sample, where coverage at the altered base was 
at least as high as the TP53 alteration in that sample, and where the ratio of the coverage of the 
mutated base to the overall sequence coverage of that sample was >20%.  Identified mutations were 
reported as present in other samples of the same patient if the mutation was present in at least 2 
distinct altered reads. Mutations present in polyN tract ≥ 5 bases, or those with an average distinct 
coverage below 50x were removed from the analysis.  
 
An analysis of each candidate mutated region was performed using BLAT.   For each mutation, 
101 bases including 50 bases 5’ and 3’ flanking the mutated base was used as query sequence 
(http://genome.ucsc.edu/cgi-bin/hgBlat).  Candidate mutations were removed from further 
analysis, if the analyzed region resulted in >1 BLAT hits with 90% identity over 70 SCORE 
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sequence length.  All candidate alterations were examined by visual inspection, and any alteration 
present. 
 
Structural variant analysis from whole genome sequencing data 
 
Structural variants were identified by modifying the trellis approach 53 for use with tumor samples 
with a matched normal sample available and integrating tumor purity and ploidy from FACETS. 
 
Tumor purity and ploidy estimation 
Tumor purity and ploidy were jointly estimated from each of 41 tumor-normal pairs using 
FACETS. These metrics were unable to be determined for four samples (PGDX3309T_WGS_Ex, 
PGDX4495T_WGS, PGDX4500T2_WGS, PGDX4500T3_WGS) which were further excluded 
from CNV analyses. 
 
Generation of Segmented Log2 Ratios 
GC-adjusted log2 ratios were obtained as previously described in both tumor samples and normal 
samples. To remove technical biases and germline alterations, log2 ratios from matched normal 
samples were subtracted from log2 ratios in tumor samples. To identify genomic segments 
harboring abnormal copy number, the normalized log2 ratios were segmented using the circular 
binary segmentation method implemented in the R package and excluded from any structural 
variant analyses (PGDX3302T_WGS_Ex, PGDX3303T_WGS_Ex, PGDX3308T_WGS_Ex, 
CGOV365T). 
 
Generation of Integer Copy Number Estimates 
The log2 ratio (R) for a segment i from a sample that is a mixture of normal and cancer cells are 
given by the following equation: 
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𝑅𝑅𝑖𝑖 = 𝑙𝑙𝑙𝑙𝑙𝑙2 �
𝐶𝐶𝐶𝐶𝑖𝑖  ×  𝑝𝑝 + 𝐶𝐶𝐶𝐶𝑖𝑖  ×  (1 − 𝑝𝑝)
𝑃𝑃𝐶𝐶 ×  𝑝𝑝 +  𝑃𝑃𝐶𝐶 ×  (1 − 𝑝𝑝)
� 
Where 𝑝𝑝 is the tumor purity, 𝐶𝐶𝐶𝐶𝑖𝑖 is the number of copies of segment i in the tumor cells, 𝐶𝐶𝐶𝐶𝑖𝑖 is the 
number of copies of segment i in the normal cells, 𝑃𝑃𝐶𝐶 is the average ploidy of the tumor cells, and 
𝑃𝑃𝐶𝐶 is the average ploidy of the normal cells. Log2 ratios were converted to integer copy numbers 




The deletion analysis was restricted to segments less than 3 Mb where the integer copy number was 
either 0 or 1. At least 2 improper read pairs supporting the deletion were required to call a deletion 
hemizygous+ or homozygous+. 
 
Somatic Amplifications  
Using the trellis approach, amplicons were seeded with high-copy focal amplifications of greater 
than three times the average ploidy of the sample.  Low copy gains with a copy number of greater 
than 1.5 times the average ploidy of the sample were linked to the seed if at least 2 read pairs 
supporting linking. 
 
Somatic Copy-Neutral Intra—and Inter-chromosomal Translocations and Inversions 
Somatic rearrangements were identified as previously described for each tumor sample and its 
matched normal sample. At least 2 improper read pairs and at least 1 split read was required to call 
a rearrangement. Rearrangements in tumor samples that overlapped any rearrangement identified 
in their matched normal samples were excluded. 
 
In-Frame Gene Fusions 
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In-frame gene fusions were identified as previously described. Fusions where the left and right 
fusion partner were in the same gene, and also fusions where none of the exons in the three prime 




We pre-processed and normalized raw IDAT files from the Infinium MethylationEPIC array using 
the funnorm function in the R package minfi69.  Probes on chomosomes X or Y, probes with 
detection p value greater than 0.5, or probes overlapping a SNP with dbSNP minor allele frequency 
greater than 10% were excluded.   
 
Unsupervised hierarchical clustering of the 1000 probes with the highest variance in the normal 
samples was performed.  Next we performed penalized least squares logistic regression (PLR) with 
leave-one-out-cross-validation that identified five methylation sites predictive of normal ovarian or 
GI tissue type (area under receiver operator characteristic curve).   We implemented the same 
leave-one-out resampling scheme to cross-validate the PLR model in the cancer samples, but 
restricted the training set to the five methylation sites that separated the tumor ovarian and GI 













A total of 130 ovarian endometrioid, uterine endometrioid, ovarian mucinous, and GI mucinous 
tumors and matching normal tissues were collected from patients of four institutions in the US and 
Japan.  A total of 13 ovarian or GI mucinous tumor samples had tumor cellularity below 20% and 
were excluded from further analyses.  We performed genomic analyses of these matched tumor and 
normal samples to identify sequence, structural and epigenetic changes (Figure 4.1).  All samples 
were analyzed by whole exome analyses (WES), and for the subset of cases where frozen tumors 
were available, we performed whole genome sequencing (WGS).  Overall, we analyzed 84 tumors 
using WES and 33 tumors using WGS. The average coverage for WES and WGS was 221X per 
and 56X per sample, respectively (Table S4.2).  We assessed substitutions, small insertions and 
deletions as well as copy number changes in samples with WES while samples with WGS were 
evaluated for these changes as well as for rearrangements, linked amplicons and gene fusions.  
Copy number analyses identifying both focal amplifications, deletions, as well as chromosomal 
gains and losses were performed for WES using Facets and for WGS using our recently developed 
Trellis approach 53,112.  We also used Trellis to evaluate linked amplicons that may be derived from 
an amplification of a single target gene that is connected to multiple different regions of the genome 
53,74,76,77.   
 
Ovarian endometrioid and uterine endometrioid cancers 
 
We employed a highly sensitive mutation analysis to identify somatic alterations in ovarian 
endometrioid (n=36) and uterine endometrial (n=15) cancers.  Consistent with previous analyses, 
we observed a bimodal distribution of the number of mutations for uterine endometrioid cancers, 
with nearly half of the 15 tumors analyzed having more than 500 mutations per exome 47 
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(Supplementary Figure 4.1).  In contrast, the probability of a hypermutator defect for ovarian 
endometrioid cancers was much lower, with only one patient out of 36 above this threshold.   
Evaluation of the altered genes in ovarian endometrioid and uterine endometrioid cancers revealed 
similar affected pathways (Figure 4.2).  Mutations involving chromatin regulating genes, and PI3K 
and RAS pathways were common in both tumor types.  The proportion of patients with alterations 
in the PTEN, PIK3CA, KRAS, PIK3R1, NF1, and ARID1A genes were similar among these two 
cancer types and consistent with previous studies 113,114.  We also observed mutations in TP53 and 
CTNNB1 in ovarian endometrioid tumors as well as in uterine endometrioid cancers as has been 
previously described 115.   
 
We identified several mutations in driver genes among patients with ovarian endometrioid cancer 
that have not been previously reported, including the homologous recombination RAD51C gene, 
the Notch signaling genes, NOTCH4 and NOTCH1, the chromatin remodeling genes SMARCA4 
and SMARCA1, the E2F1 transcription factor, the RET receptor tyrosine kinase, and the ABL1 
kinase.   
 
Surprisingly, we found that two of the eight non-hypermutator uterine endometrioid cancers had 
an identical ESR1 hotspot mutation at Tyr537 (Y537C and Y537N) (Supplementary Figure 4.2).  
This hotspot has been reported in patients with breast cancer that have become resistant to 
tamoxifen or aromatase inhibitor therapy 116,117.  Although none of the patients in this study had 
been treated with these inhibitors, it is intriguing that these two women were over the age of 60 and 
had experienced menopause, resulting in an estrogen-free environment that may be similar to anti-
estrogen therapy.   
 
To understand the role of mutations in these ovarian cancer subtypes in the context of mutational 
signatures 118, we evaluated the types of mutations and linked these to mutational processes that 
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include exogenous or endogenous mutagen exposure, enzymatic modification of DNA, and 
defective DNA repair (Supplemental Figure 4.3A).  As expected, we found that the age-related 
mutation signature, Signature 1, was present in all samples, and also identified Signatures 6 or 
Signature 15 in patients with hypermutator defects.   
 
We assessed both WES and WGS information for focal amplifications.  For WGS data, we 
examined the read-pair information to pinpoint the presence of amplicons that may be linked 
gnomically using the Trellis approach 53 (Figure 4.3A ).   In addition to sequence alterations in 
KRAS, we found amplification of this gene in ovarian endometrioid cancer CGOV61T (Figure 4.2 
and 4.3A).  KRAS has been known to be amplified in ovarian endometrioid and HGSOC 119 and has 
been associated with an aggressive phenotype of metastatic uterine endometrial cancer 120.  We also 
identified linked amplification events involving MYC and JAK1 (Figure 4.3).  MYC amplification 
has previously been observed in a variety of ovarian cancers including endometrioid 121.  While 
JAK1 amplification has been observed in triple negative breast cancer 122, this gene has not been 
previously been reported to be amplified in ovarian endometrioid cancers.    
 
We evaluated whole exome and genome sequence data for homozygous deletions and identified 
losses of the following genes that have been known to be altered in ovarian endometrioid cancers:  
PTEN, NF1, GNAS, ARID1A, CCND1, BRCA1, RAD51C, PMS2, RET, ALK, SMAD3, TP53 and 
ESR1.  Additionally, we identified deletions in TSC2 and STK11 that have not been previously 
reported in endometrioid ovarian cancer.  TSC2 deletions have been seen in high grade serous 
ovarian cancer 123 and mutations in TSC2 have been associated with increased sensitivity to 
rapamycin-induced apoptosis, making TSC2 a potentially targetable biomarker 94.  Germline STK11 
inactivating mutations have been associated with Peutz-Jeghers syndrome, and somatic changes in 
this gene have been reported in a variety of carcinomas including non-small cell lung carcinoma, 
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cervical cancer, colorectal cancer, melanoma, and pancreatic cancer with predominantly truncating 
mutations, but have not yet been reported in endometrioid ovarian cancer 124.  
 
For samples with available WGS, we also used Trellis to identify rearrangements and fusions 
(Supplementary Figure 4.4).  These analyses revealed several novel rearrangements that were 
predicted to result in in-frame protein fusions in ovarian endometrioid cancers (examples in Figure 
4.3B).  ATAD2-PTEN was found in a patient with ovarian endometrioid cancer, CGOV172T.  
Interestingly, this rearrangement was associated with homozygous deletion of a portion of PTEN 
in this tumor.  Rearrangements of PTEN associated with deletions have not been previously 
reported in ovarian endometrioid tumors and PTEN loss in the ovarian surface epithelium has been 
shown to induce papillary serous ovarian cancer123.  Fusions involving the neurofibromin genes 
NF1 and NF2 (NF1-RAB11FIP4 and UBXN6-NF2) were identified in ovarian endometrioid cancer 
CGOV161T.   Although rearrangements involving NF1 and NF2 have been reported in other 
cancers 53 and have been associated with therapeutic resistance in HGSOC 125, rearrangements of 
these genes have not been previously identified in this ovarian cancer subtype.  We identified a 
novel fusion of PPM1E-RAD51C in patient CGOV172T with ovarian endometrioid cancer.  
Although the function of this rearrangement is unknown, germline alterations of RAD41C have 
been shown to increase the risk of breast and ovarian cancer126,127.  Fusions of IPO11-CDK7 and 
PLK5-TCF3 were detected in two different tumors.  CDK7 is a member of the cyclin-dependent 
kinas family and involved in cell cycle progression and CDK7 inhibitors have been shown to exert 
broad cytotoxicity against ovarian tumors 128.  As the IPO11 gene, involved in nuclear protein 
import, is expressed in both ovarian and endometrial cells, the fusion of IPO11-CDK7 may lead 
CDK7 to constitutively activated, promoting cell cycle progression and tumor growth. The polo 
like kinase 5 gene (PLK5) has been reported to be altered in glioblastoma 129 and along with other 
members of the PLK family may normally play a role in cell division and centriole duplication 130.  
Increasing evidence suggests that aberrant expression of PLKs may affect cell division and play a 
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role in genomic instability 131,132 and may therefore be a useful target of therapeutic intervention 
133.   
 
Ovarian mucinous and GI mucinous tumors 
 
We analyzed a total of 36 patients with ovarian mucinous carcinoma and with 14 colorectal 
mucinous cancers.  Using a threshold of 500 mutations per exome, we identified two hypermutated 
tumors, including a mucinous colorectal tumor with a mutation in POLE (1/14) that had over 12,000 
mutations per exome, and one ovarian mucinous tumor (1/36) with nearly 900 mutations (Figure 
4).  The hotspot somatic mutation observed in POLE occurred in the exonuclease domain of 
encoded protein and has been reported in a small subset of microsatellite‐stable and hypermutated 
colorectal carcinomas, affecting the proofreading activity of the enzyme during DNA replication 
134.   
 
Of the genes known to be altered though sequence changes in ovarian and colorectal mucinous 
tumors, we found alterations at similar frequencies in KRAS, PIK3CA, RNF43, SMAD4, GNAS and 
TP53.  We identified several genes to be known mutated in ovarian mucinous cancers including 
ERBB2, ARID1A, CCND1, CTNNB1, EGFR, CREBBP, and ATM 36,52,135,136.  We also identified 
mutations in the chromatin modifier gene SMARCA4 that had not been previously reported in 
ovarian mucinous cancers.  None of these genes were found to be altered in colorectal mucinous 
cancers other than in the POLE mutant tumor.  In addition to the age-related mutation Signature 1 
which we found in nearly half in ovarian and GI mucinous cancers, we identified a signature 
associated with failure of DNA double-strand break-repair by homologous recombination 
Signature 3, which has been previously reported in breast, ovarian, and pancreatic cancers118 
(Supplemental Figure 4.3B). 
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Analyses of focal copy number changes revealed amplifications of CCND1 and ERBB2, and 
homozygous deletions of CDK2A/B in mucinous ovarian cancers, a finding consistent with a 
previous studies 53,137-139. Amplification of ERBB2 was observed in six of the 36 ovarian mucinous 
cancers, and provides a potentially useful target for trastuzumab therapy 140. CDKN2A deletions 
were observed in six cases, and an additional eight tumors had sequence alterations in this gene 138.  
None of the colorectal mucinous tumors had copy number changes alterations in ERBB2, CCND1 
or CDKN2A/B.    
 
Interestingly, homozygous deletions of NF1 were present in both ovarian and colorectal mucinous 
tumors.  In addition, we identified a novel rearrangement resulting in the likely inactivation of NF1 
(NF1-RAD51D) in one ovarian mucinous cancer.  Inactivating alterations of NF1 has been shown 
to lead to RAS overactivity in HGSOC 12. Although the role of RAD51D is unclear in this context, 
it has been reported that germline RAD51D carriers are likely to develop ovarian tumors at an early 
age 141.  We also identified a novel MED1-STAT5B rearrangement in the same ovarian mucinous 
tumor.  MED1 alterations have been implicated in bladder and breast cancers and may be a potential 
target for treatment in endocrine resistant breast cancer 142,143. 
 
Integrative analyses  
 
To facilitate comparisons of the molecular alterations between the different tumor types, we 
integrated the sequence and structural changes at the gene level and organized these genes by 
biologically relevant pathways including Ras, PI3K, BRCA, WNT, chromatin regulating, cell 
cycle, TK receptors, DNA repair, and TGFBR (Figures 4.2 and 4.4).  Genes observed to be 
commonly altered through this integrative analysis of sequence mutations, amplifications and 
deletions included CDKN2A, ERBB2, CCND1, EGFR, PTEN, KRAS, NF1, ARID1A, BRCA1, and 
TP53.  For example, we found changes in cell cycle genes in in 14/36 (38%) samples of ovarian 
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mucinous when combining mutations and deletions in CDKN2A and amplifications of CCND1.  
Likewise, combined analyses of the RAS pathway, including TK receptors, identified alterations 
in 30 of 36 (83%) of these tumors.    
 
To assess whether cancer subtypes had differences in the molecular alterations that commonly arise 
in the development of these cancers, we implemented a Bayesian model averaging approach for 
feature selection using a logit link function102.  This approach searches the space of 211 and 217 , 
respectively for the endometrioid and mucinous models, possible single- and multi-variate models 
using Markov Chain Monte Carlo,  allowing for the simultaneous selection of features (genes) and 
estimation of effect size.   Posterior summaries available from these models include the probability 
that the regression coefficient is non-zero (the proportion of models evaluated by MCMC that 
included the gene) and the posterior median and 90% credible interval of the odds ratio.  For the 
ovarian endometrioid and uterine endometrioid subtypes, we did not find statistically significant 
differences in the genes/pathways that were altered in these cancers (Figure 4.5A).  However, for 
the ovarian and GI mucinous cancers, we found that CDKN2A were more commonly altered in the 
ovarian mucinous tumors (Figure 5B).  These analyses revealed statistically significant differences 
between the number of alterations among the cell cycle and TK receptor pathways, and suggested 




Given the mutational differences observed, we hypothesized that ovarian and GI mucinous cancers 
may also be epigenetically distinct.  To evaluate this possibility, we performed genome-wide 
methylation analyses of the GI and mucinous cancers as well as their matched normal tissues using 
Infinium MethylationEPIC arrays that interrogated more than 850,000 CpG cites.  Methylation 
levels were evaluated for a subset of 25 mucinous tumor samples and matched normal samples with 
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sufficient material at individual CpG sites within gene promoter regions (±1500 bp upstream of 
the transcription start site) or within individual genes.  After normalization, we estimated the 
proportion of methylated CpG sites as the fraction of CpG probes with Beta > 0.3.  Overall 
methylation was higher among normal samples and more variable in cancer (Supplemental Figure 
3).   
 
Unsupervised hierarchical clustering of the 1000 probes with the highest variance in the normal 
samples revealed a clear separation of the normal ovarian and GI tissues (Figure 4.6A) that was 
present but less pronounced in the cancer tissues (Figure 4.6B).  Penalized least squares logistic 
regression (PLR) with leave-one-out-cross-validation identified five methylation sites predictive of 
normal ovarian or GI tissue type (area under receiver operator characteristic curve).  Given the 
large range of tumor purity of the biopsied cancers (20-80%), we hypothesized that these 
methylation sites would not be predictive of the histopathological diagnosis if the tumors shared 
the same tissue of origin.   To evaluate this hypothesis, we implemented the same leave-one-out 
resampling scheme to cross-validate the PLR model in the cancer samples, but restricted the 
training set to the five methylation sites that separated the tumor ovarian and GI tissues(Figure 
4.6C).   Applied to the mucinous cancers, the tumor-specific tissue methylation sites predicted the 
histopathological cancer diagnosis with a sensitivity of 100% at a specificity of 100% (AUC 1.0, 
95% CI: 0.86-1.0).  Additionally, we used the same leave-one-out resampling scheme to cross 
validate the PLR model among the cancer samples, but restricted the training set to five methylation 
sites that separated the normal ovarian and GI tissues.  Applied to the mucinous cancers, the tissue-
specific methylation sites predicted the histopathological cancer diagnosis with a sensitivity of 83% 
at a specificity of 77% (AUC 0.8, 95% CI : 0.59-0.93), indicating that these cancers likely have a 
distinct tissue of origin (Figure 4.6D).  We found no relationship between tumor purity and the 




Figure 4.1. Overview of genomic analyses  
We performed genomic analyses of these matched tumor and normal samples to identify sequence, 
structural and epigenetic changes 
The picture can't be displayed.
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Figure 4.2. Integrated genomic and epigenomic analyses of ovarian endometrioid and uterine 
endometrial cancers 
Integrated somatic point mutations, structural variants including linked amplicons, deletions and 
rearrangements ordered by pathway.  Panels within each tile plot starting from the top represent 
tumor purity, number of each type of alteration, the panel of alterations present in each sample 






Figure 4.3. Whole genome analyses of linked amplicons and rearrangements  
A) Circos plots for three tumor samples with >100 structural variants(left) each contained linked 
amplicons(right) with focal amplifications of known driver genes indicated by triangles.  Circos 
plots of 19 tumor samples with few structual variants. Circos plots depict copy number alterations 
as well as intra- and inter-chromosomal rearrangements. Segmented normalized estimates of read 
depth were used to identify candidate focal amplifications in yellow and focal deletions in green.  
Rearranged read pairs and split reads were used to identify inter- and intra-chromosomal 
rearrangements in blue. For these amplicon graphs nodes represent genes, node size represents 
number of times the segment is represented in the genome, color indicates the chromosome the 
segment is located on and edges represent how the segments are connected in the genome. B) Reads 
aligned to the fusion junction of two representative rearrangements. Split reads, that span the fusion 
junction in black, and read pairs, that reside on either side of the junction in green and blue, give 






Figure 4.4. Integrated genomic analyses of ovarian and colorectal mucinous cancers 
Integrated somatic point mutations, structural variants including linked amplicons, deletions and 
rearrangements ordered by pathway.  Panels within each tile plot starting from the top represent 
tumor purity, number of each type of alteration, the panel of alterations present in each sample 















Figure 4.5. Prevalence of alterations in related tumor types. 
Bayesian model averaging was used to identify alterations involving known drivers associated with 
ovarian and uterine endometrioid tumors(A) or ovarian and GI mucinous tumors (B). The 
probability that the gene coefficient (γ) in these models is non-zero is indicated by a bar graph (left).  
The inter-quartile range (IQR) for the difference in log odds of the regression coefficient is 
indicated by error bars (right).  The odds of a mutation in ERBB2 and CDKN2A were higher among 
patients with GI mucinous cancers compared to patients with ovarian mucinous cancers.   
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Figure 4.6. Methylation analyses of ovarian and GI mucinous tumors 
1000 most variable probes among normal samples. A) Normal ovarian and GI tissues separate 
roughly based on the most variable porbes. B) Ovarian and GI mucinous tumor separate and 
resemble their normal counterparts more than each other and also segregate with the top 1000 most 
variable probes. C) Visualization of logistic regression modeling for each tumor sample correctly 
separating the mucinous tumors by tissue of origin as trained on the tumor samples. D) 
Visualization of logistic regression modeling for each tumor sample correctly separating the 
mucinous tumors by tissue of origin as trained on the normal tissue samples. 
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Supplemental Figure 4.1. Distribution number of mutations within the endometrioid samples 
Count of samples represented in the bar graph either uterine endometrial (blue) or ovarian 
endometrioid (red) with density curve as a black line and the cut off of hypermutators at 500 









Supplemental Figure 4.2. ESR1 Y537R mutations 
ESR1 mutations found in three uterine endometrioid cancer patients at Tyr357 hotspot most 
commonly associated with aromatase inhibitor resistance in breast cancer patients.  This hotspot is 
located in close proximinty to the region of the estrogen receptor that is important for ligand-
dependent transcriptional function.  The Tyr537 mutations cause a conformational change that 
constitutively activates the receptor independent of ER binding.  Below is the conformational 



















Supplemental Figure 4.3. Mutation signature analyses 
Mutation signature analyses for various tumor types.  Color indicates the percentage for which the 
signature explains the overall mutational profile of that sample. 
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Supplemental Figure 4.4. Circos plots of 19 ovarian endometrioid tumor samples  
Circos plots depict copy number alterations as well as intra- and inter-chromosomal 
rearrangements. Segmented normalized estimates of read depth were used to identify candidate 
focal amplifications in yellow and focal deletions in green.  Rearranged read pairs and split reads 
were used to identify inter- and intra-chromosomal rearrangements in blue. 
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Supplemental Figure 4.5. Rearrangement analyses of ovarian endometrioid and ovarian 
mucinous tumors 
Rearrangements present in 2 samples of ovarian endometrioid tumors (A), and one ovarian 
mucinous tumor sample (B).  Reads aligned to the fusion junction of two representative 
rearrangements. Split reads, that span the fusion junction in black, and read pairs, that reside on 
either side of the junction in green and blue, give evidence for identifiying such rearrangements. 
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Supplemental Figure 4,6. Comparison of mutation frequencies in ovarian mucinous and 
endometrioid tumors 
Bayesian model averaging was used to identify alterations involving known drivers associated with 
endometrioid and ovarian mucinous tumors.   The probability that the gene coefficient (γ) in these 
models is non-zero is indicated by a bar graph (left).  The inter-quartile range (IQR) for the 
difference in log odds of the regression coefficient is indicated by error bars (right).  The odds of a 
mutation in ERBB2 and CDKN2A were higher among patients with GI mucinous cancers 
compared to patients with ovarian mucinous cancers.   
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Supplemental Figure 4.7. Proportion of methylated probes in mucinous tumor samples 
The proportion of methylated CpG sites (mean B >0.3) in the mucinous stomach samples, mucinous 




Supplementary Table 4.1. Summary of Ovarian and CRC Mucinous Analyzed Through 
Whole-Exome and Whole-Genome Analyses 









     
CGCRC245T WES colorectal 0 Female    
CGCRC251T WES colorectal 0 Female    
CGCRC253T WES colorectal 0 Female    
CGCRC254T WES colorectal 0 Female    
CGCRC323T_1 WES colorectal #N/A Female    
CGCRC324T WES colorectal #N/A Female    
CGCRC325T WES colorectal #N/A Female    
CGCRC328T_2 WES colorectal #N/A Female    
CGCRC330T_1 WES colorectal #N/A Female    
CGCRC331T_1 WES colorectal #N/A Female    
CGOV101T WES 
ovarian 





endometrioid 51 Female     
CGOV104T_Rep WES 
ovarian 





endometrioid 64 Female    
CGOV121T WES 
uterine 
endometrial 64 Female    
CGOV124T WES 
uterine 
endometrial 80 Female    
CGOV126T_2 WES 
uterine 
endometrial #N/A Female    
CGOV127T_2 WGS 
uterine 
endometrial 76 Female    
CGOV131T WGS 
uterine 
endometrial 71 Female    
CGOV132T WES 
uterine 
endometrial 64 Female    
CGOV134T WES 
uterine 
endometrial 56 Female    
CGOV135T_1 WES 
uterine 
endometrial 67 Female    
CGOV136T_1 WGS 
uterine 
endometrial #N/A Female    
CGOV137T_2 WES 
uterine 
endometrial 59 Female    
CGOV138T WGS 
uterine 
endometrial 54 Female    
CGOV139T_1 WGS 
uterine 




endometrial 65 Female    
CGOV141T WES 
uterine 
endometrial 59 Female    
CGOV142T WGS 
uterine 
endometrial 56 Female    
CGOV144T WGS ovarian mucinous 52 Female      
CGOV145T WGS 
ovarian 
endometrioid 53 Female        
CGOV147T WGS ovarian mucinous 37 Female      
CGOV148T WGS ovarian mucinous #N/A Female    
CGOV150T WES ovarian mucinous 48 Female     
CGOV151Tb WES ovarian mucinous 51 Female     
CGOV152T WES ovarian mucinous 58 Female      
CGOV153T_1 WES colorectal 49 Female        
CGOV154T WGS 
ovarian 
endometrioid 62 Female      
CGOV155T_1 WGS colorectal #N/A Female    
CGOV156T WES colorectal 45 Female     
CGOV157T WGS 
ovarian 
endometrioid 54 Female     
CGOV158T WES ovarian mucinous 78 Female      
CGOV159T_1 WES colorectal #N/A Female    
CGOV160T WGS 
ovarian 
endometrioid 61 Female  




endometrioid 36 Female     
CGOV162T WGS 
ovarian 
endometrioid #N/A Female    
CGOV163T WES 
ovarian 
endometrioid 60 Female     
CGOV166T WES ovarian mucinous 
79/3 
(y/m) Female     
CGOV167T WES ovarian mucinous 
47/3 
(y/m) Female     




    
CGOV169T WES ovarian mucinous 
27/3 
(y/m) Female     
CGOV170T WGS ovarian mucinous 63 Female    
CGOV172T WGS 
ovarian 
endometrioid 47 Female    
CGOV173T WGS ovarian mucinous 73 Female    
CGOV174T WGS ovarian mucinous 57 Female    
CGOV175T WES 
ovarian 
endometrioid 56 Female    
CGOV176T WGS 
ovarian 
endometrioid 76 Female    
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CGOV177T_2 WES ovarian mucinous #N/A Female    
CGOV178T WES ovarian mucinous 65 Female    
CGOV179T_Rpt WES ovarian mucinous #N/A Female    
CGOV180T_1 WES ovarian mucinous 62 Female   
 
 
CGOV181T_1 WES ovarian mucinous #N/A Female    
CGOV183T WES ovarian mucinous 36 Female    
CGOV184T WES ovarian mucinous 61 Female    
CGOV185T WES ovarian mucinous 65 Female    
CGOV186T_2 WES ovarian mucinous #N/A Female    
CGOV187T WES ovarian mucinous 88 Female    
CGOV188T_2 WES ovarian mucinous 37 Female    
CGOV189T WES ovarian mucinous 61 Female    
CGOV190T WES ovarian mucinous 29 Female   
 
 
CGOV191T WES ovarian mucinous 35 Female   
 
 
CGOV192T WES ovarian mucinous 30 Female   
 
 
CGOV193T WES ovarian mucinous 43 Female    
CGOV194T WES ovarian mucinous 44 Female   
 
 
CGOV195T WES ovarian mucinous 76 Female    
CGOV196T WES ovarian mucinous 40 Female    
CGOV197T WES ovarian mucinous 33 Female    
CGOV198T WES ovarian mucinous 70 Female    
CGOV291Te WGS 
ovarian 
endometrioid #N/A Female    
CGOV292Tb WGS 
ovarian 
endometrioid #N/A Female    
CGOV293Tb WGS 
ovarian 
endometrioid #N/A Female    
CGOV295Tb WGS 
ovarian 
endometrioid #N/A Female    
CGOV296Tb WGS 
ovarian 
endometrioid #N/A Female    
CGOV353T WGS 
ovarian 
endometrioid #N/A Female    
CGOV354T WGS 
ovarian 
endometrioid #N/A Female    
CGOV358T WGS 
ovarian 
endometrioid #N/A Female    
CGOV362T WGS 
ovarian 
endometrioid #N/A Female    
CGOV365T WGS 
ovarian 
endometrioid #N/A Female    
CGOV369T WGS 
ovarian 
endometrioid #N/A Female    
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CGOV375T WES ovarian mucinous #N/A Female    
CGOV450T WES 
ovarian 
endometrioid #N/A Female    
CGOV66T_1 WES 
ovarian 
endometrioid 63 Female     
CGOV67T WES 
ovarian 
endometrioid 60 Female     
CGOV68T WES 
ovarian 
endometrioid 37 Female     
CGOV69T WES 
ovarian 
endometrioid 61 Female     
CGOV70T WES 
ovarian 





endometrioid 41 Female     
CGOV72T_1 WES 
ovarian 
endometrioid 55 Female    
CGOV73T_1 WES 
ovarian 





endometrioid 41 Female     
CGOV99T WES 
ovarian 
endometrioid 47 Female     
CGPA361T WES pancreas #N/A Male    
CGPA364T WES pancreas #N/A Female    
CGPA365T WES pancreas #N/A Male    
CGPA366T WES pancreas #N/A Female    
CGPA367T WES pancreas #N/A Male    
CGPA369T WES pancreas #N/A Male    
CGPA370T WES pancreas #N/A Female    
CGST10T WES stomach #N/A Male    
CGST1T_2 WES stomach #N/A Male    
CGST2T_2 WES stomach #N/A Male    
CGST3T WES stomach #N/A Male    
CGST4T WES stomach #N/A Male    
CGST5T WES stomach #N/A Male    
CGST7T WES stomach #N/A     
CGST8T WES stomach #N/A Male    
CGST9T WES stomach #N/A Male    
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Supplementary Table 4.2. Summary of Next-Generation Sequencing Analyses 
Case ID Sample Type Analysis Type 
 
 





















 CGOV145N_1 Normal WGS         
CGCRC245N Normal WES         
CGCRC245T Tumor WES         
CGCRC251N Normal WES         
CGCRC251T Tumor WES         
CGCRC252N Normal WES         
CGCRC252T Tumor WES         
CGCRC253N_1 Normal WES         
CGCRC253T Tumor WES         
CGCRC254N_1 Normal WES         
CGCRC254T Tumor WES         
CGCRC323N_1 Normal WES         
CGCRC323T_1 Tumor WES         
CGCRC324Na Normal WES         
CGCRC324T Tumor WES         
CGCRC325N Normal WES         
CGCRC325T Tumor WES         
CGCRC328N Normal WES         
CGCRC328T_2 Tumor WES         
CGCRC330N_1 Normal WES         
CGCRC330T_1 Tumor WES         
CGCRC330T1_1 Tumor WES         
CGCRC331N_1 Normal WES         
CGCRC331T_1 Tumor WES         
CGOV101N Normal WES         
CGOV101T Tumor WES         
CGOV102N Normal WES         
CGOV102T Tumor WES         
CGOV103N Normal WES         
CGOV103T Tumor WES         
CGOV104N Normal WES         
CGOV104T_Rep Tumor WES         
CGOV105N Normal WES         
CGOV105T Tumor WES         
CGOV121N Normal WES         
CGOV121T Tumor WES         
CGOV124N Normal WES         
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CGOV124T Tumor WES         
CGOV126N Normal WES         
CGOV126T_2 Tumor WES         
CGOV127N_2 Normal WGS         
CGOV127T_2 Tumor WGS         
CGOV131N_1 Normal WGS         
CGOV131T Tumor WGS         
CGOV132N Normal WES         
CGOV132T Tumor WES         
CGOV133N Normal WES         
CGOV133T Tumor WES         
CGOV134N Normal WES         
CGOV134T Tumor WES         
CGOV135N Normal WES         
CGOV135T_1 Tumor WES         
CGOV136N Normal WES         
CGOV136N Normal WGS         
CGOV136T Tumor WES         
CGOV136T_1 Tumor WGS         
CGOV137N Normal WES         
CGOV137T_2 Tumor WES         
CGOV138N Normal WGS         
CGOV138T Tumor WGS         
CGOV139N Normal WGS         
CGOV139T_1 Tumor WGS         
CGOV140N_1 Normal WGS         
CGOV140T Tumor WGS         
CGOV141N Normal WES         
CGOV141N Normal WGS         
CGOV141T Tumor WES         
CGOV141T_1 Tumor WGS         
CGOV142N_1 Normal WGS         
CGOV142T Tumor WGS         
CGOV144N Normal WGS         
CGOV144T Tumor WGS         
CGOV145N Normal WGS         
CGOV145T Tumor WGS         
CGOV145T_1 Tumor WGS         
CGOV147N Normal WGS         
CGOV147T Tumor WGS         
CGOV148N Normal WGS         
CGOV148T Tumor WGS         
CGOV150N Normal WES         
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CGOV150T Tumor WES         
CGOV151N Normal WES         
CGOV151Tb Tumor WES         
CGOV152N Normal WES         
CGOV152T Tumor WES         
CGOV153N Normal WES         
CGOV153T_1 Tumor WES         
CGOV154N  Normal WGS         
CGOV154T Tumor WGS         
CGOV155N Normal WGS         
CGOV155T Tumor WES         
CGOV155T_1 Tumor WGS         
CGOV156N Normal WES         
CGOV156T Tumor WES         
CGOV157N Normal WGS         
CGOV157T Tumor WGS         
CGOV158N Normal WES         
CGOV158T Tumor WES         
CGOV159N Normal WES         
CGOV159N_2 Normal WES         
CGOV159T Tumor WGS         
CGOV159T_1 Tumor WES         
CGOV159T_2 Tumor WES         
CGOV159T_3 Tumor WGS         
CGOV160N Normal WGS         
CGOV160N_1 Normal WGS         
CGOV160N_2 Normal WGS         
CGOV160T Tumor WGS         
CGOV160T_1 Tumor WGS         
CGOV160T_2 Tumor  WGS         
CGOV161N Normal WGS         
CGOV161T Tumor WGS         
CGOV162N Normal WGS         
CGOV162T Tumor WGS         
CGOV163N Normal WES         
CGOV163T Tumor WES         
CGOV166N Normal WES         
CGOV166T Tumor WES         
CGOV167N Normal WES         
CGOV167T Tumor WES         
CGOV168N Normal WES         
CGOV168T Tumor WES         
CGOV169N Normal WES         
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CGOV169T Tumor WES         
CGOV170N Normal WGS         
CGOV170T Tumor WGS         
CGOV172N Normal WGS         
CGOV172T Tumor WGS         
CGOV173N Normal WGS         
CGOV173T Tumor WGS         
CGOV174N Normal WGS         
CGOV174T Tumor WGS         
CGOV175N Normal WES         
CGOV175T Tumor WES         
CGOV176N Normal WGS         
CGOV176T Tumor WGS         
CGOV177N_2 Normal WES         
CGOV177N_Rpt Normal WES         
CGOV177T_2 Tumor WES         
CGOV177T_Rpt_1 Tumor WES         
CGOV178N Normal WES         
CGOV178T Tumor WES         
CGOV179N Normal WES         
CGOV179T_Rpt Tumor WES         
CGOV180N_1 Normal WES         
CGOV180T_1 Tumor WES         
CGOV181N Normal WES         
CGOV181T_1 Tumor WES         
CGOV183N_Rpt_1 Normal WES         
CGOV183T Tumor WES         
CGOV184N_Rpt_1 Normal WES         
CGOV184T Tumor WES         
CGOV185N_2 Normal WES         
CGOV185T Tumor WES         
CGOV186N Normal WES         
CGOV186T_2 Tumor WES         
CGOV187N Normal WES         
CGOV187T Tumor WES         
CGOV188N_2 Normal WES         
CGOV188T_2 Tumor WES         
CGOV189N Normal WES         
CGOV189T Tumor WES         
CGOV190N Normal WES         
CGOV190T Tumor WES         
CGOV191N Normal WES         
CGOV191T Tumor WES         
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CGOV192N Normal WES         
CGOV192T Tumor WES         
CGOV193N Normal WES         
CGOV193T Tumor WES         
CGOV194N Normal WES         
CGOV194T Tumor WES         
CGOV195N Normal WES         
CGOV195T Tumor WES         
CGOV196N Normal WES         
CGOV196T Tumor WES         
CGOV197N Normal WES         
CGOV197T Tumor WES         
CGOV197T_1 Tumor WES         
CGOV198N Normal WES         
CGOV198T Tumor WES         
CGOV291N Normal WGS         
CGOV291Te Tumor WGS         
CGOV292Na Normal WGS         
CGOV292Tb Tumor WGS         
CGOV293N Normal WGS         
CGOV293Tb Tumor WGS         
CGOV295N Normal WGS         
CGOV295Tb Tumor WGS         
CGOV296N Normal WGS         
CGOV296Tb Tumor WGS         
CGOV353N Normal WGS         
CGOV353T Tumor WGS         
CGOV354N Normal WGS         
CGOV354T Tumor WGS         
CGOV358N Normal WGS         
CGOV358T Tumor WGS         
CGOV362N Normal WGS         
CGOV362T Tumor WGS         
CGOV365N Normal WGS         
CGOV365T Tumor WGS         
CGOV369N Normal WGS         
CGOV369T Tumor WGS         
CGOV375N Normal WES         
CGOV375T Tumor WES         
CGOV450N Normal WES         
CGOV450T Tumor WES         
CGOV66N Normal WES         
CGOV66T_1 Tumor WES         
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CGOV67N Normal WES         
CGOV67T Tumor WES         
CGOV68N Normal WES         
CGOV68T Tumor WES         
CGOV69N_2 Normal WES         
CGOV69T Tumor WES         
CGOV70N Normal WES         
CGOV70T Tumor WES         
CGOV71N Normal WES         
CGOV71T_1 Tumor WES         
CGOV72N Normal WES         
CGOV72T_1 Tumor WES         
CGOV73N Normal WES         
CGOV73T_1 Tumor WES         
CGOV98N Normal WES         
CGOV98T Tumor WES         
CGOV99N Normal WES         
CGOV99T Tumor WES         
CGPA361N Normal WES         
CGPA361T Tumor WES         
CGPA364N Normal WES         
CGPA364T Tumor WES         
CGPA365N Normal WES         
CGPA365T Tumor WES         
CGPA366N Normal WES         
CGPA366T Tumor WES         
CGPA367N Normal WES         
CGPA367T Tumor WES         
CGPA369N Normal WES         
CGPA369T Tumor WES         
CGPA370N Normal WES         
CGPA370T Tumor WES         
CGST10N_1 Normal WES         
CGST10T Tumor WES         
CGST1N_1 Normal WES         
CGST1T_2 Tumor WES         
CGST2N Normal WES         
CGST2T_2 Tumor WES         
CGST3N Normal WES         
CGST3T Tumor WES         
CGST4N Normal WES         
CGST4T Tumor WES         
CGST5N Normal WES         
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CGST5T Tumor WES         
CGST7N Normal WES         
CGST7T Tumor WES         
CGST8N Normal WES         
CGST8T Tumor WES         
CGST9N Normal WES         






















5.1 High grade serous ovarian carcinomas originate in the fallopian tube discussion 
These results provide a comprehensive evolutionary analysis of sporadic high-grade serous ovarian 
carcinoma in five patients.  Given the unique nature of the multiple samples we examined from 
each patient, our study may have certain limitations not typical of genome-wide efforts.  First, the 
small size of the tumor samples compared to surrounding non-neoplastic tissue could potentially 
lead to low tumor purity.  The high mutant allele fraction of TP53 among cancer samples (average 
of 56-85%) indicates that this issue was largely overcome through laser capture microdissection.  
Second, the small number of cells in p53 signature samples may have limited our genomic analyses 
for these lesions.  The observation that all sequence changes in p53 signatures were also present in 
STIC and other carcinomas of multiple sites is consistent with our evolutionary model and suggests 
that these cells are likely to represent a parental clone of other neoplastic lesions.  Third, our 
analysis was limited to ovarian cancers where STICs and other concomitant lesions were identified, 
and may therefore not be representative of all HGOCs.  The absence of STIC lesions in ~40% of 
sporadic HGSOCs is likely due to an incomplete sampling of the fallopian tube or the overgrowth 
of the STIC by the carcinoma in the context of bulky disease, but may also reflect another site of 
origin that has yet to be determined for these cancers144.  Fourth, this study did not intend to address 
the intra-tumoral heterogeneity within the carcinomas but rather focused on clonal changes within 
each tumor.  Fifth, as in any evolutionary analyses, the genomic alterations we observed provide 
the most likely model of tumor development but do not exclude the possibility of other 
relationships.  Nevertheless, our analyses of somatic alterations suggest that models where the 
ovarian cancer or metastatic lesions seed the fallopian tube tumors25,26 (including STICs or p53 
signatures) are infrequent and unlikely to be the source of most fallopian tube lesions. 
Despite these potential limitations, the data we have obtained provide new insights into the etiology 
of ovarian Type II carcinoma and have significant implications for the prevention, early detection 
and therapeutic intervention of this disease.  The results suggest that ovarian cancer is a disease of 
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the fallopian tubes, with the development of p53 signatures and STICs as early events.  The 
subsequent formation of a cancer in the ovaries represents a seeding event from a primary tumor in 
the fallopian tube that already contains sequence and structural alterations in key driver genes, 
including those in TP53, PI3K pathway, and BRCA1/BRCA2 genes.  The recurrent allelic 
imbalances observed in chromosomes 1, 6, 16, 18, 20 and 22 may suggest additional genes that 
involved in this process.  The timing of the progression from STICs to ovarian cancer in the cases 
we analyzed was on average 6.5 years, but seeding of metastatic lesions in these patients occurred 
rapidly thereafter.  This timing is consistent with recent reports showing a difference of 7.7 years 
in the age of BRCA carriers with localized vs advanced adnexal lesions145.  This evolutionary 
timeline can help explain why most HGSOC patients are diagnosed at advanced stage (III/IV) with 
pelvic and peritoneal spread of disease, and why among asymptomatic BRCA germline mutation 
carriers half of the cases diagnosed with asymptomatic adnexal neoplasia have already seeded to 
pelvis or peritoneum (>IA)145.  These observations are largely similar to other genomic analyses of 
the evolution of ovarian cancer24,25,28,146 as well as the recent analyses of STIC lesions that were 
reported while this study was under review14.  Our study highlights the role of p53 signatures as 
early lesions in this evolutionary paradigm. 
Our genomic analyses are consistent with population-based studies of the effects of salpingectomy 
on the risk of ovarian cancer.  Prophylactic bilateral salpingo-oophorectomy has been shown to 
reduce the risk of developing ovarian cancer in BRCA mutation carriers to below 5%147,148.  
Likewise, bilateral salpingectomy, performed as a contraceptive method instead of tubal 
sterilization, reduced the risk of ovarian cancer by 61% at 10 years149.  Our study provides a 
mechanistic basis for these observations and has implications for clinical management in 
prevention of ovarian cancer.  In high risk BRCA carriers, bilateral salpingectomy with delayed 
oophorectomy should be considered150 through participation in ongoing clinical trials 
(NCT02321228; NCT01907789).  In non-carriers, our work implies that for women who undergo 
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surgery for benign uterine causes, total abdominal hysterectomy and bilateral salpingectomy with 
sparing of the ovaries should be considered151, and that bilateral salpingectomy may be a preferred 
contraceptive alternative to tubal ligation.  The dual concepts in these recommendations for BRCA 
carriers and non-carriers are that removal of the fallopian tubes (rather than the ovaries) may be 
curative as it eliminates the underlying cellular precursors of ovarian cancer, and that preservation 
of the ovaries provides long term benefits due to decreased risk and fatalities from coronary heart 
disease and other illnesses152.   A limitation of this approach is that as the precise timing of when 
potentially malignant cells shed from the fallopian tube and microscopically seed the ovary is 
unknown, removal of the tubes may not provide optimal risk-reduction. 
5.2 Integrated genomic, epigenomic and expression analyses of ovarian cancer cell lines 
discussion 
 
These analyses provide the most comprehensive molecular analyses of ovarian cancer cell lines to 
date. Through integration of sequence, copy number, rearrangement, methylation, and expression 
analyses, we were able to detect frequently altered driver genes and pathways. These efforts 
revealed that ovarian cancer cell lines were largely representative of primary ovarian cancers and 
identified a variety of alterations not previously appreciated in these tumors. 
 
One of the challenges of genomic analyses of tumor cell lines has been the lack of matched normal 
samples for determination of whether alterations are truly tumor-specific. Through the development 
of Trellis, we were able to identify high-confidence copy number and rearrangement alterations in 
the absence of matched normal DNA. Additionally, the grouping of structural changes allowed 
linking of apparently disparate events that would normally have been considered separate copy 
number alterations. These efforts provide a method for detecting somatic structural changes in 
cancer cell lines and other specimens in the absence of a matched normal, without the hundreds to 
 293 
thousands of false-positive changes typically detected through other approaches. The method also 
permits identification of likely driver copy number changes by detecting the most connected 
regions of amplicons among the many such passenger alterations typically observed in human 
cancers. The identification of likely somatic structural and sequence alterations in a tumor-only 
setting is conservative. Cancer signature analyses, for example, currently require a matched normal 
sample to comprehensively identify somatic signatures across the genome, and our analyses based 
on a subset of somatic alterations may not reflect overall somatic mutation signatures. 
 
These efforts revealed alterations in ovarian cancer that may provide insights into the biology of 
this disease. The integration of methylation and expression changes together with sequence and 
structural changes identified a larger fraction of tumors that were altered in specific genes and 
pathways than whole-genome sequencing alone. For example, CDKN2A was altered in over half 
of the serous, clear-cell, and mucinous cancer cell lines analyzed, revealing a higher fraction than 
previously thought to have alterations in this gene. Additionally, changes of a variety of genes, 
including ASXL1, H3F3B, and CDC73, as well as fusions of YAP1-MAML2, IKFZ2-ERBB4, and 
those disrupting FBXW7, NF1, and CCND1 were detected in these tumors, providing pathways of 
dysregulation within ovarian cancer. 
 
The integrative molecular analyses of ovarian cancer cell lines provide opportunities for 
characterizing differences in susceptibility to targeted therapies. As an example, ovarian tumors 
with sequence alterations in PIK3CA and PPP2R1A had enhanced sensitivity to the GNE-493 
inhibitor to achieve the same therapeutic response as tumors without these alterations. Mutations 
in PIK3CA and PPP2R1A are common in ovarian clear-cell cancers, suggesting that PI3K 
inhibitors may be an effective therapeutic strategy for this subtype. 
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Cancers with HRD are more prone to genomic errors resulting in loss or duplication of 
chromosomal regions and chromosomal instability73. Drugs that inhibit PARP1 cause multiple 
double strand breaks, and in tumors with HRD such DNA damage cannot be efficiently repaired, 
leading to cell death. We found that serous and endometrioid tumors with MYC amplification were 
highly sensitive to PARP inhibitors. PARP inhibitors have been previously shown to lead to mitotic 
catastrophe in neuroblastoma with amplification of the related gene MYCN on chromosome 2p153, 
and MYC amplification on chromosome 8q has been shown to suppress BIN1, thereby increasing 
the activity of PARP1154. Additionally, MYCN amplified neuroblastoma cell lines were more 
sensitive to the PARP inhibitor BYK204165 compared to cell lines without such alterations155. In 
our study, MYC was the central driver in multiple ovarian cancers cell lines with highly linked 
amplicon groups (Table S1g; Figures S3, S4, and S5), suggesting that this gene plays a major role 
in a subset of ovarian cancers that may now be targeted therapeutically. Interestingly, we found 
that genome-wide rearrangements were a more useful biomarker of sensitivity to this therapy 
compared to the commonly used HRD scores156-158, perhaps because these latter measurements only 
identify a subset of patients that respond to PARP inhibitors, especially as shown in clinical trials 
that enriched for tumors with previous sensitivity to DNA-damaging agents159,160. Although there 
is a correlation between the HRD score and the number of inversions and intra-chromosomal 
rearrangements (Spearman correlation coefficient = 0.5), the genome-wide rearrangements we 
identified may provide a more informative signature of the underlying recombination deficiency in 
these tumors and together with MYC amplification offer potentially improved opportunities for 
identifying responsive patients. 
 
5.3 Genomic landscapes of endometrioid and mucinous ovarian cancers discussion 
 
These analyses provide an extensive genomic and epigenomic analysis of ovarian mucinous and 
endometrioid cancers.  Through the integration of somatic mutations, structural variants, including 
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deletions, linked amplicons, intra and inter-chromosomal rearrangements, as well as methylation 
analyses, we were able to detect frequently altered genes and pathways that describe the genomic 
landscape of these tumor types.  These efforts revealed that ovarian endometrioid and uterine 
endometrial cancers were genetically similar, suggesting they may share a common cellular 
precursor.  In contrast, at both genetic and epigenetic levels, ovarian and GI mucinous tumors had 
different characteristics, highlighting the unique origins of these tumors.      
 
We identified novel alterations that have not been previously observed in these tumors.  These 
included alterations in RAD51C, NOTCH4, SMARCA4, SMARCA1 and JAK1 in ovarian 
endometrioid, and SMARCA4 genes in ovarian mucinous cancers.  Whole genome sequence 
analyses using our Trellis pipeline revealed novel rearrangements involving PTEN, NF1, and NF2 
in ovarian endometrioid tumors, and NF1 and MED1 in ovarian mucinous cancers.  Many of these 
novel alterations provide new avenues for potential therapeutic intervention or new insights into 
the biology of these cancers.  For example, patients with germline NF1 mutations have shown to 
respond well to MEK1/2 inhibitors, providing a new treatment avenue for tumors with alterations 
in this gene 161.  SMARCA4 loss, while not directly targetable, may result in cyclin D1 deficiency 
leading to susceptibility to CDK4/6 inhibition and thus provide another targetable treatment avenue 
to patients with SMARCA4 mutant ovarian endometrioid tumors 162. JAK1 is essential for IL-6-class 
inflammatory cytokine signaling and plays a critical role in metastatic cancer progression in breast 
cancer, and may provide a similar role in ovarian endometrioid cancer 163. MED1 is a tissue-specific 
coactivator of the estrogen receptor that mediates breast cancer metastasis and treatment resistance 
164 and when targeted in model systems results in reduced growth and metastasis of breast cancer 
xenografts 165.  MED1 rearrangements involving exons  may lead to overexpression of this protein 
that could be exploited in ovarian mucinous cancer patients. 
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In uterine endometrioid cancers, we identified ESR1 activating mutations in three of 15 patients at 
amino acid residue 537 resulting in a mutation hotspot commonly seen in breast cancer patients 
who have become resistant to estrogen targeted therapies.  Although aromatase inhibitors have been 
shown to select for Tyr537 ESR1 mutations 116,117, none of the patients in this study had been treated 
with these therapies.  We hypothesize that these three women, each over the age of 60, may have 
been in a post-menopausal estrogen-free environment similar to estrogen therapy that increased 
selection for ESR1 mutations.  The significant interest in overcoming ESR1 mutations for patients 
with resistance to aromatase inhibitors may ultimately provide new avenues for patients with these 
de novo alterations in uterine endometrioid cancers.    
 
5.4 Overall Discussion 
Our observations also have implications for improved detection of ovarian cancer.  Unfortunately, 
less than 1.25% of HGSOC are confined to the ovary at diagnosis27.  Earlier detection of this disease 
is likely to benefit from the identification of a precursor lesion, as has been the case for many other 
tumor types.  Our data suggest that fallopian tube neoplasia is the origin of ovarian serous 
carcinogenesis, and can directly lead to cancer of the ovaries and of other sites.  Currently, the 
typical histopathologic evaluation of fallopian tubes typically involves a cursory evaluation of one 
or two representative sections.  Our study suggests that systematic sectioning and extensive 
examination of total fallopian tubes21 should become common practice in pathology, and not 
confined to academic tertiary care centers.  Depending on whether the fallopian tubes are removed 
for benign conditions, risk-reducing bilateral salpingectomy, or gynecological cancers, specific 
examination protocols should be applied21,166.  Given the window of time that appears to exist 
between the formation of fallopian tube lesions and development of ovarian cancer, these insights 
open the prospect of novel approaches for screening.  Such approaches may be especially important 
given the limited therapeutic options currently available for ovarian cancer4,5.  Recent advances for 
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ultrasensitive detection of genetic alterations in blood-based liquid biopsies, pap smears, and other 
bodily fluids167 168 or imaging approaches may provide opportunities in early diagnosis and 
intervention. 
Although our analyses provide a comprehensive integration of molecular alterations for ovarian 
cancer, certain types of changes have not been evaluated. In the future, proteomic, metabolomic, 
and carbohydrate changes can be added to the compendium of genomic, epigenomic, and 
transcriptomic information for these cell lines. Additionally, further efforts will be needed to 
demonstrate that these observations can be translated broadly to ovarian cancer patients. 
Nevertheless, these data provide a foundation for using ovarian cell line models in screening 
novel therapeutic strategies. Evaluation of additional compounds using these well-characterized 
tumor cell lines will provide rational translational opportunities for development of new therapies 
in ovarian cancer. 
 
Integrated analyses of the sequence and structural changes through Bayesian modeling revealed 
that the genomic landscapes of ovarian GI mucinous tumors were different, but that ovarian 
endometrioid and uterine endometrial tumors were related and may share similar origins.  Our 
observation that ovarian and uterine endometrioid tumors may share a similar cellular precursor is 
consistent with previous observations of co-occurrence of these diseases at a higher than expected 
frequency based on the individual prevalence of these cancers .  The common origin of these tumors 
remains to be determined, but accumulating evidence that that other ovarian cancers such as 
HGSOC arise in the fallopian tube 13, together with pathologic evidence suggests that the 
endometrium is the likely source of this cancer.   These observations have important implications 
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